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Adipose tissue is a rich, ubiquitous, and easily accessible source for multipotent mesenchymal
stromal/stem cells (MSCs), so-called adipose-derived stromal/stem cells (ASCs). Primary isolated ASCs
are a heterogeneous preparation consisting of several subpopulations of stromal/stem and precursor
cells. Donor-specific differences in ASC isolations and the lack of culture standardization hinder
the comparison of results from different studies. Nevertheless, ASCs are already used in different
in vivo models and clinical trials to investigate their ability to improve tissue and organ regeneration.
Many questions concerning their counterparts and biology in situ, their differentiation potential
in vitro and in vivo, and also the mechanisms of regeneration (paracrine effects including regeneration
promoting factors and extracellular vesicles, differentiation, immunomodulation) are not completely
understood or remain unsolved. For this reason, this special edition aims to expand current knowledge
about the extremely diverse potential of ASCs.
This Special Issue covers research articles investigating various adipose tissues as a source for
ASC isolation [1–3], specific cultures methods to enhance proliferation or viability [4–7], and the
differentiation capacity [8–12]. Furthermore, other studies highlight aspects of various diseases [13,14],
the immunosuppressive potential of ASCs and their derivates [15] or the in vivo tracking of transplanted
ASCs [16].
Ritter and co-workers analyzed the functional similarities and differences of ASCs isolated from
different adipose depots [3]. The authors described that ASCs isolated from subcutaneous and visceral
fat share multiple cellular features, but significantly differ in their functions. The functional diversity
of ASCs depends on their origin, cellular context, and surrounding microenvironment within adipose
tissues. Stojanović and co-workers characterized the molecular signature and the differentiation
capacity of ASCs isolated from lipoma [2]. A study by our group from the nephrological research
laboratory summarized the isolation and culture of ASCs from perirenal adipose tissue, characterized
the cultured cells, and demonstrated their immunomodulatory potential and their high permissiveness
for human cytomegalovirus [1].
Platelet lysate has been shown to be an effective replacement for serum in the culture, expansion,
and differentiation of ASCs [4,7]. Metformin has been shown as a preconditioning agent that stimulates
proliferative activity and viability of ASCs [6]. The addition of metformin improved metabolism and
viability, correlated with higher mitochondrial membrane potential, and reduced apoptosis. As a
possible alternative to standard cell culture, Ryu and co-workers reviewed spheroid culture systems
that could provide a physicochemical environment similar to that in vivo by facilitating cell-cell and
cell-matrix interaction, thereby overcoming the limitations of traditional monolayer cell culture [5].
The findings of Ng and co-workers suggest that the epigenetic state of MSCs is associated with
the biased differentiation plasticity towards its tissue of origin, proposing a mechanism related to
the retention of epigenetic memory [11]. This result could improve the selection of optimal tissue
sources for MSCs for therapeutic applications. Others studied various effects of differentiation events
induced by differentiation-inducing agents. Using valproic acid, the induced neural differentiation of
ASCs was demonstrated by the upregulation of characteristic neuro-specific factors [8]. Zöller and
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co-workers showed that collagen I was able to modulate lipogenesis and adiponectin expression,
and hypothesized that this could contribute to age-related metabolic disorders [10]. Klemenz and
co-workers determined volatile organic compounds during adipogenic differentiation of ASCs in order
to avoid cell destruction during monitoring of cell status [9]. Their data indicated that measuring
these compounds could be a useful, non-invasive tool for the metabolic monitoring of cells in vitro.
Di Somma and co-workers tested the ability of Histogel, a natural mixture of glycosaminoglycans,
to sustain the differentiation of ASCs into brown-like cells and brown adipose tissue [12]. A study
by Plava and co-workers identified that ASCs are permanently altered in the presence of tumor
breast tissue and have the potential to increase tumor cell invasive ability through the activation of
epithelial-to-mesenchymal transition in tumor cells [13]. Another study characterized ASCs isolated
from patients with rheumatoid arthritis and described their altered phenotype and secretory activity
compared to ASCs from healthy donors [14].
In recent years, several in vitro preconditioning (also called pretreatment or licensing) strategies
have been investigated to enhance the regenerative and immunomodulatory potential of ASCs.
Serejo and co-workers investigated how a preconditioning regime with interferon-γ affects the
immunomodulatory functions of ASCs and examined their secretome and released extracellular
vesicles [15]. Preconditioned ASCs showed a higher immunosuppressive potential compared to
unlicensed ASCs. Another study by our group from the nephrological research laboratory shows
in vivo tracking of luciferase-transgenic ASCs after transplantation in a model of inflammatory lung
disease [16]. In vivo imaging demonstrated a significantly longer retention time of transplanted ASCs
in the injured lung parenchyma compared to healthy wild type mice, which could indicate increased
regeneration of the damaged tissue.
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Abstract: Adipose-derived mesenchymal stem cells (ASCs) are considered to be a useful
tool for regenerative medicine, owing to their capabilities in differentiation, self-renewal, and
immunomodulation. These cells have become a focus in the clinical setting due to their abundance
and easy isolation. However, ASCs from different depots are not well characterized. Here, we
analyzed the functional similarities and differences of subcutaneous and visceral ASCs. Subcutaneous
ASCs have an extraordinarily directed mode of motility and a highly dynamic focal adhesion turnover,
even though they share similar surface markers, whereas visceral ASCs move in an undirected random
pattern with more stable focal adhesions. Visceral ASCs have a higher potential to differentiate
into adipogenic and osteogenic cells when compared to subcutaneous ASCs. In line with these
observations, visceral ASCs demonstrate a more active sonic hedgehog pathway that is linked to
a high expression of cilia/differentiation related genes. Moreover, visceral ASCs secrete higher
levels of inflammatory cytokines interleukin-6, interleukin-8, and tumor necrosis factor α relative to
subcutaneous ASCs. These findings highlight, that both ASC subpopulations share multiple cellular
features, but significantly differ in their functions. The functional diversity of ASCs depends on their
origin, cellular context and surrounding microenvironment within adipose tissues. The data provide
important insight into the biology of ASCs, which might be useful in choosing the adequate ASC
subpopulation for regenerative therapies.
Keywords: adipose-derived mesenchymal stem cells; differentiation; migration; secretion; primary
cilium; sonic hedgehog signaling
1. Introduction
For several decades, adipose tissue (AT) was thought to be a passive organ with functions in
energy homeostasis, accumulation of lipids as energy-storage depot, and supplying energy-rich fat
molecules for generating energy and membrane synthesis [1,2]. Nowadays, AT is known to be an
important endocrine organ with diverse functions in multiple cellular processes. Cytokine and hormone
signals convey immune functions and inflammatory responses that module the energy homeostasis
by regulating the food intake, insulin sensitivity, and energy expenditure in tight association with
other organs [3]. In line with these complex roles, the ATs of different depots display heterogeneity in
Cells 2019, 8, 1288; doi:10.3390/cells8101288 www.mdpi.com/journal/cells5
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their morphological, molecular, and metabolic profiles tightly adjusted to their biological context [4].
Visceral AT in the mesentery and omentum contains increased the numbers of inflammatory and
immune cells, is more metabolically active, has an higher uptake of free fatty acids and glucoses, and is
less sensitive to insulin [5]. By contrast, subcutaneous AT has a higher affinity for free fatty acids and
triglycerides, and its primary function is the energy storage, protection against mechanical damage,
and homeostatic heat control [6].
Adipocytes within AT originate from the differentiation process of multipotent progenitor cells,
named adipose-derived mesenchymal stem cells (ASCs) [7]. These cells are key regulators of AT.
They are involved in tissue homeostasis with their potent differentiation capacity in adipogenesis
and angiogenesis. Additionally, ASCs coordinate and maintain the local and systemic environment
by immunomodulation and damage repair through their paracrine signaling and direct cell-cell
interaction [8,9]. These cells are considered to be useful for novel regenerative medicine applications
due to their accessibility and their various functions concerning tissue remodeling and homeostasis
and become the focus of many translational clinical studies [10].
Numerous studies have been conducted to analyze the key properties of ASCs isolated from
different AT depots (visceral, subcutaneous, and preperitoneal) [11]. In particular, subcutaneous and
visceral ASCs have received great attention. However, the results of these studies were inconsistent
regarding their differentiation potential, proliferation, and paracrine signaling [11,12]. We have already
investigated the interaction of ASCs with breast cancer cells [13], the effect of Polo-like kinase 1 (Plk1)
inhibitors on ASCs [14], and the influence of obesity on ASCs [15,16]. During these studies, we have
observed similarities and disparities between subcutaneous and visceral ASCs. In the present work,
we focus on the features of both ASC subtypes and further analyze their main functions. Our results
highlight similarities in their cell surface marker profile, cell viability, and cell cycle progression,
and diversities in the motility, differentiation capacity, and the cilium related sonic hedgehog (Hh)
signal pathway.
2. Materials and Methods
2.1. Human Visceral and Subcutaneous ASC Isolation and Cell Surface Marker Measurement
This work was approved by the Ethics Committee of the Johann Wolfgang Goethe University
Hospital Frankfurt and informed written consent was obtained from all the participants. Visceral
(omental) and subcutaneous (abdominal) adipose tissues were taken from women undergoing
Caesarean section. Table 1 lists participant information. Their age ranged between 25 and 35 years.
Body mass index (BMI) of both ASC subgroups was 24.1 ± 2.9. ASCs were isolated, as described
previously [13,14]. After isolation, the cells were cultured and expanded for three passages. Cells were
then stored at −80 ◦C until use. Early passages (P3 to P6) of ASCs were used for all analyses. All
experiments, unless otherwise indicated, were independently performed with ASCs that were isolated
from at least three different donors.
FACSCaliburTM (BD Biosciences, Heidelberg, Germany) was used for determining the surface
markers of ASCs. The cells were harvested with 0.25% trypsin and fixed for 15 min. with
ice-cold 2% paraformaldehyde (PFA) at 4◦C. Cells were washed twice with flow cytometry
buffer (FCB: PBS with 0.2% Tween-20, and 2% fetal calf serum (FCS)) and stained with the
following antibodies from eBioscience/BD-Pharmingen (Frankfurt, Germany): FITC-conjugated
anti-human cluster of differentiation 90 (CD90) (#11-0909-42), PE-conjugated anti-human CD73
(#550257), PE-conjugated anti-human CD 105 (#323206), PE-conjugated anti-human CD146 (#561013),
PerCP-Cy5.5-conjugated anti-human CD14 (#555397), FITC-conjugated anti-human CD34 (#343504),
APC-conjugated anti-human CD106 (#551147), and APC-conjugated anti-human CD31 (#17-0319-41).
Anti-mouse Ig, κ/negative control compensation particles (eBioscience/BD-Pharmingen, #552843), flow
cytometry setup beads (eBioscience/BD-Pharmingen, #340486 and #340487), and non-stained ASCs
were used as negative controls for FACS gating.
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2.2. Indirect Immunofluorescence Staining, Microscopy, Fluorescence Intensity Quantification, and
Nocodazole Washout
Indirect immunofluorescence staining was performed, as reported [17]. Cells were seeded on
NuncTM Lab-TekTM SlideFlask chambers from Thermo Fisher Scientific (Schwerte, Germany). Cells
were fixed for 8–10 min. with methanol at −20 ◦C or with 4% PFA containing 0.2% Triton X-100 for
15 min. at room temperature, as described [16]. The following primary antibodies were used: mouse
monoclonal antibody against acetylated α-tubulin (Sigma-Aldrich, Darmstadt, Germany, #T6793),
mouse monoclonal antibody against CD90 (Abcam, Cambridge, UK, ab133350), rabbit monoclonal
antibody against CD73 (GenTex, Eching, Germany, GTX101140), mouse monoclonal antibody against
Smo (Santa Cruz Biotechnology, Heidelberg, Germany, #sc-166685), rabbit polyclonal antibody against
phospho-histone H3 (pHH3, Ser10, Merck Millipore, Darmstadt, Germany, #06-570), mouse monoclonal
antibody against phospho-focal adhesion kinase (p-FAK, Cell Signaling, Frankfurt, Germany, #3283),
rabbit monoclonal antibody against FAK (Proteintech, Manchester, UK, 66258-1-Ig), mouse monoclonal
antibody against paxillin (BD Transduction LaboratoriesTM, Frankfurt, Germany, #610619), and rabbit
polyclonal antibody against p-paxillin (Cell Signaling, Frankfurt, Germany, #2541). FITC-, Cy3-, and
Cy5 conjugated secondary antibodies were obtained from Jackson ImmunoResearch (Cambridgeshire,
UK). DNA was visualized by using DAPI (4′,6-diamidino-2-phenylindole-dihydrochloride, Roche,
Mannheim, Germany). The filamentous actin (F-actin) cytoskeleton was stained while using phalloidin
(Phalloidin-Atto 550; Sigma-Aldrich, Munich, Germany). The slides were examined while using an
AxioObserver.Z1 microscope (Zeiss, Göttingen, Germany) and images were taken using an AxioCam
MRm camera (Zeiss, Göttingen, Germany). The immunofluorescence stained slides were further
examined by confocal laser scanning microscopy (CLSM) using Z-stack images with a HCXPI APO CS
63.0 x 1.4 oil objective (Leica CTR 6500, Heidelberg, Germany) in sequential excitation of fluorophores.
A series of Z-stack images were captured at 0.5 μm intervals. All the images in each experiment were
taken with the same laser intensity and exposure time. Representatives are generated by superimposing
(overlay) individual images from confocal Z-sections.
Fluorescent intensity was measured while using line-scan-based analysis in ImageJ (National
Institutes of Health), as described [15,18]. The average intensities over a three-pixel-wide line along the
axoneme were measured and then normalized against cilium length by using the ImageJ plugin Plot
Roi Profile. The intensity was measured from the axonemal base to its tip in 10% intervals. The mean
values of thirty cilia from three different donors were obtained for each group within the intervals and
were plotted to GraphPad Prism 7 (GraphPad software Inc., San Diego, USA).
We performed a nocodazole washout assay to analyze the dynamics (disassembly/reassembly)
of focal adhesions (FAs). The cells were treated with nocodazole (10 μM; Sigma-Aldrich, Darmstadt,
Germany) for 5 h to depolymerize microtubules (MTs) [19]. The drug was washed out with
phosphate-buffered saline (PBS), and MTs were repolymerized in medium for different time periods
(0, 30, 75 min.). Cells were fixed and stained for paxillin and p-FAK. The slides were examined while
using an AxioObserver.Z1 microscope (Zeiss, Göttingen, Germany) and the images were taken using
an AxioCam MRm camera (Zeiss, Göttingen, Germany).
2.3. Sonic Hedgehog Stimulation, Cytokine Array and ELISA
Cells were incubated with 200 nM smoothened agonist (SAG) (Bioscience, Wiesbaden, Germany)
in the absence of FCS for 24 h for activating the Hedghog (Hh) pathway. Immunofluorescence
line-scan-based analysis and quantitative RT-PCR analysis were then performed [15].
For cytokine measurement, visceral and subcutaneous ASC in passage 3 were cultured for three
days to a confluence of 90% and supernatants were taken. The levels of chemokines, cytokines, and
growth factors in the supernatants were determined by applying a human cytokine antibody array
according to the manufacturer’s instructions (R&D, Wiesbaden, Germany). The chemiluminescent
membranes were developed using the ChemiDocTM MP System (Bio-Rad, Munich, Germany) and the
signal intensity was assessed with ImageJ 1.49i software (National Institutes of Health, Bethesda, USA)
7
Cells 2019, 8, 1288
by determining the pixel intensity of the detected spots. The signal value from the provided negative
control was subtracted from every measured sample [13].
The 72 h supernatants of visceral or subcutaneous ASCs were also used for evaluating IL-6, IL-8,
and TNFα via ELISA, as instructed by the manufacturers (PeproTech, Hamburg, Germany).
2.4. Cell Cycle Analysis and Cell Proliferation
The cell cycle distribution was analyzed using a FACSCaliburTM (BD Biosciences, Heidelberg,
Germany), as reported [20]. Briefly, cells were harvested, washed with PBS, fixed in chilled 70% ethanol
at 4 ◦C for 30 min., treated with 1 mg/mL of RNase A (Sigma-Aldrich, Munich, Germany) and stained
with 100 μg/mL of propidium iodide (PI) for 30 min. at 37 ◦C. DNA content was determined.
Cell proliferation assays were carried out by using Cell Titer-Blue® Cell Viability Assay (BD
Biosciences, Heidelberg, Germany) on treated cells in 96-well plates (Promega, Mannheim, Germany).
20 μL of CellTiter-Blue® reagent was added to each well and then incubated at 37 ◦C with 5% CO2
for 4 h before fluorescence reading while using a Victor 1420 Multilabel Counter (Wallac, Finland), as
reported [20].
2.5. ASC Differentiation And Western Blot Analysis
ASC differentiation was performed, as reported [13]. ASCs were cultured with StemMACS
AdipoDiff media (Miltenyi Biotec, Gladbach, Germany) up to 14 days to induce adipogenic
differentiation. Cells were then fixed and stained for adiponectin (Abcam, Cambridge, #ab22554) and
analyzed for lipid droplets characteristic of adipocytes. For osteogenic differentiation, ASCs were
incubated with StemMACS OsteoDiff media (Miltenyi Biotec, Gladbach, Germany) up to 14 days,
fixed, and stained with 2% Alizarin Red S (pH 4.2) to visualize calcific deposition, a hallmark of
osteogenic cells.
Western blot analysis was performed, as reported [21,22], with the following antibodies: mouse
monoclonal antibodies against cyclin B1 (Santa Cruz Biotechnology, Heidelberg, Germany, GNS1),
monoclonal mouse against p53 (Santa Cruz Biotechnology, Heidelberg, Germany, DO-8), and rabbit
polyclonal antibodies against cyclin B1 (Santa Cruz Biotechnology, Heidelberg, Germany, H-433), mouse
monoclonal antibodies against p21 (Cell Signaling, Frankfurt, Germany, DSC60), rabbit monoclonal
antibodies against E-cadherin (Cell Signaling, Frankfurt, Germany, 24E10), mouse monoclonal
antibodies against vimentin (Dako, Hamburg, Germany, M0725), rabbit monoclonal antibody against
fibronectin (BD Biosciences, 1573-1), mouse monoclonal β-actin (A2228) (Sigma-Aldrich, Munich,
Germany), and GAPDH (GTX627408) from GeneTex (Eching, Germany).
2.6. RNA Extraction And Real-Time PCR
Total RNAs of ASCs were extracted with RNeasy Mini kit (7Bioscience, Neuenburg, Germany).
Reverse transcription was performed while using High-Capacity cDNA Reverse Transcription Kit
(Promega, Mannheim, Germany), as instructed. All the probes for gene analysis were obtained from
Applied Biosystems: ADIPOQ (#Hs00605917_m1), IL-6 (#Hs00985639_m1), IL-8 (#00175123_m1), IL-10
(#Hs00961622_m1), TNFα (Hs00174128_m1), PLK1 (#Hs00153444_m1), PLK4 (#Hs00179514_m1),
KIF2A (#Hs00189636_m1), SMO (#Hs01090242_m1), GLI1 (#Hs00171790_m1), NANOG
(#Hs04260366_g1), PTCH1 (#Hs00181117_m1), RUNX2 (#Hs01047973_m1), KLF4 (#Hs00358836_m1),
c-MYC (#Hs00153408_m1), PPARγ (#Hs01115513_m1), LEPTIN (#Hs00174877_m1), SOX2
(#Hs01053049_s1), EpCAM (Hs0090188s_m1), VIM (#Hs00958111_m1), SNAIL1 (Hs00195591_m1),
TWIST (Hs01675818_s1), ZEB1 (Hs01566408_m1), and GAPDH (#Hs02758991_g1). Real-time PCR was
performed with a StepOnePlus Real-time PCR System (Applied Biosystems). The data were analyzed
while using StepOne Software v.2.3 (Applied Biosystems), as described previously [23].
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2.7. Cell Motility, Migration, Attraction, and Invasion
For motility assay, the cells were seeded into 24-well plates with a low confluency and they
were imaged for 12 h at 5 min. time intervals. All time-lapse imaging was performed with an
AxioObserver.Z1 microscope (Zeiss, Göttingen, Germany) and imaged with an AxioCam MRc camera
(Zeiss, Göttingen, Germany) that was equipped with an environmental chamber to maintain proper
environmental conditions (37 ◦C, 5% CO2). The time-lapse movies were analyzed by using ImageJ
1.49i software (National Institutes of Health) with the manual tracking plugin, and Chemotaxis and
Migration Tool (Ibidi GmBH, Munich, Germany). The tracks were derived from raw data points and
they were plotted in GraphPad Prism 7 (GraphPad software Inc.). The accumulated distance was
calculated by using the raw data points by the Chemotaxis and Migration Tool. Thirty random cells per
experiment were analyzed and the experiments were independently repeated three times. The patterns
of motility were evaluated, as described previously [15,16,24].
Cell migration assays were performed with culture-inserts from ibidi (Martinsried, Germany).
Visceral or subcutaneous ASCs (6.5 × 104) cells were seeded in each well of the culture-inserts.
Culture-inserts were gently removed after at least 8 h. The cells were acquired and imaged at indicated
time points with bright-field images. Four pictures of each insert were taken (three inserts for each
experimental condition) and the experiments were performed in triplicates. The open area was
measured while using the AxioVision SE64 Re. 4.9 software (Zeiss, Göttingen, Germany).
For attraction assay, cells were placed in six-well plates and one well of each insert was filled with
visceral or subcutaneous ASCs (5.5 × 104) or with the investigated cells (MCF-7 or MDA-MB-231).
After 8 h, the culture-inserts were removed and the images were obtained at the indicated time points.
Cellular movement toward other migration front was evaluated by measuring the distance between
the cell nucleus and the outermost cellular protrusion using the AxioVision SE64 Re. 4.9 software
(Zeiss, Göttingen, Germany). The experiments were independently performed three times.
Visceral or subcutaneous ASCs were seeded (7.5 × 104) in 24-well transwell matrigel chambers for
invasion assay, according to the manufacturer’s instructions (Cell Biolabs Inc, San Diego), as previously
reported [13]. The cells were fixed with ethanol and stained with DAPI. The invaded cells were counted
with a microscope. The experiments were independently performed three times.
2.8. Statistical Analysis
Student’s t-test (two tailed and paired or homoscedastic) was used to evaluate the significance
of difference between different groups for gene analysis, cell viability assay, cell cycle distribution,
and ciliated cell population. An unpaired Mann–Whitney U test was used to perform the statistical
evaluation of the single cell tracking assay, line-scan analysis, and the measurement of the cilium
length (two tailed). Difference was considered to be statistically significant when p < 0.05.
3. Results
3.1. Subcutaneous and Visceral ASCs Have a Comparable Cell Surface Marker Profile and Proliferation Rate
For this study, subcutaneous and visceral ASCs were isolated from age and BMI matched donors
undergoing Caesarean sections. Table 1 lists the clinical information.
Table 1. Clinical information of 16 participants.
Age Gestational Age (weeks) Body Mass Index (BMI) Birth Weight (g)
mean value 31.6 ± 4.6 37.7 ± 2.8 24.1 ± 2.9 2964 ± 581
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Figure 1. Subcutaneous and visceral adipose-derived mesenchymal stem cells (ASCs) display comparable
cell surface marker profiles, cell cycle distribution and cell proliferation. (A) Immunofluorescence staining
of mesenchymal stem cell surface markers CD90 (green) and CD73 (red), and DNA (DAPI, blue)
in subcutaneous ASCs (ASCsub) and visceral ASCs (ASCvis). Scale: 20 μm. (B) Flow cytometric
analyses of positive cell surface markers CD90, CD73, CD146, and CD105, and negative markers CD14,
CD31, CD106, and CD34 for mesenchymal stem cells (MSCs). Values represent the percentages of
ASCs expressing the indicated protein. The results from eight independent experiments (donors) are
presented as mean ± standard error of the mean (SEM). (C,D) Cell cycle distribution was analyzed
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using a FACSCaliburTM. Profile examples were shown (C). Cell cycle phases of ASCs were presented
in percentage and the results were derived from four independent experiments (D). (E,F) ASCs
were stained for pHH3 (S10) (green), α-tubulin (yellow), pericentrin (red) and DNA (blue), and
representatives are shown (E). Scale: 10 μm. pHH3 positive cells were quantified in ASCsub and
ASCvis (F). The results are from three independent experiments with ASCs from three different donors
and presented as median ±min/max whiskers in box plots. n.s. > 0.05. (G) Cellular extracts from ASCs
were prepared for Western blot analyses with indicated antibodies. β-actin served as loading control.
(H) ASCs were seeded in 96-well plates for 0, 24, 48, 72, and 96 h. Cell viability was measured via
CellTiter-Blue® assay. The results are presented as mean ± SEM and statistically analyzed, showing no
significant difference (n.s.).
The expression of cell surface markers was compared between subcutaneous ASCs (ASCsub) and
visceral ASCs (ASCvis). The indirect immunofluorescence staining of CD90 and CD73, two important
markers for mesenchymal stem cells (MSCs), including ASCs, showed positive signals to a comparable
extent in both types of ASCs (Figure 1A). This was further underscored by flow cytometric analyses of
CD90, CD73, CD146, and CD105 as positive markers and CD14, CD31, CD106, and CD34 as negative
markers (Figure 1B), as described [25,26]. The percentages of cell surface markers were comparable
between ASCsub and ASCvis (Figure 1B). Additionally, the cell cycle distribution of both ASC subtypes
differed by only 3% in G0/G1-phase (ASCsub: 72%, ASCvis: 69%) and G2/M-phase (ASCsub: 18%,
ASCvis: 15%) (Figure 1C,D). Furthermore, the cells were stained for phospho-histone H3 (pHH3
(Ser10)) (Figure 1E), a mitotic marker, for the evaluation of mitotic cells. No significant difference in
the mitotic cell population was observed between two subtypes of ASCs (Figure 1F). ASCs were also
harvested for Western blot analysis. The important mitotic proteins cyclin B1 and Aurora A showed no
differences in their protein expression (Figure 1G, lane 1 and 2), whereas the cellular stress response
proteins p53 and p21 were slightly elevated in visceral ASCs (Figure 1G, lane 4 and 5). Finally, the
subcutaneous ASCs showed marginally increased cell viability upon 72 h and 96 h, which could not
reach a significant level (Figure 1H, 72 h and 96 h). In summary, the results reveal no significant
differences between matched ASCsub and ASCvis cells in the expression of their cell surface markers,
cell cycle distribution, important mitotic regulators, and cell viability.
3.2. Both ASC Subtypes Display Comparable Migration and Invasion Rates but Different Modes of Motility
An important function of MSCs, to which ASCs belong, is their migration and homing ability
to a target tissue or cell type [27]. Several assays were performed with ASCsub and ASCvis to
investigate this issue in detail. At first, wound healing/migration assays were carried out, as previously
described [13]. After 16 and 24 h, ASCsub cells showed a significantly increased migration capacity
when compared to ASCvis (Figure 2A,B). Surprisingly, this pattern could not be observed in a single-cell
tracking experiment, which analyzes the random movement of cells up to 12 h, as reported [14].
The results illustrated even a slightly increased accumulated distance in visceral ASCs with 523 μm
as compared to 449 μm in subcutaneous ASCs (Figure 2C, left graph, and D). As calculated by time
and distance, the velocity of these cells was also moderately elevated (ASCvis: 0.78 μm/min., ASCsub:
0.67 μm/min.) (Figure 2C, middle graph). In contrast, the intrinsic directionality of ASCvis was
significantly reduced when compared to ASCsub (ASCvis: 0.23 d/D, ASCsub: 0.62 d/D) (Figure 2C,
right graph), indicating that the ASCsub cells move in a directed fashion. To study the motility in a
three-dimensional (3D) environment, invasion assays were carried out [13]. Interestingly, 39.6% of
ASCsub and 40.3% of ASCvis were able to invade through the matrigel layer (Figure 2E,F) and no
significant difference (p = 0.49) could be observed between both subpopulations.
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Figure 2. Both ASC subtypes display a comparable motility rate, but subcutaneous ASCs have a
significantly higher directed migration capacity. (A,B) Wound healing/migration assays were performed
with subcutaneous and visceral ASCs, and images were taken at indicated time points (0, 8, 16, 24 h) to
document the migration front. (A) Representatives are shown. White dashed line depicts the migration
front. Scale: 300 μm. (B) Quantification of the open area between both migration fronts at various time
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points. The cell-free area at 0 h was assigned as 100%. The results from three independent experiments are
presented as mean± SEM. *** p< 0.001. (C,D) Time-lapse microscopy was performed with subcutaneous
or visceral ASCs for up to 12 h. Random motility of these cells was analyzed. (D) Representative
trajectories of individual cells (n = 30) are shown. (C) Evaluated accumulated distance (left), velocity
(middle), and directionality (right) from three independent experiments are shown as box plots with
variations. Unpaired Mann–Whitney U-test, * p < 0.05, *** p< 0.001. (E,F) Invasion assay. ASCs were
seeded into transwells and starved for 12 h. The cells were released into fresh medium for 24 h and
fixed for quantification. (E) Quantification of invaded cells per field in percent. The results from three
independent experiments are presented as mean ± SEM. Student’s t test was performed showing no
significant difference (n.s. > 0.05). (F) Representatives of invaded ASCs are shown. Scale: 25 μm.
(G,H) Homing assays. ASCs and breast cancer cells were seeded in separated chambers of a culture
insert and cultured for 0, 8 and 15 h. (G) Evaluation of cell homing distance, the length between the
nucleus and the outermost cell protrusion, in subcutaneous and visceral ASCs toward MCF-7 cells
(left), MDA-MB-231 cells (middle), and ASC themselves (right). Each experiment was performed in
triplicate, and the results are based on three independent experiments and presented as scatter plot
showing mean ± SEM. (red dashed line indicates median value of ASCsub). ** p < 0.01, *** p < 0.001.
(H) Representatives of ASCs on both migration fronts stained against phalloidin (red) and DAPI (blue)
are depicted. White bars indicate cellular protrusion length. Scale: 50 μm.
Many studies have reported a tropism of ASCs toward cancer cells [28], which can be demonstrated
via homing experiments [13]. Homing experiments were performed with ASCs and breast cancer
cells seeded in separated chambers of a culture insert with a defined cell free gap to corroborate the
observation that ASCsub cells move in a more directed fashion compared to ASCvis. We measured the
cell homing distance, the length between the nucleus, and the outermost cell protrusion, including
lamellipodia and filopodia, of ASCs toward distinct breast cancer cell lines MCF-7 and MDA-MB-231
demonstrating the tropism of ASCs at 8 h and 16 h. ASCsub showed a significantly increased
homing ability after 8 h and 15 h toward MCF-7 and MDA-MB-231 cell lines as compared to ASCvis
(Figure 2G, left and middle graphs). Interestingly, subcutaneous ASCs home even to their own cell
type (Figure 2G,H, right graphs). In contrast, visceral ASCs were homing less efficiently toward other
cell types (Figure 2G,H). Collectively, these results strongly suggest that subcutaneous ASCs have
an extraordinarily directed mode of motility, whereas visceral ASCs seem to move in an undirected
random fashion.
3.3. Subcutaneous ASCs Display Higher Gene Levels of Mesenchymal Transcription Factors and Have More
Dynamic and Composition Altered FAs Compared to Visceral ASCs
Both subtypes of ASCs displayed distinct morphologies that are shown by staining with phalloidin,
an actin cytoskeleton dye, and paxillin, a focal adhesion marker, especially in their early 3–4 passages.
Subcutaneous ASCs were more “classical” mesenchymal-like, showing characteristics of a fibroblast-like
morphology with a small and long cell body (Figure 3A, upper panel). Visceral ASCs were less
mesenchymal-like with some likeness of apical-basal polarity and a large cell body (Figure 3A, lower
panel). Western blot analyses corroborated this notion, by showing less protein levels of fibronectin and
vimentin (Figure 3B, lane 1 and 3), mesenchymal cell markers, and higher levels of E-cadherin (Figure 3B,
lane 2), an epithelial cell marker, in visceral ASCs as compared to subcutaneous ASCs (Figure 3B).
In line with these data, the gene levels of zinc finger E-box-binding homeobox 1 (ZEB1), snail family
transcriptional repressor 1 (SNAIL1), and twist family basic helix-loop-helix (bHLH) transcription
factor 1 (TWIST), three important mesenchymal transcription factors, were enriched in ASCsub when
compared to ASCvis (Figure 3C). Moreover, the epithelial cell adhesion molecule (EpCAM) gene was
more demonstrative in ASCvis, while the expression of mesenchymal gene vimentin (VIM) encoding a
type III intermediate filament was higher in ASCsub (Figure 3D, left) (Figure 3D, right). These results
suggest that subcutaneous and visceral ASCs differ in the expression of mesenchymal and epithelial
markers contributing to the different migration behavior of these cells (Figures 2 and 3A–D).
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Figure 3. Subcutaneous ASCs show a typical mesenchymal-like phenotype compared to their visceral
counterparts. (A) Immunofluorescence staining of ASCsub and ASCvis. ASCs were stained for
phalloidin (green), paxillin (red) and DNA (blue) to underline their cell morphology. Examples are
shown. Scale: 25 μm. (B) Cellular extracts from ASCs were prepared for Western blot analyses
with antibodies against β-actin, E-cadherin, fibronectin and vimentin. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) served as loading control. (C,D) Gene levels of mesenchymal associated
transcription factors and cytoskeleton proteins ZEB1, SNAIL, TWIST, VIM, and EpCAM are shown
for subcutaneous and visceral ASCs. The results are from three experiments, presented as RQ with
minimum and maximum range. RQ, relative quantification of gene expression. Student’s t test,
∗ p < 0.05. (E–K) The focal adhesion composition was analyzed by staining ASCs for focal adhesion
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kinase (FAK) (green), p-FAK (red), and DNA (DAPI, blue), or for p-paxillin (red), paxillin (green) and
DNA (DAPI, blue) for fluorescence microscopy. Quantification of the mean fluorescence intensity of
FAK (E), p-FAK (F), paxillin (G) p-paxillin (H), and focal adhesion area (I) in ASCsub versus ASCvis (at
least 200 FAs per staining). The results are based on three independent experiments and presented
as scatter plot showing mean ± SEM. Unpaired Mann–Whitney U-test, ** p < 0.01, *** p < 0.001. a.u.,
arbitrary units. Representatives are depicted (J,K). Scale: 25 μm.
The FAs of both ASC types were analyzed in depth by immunofluorescence staining of focal
adhesion kinase (FAK), phospho-FAK (p-FAK), paxillin, and p-paxillin (Figure 3E–K), the most
important components of FAs, since the protein expression, phosphorylation status, and the FA
composition are influenced by a variety of transcription factors, including TWIST, SNAIL1, and
ZEB1 [29,30]. Though showing no difference in p-paxillin signal, subcutaneous ASCs displayed
significantly less mean fluorescence intensity of FAK (88 a.u.), p-FAK (123 a.u.), and paxillin (60 a.u.), in
comparison with visceral ASCs (FAK (123 a.u.), p-FAK (131 a.u.), and paxillin (68 a.u.)) (Figure 3E–K).
Furthermore, the size of FA correlates with its stability [31,32]. Indeed, the FA size was significantly
enlarged in ASCvis (ASCvis; 7.07 μm), relative to ASCsub (5.66 μm) (Figure 3I).
More FA components (Figure 3E–H) and enlarged FA size (Figure 3I) indicate altered FA dynamics
of visceral ASCs. We performed a nocodazole washout experiment to delineate this issue, in which MT
depolymerization induced by nocodazole leads to stabilized FAs through stress fiber formation and the
release from the nocodazole treatment triggers FA disassembly through rapid MT regrowth [33]. ASCs
were subjected to nocodazole (10 μM), released for 0, 30, and 75 min., stained for p-FAK and paxillin,
two important FA assembly factors, for microscopic evaluation (Figure 4A). Subcutaneous ASCs
dynamically responded to the nocodazole release evidenced by rapidly decreased paxillin, p-FAK, and
FA size at 30 min. Followed by efficiently recruiting these FA components, leading to enlarging FA
size at 75 min. (Figure 4B–E, left panels). In line with the observations (Figure 3F,H,I), visceral ASCs
showed high levels of paxillin and p-FAK and the large FAs, even after the cells were treated with
nocodazole (Figure 4B–E, right panels, 0 h). Furthermore, despite disassembled FAs being triggered by
the nocodazole release at 30 min., visceral ASCs had difficulty in reassembling their FAs at 75 min. by
showing low p-FAK level and small FA size (Figure 4B–E, right panels). In sum, these results clearly
suggest that visceral ASCs have stabilized FAs with a static turnover, whereas subcutaneous ASCs
confer dynamic FAs, which contributes to their efficiently directed motility.
3.4. Visceral ASCs Have a Higher Osteogenic and Adipogenic Differentiation Capacity and Upregulated Levels
of Stemness-Like Associated Genes
The differentiation capacity of ASCs that were isolated from different adipose tissue depots
is the subject of controversial debates over the last decade, with multiple investigations reporting
inconsistent results [5,6,11]. This could be ascribed to the usage of ASCs that were isolated from
distinct donors with varied age, BMI, and gender, different isolation methods or varying ASC passages.
We used matched ASCs from the same donor and in identical passage for differentiation experiments.
We first analyzed multiple classical stemness/self-renewal associated genes, like myelocytomatosis
proto-oncogene cellular homolog (c-MYC), SRY-box transcription factor 2 (SOX2), Krüppel-like factor
4 (KLF4), and NANOG, which are also known for their crucial role in osteogenic and adipogenic
differentiation of ASCs [34–36]. In fact, ASCvis showed a significantly higher expression of stemness
associated genes, like c-MYC, SOX2, KLF4, and NANOG, when compared to ASCsub (Figure 5A).
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Figure 4. Subcutaneous ASCs dynamically disassemble and reassemble their FAs. (A) Schedule of
the nocodazole washout assay. (B) ASCs were incubated for 5 h with 10 μM nocodazole followed by
washout, where the microtubules (MTs) were allowed to regrow for 0, 30 and 75 min. Cells were stained
for paxillin (green), p-FAK (red), and DNA (DAPI, blue). Representatives of FA disassembly/reassembly
are shown. Scale: 15 μm. (C–E) Kinetics of FA disassembly during MT regrowth and FA reassembly
after MT regrowth. Quantification of the mean fluorescence intensity of paxillin (C), p-FAK (D), and
FA size (E) (270 FA per condition) is depicted. The results are based on three independent experiments
and presented as scatter plots showing mean ± SEM. Unpaired Mann–Whitney U-test, ** p < 0.01,
*** p < 0.001. a.u., arbitrary units.
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Figure 5. Visceral ASCs are superior in osteogenic and adipogenic differentiation compared to
subcutaneous ASCs. (A) Gene levels of stemness/self-renewal associated genes c-MYC, SOX2, KLF4,
and NANOG are shown for subcutaneous and visceral ASCs. The results are from three experiments,
presented as RQ with minimum and maximum range. Student’s t test, ∗ p < 0.05, ** p < 0.01. (B–D)
ASCsub and ASCvis cells were induced into osteogenic differentiation for up to 14 days. The percentage
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of differentiated ASCs was evaluated by Alizarin Red S staining. (B) The quantification data are
presented as median ±min/max whiskers (red dashed line indicates median value of ASCsub, n = 300
cells for each condition, pooled from three experiments). Student’s t test, ∗ p < 0.05. (C) Example images
for Alizarin Red S staining are shown. Scale: 20 μm. (D) Expression levels of differentiation related
genes PTCH1 (1st graph), RUNX2 (2nd graph), KLF4 (3rd graph), and c-MYC (4th graph) in differentiated
subcutaneous and visceral ASCs. The results are from three experiments and presented as RQ with
minimum and maximum range. Student’s t test, ∗ p < 0.05, ** p < 0.01. (E–G) Analyses of cells with
lipid vacuoles after 14 days of adipogenic differentiation. (E) The quantification shows the percentage
of cells differentiated into adipogenic-like cells. Results are presented as median ±min/max whiskers
in visceral ASCs (n = 200 cells for each condition, pooled from three experiments) and the red dashed
line illustrates the median value of ASCsub. Student’s t test, ∗ p < 0.05. (F) Representative images of
cells displaying lipid vacuoles stained for adiponectin (red) and DNA (DAPI, blue). (G) Gene levels of
ADIPOQ, LEPTIN, and PPARγ after adipogenic differentiation are shown for subcutaneous and visceral
ASCs. The results are from three experiments, presented as RQ with minimum and maximum range.
Student’s t test, ∗ p < 0.05.
ASCs were then differentiated to osteocytes or adipocytes for up to 14 days. The cells were stained
with Alizarin Red S to visualize calcific deposition (osteogenic lineage) or adiponectin (adipogenic
lineage). Relative to ASCvis (Figure 5C,F, lower panels), ASCsub showed lower numbers of positive
cells that were stained with Alizarin Red S (Figure 5C, upper panel) or adiponectin (Figure 5F, upper
panel). Further analysis revealed that, as compared to visceral ASCs with 24.4% osteogenic-like
and 45.5% adipogenic-like cells, subcutaneous ASCs displayed 15.7% osteogenic-like and 35.6%
adipogenic-like cells (Figure 5B,E). Total RNAs from these cells were also isolated for gene analysis.
ASCvis showed enhanced levels of osteogenic related genes, including protein patched homolog 1
(PTCH1) and runt-related transcription factor (RUNX2) (Figure 5D, 1st and 2nd graph), as well as c-MYC
(Figure 5D, 3rd graph). Interestingly, KLF4, which is a negative regulator for osteogenic differentiation,
was upregulated in subcutaneous ASCs after differentiation (Figure 5D, 4th graph). Similar results
were also obtained for adipogenic differentiation. Adiponectin (ADIPOQ), LEPTIN, and peroxisome
proliferator activated receptor gamma (PPARγ), three adipogenic related genes, were increased in
ASCvis upon differentiation (Figure 5G). These data strengthen the notion that visceral ASCs have an
improved differentiation capability that is likely associated with a higher gene expression of stemness
associated genes.
3.5. Subcutaneous ASCs are More Ciliated but Have A Less Active Sonic Hedgehog (Hh) Pathway
The primary cilium is a sensor organelle that is critical for responding to a variety of extra
and intracellular stimuli as a central processing unit [37]. It is connected to many key functions of
ASCs, like migration, secretion, and differentiation [38,39], and indispensable for the Hh signaling
in mammals [40]. To compare the cilium size as well as the ciliated cell population between ASCsub
and ASCvis, the cells were stained for acetylated α-tubulin, adenosine diphosphate ribosylation
factor-like GTPase 13B (Arl13b), two typical cilium markers, and DNA followed by microscopic
analysis (Figure 6A). The primary cilium size was comparable between both ASC subtypes with a
mean cilium length of 4.61 μm in ASCsub and 4.60 μm in ASCvis (Figure 6A,B). While 28.6% of visceral
ASCs were ciliated, the primary cilium was present in 43.9% of subcutaneous ASCs (Figure 6C). In line
with less ciliated cells, the gene levels of Polo-like kinase 1 (PLK1), Polo-like kinase 4 (PLK4), and
kinesin family member 2A (KIF2A), genes that are responsible for deciliation and here independent
from their roles in mitosis, are upregulated in visceral ASCs (Figure 6D).
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Figure 6. Visceral ASCs display high deciliation gene levels and enhanced activation of the sonic
hedgehog (Hh) signaling pathway. (A) Primary cilia of ASCsub and ASCvis were stained for acetylated
α-tubulin and Arl13b. Representatives are shown. Scale: 10 μm. Regions outlined in boxes are shown
in a higher magnification. Inset scale: 10 μm. (B) The cilium length was evaluated. The results are
based on six experiments using ASCs from six donors (n = 180 cilia for each group). (C) Ciliated ASCs
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were evaluated and the results are presented as mean± SEM (n= 600 cells, pooled from six experiments).
Unpaired Mann–Whitney U-test, * p < 0.05. (D) The gene levels of deciliation regulators PLK1, PLK4,
and KIF2A. The data are based on three experiments and presented as RQ with minimum and
maximum range. Student’s t test, ∗ p < 0.05, ** p < 0.01. (E–G) Fluorescence intensities and expression
levels of important genes related to the Hh pathway are shown for ASCs treated with SAG for 24 h.
(E) Each point of the curve represents the mean fluorescence intensity (mean ± SEM) based on three
experiments (n = 30 cilia). Unpaired Mann–Whitney U-test, * p < 0.05. (F) Representatives are shown
for measurements of primary cilium staining of acetylated α-tubulin, Arl13b and Smoothened (Smo).
Scale: 3 μm. (G) The gene levels of GLI1, PTCH1, NANOG, SMO, and TP53 are shown for ASCs treated
or non-treated with 200 nM SAG for 24 h. The results are from three experiments, merged as biological
group, and presented as mean ± SEM. Student’s t test, ∗ p < 0.05, ** p < 0.01.
The Hh signaling pathway is exclusively mediated by the primary cilium and it is involved in
the differentiation processes of multiple types of various stem/mesenchymal stem cells, including
ASCs [38,41]. The activation of the Hh pathway is a signaling cascade recruiting Smoothened (Smo)
and glioma-associated oncogene homolog 1–3 (Gli1-3) to the primary cilium, which leads to an
accumulation of these proteins on the proximal base and distal tip of the cilium [42]. ASCs were treated
with 200 nM of SAG, a smoothened agonist, for 16 h, to compare the activation and response of this
pathway between both subtypes. The treated ASCs were stained for Arl13b, Smo, and pericentrin
for microscopy. Line scan analysis of fluorescent Smo was performed from the proximal base to the
distal tip of cilia (Figure 6F). Subcutaneous ASCs demonstrated a significantly lowered intensity of
Smo on the proximal as well as the distal part of the primary cilium when compared to visceral ASCs
(Figure 6E), which suggests the hampered recruitment of Smo to the cilium in ASCsub. Furthermore,
gene analysis revealed a significantly lower expression of Hh related genes GLI1, PTCH1, SMO, and
two downstream targets TP53 and NANOG after 24 h SAG stimulation in subcutaneous ASCs relative
to visceral ASCs (Figure 6G). The less active Hh signaling could be an additional explanation for the
reduced adipogenic/osteogenic differentiation capacity of subcutaneous ASCs.
3.6. Visceral ASCs Secrete More Inflammatory Cytokines
MSCs, especially ASCs, are well known as a source of many secreted cytokines, chemokines, and
growth factors regulating diverse cell-cell communications [43]. As reported previously, we analyzed
the secretion of multiple factors from ASCsub and ASCvis by using a cytokine array demonstrating
the secretion of various inflammation cytokines [13]. To corroborate these results, the concentrations of
interleukin 6 (IL-6), interleukin 8 (IL-8), and tumor necrosis factor α (TNFα) were measured in the
supernatant of both ASC subtypes by enzyme-linked immunosorbent assay (ELISA). Subcutaneous
ASCs secreted significantly less of all three inflammatory cytokines, with 186 pg/mL of IL-6, 676 pg/mL
of IL-8, and 111 pg/mL of TNFα when compared to 236 pg/mL of IL-6, 761 pg/mL of IL-8, and 194
pg/mL of TNFα secreted by ASCvis (Figure 7A). In support of these observations, the gene levels of IL-6,
IL-8, IL-10, and TNFαwere higher in visceral ASCs as compared to subcutaneous ASCs (Figure 7B).
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Figure 7. Visceral ASCs secrete more pro-inflammatory cytokines. (A) The supernatants of subcutaneous
and visceral ASCs in the third passage were collected after 72 h culture and used for evaluation of IL-6
(left), IL-8 (middle) and TNF-α (right) by enzyme-linked immunosorbent assay (ELISA). The results
are from four experiments and presented as median ± min/max whiskers in box plots. Student’s t
test, ∗ p < 0.05, ** p < 0.01. (B) The gene levels of IL-6, IL-8, IL-10, and TNFα. The data are based
on three experiments and presented as RQ with minimum and maximum range. Student’s t test,
∗ p < 0.05. (C) Schematic illustration of the proposed similarities and dissimilarities between both ASC
subtypes. The key dissimilarities between subcutaneous and visceral ASCs are their migration mode,
differentiation capacity, and cytokine secretion, which affect a variety of different pathways, like the Hh
signaling on the primary cilium.
4. Discussion
ASCs have gained high attention as a promising tool for novel cell-based therapies in the field of
regenerative medicine, supported by multiple encouraging preclinical studies in a variety of human
diseases [44,45]. However, the diversity among ASCs that were isolated from different adipose tissue
depots affects their biological functions and features [5,6,11]. In this work, we have isolated ASCs from
subcutaneous and visceral adipose tissue of the same donors and systematically characterized multiple
features of these paired ASCs in detail.
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The results show that both subcutaneous and visceral ASCs display relatively comparable
percentages of cells positive for cell surface markers, which are characteristic for MSCs [25]. Cell
viability, cell cycle distribution, and mitotic cell population are also similar between subcutaneous
and visceral ASCs, which is in agreement with the results from several groups [46–48] and yet
inconsistent with the data from other studies [11,49–51]. This discrepancy generally results from
non-matched donors and varied methodology for ASC isolation/culture. It is observed in many studies
that subcutaneous and visceral ASCs were derived from donors without further description of related
clinical information, like age, gender, and BMI, or from other species [46–50,52]. These heterogeneous
data underscore the requirement of matched donor collectives and standardized protocols. Although
it is reported that the proliferation rate of ASCs is hardly changed by the reproductive status [53], we
do not exclude the possibility that pregnancy related hormones influence some of ASC features.
One key feature of mesenchymal stem cells is their homing ability toward damaged tissue and
to serve in these areas as a reservoir for growth factors and regenerative promoters [54]. We showed
that, relative to visceral ASCs, subcutaneous ASCs have a more directed mode of motility, evidenced
by single-cell tracking, and especially homing assays, in which ASCs move toward different cell
lines, like MCF-7, MDA-MB231, or themselves. Moreover, subcutaneous ASCs display a classical
mesenchymal phenotype with a spindle-like form and a small cell body, whereas visceral ASCs show
a large cell body and some likeness of an “apical-basal polarity” [55]. In line with these findings,
well-known mesenchymal markers, like fibronectin and vimentin, as well as genes of mesenchymal
related transcription factors, including SNAIL, SLUG, TWIST, and ZEB1, were low in visceral ASCs.
This could contribute to the decreased directional movement of visceral ASCs, since an increased
mesenchymal phenotype correlates with an enhanced directional motility, as reported for multiple cell
lines during the process of the epithelial-to-mesenchymal transition (EMT) [56,57]. The analyses of
important FA proteins illustrate a more complex pattern: FAK, p-FAK, and paxillin were significantly
higher in visceral ASCs, which is often associated with efficient cellular migration [58]. However, FA
size is related to the migration rate and the residence time of FAK and paxillin [31,32]. Indeed, visceral
ASCs displayed highly enlarged FAs, as shown in cells switching from an epithelial to mesenchymal
phenotype [30], which implies an accumulation of these proteins mediated by a slower FA turnover rate
in visceral ASCs. This assumption was further corroborated by the data from the nocodazole washout
assay, illustrating more dynamic FAs in subcutaneous ASCs with a higher rate of FA disassembly and
reassembly after the nocodazole release as compared to visceral ASCs.
In conclusion, we show that subcutaneous ASCs conduct a more directional movement that
is associated with an efficient FA turnover than visceral ASCs, though both subtypes move with
comparable rates. This difference could be likely ascribed to their different origins [59] with distinct
biological functions. An enhanced homing ability might be important to execute the protective and
cell renewal functions of the subcutaneous AT [6], whereas the visceral AT is important in controlling
metabolism and inflammatory signals [5], which are less dependent on the homing/migration ability of
these cells.
In agreement with this notion, visceral ASCs secreted high levels of different chemokines/cytokines
that are involved in autocrine and paracrine regulation. Among these cytokines, IL-6, IL-8, and TNFα
were highly secreted by visceral ASCs, which is in line with the results that were derived from a recent
report [60]. This substantial secretion of inflammatory cytokines is likely associated with their impact
on the surrounding cells and microenvironment, which was previously shown in breast cancer cell
lines MCF-7, MDA-MB-231, and non-tumorigenic breast epithelial cells, like MCF-10A [13,61].
Another characteristic property of ASCs is their capacity to differentiate into multiple cell types,
including osteocytes and adipocytes [8]. We found that visceral ASCs have an increased differentiation
potential toward the osteogenic and adipogenic lineage as compared to subcutaneous ASCs. This could
be ascribed to an enhanced gene expression of stemness/self-renewal associated genes c-MYC, KLF4,
NANOG, and SOX2, which are reported to be essential for the differentiation of MSCs/ASCs [35,36,62,63].
Especially, c-MYC has been shown to be crucial for the initiation of the adipogenic differentiation
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by regulating key genes, like fatty acid-binding protein 4 (FABP4), PPARγ, ADIPOQ, and LEPTIN in
ASCs [63]. These results are not consistent with data from other studies, showing that subcutaneous
ASCs are more competent in differentiation [50,64], again indicating the inconsistent results in this field.
Again, this might be attributable to species differences and non-matched donors. Additionally, we are
not able to exclude the impact of donors’ reproductive state, which might enhance this capability of
visceral ASCs, although Ng et al. have reported no significant differences between isolated ASCs from
pregnant, premenopausal, and menopausal donors [53].
Interestingly, an increased number of subcutaneous ASCs were ciliated, which could be associated
with their motility, as primary cilia are especially involved in directional migration [65]. However,
relative to visceral ASCs, subcutaneous ASCs displayed less activation of the sonic Hh pathway upon
stimulation, which is associated with less expression of its downstream targets. The Hh pathway
is important for differentiation, since a report showed that the removal of the primary cilia and
its associated Hh signaling leads to an increased ASC proliferation and decreased Runx2, alkaline
phosphatase, and bone morphogenetic protein-2 mRNA (BMP2) expression, finally reducing their
osteogenic differentiation potential [39]. Moreover, we have recently reported that the impaired
differentiation capacity of obese ASCs is rescuable through the restoration of the cilium length and the
sonic Hh pathway [16]. These data suggest that the less active Hh pathway in subcutaneous ASCs
could be linked to their lower differentiation ability.
5. Conclusions
This work demonstrates that the ASCs isolated from subcutaneous and visceral AT share some
characteristics, including their cell surface marker profile, cell viability, and cell cycle distribution, but
they differ in multiple key aspects, like motility, FA dynamics, secretion of inflammatory cytokines, the
expression of stemness related genes, differentiation capability, and primary cilia associated signaling
(Figure 7E). These data may be of help for cell-based therapeutic strategies in a wide spectrum of
diseases. Heterogeneous results in differentiation and proliferation emphasize the necessity for a
standardization of donor selection and matched donor collectives, ASC isolation, characterization, and
experimental protocols. Particularly, the donor age and BMI are reported to have great influence on
the proliferation and differentiation ability of ASCs. Further investigations are required for studying
the interactions of ASCs with their surrounding cells, like immune cells and fibroblasts, and to define
their biological functions and molecular mechanisms in vivo via animal models.
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Abstract: Lipomas are benign adipose tissue tumors of unknown etiology, which can vary in size,
number, body localization and cell populations within the tissue. Lipoma-derived stem cells (LDSCs)
are proposed as a potential tool in regenerative medicine and tissue engineering due to their similar
characteristics with adipose-derived stem cells (ADSCs) reported so far. Our study is among the first
giving detailed insights into the molecular signature and differences in the differentiation capacity
of LDSCs in vitro compared to ADSCs. Mesenchymal stem cell phenotype was analyzed by gene
expression and flow cytometric analysis of stem cell markers. Adipogenesis and osteogenesis were
analyzed by microscopic analysis, cytochemical and immunocytochemical staining, gene and protein
expression analyses. We showed that both LDSCs and ADSCs were mesenchymal stem cells with
similar phenotype and stemness state but different molecular basis for potential differentiation.
Adipogenesis-related genes expression pattern and presence of more mature adipocytes in ADSCs
than in LDSCs after 21 days of adipogenic differentiation, indicated that differentiation capacity of
LDSCs was significantly lower compared to ADSCs. Analysis of osteogenesis-related markers after
16 days of osteogenic differentiation revealed that both types of cells had characteristic osteoblast-like
phenotype, but were at different stages of osteogenesis. Differences observed between LDSCs and
ADSCs are probably due to the distinct molecular signature and their commitment in the tissue that
governs their different capacity and fate during adipogenic and osteogenic induction in vitro despite
their similar mesenchymal phenotype.
Keywords: lipomas; adipose tissue; stem cells; adipogenesis; osteogenesis
1. Introduction
Adipose-derived stem cells (ADSCs) are adult mesenchymal stem cells (MSCs) originated from
adipose tissue that show a great morphological and functional similarity with MSCs from bone marrow
but with additional advantages [1]. ADSCs can be isolated from abundant and easily accessible adipose
tissue in large quantities with a minimal invasive procedure either from liposuction aspirates or adipose
tissue biopsies [2] and have properties that make them good candidates for regenerative medicine
applications [3]. The use of ADSCs in tissue engineering and regenerative medicine is very promising
due to their self-renewal potential, proliferation capacity and great potential to differentiate into
numerous cell types particularly adipocytes, osteoblasts, chondrocytes and endothelial cells [4–7]. It is
reported that ADSCs can be successfully differentiated into the cells of all three germ lines which
means that they can be considered as pluripotent and makes them a good candidate for wide range
applications in the field of biomedical sciences [4].
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Lipomas are benign tumors of adipose tissue and represent one of the most common soft tissue
neoplasms of mesenchymal origin [8,9]. Lipomas can be solitary, multiple generalized lipomatosis and
multiple symmetric, usually slowly growing, diffused or encapsulated, can vary in size and shape and
show great heterogeneity in cell populations presented within the tissue [10,11]. The occurrence of
lipomas in all body parts has been reported, mostly in subcutaneous depots but also in other tissues,
organs and body cavities. Both male and female can be affected and all ages although they usually
appear in the middle age [9,12]. Several studies reported that lipoma tissue is a good source of stem
cells that might be used for regenerative medicine purposes, naming lipoma “useless tissue useful in
the application of regenerative medicine and tissue engineering” [13]. Isolation and characterization of
MSCs from lipoma, so called lipoma-derived stem cells (LDSCs) was reported and it has been shown
that those cells are very similar to ones isolated from normal adipose tissue [14]. It has been shown
that LDSCs can proliferate in a similar manner as ADSCs, express characteristic mesenchymal stem
cell markers and can differentiate into adipocytes, osteoblasts and chondrocytes like ADSCs [13,15,16].
There are, however, only few publications and studies that dealt with some of the LDSCs properties.
In almost all publications authors showed that LDSCs have the same potential to differentiate into
osteoblasts and adipocytes as ADSCs with very few reports on different proliferation potential and
characteristics of LDSCs compared to ADSCs [17]. Also, there are reports about formation of bone and
cartilaginous structures within lipoma tissue and its ossification in various parts of the body [18], with
considerations that stem cells from lipoma tissue may be responsible for those processes [19].
Bearing in mind that lipomas are adipose tissue tumors with insufficiently clarified etiology and
pathogenesis, and that transformations of lipoma tissue into hard tissue structures can occur, which
implies the role of LDSCs, as well as potential use of LDSCs in regenerative purposes reported so
far and lack of detailed comparison with ADSCs; the request and the need for further investigation
on molecular and cellular features of LDSCs arises, as potential cause of lipoma formation and their
possible application in regenerative medicine, as well as detailed comparison with ADSCs from normal
adipose tissue. To the best of our knowledge, our study is among the first giving detailed insights into
the molecular signature of LDSCs, with the first data on adipogenic- and osteogenic-related markers’
expression and comparison with ADSCs, as well as showing that LDSCs and ADSCs have different
characteristics particularly in the differentiation capacity in vitro. Here we presented the cellular and
molecular features and comparison of those two types of MSCs with special emphasis on adipogenic
and osteogenic differentiation capacity.
2. Materials and Methods
2.1. Patients
Lipoma tissue samples were obtained at surgical clinics of the Clinical Center Niš, Serbia after
surgical removal of solitary subcutaneous lipomas that were clinically and pathologically diagnosed
as lipoma and distinguished from other adipose tissue neoplasms. Subcutaneous adipose tissue
samples were obtained from non-cancer patients during other surgeries. All patients gave their
informed written consent and the study was approved by the Local Ethical Committee of the Faculty of
Medicine, University of Niš, Serbia (approvals no. 01-6481-15 and 12-6316-2/4). Tissue sample biopsies
from 14 patients were analyzed, among them 8 lipomas and 6 normal adipose tissue samples. Average
age of patients with lipoma was 48.3 ± 8.3 while average age of non-lipoma patients was 49.5 ± 11.1.
In the group of patients with lipoma, 5 were female and 3 were male, while in the non-lipoma group of
patients 4 were female and 2 were male. Lipomas and adipose tissue samples were taken from several
subcutaneous body depots: upper arm, back, neck, abdomen, hip and thigh. Body mass index (BMI)
for all patients was less than 30, indicated non-obese patients.
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2.2. Isolation and Cultivation of Mesenchymal Stem Cells
Both lipoma-derived stem cells (LDSCs) and adipose-derived stem cells (ADSCs) were isolated
by enzymatic digestion of tissue samples, respectively. Tissue samples were washed, cut into small
pieces and placed in 0.1% collagenase type I solution (StemCell Technologies, Vancouver, CO, Canada),
in a water bath at 37 ◦C for 45 min. Tissue homogenates were then vortex and filtered and cell
culture media was added to stop collagenase. Stromal vascular fraction (SVF) of cells was obtained
by centrifugation for 15 min at 1500 rpm, collected from the bottom of the tube and seeded in 25 cm2
cell culture flask (Greiner Bio One, Kremsmünster, Austria) in standard cell culture medium (DM)
that contained Dulbecco’s Modified Eagle’s medium (DMEM), 10% fetal bovine serum (FBS), 2 mM
stable glutamine and 1% antibiotic-antimycotic solution (all purchased from Capricorn Scientific,
Ebsdorfergrund, Germany). Cells were washed and media was changed 16–18 h after isolation to
remove non-attached cells. After reaching the 70–80% confluency, first cell passage was performed (P1),
which enabled purification of mesenchymal stem cells. Cells were cultured in standard cell culture
conditions which mean temperature of 37 ◦C and humidified atmosphere with the presence of 5% CO2.
Medium was changed every three days.
2.3. Differentiation of Cells
For differentiation assays, cells at passage 2 (P2) were used. Cells were passaged by using
0.25 U/mL dispase in DMEM/F-12 (StemCell Technologies, Vancouver, CO, Canada) and 0.05%
trypsin-EDTA solution (Capricorn Scientific, Ebsdorfergrund, Germany), centrifuged and cell
number was determined by Trypan blue dye exclusion assay on Countess™ automated cell counter
(Thermo Scientific, Waltham, MA, USA). For adipogenic differentiation assay, 5000 cells per cm2 were
seeded onto sterile glass coverslips in 24-well culture plates (Greiner Bio One, Kremsmünster, Austria)
and left to attach overnight. Medium in which cells were seeded was then replaced with adipocyte
differentiation media (AM) which was purchased from Gibco® (Carlsbad, CA, USA), (StemPro™
Adipogenesis Differentiation Kit) or standard cell culture media (DM). Cells were cultured in AM and
DM media up to 21 days. Media were changed every 3 to 4 days. For osteogenic differentiation assay,
3000 cells per cm2 were seeded onto sterile glass coverslips in 24-well culture plates and left to attach
overnight. Medium in which cells were seeded was then replaced with osteogenic differentiation
media (OS) or standard cell culture media (DM). Osteogenic differentiation media was prepared
by adding 0.1 μM of dexamethasone (D4902, Sigma, St. Louis, MO, USA), 50 μM L-ascorbic acid
2-phosphate (49752, Sigma) and 2 mM β-Glycerophosphate (AppliChem, Darmstadt, Germany) to the
DM medium. Cells were cultured in OS and DM media up to 16 days. Media were changed every 3 to
4 days in both assays and cells were cultured in standard cell culture conditions.
2.4. Light Microscopy
Cells after isolation, during differentiation studies and after staining were monitored on inverted
light microscope (Observer Z1, Carl Zeiss, Oberkochen, Germany), under phase contrast and bright
field. The images were acquired using the camera AxioCam HR (Carl Zeiss, Germany) and the software
ZEN 2 blue edition (Carl Zeiss, Germany).
2.5. Flow Cytometry
Expression of mesenchymal stem cell surface marker CD105 was analyzed on both LDSCs and
ADSCs, respectively, at P2 (before differentiation assays). After trypsinization, centrifugation and
washing, cells were stained for 15 min with PE conjugated monoclonal mouse anti-CD105 human
antibody (Clone 43A4E1, Miltenyi Biotec, Bergisch Gladbach, Germany) at 4 ◦C. After washing
steps, cells were re-suspended in a buffer and analyzed on BD LSRFortessa™ cell analyzer with BD
FACSDiva™ software v8 (BD Biosciences, Heidelberg, Germany). A total of minimum 100,000 cells
were usually acquired for each sample.
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2.6. RNA Isolation and Reverse Transcription
LDSCs and ADSCs at passage 2 (day 0 in differentiation assay), at day 21 in adipogenic
differentiation assay and days 8 and 16 in osteogenic differentiation assay were placed in RNAlater®
(Ambion, Life Technologies, Carlsbad, CA, USA) and stored at −80◦C until RNA purification
step. The total RNA was isolated from the cells using RNeasy Mini Kit (Qiagen, Venlo, The
Netherlands) according to the manufacturer’s instructions. DNase I RNase-free set (Qiagen) was used
for on-column digestion of residual genomic DNA, according to the manufacturer’s instructions. The
RNA concentration was determined immediately after isolation using Qubit™ RNA HS Assay Kit
(Thermo Scientific, Waltham, MA, USA) on Qubit® 2.0 fluorimeter (Invitrogen, Thermo Scientific,
Waltham, MA, USA), according to the manufacturer’s instructions. Total RNA was reversely
transcribed into single-stranded cDNA using High-capacity cDNA Reverse Transcription Kit (Applied
Biosystems®, Foster City, CA, USA), according to the manufacturer’s instructions, with 100 ng per
reaction per sample. Reverse transcription was performed in the PCR thermal cycler SureCycler8800
(Agilent Technologies, Santa Clara, CA, USA). The protocol conditions were: 10 min at 25 ◦C, 120 min
at 37 ◦C, 5 min at 85◦C and cooling at 4 ◦C. The synthesized cDNA was stored at −80 ◦C and was later
used as a template for qPCR to determine the relative gene expression.
2.7. Real Time PCR
Quantitative real time PCR reactions were performed by real time thermal cycler Stratagene
Mx3005P (Agilent Technologies, Santa Clara, CA, USA). The qPCR reactions were prepared by using
SYBR Fast Universal 2x qPCR Master Mix (Kapa Biosystems, Wilmington, MA, USA), according
to the manufacturer’s instruction. ROX was used as a reference dye. Pre-designed primer sets
(QuantiTect primer assay kits) were purchased from Qiagen, The Netherlands. Primer kits, consisted
of both forward and reverse primers, were used for the following genes: GAPDH (QT00079247),
CD44 (QT00073549), POU5F1 (QT00210840), BGLAP (QT00232771), RUNX2 (QT00998102), DLK1
(QT00093128), PPARG (QT00029841), LEP (QT00030261), and ADIPOQ (QT00014091). The protocol
conditions were: (1) enzyme activation: 3 min at 95 ◦C (1 cycle); (2) denaturation: 3 s at 95 ◦C and
annealing/extension (with data acquisition): 30 s at 60 ◦C (40 cycles). The specific binding of primers
was confirmed by melting curve analysis and specific length product visualization on electrophoresis
gel. The expression level of each target gene was normalized to the glyceraldehyde-3-phosphate
dehydrogenase housekeeping gene expression (GAPDH) in the same sample. The relative gene
expression data analysis was performed by the relative quantification method 2–ΔΔCt as described by
Livak and Schmittgen [20]. Human XpressRef Universal Total RNA (338112, Qiagen) was used as
calibrator for all qPCR reactions.
2.8. Oil Red O Staining
To assess the mature adipocytes’ formation after 21 days of adipogenic differentiation, the presence
of lipid droplets was analyzed by Oil Red O staining. LDSCs and ADSCs cells were fixed in 10%
neutral buffered formalin (NBF), washed, incubated for 3 min in 60% isopropanol and then Oil Red O
solution was applied for 15 min. After washing, cells were counterstained with Mayer’s hematoxylin
(Bio-Optica, Milan, Italy) for 1 min and imaged. Quantification of lipid droplets was performed by
dissolving the Oil red O dye in 100% isopropanol and measuring absorbance at 450 nm on multichannel
spectrophotometer (Multiskan Ascent plate reader, ThermoLab Systems, Helsinki, Finland).
2.9. Cytochemical Staining for Calcium Deposits
For the detection of calcium deposits in cells underwent osteogenic differentiation, Alizarin red S
(ARS) and Von Kossa staining was performed. After 16 days of osteogenic differentiation, LDSCs and
ADSCs were fixed in 10% NBF. Alizarin red S (A5533, Sigma-Aldrich, St. Louis, MO, USA) staining
solution at concentration 2% was applied to the cells and incubated for 45 min at room temperature
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(RT) in the dark. Cells were then washed and analyzed under the microscope. Quantification of
inorganic deposits was performed by dissolving ARS in 10% acetic acid solution and absorbance
measurement at 405 nm on plate reader. For Von Kossa staining, 2% silver nitrate solution was applied
to the fixed cells and exposed to the UV light for 30 min at RT. After washing cells were treated with
5% sodium thiosulfate solution for 5 min at RT, counterstained with Nuclear Fast Red Solution (N069.1,
Carl Roth, Karlsruhe, Germany) for 5 min and mounted with DPX mounting medium (06522, Sigma).
2.10. Immunocytochemistry
Immunoexpression of adiponectin in LDSCs and ADSCs differentiated for 21 day toward
adipocytes was analyzed by immunocytochemical staining. Cells were fixed in 10% NBF for
15 min, washed and endogenous peroxide and protein block were applied. Anti-adiponectin
antibody ([19F1], ab22554, Abcam, Cambridge, UK) was applied on cells at dilution 1:400 and
incubated over night at +4 ◦C. For visualization, rabbit specific HRP/DAB (ABC) detection IHC
kit (ab64261, Abcam, Cambridge, UK) was used according to the manufacturer’s protocol. Cells
were counterstained with Mayer’s hematoxylin and mounted with VectaMount Permanent Mounting
Medium (Vector Laboratories, Peterborough, UK).
2.11. ELISA Assays
Measurement of secretion products in cell culture media of LDSCs and ADSCs differentiated into
adipocytes and osteoblasts was performed by ELISA assays. Level of osteoprotegerin, as osteoblast
marker, was analyzed at day 16 of osteogenic differentiation while level of leptin, as mature adipocyte
marker, was analyzed at day 21 of adipogenic differentiation in cell culture supernatant. Both leptin and
osteoprotegerin measurements were performed using 72 h conditioned media. Human Osteoprotegerin
ELISA Kit (ab100617) was purchased from Abcam, UK while Human Leptin Quantikine ELISA Kit
(DLP00) was purchased from RnD systems (Minneapolis, MN, USA). Both ELISAs were performed
according to the manufacturer’s instructions, respectively. Values are expressed as pg of leptin or
osteoprotegerin per ml.
2.12. Statistical Analysis
Results of real time PCR analyses and ELISA assays are presented as scatterplots with median
using the templates published by Weissgerber et al. [21]. All the results are statistically processed
and for all samples median as well as mean values were calculated. Mean values are presented
with standard deviation (SD). Data were analyzed by one-way ANOVA or Mann–Whitney U-test to
compare and determine statistically significant differences between the samples. The value of p < 0.05
was considered as significant.
3. Results
3.1. Analysis of Mesenchymal Stem Cell Phenotype
In Figure 1 the morphology of LDSCs (a,b) and ADSCs (c,d) is presented. There were no differences
in morphology between LDSCs and ADSCs either at day 3 after isolation (Figure 1a,c) or at passage
1 day 4 (Figure 1b,d).
Flow cytometric analysis (Figure 2a–d) showed high expression of surface stem cell marker
CD105 in both LDSCs (Figure 2a) and ADSCs (Figure 2c) at passage 2, just before differentiation assays.
Non-specific antibody binding was excluded by using isotype control (Figure 2b,d).
Real time PCR analysis of CD44 and POU5F1 stem cell markers’ expression (Figure 2e,f) confirmed
that both LDSCs and ADSCs express these genes at passage 2. Slightly higher expression of CD44 in
ADSCs compared to LDSCs (Figure 2e) was not statistically significant (p = 0.1).
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Figure 1. Morphology of lipoma-derived stem cells (LDSCs) (a,b) and adipose-derived stem cells
(ADSCs) (c,d) cultures; Images were acquired at day 3 after isolation (a,c) and at day 4 after passage 1
(b,d); phase contrast with objective magnification 10×; cells are spindle-like in shape which is typical
for mesenchymal stem cells.
 
Figure 2. Flow cytometric analysis of CD105 cell surface marker expression in LDSCs (a) and ADSCs
(c) at passage 2 (representative histograms per each group of samples with % of CD105 positive cells
presented as mean ± SD, n (LDSCs) = 6 and n (ADSCs) = 4); corresponding isotype controls (b,d);
Relative expression of CD44 (e) and POU5F1 (f) genes in LDSCs and ADSCs at passage 2 (day 0 in
differentiation assays), normalized to GAPDH, presented as scatterplots with median; sample size for
CD44: n (LDSCs) = 8 and n (ADSCs) = 5, for POU5F1: n (LDSCs) = 6 and n (ADSCs) = 4.
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We also analyzed expression levels of genes characteristically expressed during osteogenesis
(RUNX2 and BGLAP) and adipogenesis (ADIPOQ, LEP, PPARG and DLK1) in cells at passage 2, day
0 in differentiation studies (Figure 3). Differences in expression levels of all examined genes were
noticed between LDSCs and ADSCs, but statistically significant only for RUNX2 and BGLAP. RUNX2
expression was higher in LDSCs compared to ADSCs while BGLAP expression was higher in ADSCs
compared to LDSCs (p < 0.05).
 
Figure 3. Relative expression of RUNX2 (a), BGLAP (b), PPARG (c), LEP (d), ADIPOQ (e) and
DLK1 (f) genes in LDSCs and ADSCs at passage 2 (day 0 in differentiation assays), normalized to
GAPDH; significant difference between cells was noticed for RUNX2 and BGLAP expression (p < 0.05);
scatterplots with median; n (LDSCs) = 6 and n (ADSCs) = 4 for all genes.
3.2. Adipogenic Differentiation
Adipogenic differentiation of both LDSCs and ADSCs was analyzed after 21 days of cultivation
in adipogenic medium (AM). As control, cells were cultivated in standard medium (DM) under the
same conditions. Characteristic adipocyte-like phenotype and the presence of lipid droplets were
noticed in both LDSCs (Figure 4a,b) and ADSCs (Figure 4e,f) after 21 days of differentiation. However,
lipid droplets were noticeably significantly more present in the ADSCs (Figure 4e,f) compared to
LDSCs (Figure 4a,b) which indicates higher adipogenic potential of ADSCs compared to LDSCs.
Further, changes in the morphology, from mesenchymal to epithelial-like, characteristic for adipocytes,
were noticed in both ADSCs and LDSCs culture. Cells cultivated in medium DM retained their
mesenchymal-like and fibroblastic-like shape, very similar in both LDSCs (Figure 4c,d) and ADSCs
(Figure 4g,h).
After 21 days of adipogenic differentiation, presence of lipids was confirmed by Oil red O staining
(Figure 5). Significantly more lipids were accumulated in ADSCs culture (Figure 5e,f) than LDSCs
culture (Figure 5a,b), as confirmed by quantification of Oil red O dye (Figure 5i), indicating higher
adipogenic differentiation potential of ADSCs. This was confirmed by adiponectin immunostaining
after 21 days of adipogenic differentiation of ADSCs and LDSCs (Figure 6). Although both ADSCs and
LDSCs were positive for adiponectin, much stronger staining was observed in ADSCs (Figure 6a,c).
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Neither LDSCs nor ADSCs cultivated in DM medium were positive for adiponectin excluding
possibility of spontaneous adipogenesis (Figure 6b,d). Non-specific staining was not present, indicated
by control staining omitting primary antibody (Figure 6e,f).
 
Figure 4. Light microscopic analysis of adipocytes’ formation after 21 day of adipogenic differentiation;
LDSCs in adipogenic medium (AM) (a,b), LDSCs in standard medium (DM) (c,d), ADSCs in AM
medium (e,f) and ADSCs in DM medium (g,h); phase contrast with objective magnification 10×
(a,c,e,g) and 20× (b,d,f,h); arrows indicate mature adipocytes.
 
Figure 5. Oil red O staining of cells after 21 day of adipogenic differentiation; LDSCs in adipogenic
medium (AM) (a,b), LDSCs in standard medium (DM) (c,d), ADSCs in AM medium (e,f) and ADSCs
in DM medium (g,h); bright field with objective magnification 10× (a,c,e,g) and 20× (b,d,f,h); arrows
indicate accumulation of lipids in cells; quantitative measurement of Oil red O dye (i), presented as
mean ± SD, n = 4 for all groups; (*) p < 0.05.
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Figure 6. Immunoexpression of adiponectin in cells after 21 day of adipogenic differentiation; LDSCs
in adipogenic medium (AM) (a), LDSCs in standard medium (DM) (b), ADSCs in AM medium (c) and
ADSCs in DM medium (d); cells stained without primary antibody (non-specific background staining
control – negative control) in AM medium (e) and in DM medium (f); bright field with objective
magnification 20×; arrows indicate positive adiponectin immunostaining (brown).
After 21 days of adipogenic differentiation, leptin concentration was measured in cell culture
supernatant, by ELISA assay (Figure 7). Significantly higher concentration of leptin was observed
in ADSCs in AM than in DM medium (p < 0.05), but no significant difference in leptin secretion
was observed in LDSCs during differentiation. Leptin concentration was higher, but not statistically
significant, in ADSCs than in LDSCs cultured in AM medium.
We performed quantitative real time PCR to determine the expression levels of adipogenesis-
related genes: adiponectin (ADIPOQ), leptin (LEP), PPAR-gamma (PPARG) and Pref-1 (DLK1), after
21 days of adipogenic differentiation (Figure 8, Table 1). As expected, expression of mature adipocytes’
markers ADIPOQ, LEP and PPARG increased in differentiated ADSCs (Figure 8a–c; Table 1) statistically
significant (p < 0.05) while expression of DLK1, characteristic marker of pre-adipocytes, decreased
(Figure 8d; Table 1). Expression levels of ADIPOQ and LEP slightly increased in LDSCs during
differentiation (p < 0.05 only for ADIPOQ), but at much lower extent than in ADSCs. No significant
changes in PPARG expression were observed in LDSCs (Figure 8c; Table 1) while DLK1 expression
significantly increased in LDSCs during differentiation (Figure 8d; Table 1). Cells cultivated in DM
media did not show significant increase in adipogenic genes expression (Figure 8, Table 1).
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Figure 7. Leptin concentration in cell culture supernatant of LDSCs and ADSCs measured by ELISA at
day 21 of adipogenic differentiation; scatterplots with median; n = 4 for all groups; (*) p < 0.05.
Figure 8. Relative expression levels (2-ΔΔCt) of genes for adiponectin (ADIPOQ) (a), leptin (LEP)
(b), PPAR-gamma (PPARG) (c) and Pref-1 (DLK1) (d), measured in LDSCs and ADSCs at day 21 of
adipogenic differentiation and normalized to GAPDH; scatterplots with median; n = 4 for all groups
and genes.
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Table 1. Relative expression of ADIPOQ, LEP, PPARG and DLK1 in LDSCs and ADSCs at day 21 of
adipogenic differentiation, normalized to GAPDH and compared to the cells at P2 (day 0). Results are
expressed as mean values ± SD. Asterisks represent statistical significance compared to P2 (day 0).
Cell Type
ADIPOQ LEP
P2 (Day 0) 21 Day P2 (Day 0) 21 Day
AM DM AM DM
LDSCs 0.033 ± 0.033 12.530 ± 7.31 * 0.400 ± 0.35 0.0130 ± 0.011 0.03 ± 0.012 * 0.030 ± 0.025
ADSCs 0.061 ± 0.019 993.84 ± 174.09 *** 0.515 ± 0.45 0.0041 ± 0.003 0.46 ± 0.41 *** 0.025 ± 0.006 **
PPARG DLK1
P2 (Day 0) 21 Day P2 (Day 0) 21 Day
AM DM AM DM
LDSCs 0.159 ± 0.151 0.30 ± 0.187 0.32 ± 0.247 0.32 ± 0.725 6.86 ± 4.38 * 1.50 ± 1.73
ADSCs 0.250 ± 0.188 4.92 ± 3.50 * 0.42 ± 0.315 0.10 ± 0.105 0.57 ± 1.13 2.61 ± 4.92
* p < 0.05, ** p < 0.01, *** p < 0.001.
3.3. Osteogenic Differentiation
Osteogenic differentiation of both LDSCs and ADSCs was analyzed after 8 and 16 days of
cultivation of cells in OS medium. As control, cells were cultivated in medium DM under the same
conditions. Characteristic osteoblast-like phenotype and accumulation of inorganic material were
noticed at day 16 in both LDSCs and ADSCs cultured in OS medium, as observed by light microscopy
(Figure 9a,c). The cells cultivated in medium DM retained their mesenchymal-like and fibroblastic-like
shape, very similar in both LDSCs (Figure 9b) and ADSCs (Figure 9d).
 
Figure 9. Light microscopic analysis of osteoblasts’ formation after 16 days of osteogenic differentiation;
LDSCs in osteogenic medium (OS) (a) LDSCs in standard medium (DM) (b) ADSCs in OS medium
(c) and ADSCs in DM medium (d); phase contrast with objective magnification 10×; arrows indicate
inorganic material deposition.
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Inorganic deposits were stained by Von Kossa and Alizarin red S staining methods (Figure 10).
Dark grey/black deposits in LDSCs (Figure 10a) and ADSCs (Figure 10e), indicating positive Von
Kossa staining, and red colored deposits, indicating positive ARS staining, in LDSCs (Figure 10c) and
ADSCs (Figure 10g) were noticed after 16 days in OS media. No colored deposits were observed in DM
media neither in LDSCs nor ADSCs, after Von Kossa (Figure 10b,f) and ARS staining (Figure 10d,h).
 
Figure 10. Von Kossa staining of cells at day 16 of osteogenic differentiation; LDSCs in osteogenic
medium (OS) (a) LDSCs in standard medium (DM) (b) ADSCs in OS medium (e) and ADSCs in
DM medium (f); dark grey/black deposits’ color in (a) and (e) indicates positive staining; Alizarin
red S staining of cells at day 16 of osteogenic differentiation; LDSCs in OS medium (c) LDSCs in
DM medium (d) ADSCs in OS medium (g) and ADSCs in DM medium (h); red deposits’ color in
(c) and (g) indicates positive Alizarin red S (ARS)staining; All images were acquired at bright field
with objective magnification 10×; quantitative measurement of ARS dye (i), presented as mean ± SD,
n (LDSCs) = 5 and n (ADSCs) = 4 for all groups; (*) p < 0.05.
After 16 days of osteogenic differentiation, osteoprotegerin (OPG) concentration was measured in
cell culture supernatant by ELISA (Figure 11). Significantly higher concentration of OPG (p < 0.05)
was observed in ADSCs cultured in OS medium than in standard DM medium, and ADSCs than in
LDSCs cultured in OS medium. No statistical significance was found between LDSCs cultured in OS
compared to DM medium.
Relative expression levels of osteogenesis-related genes: runt related transcription factor 2
(RUNX2) and osteocalcin (BGLAP) were measured at two time points during osteogenic differentiation,
8 and 16 days (Figure 12, Table 2). After 8 days, the increase in RUNX2 expression was observed
in both LDSCs and ADSCs, but more pronounced in ADSCs than in LDSCs (Table 2). After
16 days of differentiation, RUNX2 expression pattern has changed so that expression was higher
in LDSCs cultured in OS than in DM medium, while lower in ADSCs cultured in OS than in DM
medium (Figure 12b, Table 2). BGLAP expression slightly increased during differentiation and it was
significantly higher in ADSCs than in LDSCs at both time points.
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Figure 11. Osteoprotegerin concentration in cell culture supernatant of LDSCs and ADSCs, measured
by ELISA at day 16 of osteogenic differentiation; scatterplots with median; n = 4 for all groups;
(*) p < 0.05.
Figure 12. Relative expression levels (2-ΔΔCt) of RUNX2 (a,b) and BGLAP (c,d) measured in LDSCs
and ADSCs at day 8 (a,c) and day 16 (b,d) of osteogenic differentiation and normalized to GAPDH;
scatterplots with median; n (LDSCs) = 5 and n (ADSCs) = 4 for all groups.
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Table 2. Relative expression of RUNX2 and BGLAP in LDSCs and ADSCs at days 8 and 16 of osteogenic
differentiation, normalized to GAPDH and compared to the cells at P2 (day 0). Results are expressed as
mean values ± SD. Asterisks represent statistical significance compared to P2 (day 0).
Cell Type
RUNX2
P2 (Day 0) 8 Days 16 Days
OS DM OS DM
LDSCs 1.620 ± 0.622 2.156 ± 1.133 2.27 ± 1.390 7.194 ± 4.76 * 6.478 ± 5.83
ADSCs 1.013 ± 0.214 2.670 ± 1.799 4.01 ± 1.747 * 5.685 ± 1.29 *** 8.960 ± 3.35 **
BGLAP
P2 (Day 0) 8 Days 16 Days
OS DM OS DM
LDSCs 0.23 ± 0.039 0.312 ± 0.091 * 0.368 ± 0.099 * 0.323 ± 0.072 * 0.388 ± 0.081 **
ADSCs 0.33 ± 0.085 0.395 ± 0.091 0.503 ± 0.147 0.554 ± 0.155 * 0.600 ± 0.062 **
* p < 0.05, ** p < 0.01, *** p < 0.001.
4. Discussion
Our study is among the first giving detailed analysis of stem cells isolated from lipoma and
comparison with stem cells isolated from normal adipose tissue. The distinct signature of these cells
governs the capacity for adipogenic and osteogenic differentiation which we analyzed on cellular and
molecular levels.
Lipomas, used in our study, were located subcutaneously at different body locations. To compare
cells isolated from lipoma with the cells isolated from normal adipose tissue, we used samples of
subcutaneous adipose tissue from different body depots as well. It was reported that there is no
statistically significant evidence of depot-related effects on proliferation and differentiation potential of
ADSCs, while difference was noticed in apoptosis susceptibility and lipolysis [22]. Other study
has shown that subcutaneous ADSCs, compared with ADSCs from other depots, have greater
differentiation potential and recommend them as optimal choice for angiogenic and osteogenic
regeneration [23]. Regarding the impact of donor age on the properties of ADSCs, results found in
published data are diverse. Some studies showed that there are age-related differences in proliferation
of ADSCs and lipid accumulation during adipogenic differentiation, with decrease in proliferation rate
and increased lipid accumulation during aging [22]. Others reported that growth kinetics, osteogenic
and chondrogenic differentiation potentials of ADSCs were adversely affected by increased donor age
while adipogenic differentiation potential was maintained during aging [24]. On the other side, it is
reported that the use of adipose stem cells for bone tissue engineering is not limited by the donor’s
age as shown by osteogenic differentiation of ADSCs isolated from differently aged patients, on the
scaffold-free 3D osteogenic graft intended for the treatment of bone defects [25]. In our study, both
groups of patients were of similar age (average age of patients with lipoma was 48.3 ± 8.3 while
average age of non-lipoma patients was 49.5 ± 11.1) which means that differences in the properties of
LDSCs and ADSCs could not be affected by the differences in patients’ age.
Mesenchymal stem cells isolated from adipose tissue show a spindle-cell-like bipolar morphology
which is typical for mesenchymal stem cells [23,26]. It has been shown that subcutaneous ADSCs are
more homogenous in morphology with less variations in cell diameter up to passage 12, compared to
other adipose tissue depots [23]. In our study, the morphology of LDSCs and ADSCs was very similar
and typical mesenchymal-like, without significant differences observed between LDSCs and ADSCs
after isolation as well as after cell passage (Figure 1). Although, some authors reported that ADSCs
have consistent morphology while LDSCs did not [17], several studies showed that morphology of
LDSCs is very much alike ADSCs and there were no morphological differences between those two cell
types after long-term culture [13,14].
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To be considered as stem cells, cells should fulfil some phenotypic criteria and to express so called
stemness-related markers which include panel of both intracellular and surface molecules. Oct4, the
most commonly examined intracellular marker, is a transcriptional factor encoded by the POU5F1 gene.
It is expressed in embryonic stem cells [27] and also in adult human stem cells [28], and is essential for
pluripotency, self-renewal, proliferation and survival of mesenchymal stem cells [29]. Expression level
of Oct4 in cells is reported to define the balance between differentiation and de-differentiation in stem
cells [30]. In our study, both LDSCs and ADSCs expressed POU5F1 with no statistically significant
difference in expression level when compared (Figure 2f). There is a lack of data in the literature
on Oct4 expression in LDSCs, however, there are some reports on expression of POU5F1 in lipoma
tissue, and it has been shown that this gene is up-regulated in lipoma compared to the normal adipose
tissue [31].
CD44 is a transmembrane glycoprotein which is very important for cell differentiation and
functions as a receptor for hyaluronic acid that is involved in cell–cell and cell-matrix interactions,
mediates cell adhesion and migration, and interacts with other ligands, such as osteopontin, collagen,
and matrix metalloproteinases (MMPs). Numerous studies have shown that CD44, as well as CD44
gene, is expressed in ADSCs and is considered as one of the highly expressed positive stem cell
markers in ADSCs [4,23,32,33]. In a very few studies dealing with LDSCs, it was shown that CD44 is
expressed in LDSCs and there is no difference in expression level between LDSCs and ADSCs [17].
Zavan et al. [31] showed that CD44 is up-regulated in lipoma tissue compared to normal adipose tissue.
In our study, both ADSCs and LDCSs express the CD44 (Figure 2e) although LDSCs slightly less but
not significantly. The lower CD44 expression in LDSCs may be the consequence of hypermethylation
of the CD44 gene which is the case in tumor development [34]. This finding could be taken into
consideration to explain weaker differentiation potential of LDSCs as shown later.
Endoglin (ENG) or CD105 is a type I membrane glycoprotein and is a part of the TGF beta receptor
complex. It is highly expressed in ADSCs and MSCs in general, and represents one of the commonly
used positive markers for their characterization [4,23,32,33,35]. In our study both LDSCs and ADSCs
expressed high levels of CD105 as evaluated by flow cytometry (Figure 2a,c). There are opposite
findings in literature about expression of CD105 in LDSCs. Some authors reported that expression of
CD105 is similar in LDSCs and ADSCs as analyzed by flow cytometry [17], which is in accordance
with our results, while others reported low CD105 expression in LDSCs [15]. This opposite finding of
Tremp et al. [15] is probably due to the different type of lipoma used, lack of comparative measurement
of its expression in normal ADSCs and analysis in SVF cells while our cells were characterized at
passage 2. Chang et al. [36] analyzed, by flow cytometry, the expression of CD105 in cells isolated from
two different types of lipoma and showed that all cells highly express CD105 (greater than 90%) with
no difference between different types of lipoma samples. It has been shown that expression of CD105,
and other stem cells surface markers, is low in SVF cells, but increases during cultivation and passages
while isolated SVF has high expression levels of pluripotency (embryonic stem cell) markers, which
decrease with cultivation and passages [37,38]. This is one of the main reasons why we used cells at
passage 2 for further differentiation studies since they expressed both pluripotency markers (Oct4) as
well as stem cell surface markers CD44 and CD105, at this point (Figure 2).
The ADSCs at passage 2 or 3 uniformly express stem cell markers and are morphologically a
homogeneous population [26,39]. This finding is confirmed in our study as well, showing that both
LDSCs and ADSCs express stem cell markers and are morphologically homogeneous at passage 2.
Our results of stemness-related markers’ analysis suggest that both LDSCs and ADSCs in our study
were mesenchymal stem cells, which means that both had similar phenotype and stemness state before
differentiation. Senescence (or aging) of cells represents an irreversible process during which stem
cells lose their stemness-related phenotype and differentiation potential, and occurs in long-term cell
culture and at late cell passages [40–42]. ADSCs are shown to enter into senescence after passage
10 [41] and at lower extent than stem cells of other origin [42]. We used cells at early passage (P2) for
differentiation studies thus avoiding the influence of cell senescence on differentiation potential.
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Our results are among the first presenting detailed analysis of molecular signature of LDSCs in
comparison with ADSCs, which were examined at the same time and under the same conditions. To the
best of our knowledge, there are no data on expression of adipogenic- and osteogenic-related markers
in stem cells isolated from lipoma tissue. We analyzed relative expression levels of genes ADIPOQ, LEP,
PPARG, DLK1, RUNX2 and BGLAP in LDSCs and ADSCs at passage 2, before differentiation started
(Figure 3). These results are of great importance for analysis of differentiation capacity of those cells
and differences between them, since these results gave us information about the basal levels of mRNA
from genes that we examined during adipogenic and osteogenic differentiation. We showed that there
are slight differences in all analyzed genes, however, statistically significant difference between LDSCs
and ADSCs was observed for RUNX2 and BGLAP only. This could explain the differences in the
osteogenic differentiation dynamics between LDSCs and ADSCs noticed in our study. There is one
report on adiponectin and PPAR-γ expression in sorted LDSCs (distinguished CD34+ cells) evaluated
by immunocytochemical staining, and it has been shown that adiponectin expression was lower in
CD34+ cultured cells from lipoma compared to CD34+ isolated from normal adipose tissue with no
difference in the expression of PPAR-γ [31]. This finding correlates with our results of gene expression
analysis (Figure 3c,e). Although there are no studies on gene expression in isolated cells some research
groups investigated the differences in expression of ADIPOQ, LEP and PPARG, RUNX2 and BGLAP in
lipoma tissue and compared it with normal adipose tissue [14,31]. It has been shown that, in tissue
samples, expression of LEP was higher while expression of ADIPOQ was lower in lipoma compared
to normal adipose tissue, which is the expression pattern characteristic for obesity [14]. The same
pattern of LEP and ADIPOQ gene expression was observed in our study in isolated cells (Figure 3d,e).
Suga et al. [14], in the same study, showed that expression of PPARG in lipoma was not distinctly
different from that in normal adipose tissue. Our results showed that PPARG is more expressed in
ADSCs compared to LDSCs, but not statistically significant, probably due to heterogeneity among
samples (Figure 3c). In the study by Zavan et al. [31], authors showed that expression of LEP, ADIPOQ
and PPARG genes is up-regulated while RUNX2 was less expressed in lipoma compared to normal
adipose tissue, which is, except LEP, different from the findings in previous study, and our results on
isolated cells.
Stem cells isolated from adipose tissue have great ability to differentiate into adipocytes
and therefore are promising tool in soft tissue engineering and regenerative medicine [43]. We
induced both LDSCs and ADSCs into adipocytes by cultivation in adipogenic medium for 21 day.
Microscopic analysis of cells (Figure 4), Oil red O staining of lipid droplets (Figure 5), adiponectin
immunoexpression (Figure 6) and leptin concentration measurement in media after 21 day (Figure 7)
showed that adipogenesis in LDSCs was restricted and that LDSCs have weaker capacity to
differentiate into adipocytes compared to ADSCs. These findings on cellular and protein expression
levels were confirmed at gene expression level as well. Adiponectin and leptin are adipokines
secreted by mature adipocytes and are commonly used as markers of adipocytes [44]. In our study,
ADIPOQ, LEP and PPARG were significantly less expressed in LDSCs compared to ADSCs in AM
medium (Figure 8) with no significant difference in LEP and PPARG expression between LDSCs
cultured in different media like for ADSCs. Pref-1 is a preadipocyte marker encoded by DLK1
gene, whose expression decreases during adipogenesis with its high expression in preadipocytes
and very low or absent expression in mature adipocytes [45–48]. For mature adipocytes’ formation,
decreased Pref-1 level is necessary. It has been shown that Pref-1 expression is high in ADSCs before
differentiation while 14 days of adipogenic differentiation it is almost non-detectable [48]. Our results
showed that DLK1 is significantly more expressed in LDSCs cultured in AM medium for 21 day
compared to ADSCs in the same medium (p < 0.05) (Figure 8d). Regarding ADSCs, DLK1 expression
was decreased in AM medium compared to DM medium which is in accordance with the dynamics
of Pref-1 expression during adipogenesis. High levels of DLK1 could be related with lower degree
of LDSCs differentiation into adipocytes in our study. There are only few publications reported
adipogenic differentiation of LDSCs. Suga et al. [14] reported that there were no differences in the
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capacity for adipogenic differentiation of LDSCs compared to ADSCs, at passage 1, as evaluated by
lipid droplets staining and quantification. By the same analyses employed, other studies revealed
that high lipid content was observed in differentiated LDSCs [15] and that cells were differentiated
into adipocytes successfully, similar to ADSCs [16], but no comparative results with normal ADSCs
were shown in those two studies. The ability of LDSCs to differentiate into adipocytes at early as well
as late passages was reported to be similar as of ADSCs, evaluated by lipid droplets presence and
staining [13]. Our results are more complex since we assessed the adipogenic differentiation potential
of both LDSCs and ADSCs at different levels and by different methods. This study is, according to our
knowledge, the first dealing with the adipogenic differentiation of LDSCs by analyzing the markers of
this process on several levels—cellular, molecular and gene, but in the same time comparing that with
ADSCs isolated from normal tissue. According to the adipogenesis-related gene expression signature
as well as phenotypic changes and protein levels in LDSCs and ADSCs after 21 day of adipogenic
differentiation, compared to the cells at day 0 (passage 2), we can conclude that adipogenesis was not
complete in LDSCs and differentiation capacity of LDSCs compared to ADSCs was significantly lower.
Adipose-derived stem cells have a great potential to differentiate into osteoblasts and therefore
represent a promising tool in bone tissue engineering for making bone grafts with different biomaterials
to regenerate and repair the bone defects [23,49,50]. It has been shown that stem cells from
subcutaneous adipose tissue show good osteogenic differentiation potential at passage 2 [23], that we
also used in our study. After 16 days of osteogenic differentiation, phenotypic changes in both LDSCs
and ADSCs cultured in OS medium were observed so that cells became more epithelial-like and less
fibroblastic-like, and accumulation of inorganic matrix components was noticed (Figure 9), slightly
more in ADSCs culture. No significant difference was found in ARS staining between LDSCs and
ADSCs but slightly darker Von Kossa staining was observed in ADSCs.
Osteoprotegerin (OPG) is secreted by osteoblasts, is a marker of their functional state since it
is important for regulation of osteoblast-osteoclast homeostasis [51], promotes pre-osteoblasts and
matrix maturation [52] and its secretion is up-regulated during osteogenic differentiation in vitro [53].
In our study, significant difference in osteoprotegerin (OPG) secretion, measured by ELISA, between
LDSCs and ADSCs cultured in OS medium for 16 days, was noticed with higher OPG concentration
found in ADSCs compared to LDSCs (Figure 11).
Differences between LDSCs and ADSCs in osteogenic differentiation capacity were also observed
at gene expression level in our study. RUNX2 expression increased in both cell cultures during
differentiation so it was higher in ADSCs than in LDSCs at day 8 and higher in LDSCs than ADSCs at
day 16 (Figure 12a,b; Table 2). RUNX2 is a transcription factor involved in osteogenesis and is essential
for osteoblast differentiation [54–56]. RUNX2 promotes osteoblast differentiation at an early stage, by
inducing the expression of genes for bone matrix proteins such as osteopontin, osteocalcin, collagen
type 1, etc., but also its high expression can inhibit osteoblast differentiation at a late stage [54,57].
In order to achieve osteoblast maturation, it is necessary that RUNX2 is initially upregulated to induce
the expression of bone matrix proteins, but its expression should then decrease to enable the process of
differentiation into mature osteoblasts to be continued. However, if RUNX2 is constantly upregulated,
then osteoblasts maturation cannot be achieved. In our study, RUNX2 is upregulated in LDSCs after
16 days, compared to ADSCs, which could be one of the reasons for lower expression of BGLAP in
LDSCs compared to ADSCs. It was reported that OPG was overexpressed in pre-osteoblasts when
RUNX2 was downregulated while osteoblast differentiation was arrested in RUNX2 overexpressing
cells [52]. Our results are similar with these findings, since LDSCs have higher expression of RUNX2
but lower expression of OPG, compared to ADSCs at day 16 of osteogenic differentiation where
RUNX2 expression was down-regulated and OPG was up-regulated. Osteocalcin is a protein secreted
by mature osteoblasts and plays important role in bone calcification and mineralization of MSCs
during osteogenic differentiation [58,59]. It was reported that BGLAP expression begins to increase
after 14 days of osteogenic differentiation of MSCs [58,59]. In our study, BGLAP expression increased
during differentiation in both cultures and it was higher in differentiated ADSCs than LDSCs after
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16 days (Figure 12c,d; Table 2). Both LDSCs and ADSCs in our study had characteristic osteoblast-like
phenotype after 16 days of osteogenic induction but, based on osteogenic genes’ expression dynamics,
osteogenesis was at different stages in those cells and one of the reasons could be higher RUNX2
expression in LDSCs at passage 2 (Figure 3a).
There are very few publications with data about osteogenic differentiation of stem cells isolated
from lipoma tissue. Makiguchi et al. [16] showed that ADSCs isolated from lipoma tissue can
differentiate into osteoblasts after 21 days in OS media, as evaluated by alkaline phosphatase activity
and calcium concentration measurement. It was also reported by Lin et al. [13] that LDSCs can be
successfully differentiated into osteoblasts, but only Von Kossa staining of calcium deposits was
performed in this study. No other markers or details on osteogenic differentiation of these cells were
reported. However, there are numerous reports on lipoma tissue ossification observed in different
parts of the body [8,16,18,19,60–63] and this phenomenon could be explained by the existence of stem
cells in lipoma tissue that may differentiate into osteoblasts and chondrocytes.
Upregulated expression of RUNX2 in LDSCs, in our study, could be also considered as a reason
why adipogenic differentiation of LDSCs was at lower extent since it has been shown by other authors
that overexpression of RUNX2 inhibits adipogenesis [55,64,65]. Taking this finding together with
the previously considered higher RUNX2 expression before differentiation, at day 0 (passage 2) in
LDSCs compared to ADSCs, it is a significant indication that RUNX2 expression, together with DLK1
expression pattern, is an important mechanism for suppressing LDSCs differentiation capabilities.
On the other side, higher expression of RUNX2 in LDSCs may suggest potential osteogenic capacity
of those cells, which could be one of the possible mechanisms of bone and cartilaginous structures’
formation in the cases of aforementioned osteolipoma, since higher expression of RUNX2 is necessary
at an early stage of both osteogenesis and chondrogenesis.
5. Conclusions
Our study is among the first that provides detailed analysis of stem cells isolated from lipoma
and comparison with the stem cells isolated from normal adipose tissue, on cellular and molecular
levels. Results of our study suggest that both LDSCs and ADSCs were mesenchymal stem cells
with similar phenotype and stemness state for potential differentiation. According to analyzes of
adipogenesis-related markers at cellular and molecular level and microscopic analysis after 21 day of
adipogenic differentiation we can conclude that differentiation capacity of LDSCs compared to ADSCs
was significantly lower. Analysis of osteogenesis-related markers revealed that both types of cells had
characteristic osteoblast-like phenotype after 16 days of osteogenic induction but were at different
stages of osteogenesis. Differences between LDSCs and ADSCs, after isolation from the tissue, are
probably due to the distinct molecular signature and their commitment in the tissue that will governs
their different capacity and fate during adipogenic and osteogenic induction in vitro. These results
provide new insights into the cellular and molecular basis of lipoma etiopathogenesis and imply that
the potential use of LDSCs in tissue engineering and regenerative medicine should be re-considered or
at least other ways of using these cells for regeneration purposes should be discussed.
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Abstract: Mesenchymal stromal/stem cells (MSCs) are immature multipotent cells, which represent
a rare population in the perivascular niche within nearly all tissues. The most abundant source to
isolate MSCs is adipose tissue. Currently, perirenal adipose tissue is rarely described as the source of
MSCs. MSCs were isolated from perirenal adipose tissue (prASCs) from patients undergoing tumor
nephrectomies, cultured and characterized by flow cytometry and their differentiation potential into
adipocytes, chondrocytes, osteoblasts and epithelial cells. Furthermore, prASCs were stimulated with
lipopolysaccharide (LPS), lipoteichoic acid (LTA) or a mixture of cytokines (cytomix). In addition,
prASC susceptibility to human cytomegalovirus (HCMV) was investigated. The expression of
inflammatory readouts was estimated by qPCR and immunoassay. HCMV infection was analyzed by
qPCR and immunostaining. Characterization of cultured prASCs shows the cells meet the criteria
of MSCs and prASCs can undergo trilineage differentiation. Cultured prASCs can be induced to
differentiate into epithelial cells, shown by cytokeratin 18 expression. Stimulation of prASCs with LPS
or cytomix suggests the cells are capable of initiating an inflammation-like response upon stimulation
with LPS or cytokines, whereas, LTA did not induce a significant effect on the readouts (ICAM-1,
IL-6, TNFα, MCP-1 mRNA and IL-6 protein). HCMV broadly infects prASCs, showing a viral load
dependent cytopathological effect (CPE). Our current study summarizes the isolation and culture of
prASCs, clearly characterizes the cells, and demonstrates their immunomodulatory potential and
high permissiveness for HCMV.
Keywords: mesenchymal stromal/stem cells; perirenal; adipose tissue; fat; characterization;
stimulation; lipopolysaccharide; cytokines; cytomegalovirus
1. Introduction
Mesenchymal stromal/stem cells (MSCs) are immature multipotent stromal cells, which represent
a rare population in the perivascular niche within fully specialized tissues throughout the whole
body [1]. The cells can be isolated from nearly all adult tissues, for example, adipose tissue, solid organs
Cells 2019, 8, 1346; doi:10.3390/cells8111346 www.mdpi.com/journal/cells51
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and bone marrow [2,3], and proliferated in vitro. Cultured MSCs release a broad range of growth
factors, cytokines, and chemokines [4,5] in the culture supernatant that may improve regeneration in
injured cells, organs or tissue. Therefore, MSCs are an optimal source for tissue regeneration support
therapies after tissue injury. The organ-protective effects of MSCs, their conditioned medium or
extracellular vesicles have been investigated in the last decade, demonstrating that either infused
stem cells or their derivates facilitated tissue and organ regeneration predominantly by released
regeneration-promoting factors. Furthermore, MSCs have immunological properties, including
anti-inflammatory, immunoregulatory and immunosuppressive capacities [6,7], and are, therefore,
active immunomodulators during inflammation and sepsis. This immunomodulatory activity has
been attributed to the secretion of soluble factors. The MSCs were shown to interact with a variety of
immune cells, including CD4 and CD8 T cells, natural killer cells, B cells, monocytes and dendritic
cells [8]. The MSCs have also been shown to express Toll-like receptors (TLRs), the major molecules
linking innate and adaptive immunity [9]. The TLRs act as sensors for invading pathogens broadly
distributed on immune cells and are involved in the pathogenesis of chronic inflammatory and
infectious diseases [10].
Recent data have suggested that adipose tissue located in different anatomical locations of
the body appear to have distinct cellular compositions and diverse functions [11–13]. In humans,
fat depot-specific differences are clinically relevant owing to the observation that increased abdominal
white fat is associated with insulin resistance, while subcutaneous white adipose tissue exerts a
protective effect against metabolic syndrome [11]. Para- and perirenal adipose tissue is a fat pad
located in the retroperitoneal space. Perirenal fat is separated from pararenal fat by the renal fascia,
and surrounds each kidney [14]. It is a collection of adipose tissue located superficial to the renal cortex
and is part of the visceral fat, which can be divided into perirenal, gonadal, epicardial, retroperitoneal,
omental and mesenteric fat depots [15]. They are composed mainly of white adipose cells that
store energy and produce soluble inflammatory cytokines [14,16]. Perirenal fat shares the same
developmental origin as typical visceral fat [14]. However, each white adipose tissue depot can be
described as a separate mini-organ [15], and perirenal fat and typical visceral fat are different in
histology, physiology and functions [14]. The vascularization of perirenal adipose tissue grows from
branches of the abdominal aorta, which also supplies blood to the kidney cortex. Therefore, effects on
renal cells through soluble factor released by cells from the perirenal adipose tissue are possible [16].
Renal adipose tissue has been linked recently to effects on kidney function and blood hypertension [17]
and a neuronal link from perirenal adipose tissue to multiple central nervous system’s regions has
been shown in animal data [18]. Perirenal tissue is rarely analyzed for viral infections, however MSC
from selected organs other than perirenal tissue show susceptibility and permissiveness for human
cytomegalovirus (HCMV) infection [19,20]
The object of this study was to describe the isolation and culture of human perirenal
adipose-derived stromal/stem cells (prASCs) in detail and to characterize cultured cells and their
differentiation potential into adipocytes, chondrocytes, osteoblasts and epithelial cells. The present
study further investigated the immunomodulatory potential of prASCs after stimulation with
lipopolysaccharide (LPS), lipoteichoic acid (LTA), a mixture of cytokines (cytomix), or infection
with HCMV. Whereas, few studies used human prASCs in vitro [21–23], there is currently no other
study which fully described the isolation, characterization, differentiation and immunomodulatory
potential of human prASCs as well as their susceptibility to HCMV.
2. Materials and Methods
2.1. Perirenal Adipose Tissue
Human perirenal adipose tissue was obtained from patients undergoing tumor nephrectomies.
This study was approved by the ethics committee of the clinic of the Goethe University, Frankfurt
(UGO 03/10, Amendment).
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2.2. Cell Isolation and Culture
Human MSCs were isolated from perirenal adipose tissue from 15 different donors. The tissue
was minced by using two scalpels and disintegrated as small as possible for cell isolation. The minced
tissue was then digested at 37 ◦C with collagenase (1 mg/mL; CellSystems, Troisdorf, Germany) and
continuous agitation for 60 min. Cells were then separated from the remaining fibrous material
and the floating adipocytes by centrifugation at 300× g. The pelleted cells were collected, and the
procedure was repeated twice. The sedimented cells were washed with phosphate-buffered saline
(PBS) and filtered through a 125-μm plastic mesh (Millipore, Schwalbach, Germany). Erythrocyte
contamination, if required, was reduced by density gradient centrifugation with Bicoll (Biochrom,
Berlin, Germany), because high erythrocyte contamination was found to decrease ASCs adherence and
proliferation markedly. It was observed in previous experiments, that a preceding density gradient
separation provided a better yield of adipose-derived stromal/stem cells (ASCs) than treatment with
an erythrocyte lysing buffer [24]. Finally, the cells were plated for initial cell culture and cultured at
37 ◦C in an atmosphere of 5% CO2 in humid air. Dulbecco’s modified Eagle’s medium (DMEM; Sigma,
Taufkirchen, Germany) was used with a physiologic glucose concentration (100 mg/dl) supplemented
with 10% fetal bovine serum (FBS; Biochrom, Berlin, Germany) as the standard culture medium.
Primary isolated cells were intensively washed with PBS after 18–24 h of initial plating to remove
debris and non-adherent cells. The medium was then replaced every three to four days. Subconfluent
cells were passaged by trypsinization. In all experiments we used cultured prASCs in early passages
(between 2 and 5).
2.3. Cell Characterizations Using Flow Cytometry and Immunofluorescence Staining
Cell morphology was examined by phase contrast microscopy. Flow cytometric analysis was
used to show the characteristic marker expression of cultured prASCs. Cells were detached from the
cell culture plastic and stained with directly labeled antibodies (CD73-PerCP-eFluo710 (eBioscience,
San Diego, CA, USA), CD90-FITC (BD Bioscience, Heidelberg, Germany), CD105-PE, CD29-FITC and
CD45-PE (all from Immunotools, Friesoythe, Germany)). The labeled prASCs were then measured
using a flow cytometer (BD Biosciences, Heidelberg, Germany). All experiments included negative
controls with corresponding isotype controls. Cells were gated by forward and sideward scatter to
eliminate debris.
Cells were cultured on chamber slides (Nunc Lab-Tech®), rinsed three times with PBS and fixed
with ice-cold methanol/acetone (1:1) for 5 min for immunofluorescence staining. Unspecific binding sites
were blocked with PBS containing 5% normal goat serum for 20 min. Primary antibody (anti-vimentin
or anti-cytokeratin 18 (CK-18); both from ExBio, Vestec, Czech Republic) was applied after washing
and incubated for 45 min at 37 ◦C with gentle shaking. Afterwards, cells were washed and incubated
with a Cy3-conjugated secondary monoclonal antibody for 45 min at 37 ◦C. All dilutions of antibodies
were made in PBS containing 1% goat serum. 4,6-diamidino-2-phenylindole dihydrochloride (DAPI;
0.5 μg/mL) was added to the secondary antibody solution for nuclear staining. Controls of nonspecific
fluorescence were performed on fixed cells processed without the primary antibody. The cells were
washed and covered in Moviol. The slides were stored at 4 ◦C and analyzed with a fluorescence
microscope (Zeiss, Heidelberg, Germany).
2.4. Induction of Cell Differentiation
The trilineage differentiation potential of cultured prASCs was induced by incubation in
differentiation media for 14 days, followed by the verification of differentiation by standard staining
methods (Oil Red O, Alcian Blue, and Alizarin staining, respectively), as further described. Media
were changed every three to four days.
Adipogenic differentiation was induced in adipogenic medium containing high glucose
content (4.5 g/L), insulin (1.74 μM, Novo Nordisk), dexamethasone (0.1 μM, Ratiopharm),
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isobutyl-methylxanthin (0.5 mM, Sigma), indomethacine (200 μM, Fluka), and 10% FBS. Oil Red
O (Sigma) staining revealed the accumulation of lipid droplets in intracellular vacuoles indicating
adipogenic differentiation.
The chondrogenic differentiation of prASCs was induced in chondrogenic medium containing
ascorbic acid (50 nM; Merck), insulin (6.25 μg/mL, Novo Nordisk), transforming growth factor β
(10 ng/mL, Peprotech) and 1% FBS. The chondrogenic phenotype was assessed by Alcian Blue 8GX
staining (Fluka).
Osteogenic differentiation of prASCs was induced in osteogenic medium containing ascorbic acid
(50 μM; Merck), glycerophosphate (10 mM, Sigma), dexamethasone (1 μM, Ratiopharm), recombinant
bone morphogenic protein-2 (100 ng/mL, Immunotools, Friesoythe) and 15% FBS. After 14 days
of incubation, the osteogenic phenotype was assessed by staining according to Alizarin Red S
staining (Fluka).
The cells were incubated with all-trans retinoid acid (ATRA; Sigma) at a final concentration of
5 μM for epithelial differentiation. This concentration was determined by taking a pattern of our
previous studies and testing with proliferation and vitality assays [25,26]. A stock solution of ATRA
dissolved in dimethyl sulfoxide at 10 mM was kept at −80 ◦C. The ATRA was dissolved in DMEM
substituted with 10% FBS for cell culture. The equivalent volume of solvent (dimethyl sulfoxide)
without ATRA was used in control samples. Epithelial differentiation medium was replaced every
three to four days during a total incubation period of 14 days, followed by analysis of the epithelial
differentiation by expression of CK-18 using qPCR, Western blotting and immunofluorescence staining
2.5. Stimulation with LPS, LTA, and Cytokines
Cells were grown in 24-well culture plates (for IL-6 measurements in the supernatant) or small
cell culture flasks (25 cm2 for PCR analyses) to subconfluence. Cells were then washed with PBS
and treated with TLR-4 ligand LPS (LPS-EB ultrapure from E. coli 0111: B4; 10, 100, 1000 ng/mL;
Invivogen, San Diego, USA, Cat. No. tlrl-3pelps), TLR-2 ligand LTA (from Staphylococcus aureus;
1000 ng/mL; Invivogen, Cat. No. tlrl-slta), or cytomix (IFNγ, 200 U/mL; IL-1β, 25 U/mL, and TNFα,
10 ng/mL) diluted in DMEM with 10% FBS. The RNA was isolated after 4 h of stimulation, and
supernatants were harvested after 48 h for IL-6 quantification. Therefore, supernatants were collected,
centrifuged at 300× g for 5 min and assessed for the cytokine by an immunoassay or stored at −20 ◦C
for later measurement.
2.6. HCMV Infection
prASCs were infected with HCMV patient isolate Hi91 [27] at a multiplicity of infection (MOI)
of 0.05, 0.5, 1 and 4. Expression of HCMV-specific late antigen was detected 96 h post-infection by
immunoperoxidase staining using monoclonal antibodies directed against gB/gpUL55-encoded antigen
(kindly provided by K. Radsak, Institut für Virologie, Marburg, Germany) as previously described [28].
Other samples were used for extraction of total RNA and cDNA synthesis. Changes in gene expression
of selected targets were quantified by qPCR in triplicate measurements.
2.7. Cell Viability Assays
Cell viability of prASCs was determined by by two viability assays, a photometric assay
using 2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide (XTT), as described
previously [29], and a fluorescent-based assay using calcein-acetoxymethyl (calcein-AM, Biolegend, San
Diego, USA), to determine any possible cytotoxic effects during the stimulations. In brief, 5000 cells/well
were seeded in 96-well plates. We measured each stimulation in quintuplicate for each biological
replicate. One day after seeding, the prASCs were stimulated for 96 h as described above. The XTT
reagent was then added to the wells, as described by the manufacturer (AppliChem, Darmstadt,
Germany), and incubated at 37 ◦C for 4 h. Absorbance was measured in an Apollo LB911 microplate
reader (Berthold, Bad Wildbad, Germany) at 492 vs. 650 nm. Data are expressed as arbitrary units
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and calculated as a percent in relation to the control. For the fluorescence assay, cells were washed
and calcein-AM (1 μM) was added incubated at 37 ◦C for 30 min. Then, fluorescence was measured
immediately using a fluorescence reader (BMG Fluostar, Ortenberg, Germany) with excitation and
emission wavelengths of 485 and 515 nm. Cells incubated in buffer without calcein-AM were used as
background controls. Data are expressed as arbitrary fluorescence units.
2.8. PCR
We performed a single-step RNA isolation protocol using Nucleozol (Macherey-Nagel, Düren,
Germany) to extract RNA from cultured prASCs. Then, cDNAs were synthesized from isolated RNA
for 30 min at 37 ◦C using 1 μg RNA, 50 μM random hexamers, 1 mM deoxynucleotide-tripheosphate
mix, 50 units of reverse transcriptase (Fermentas, St. Leon-Rot, Germany) in 10× PCR buffer, 1 mM
β-mercaptoethanol and 5 mM MgCl2. A Hot FIREPol EvaGreen Mix Plus was used (Solis Biodyne,
Tartu, Estonia) for the master mix; the primer mix and RNAse-free water were added. Quantitative
PCR (qPCR) was carried out in 96-well plates using the following conditions: Twelve minutes at 95 ◦C
for enzyme activation, 15 s at 95 ◦C for denaturation, 20 s at 63 ◦C for annealing and 30 s at 72 ◦C for
elongation (40 cycles). Finally, a melting curve analysis was executed. The quantification of the PCR
fragment was performed using the ABI Prism® 7900HT Fast Real-Time PCR System with a Sequence
Detection System SDS 2.4.1 (Thermo Fisher Scientific). Relative quantification was assessed by the
ΔΔCT method [30], using β-actin as a calibrator, and levels of target gene expression were estimated
by 2−ΔΔCt. In selected experiments, PCR products were separated by agarose gel electrophoresis (2%)
and observed under UV illumination. Primer pairs were synthesized by Thermo Fisher Scientific
(Germany) and are listed in Table 1.
Table 1. Primer used for qPCR analyses.






CK-18 CAC AGT CTG CTG AGG TTG GA CAA GCT GGC CTT CAG ATT TC 110 NM_000224
ICAM-1 CAGTGACTGTCACTCGAGATCT CCTCTTGGCTTAGTCATGTGAC 500 NM_000201.3
IL-6 AAAGATGGCTGAAAAAGATGGATGC ACAGCTCTGGCTTGTTCCTCACTAC 150 NM_000600.4
MCP-1 CCCCAGTCACCTGCTGTTAT AGATCTCCTTGGCCACAATG 135 NM_002982.4
TNFα CGGGACGTGGAGCTGGCCGAGGAG CACCAGCTGGTTATCTCTCAGCTC 354 NM_000594.4
TLR-2 GCCCATTGCTCTTTCACTGCTT ATGACCCCCAAGACCCACAC 96 NM_003264.4
TLR-4 CCCGACAACCTCCCCTTCTC GGGCTAAACTCTGGATGGGGT 211 NM_003266
UL83 GCAGCCACGGGATCGTACT GGCTTTTACCTCACACGAGCATT 159 NC_006273
β-actin ACT GGA ACG GTG AAG GGT GAC AGA GAA GTG GGG TGG CTT TT 169 NM_001101
2.9. Western Blot
The cells were processed for Western blotting, as described previously [31]. In brief, the cells
were lysed using 10 mM Tris pH 7.4, 0.1% SDS, 0.1% Tween20, 0.5% TritonX100, 150 mM NaCl,
10 mM EDTA, 1 M urea, 10 mM NEM, 4 mM benzamidine and 1 mM PMSF and collected by scraping.
After centrifugation, the pellet was suspended in Laemmli’s buffer and heated at 95 ◦C for 5 min
prior to electrophoresis on a 10% SDS polyacrylamide gel. The protein content was determined by a
standard assay and an equal volume of protein was loaded into each lane. The separated proteins were
transferred electrophoretically to Immobilon transfer membrane (Millipore). Membranes were blocked
for 2 h. Immunoblotting was performed by incubating with antibodies against CK-18 (resulting in a
45 kDa band, ExBio, Vestec, Czech Republic) or β-Actin (resulting in a 42 kDa band, Sigma Aldrich),
followed by a secondary antibody (horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG;
Amersham Pharmacia). Protein bands were made visible using the Peqlab Fusion FX system (VWR,
Darmstadt, Germany) followed by densitometric evaluation using ImageJ 1.8.0 (NIH, www.nih.gov).
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2.10. Immunoassay
Interleukin-6 was quantified using a commercially available enzyme-linked immunosorbent
assay kit (ELISA) (Immunotools, Friesoythe, Germany). In brief, the wells of 96-well microtiter plates
were coated with an anti-human IL-6 antibody overnight at room temperature (RT). Nonspecific
binding sites were blocked with PBS/2% BSA/0.05% Tween20 for 1 h. The plates were then washed
with PBS/0.05% Tween and the standard (8–500 pg/mL), and the samples were added for 2 h
at RT. All samples were diluted in assay buffer (1:25) and run in duplicate. The plates were
washed and incubated with biotinylated anti-IL-6 for 2 h at RT, washed again and incubated with
horseradish-peroxidasestreptavidin for 30 min. After washing, TMB was added for 5–20 min and the
substrate reaction was stopped and measured (450 vs. 620 nm). The data are presented as ng/mL of
IL-6 in the supernatant.
2.11. Statistical Analysis
The data are expressed as mean ± standard deviation (SD). Analysis of variance with Dunnett’s
Multiple Comparison Test or Student’s t-test were used for statistical analysis. p values < 0.05 were
considered significant.
3. Results
3.1. Isolation and Characterization of prASCs
We used an average of 75 g of perirenal adipose tissue to isolate prASCs, yielding 6.9 × 108 cells
seeded in total, corresponding to approximately 9.2 × 106 primary isolated cells per gram tissue.
Nevertheless, only some of these cells adhere to cell culture plastic and proliferate. Approximately
80–90% of the isolated cells do not adhere and were aspirated with the first washing after 24 h. Adhered
primary cells cultured in a 75 cm2 cell culture flask need up to seven days to reach subconfluence
(~80–85%), the situation where the cells were subcultured for the first time. At this time, an average of
3.75× 105 cells were grown in the 75 cm2 cell culture flask (corresponding to 5000 cells/cm2 growth area).
Cultured prASCs displayed a spindle-shaped fibroblastoid morphology (Figure 1A). Primary
isolated cells are morphologically more heterogeneous than cultures after passaging. Nevertheless,
cultured cells became morphologically increasingly homogeneous in higher passages. Contaminations
with cells of epithelial morphology or pre-adipocytes were not detectable in the culture at passage
2. In addition, immunofluorescence staining in passage 2 revealed that all the cells cultured (100%)
expressed vimentin (Figure 1B), also showing a very homogeneous cell culture of mesenchymal origin.
There were no vimentin-negative cells detectable in any staining done.
The cells were also characterized by flow cytometric analysis utilizing characteristic markers for
MSCs in vitro. Cultured prASCs expressed CD29, CD73, CD 90 and CD105 but did not express CD45
(Figure 1C). Furthermore, cultured prASCs were positive for CD44 and CD166 and did not express the
endothelial markers CD31 and C11b, which are expressed on the surface of many leukocytes, including
monocytes, granulocytes and macrophages (data not shown).
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Figure 1. Characterization of human perirenal mesenchymal stromal/stem cells (prASCs)
in vitro. (A) Characteristic phase contrast microscopy of prASCs in passage 2 (bar: 100 μm);
(B) Immunofluorescence staining of intermediate filament vimentin, nuclei were counterstained
with DAPI (bar: 20 μm); (C) Representative flow cytometric overlay histograms of characteristic marker
expression (CD73, CD90, CD105, CD29) and of CD45, a pan leukocyte marker which is not expressed on
MSCs. Thick black histograms represent isotype controls. A dot plot shows the forward and sideward
scatter analysis with the gating strategy to eliminate debris.
3.2. Differentiation of prASCs
We investigated the differentiation potential of prASCs into adipocytes, chondrocytes, osteoblasts
and epithelial cells. We used the differentiation media described in the case of trilineage differentiation
of cultured prASCs. After 14 days of incubation, the verification of differentiation was done by
standard staining methods (Oil Red O, Alcian Blue and Alizarin staining, respectively). Incubation
of undifferentiated prASCs for 14 days under adipogenic conditions induced the de novo formation
of cytoplasmatic lipid droplets, a characteristic of pre-adipocytes, stained by Oil Red O staining
(Figure 2B). Chondrogenic-induced prASCs exhibit an intense blue color following Alcian Blue 8GX
staining (Figure 2D), indicative of cartilage extracellular matrix accumulation. Induction of osteogenic
differentiation of the cells for 14 days resulted in the deposition of mineralized nodules that stained
red by Alizarin Red S staining (Figure 2F), characteristic for osteoblasts. Cells cultured in osteogenic
induction medium changed from an elongated mesenchymal appearance to a multilateral form with a
tightly packed multilayer.
Control cells cultured in standard medium were not stained by Oil Red O (Figure 2A), Alcian
Blue 8GX (Figure 2C) or Alizarin Red staining (Figure 2E).
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Figure 2. Trilineage differentiation of cultured prASCs. Differentiation into adipocytes, chondrocytes
and osteoblasts was induced by adipogenic (B), chondrogenic (D) and osteogenic (F) medium for
14 days. Control cells were cultured in standard culture medium for 14 days (A,C,E) After 14 days of
incubation in either standard or differentiation medium, cultures were stained with Oil Red O (A,B),
Alcian Blue 8GX (C,D) or Alizarin Red S (E,F) (bar: 100 μm).
In addition to their trilineage differentiation potential, prASCs were also able to differentiate into
the epithelial lineage. In order to elucidate the influence of ATRA on prASCs differentiation, expression
of CK-18, an early epithelial marker, was evaluated by qPCR analysis (Figure 3A), immunofluorescence
staining (Figure 3B) and Western blotting (Figure 3C,D). After incubation with ATRA for 14 days, the
expression of CK-18 mRNA was 6.2-fold induced compared to unstimulated control cells (Figure 3A).
Immunofluorescence staining revealed that approximately 45% of the cells were CK-18 positive
(Figure 3B), and Western blot analysis also clearly showed the significant induction of CK-18 protein in
epithelial-induced prASCs (Figure 3C) (densitometric analysis calculated in percent: control (standard
medium) = 100% (background signal); ATRA = 286% (Figure 3D)).
Figure 3. Induction of epithelial differentiation. (A) Analysis of cytokeratin 18 (CK-18) induction by
qPCR. The expression levels in each experiment were normalized using β-actin as a housekeeping
gene and are expressed relative to the unstimulated control using the ΔΔCT method (n = 6; * p < 0.05);
(B) Characteristic immunofluorescence staining of CK-18 after epithelial differentiation with ATRA
(14 days). Nuclei were stained with DAPI (bar: 100 μm); (C) Characteristic Western blots. Expression
of CK-18 (45 kDa) and β-actin (42 kDa) of the unstimulated control cells (Co) and after incubation with
ATRA (5μM) for 14 days; (D) Densitometric evaluation of CK-18 induction in relation to undifferentiated
controls (= 100%) (n = 5; * p < 0.05).
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3.3. Stimulation with LPS, LTA and Cytokines
We added increasing concentrations of LPS, a major component of the outer membrane of
Gram-negative bacteria, to the cell supernatant and evaluated the response by qPCR and an
immunoassay to test the responsiveness of prASCs to pro-inflammatory stimuli. In addition,
we stimulated the cells with LTA, a key cell wall component of Gram-positive bacteria and potent
stimulator of TLR-2. A mixture of pro-inflammatory cytokines (cytomix: IFNγ, 200 U/mL; IL-1β,
25 U/mL; and TNFα, 10 ng/mL) was used as a positive stimulation control. In particular, prASCs
produced a set of inflammatory mediators in response to the bacterial or cytokine stimulation.
The mRNA expression of ICAM-1, MCP-1, TNFα and IL-6 was upregulated in response to the TLR-4
agonist LPS (Figure 4A–D). The cytomix induced a significantly higher induction of ICAM-1, MCP-1
and IL-6 than stimulation with LPS, whereas there were no significant differences in the induction of
TNFα mRNA expression. We also detected no significant differences between the different stimulation
doses of LPS. On the other hand, LTA induced no significant effect on the cytokines analyzed, whereas
TLR-2 was shown to be expressed (Figure 4E). Total mRNA was isolated from the prASCs in passage 2
cultured in standard medium to determine the constitutive expression of the relevant receptors for the
bacterial infections (TLR-2 for LTA and TLR-4 for LPS). Both receptors were found to be expressed,
whereas TLR-2 only showed a weak but specific signal at 96 bp.
Furthermore, qPCR analysis revealed that some mRNAs were constitutively expressed in vitro.
IL-6 and MCP-1 mRNA were highly detectable in the unstimulated control (CT values approximately
22 and 28, respectively (water: undetectable)), and ICAM-1 was slightly expressed compared with the
unstimulated control (CT value approximately 30 (water: 37)). On the other hand, TNFα mRNA was
not detected in the unstimulated prASCs.
At the protein level, IL-6 is constitutively released by prASCs (8.9 ± 1.5 ng/mL; mean ± SD,
n = 4). When the cells were stimulated by LPS or exposed to an inflammatory environment by the
cytomix, the production of IL-6 was significantly upregulated (Figure 4F). Nevertheless, we found no
dose-dependent effect of the LPS stimulation, and the release of LPS- and cytokine-stimulated IL-6
protein was nearly comparable (LPS 10: 29.3 ± 3.3; LPS 100: 30.5 ± 7.2; LPS 1000: 32.5 ± 4.9; cytomix
33.5 ± 9.3 ng/mL, mean ± SD, n = 4)). The LTA also induced an increase in IL-6 release, but the effect
was not significant (17.0 ± 7.1 ng/mL; mean ± SD, n = 4) (Figure 4F).
These results suggest that, under these culture conditions, prASCs are capable of initiating an
inflammation-like response upon stimulation with LPS or cytokines. Interestingly, only LPS (from
gram negative bacteria) induced a significant stimulation of prASCs, but no significant stimulation
was found by after incubation with the pathogen of gram-positive bacteria.
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Figure 4. Effect of lipopolysaccharide (LPS) (10, 100, 1000 ng/mL), LTA (1000 ng/mL) or a cytokine mix
(cytomix). (A–D) Assessment at the mRNA level by qPCR for ICAM-1, MCP-1, IL-6, and TNFα after
4 h stimulation. The expression levels in each experiment were normalized to a housekeeping gene
(β-actin) and are expressed relative to the control using the ΔΔCT method. (mean ± SD; * p < 0.05,
** p < 0.01, *** p < 0.001 versus control), n = 4.; (E) Constitutive expression of TLR-2- and TLR-4-mRNA
of prASCs in vitro. The PCR products were separated by agarose electrophoresis and observed under
UV illumination (TLR-2: 96 kb, TLR-4: 211 kb, and β-actin: 169 kb (housekeeper)); (F) Quantification
of IL-6 protein in the supernatant after 48 h stimulation. Data from four independent immunoassays
(ELISA) are represented as mean ± SD (*** p < 0.0001).
To investigate the effects of LPS, LTA and the cytomix on prASCs viability, we used two viability
assays using XTT or calcein-AM. The XTT assay is a colorimetric assay used to determine viability
based on the metabolic activity of the cultured cells. Calcein-AM is a cell permeant non-fluorescent
dye, which is in live cells intracellularly converted into calcein, a dye with intense green fluorescence.
Whereas a slightly reduced metabolic activity after each stimulation regimen could be detected with the
XTT assay (XTT calculated in percent: control, 100%; LPS 10, 80.02%; LPS 100, 76.86%; LPS 1000, 74.86%;
LTA, 83.91%; cytomix, 84.24%), the differences in live cell detection were very low. No statistically
significant difference could be found, either with the XTT assay (Figure 5A) or with the calcein assay
(Figure 5B).
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Figure 5. Cell viability after stimulation with LPS, LTA or cytomix for 96 h. A total of 5000 cells were
cultured in 96 well plates (n = 3, each in quintuplicate) and stimulated for 96 h. (A) The XTT assay was
performed and optical density (OD) was measured in a microplate reader at 492 vs. 650 nm (arbitrary
units). (B) The calcein assay was performed and fluorescence was measured in a reader at 485 nm
(excitation) and 515 nm (emission). No significant effects of the different stimulations could be detected
with both assays (mean ± SD, n = 3, each in quintuplicate).
3.4. Infection with HCMV
Experiments with prASCs infection were done by HCMV strain Hi91, using a MOI of 0.05, 0.5, 1
and 4. Our results showed prASCs to be susceptible to HCMV even at MOI 0.05. The increase of viral
load resulted in an augmented number of infected prASCs and progressive CPE (Figure 6B). Only
very few cells were still adherent at 96 h post infection (MOI of 4), all being highly positive for HCMV
gB/late antigen (Figure 6B). The HCMV specific mRNA of UL83-coded phosphoprotein HCMV virion
protein was absent in controls and strongly expressed in prASCs 96 h after infection (Figure 6C), thus
showing permissiveness of the cells.
Figure 6. Infection of prASCs with HCMV Hi 91 for 96h. (A, B) Bright field microscopy of mock-infected
prASCs (A) and HCMV-infected cells (B). Compared to the mock-infected controls (A) a strong CPE
with very few adherent cells is seen 96 h after infection with HCMV at a MOI of 4 (B). All remaining
cells are positive for HCMV late antigen, as shown by immunostaining. (C) Levels of UL83 mRNA
were assessed after 96h. The expression levels in each experiment were normalized to β-actin and are
calculated relative to the control using the ΔΔCT method (mean ± SD; * p < 0.05 versus control, n = 3).
4. Discussion
The abundance of MSCs, their multipotency and ability to secrete various cytokines, and their
immunomodulatory effects account for their key role in current tissue regeneration approaches (i.e.,
Regenerative Medicine) [6]. The MSCs are present in all organs and tissues in vivo [2], and it has also
been demonstrated that adipose tissue is a rich source of MSCs. Recent studies have explored the
isolation, culture and characterization of MSCs from different adipose tissue depots [32]. The differences
in gene expression between subcutaneous and visceral adipose tissue depots—when looking at total
fat—have been described [32]. Regarding the tissue source, attention has also been paid to differences
between cells derived from subcutaneous and visceral adipose tissue, and emerging evidence shows
that there is also a significant variation between different visceral depots [32,33]. There is clear evidence
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that distinct differences in the expression profiles of developmental genes exist between all adipose
tissue depots [32]. Nevertheless, we have not compared the ASCs isolated from different adipose origin
in our current study. Adipose tissues have generally been classified as loose connective tissues [14].
Perirenal fat shares the same developmental origin as typical visceral fat. However, the perirenal
adipose tissue is an atypical visceral fat pad with a complete system of blood supply, lymph fluid
drainage and innervation [14] with near proximity to the kidneys. Perirenal adipose tissue is rarely
described as the source of MSCs (or ASCs in particular). One possible reason for this is that the perirenal
tissue cannot be easily recovered and an intervention in the perirenal space must be indicated for the
removal. Our current study was conducted to characterize cultured MSCs from this cell source and to
prove the potential of prASCs. The possible clinical use of prASCs for regenerative therapies is clearly
restricted due to the limited tissue source. Thus, liposuction aspirate is easier to access as a cell source
and, thus, better explored. In this study, we described the isolation and culture of human prASCs
in detail, characterized cultured cells, investigated their multipotential differentiation, including
epithelial differentiation, and their immunomodulatory capabilities in response to inflammatory
stimuli. The isolation of prASCs could be done according to a protocol from liposuction aspirate
established already [25,26]. Perirenal fat is another suitable source of ASC isolation, as also shown by
others [21,22]. However, not all of our isolations could be successfully cultured. The cells were from
morbid donors who had to be nephrectomized due to a malignant disease. Variability in the tumor
dignity could be an explanation, in addition to genetic factors, for the inadequate growth of some
isolations. A comparison of MSCs from different tissues, however, showed that MSCs from perirenal
fat tissue have the same morphology and phenotypic characteristics as MSCs from other sources.
Since the first description of ASCs and their trilineage differentiation potential by Zuk and
co-workers in 2001, many other lineages have been explored where ASCs can differentiate and how
this differentiation can be induced. Several studies have shown that ASCs are able to differentiate
into epithelial cells when cultured in media containing a retinoid (ATRA) [26], conditioned medium
from epithelial cells [34] or a breast cancer cell line [35]. ATRA is an active metabolite of vitamin A
and belongs to the retinoids. Retinoids have important functions in the growth and differentiation of
tissues in vertebrates. An earlier study from our group showed the de novo expression of CK-18 and a
reduction expression of the mesenchymal intermediate filament vimentin [26]. The type I intermediate
filament CK-18 is characteristic of cells of single-layered epithelia and essential for normal tissue
structure and function. Thus, CK-18 forms an important marker for the identification of epithelial cells.
This result is considered to be the first step towards epithelial differentiation, because the intermediate
filament vimentin is expressed exclusively in cells of mesenchymal origin. In the present work, medium
containing ATRA was also used to stimulate the epithelial differentiation of prASCs. After two weeks
of culture in induction media, we verified the epithelial differentiation by the induced expression of
the characteristic marker CK-18.
The ASCs were also shown to play a role in the control of tissue inflammation and
immunomodulation. The MSCs adopt an immunoregulatory phenotype in response to incubation
(or pre-conditioning) with inflammatory factors (e.g., γ-Interferon (IFNγ), Interleukin 1β (IL-1β) or
Tumor Necrosis Factor-a (TNFα)), in vivo secreted by activated immune cells [36]. In this context,
administration of (pre-conditioned) ASCs could be used to decrease the severity of inflammation.
Exemplarily, pre-conditioning of ASCs with inflammatory cytokines prior to cell transplantation is
considered as a way to boost their immune regulatory function [37]. IFNγ, a pro-inflammatory cytokine
acting against viral and bacterial infections, is one representative source for a pre-conditioning regimen
for functional enhancement and upregulation of (pro- and anti-) inflammatory mediators [38,39].
The ASCs incubated with TNFα increased the secretion of IL-6 and IL-8, resulting in promoting
endothelial progenitor cell homing and stimulating angiogenesis in an ischemic hindlimb model [40].
The ASCs pre-conditioned with IFNγ, TNFα and IL-6 showed enhanced immunosuppressive properties
in vitro [41]. MSCs have also been shown to execute an immunosuppressive effect on lymphocyte
proliferation in vitro [42]. In this context„ the inhibitory effect of histocompatibility locus antigen
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(HLA)—G, expressed and released by MSCs, has been shown [43]. Nevertheless, we did not evaluate
the effects of stimulated prASCs on lymphocyte populations and also have not determined the HLA-G
expression of prASCs. In the current study, we used a mixture of three cytokines to investigate the
stimulatory response of prASCs and measured the induction of pro-inflammatory cytokines (IL-6 and
TNFα), a chemokine (MCP-1) and a cell adhesion molecule (ICAM-1). Taken together, pre-conditioning
with inflammatory cytokines is a potential way to improve the therapeutic effectiveness for tissue
injury and inflammatory disease [37,38].
In addition, ASCs also get in contact with bacterial components during invasive infections.
Not much is known about how these pathogens (i.e., LPS and LTA) interact with ASCs and how contact
to bacteria influences the secretome in ASCs. The TLRs mediate the activation process of cells by
recognizing pathogen-associated molecular patterns, such as LPS or LTA. Activation of TLRs promotes
the expression of various inflammatory cytokines, such as TNFα and other costimulatory molecules,
and, therefore, initiates adaptive immune responses. Nevertheless, we were not able to show a
significant stimulation via TLR-2 induced by LTA. Whereas most reports describe the anti-inflammatory
properties (or immune suppressive) of MSCs, other reports target the pro-inflammatory characteristics
of pre-conditioned MSCs. Studies reported that the activation of TLR-4 via LPS turned MSCs into a
pro-inflammatory phenotype, whereas TLR-3 activation modified MSCs into an anti-inflammatory
phenotype [38,44]. Incubation with low-dose LPS limited the immunosuppressive effects of ASCs by
increasing IL-6 and TNFα expression, and also some growth factors [45]. Furthermore, it has been
demonstrated that proliferation and osteogenic differentiation of adipose-derived MSCs is influenced
by LPS [46,47]. Another study showed no significant influence of LPS or LTA on the migration rate
and chemotaxis of MSCs [48]. More in vivo studies are needed to understand the immunomodulatory
mechanisms of MSCs and the enhancement of this potential by in vitro pre-conditioning regimens.
The susceptibility and permissibility of prASCs to HCMV was not known before our experiments,
but is consistent with reported productive infection of MSC derived from bone marrow [20], umbilical
cord Wharton’s jelly [49], placenta [50] and MSC from subcutaneous adipose tissue [51] The perivascular
niche was described as a relevant MSC origin across the human organs [1]. In addition perivascular
stromal cells host HCMV and are a likely long term reservoir [52]. Cell susceptibility to HCMV
depends on entry receptor expression, like e.g., b3-Integrin (CD61), which is expressed on ASC [53]
and the expression pattern of b1-integrin ((CD29) [54] which is also present on prASCs (see Figure 1C).
Pathophysiologically, HCMV can induce an impairment of bone marrow-derived MSCs effector
functions [55] and MSCs’ differentiation potential [51]. Because of the perivascular cells’ impact on
vascular health further studies elucidating the in vitro and in vivo effects of HCMV infection in prASCs
are warranted.
In summary, this study is the first comprehensive description of MSCs from perirenal adipose
tissue in vitro. Our current study describes the isolation and culture of human prASCs, characterized
cultured cells and the differentiation potential of prASCs into adipocytes, chondrocytes, osteoblasts
and, for the first time, into epithelial cells. Furthermore, we showed the immunomodulatory potential
of prASCs after stimulation with LPS or cytomix, and—also for the first time—high susceptibility
as well as permissivity to HCMV. Interestingly, only LPS (from gram negative bacteria) induced a
significant stimulation of prASCs, but no significant stimulation was found by after incubation with
the pathogen of gram-positive bacteria.
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Abbreviations
ASCs Adipose-derived MSCs
ATRA All-trans retinoic acid
CK Cytokeratin
CPE Viral load dependent cytopathological effect
FBS Fetal bovine serum
HCMV Human cytomegalovirus
ICAM-1 Intercellular adhesion molecule 1
IFNγ γ−Interferon
IL Interleukin
MCP-1 Monocyte chemotactic protein
MSCs Mesenchymal stromal/stem cells
MOI Multiplicity of infection
PCR Polymerase chain reaction
prASCs ASCs from perirenal adipose tissue
qPCR Quantitative real-time polymerase chain reaction
RT Room temperature
TLR Toll-like receptor
TNFα Tumor necrosis factor-α
UL83 HCMV-specific mRNA of UL83-coded phosphoprotein 65
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Abstract: Mesenchymal stromal/stem cells (MSCs) reside in many human tissues and comprise
a heterogeneous population of cells with self-renewal and multi-lineage differentiation potential,
making them useful in regenerative medicine. It remains inconclusive whether MSCs isolated from
different tissue sources exhibit variations in biological features. In this study, we derived MSCs
from adipose tissue (AT-MSC) and compact bone (CB-MSC). We found that early passage of MSCs
was readily expandable ex vivo, whereas the prolonged culture of MSCs showed alteration of cell
morphology to fibroblastoid and reduced proliferation. CB-MSCs and AT-MSCs at passage 3 were
CD29+, CD44+, CD105+, CD106+, and Sca-1+; however, passage 7 MSCs showed a reduction of MSC
markers, indicating loss of stem cell population after prolonged culturing. Strikingly, CB-MSC was
found more efficient at undergoing osteogenic differentiation, while AT-MSC was more efficient
to differentiate into adipocytes. The biased differentiation pattern of MSCs from adipogenic or
osteogenic tissue source was accompanied by preferential expression of the corresponding lineage
marker genes. Interestingly, CB-MSCs treated with DNA demethylation agent 5-azacytidine showed
enhanced osteogenic and adipogenic differentiation, whereas the treated AT-MSCs are less competent
to differentiate. Our results suggest that the epigenetic state of MSCs is associated with the biased
differentiation plasticity towards its tissue of origin, proposing a mechanism related to the retention of
epigenetic memory. These findings facilitate the selection of optimal tissue sources of MSCs and the ex
vivo expansion period for therapeutic applications.
Keywords: mesenchymal stromal cell; differentiation; tissue of origin; prolonged culture; epigenetic
memory
1. Introduction
Mesenchymal stromal cells (MSCs), also referred to mesenchymal stem cells [1], represent
a heterogeneous population of cells that can be isolated from a wide range of tissues, including bone
marrow, compact bone, placenta and adipose tissue [2–6]. MSC was first isolated from mouse bone
marrow as fibroblast colony-forming units, which were distinguished by their ability to adhere to
plastic culture dishes [2]. They display fibroblastic morphology and are capable of differentiation
to chondrocytes, adipocytes, and osteoblasts in vitro [1,7]. Differentiation to other non-mesodermal
cell types, such as neurons, muscles, endothelial cells, and hepatocytes, has also been reported [8–11].
MSCs are intensely studied in clinical research because of their multi-lineage potential and ease of
isolation and culture [1,12]. In addition, their ability to evade the host immune system by suppressing
T cells, B cells, and natural killer cells [13], and releasing anti-inflammatory proteins [14,15] have
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made them an important tool for disease treatment. Clinical trials using MSCs for the treatment of
osteoarthritis, degenerative disc disease, ischemic heart disease, and stroke are currently undergoing
to explore their therapeutic applications [12].
Harvesting MSCs from the non-bone marrow tissue sources can be done by less invasive methods
and the primary isolated MSCs can be expanded ex vivo to yield a larger number. Therefore, these
non-bone marrow-derived MSCs are considered as an attractive repertoire for stem cell and regenerative
medicine. In light of the broad potentials for therapeutic applications and the variety of sources
for MSCs, it has been reported that MSCs, regardless of their tissue of origins, displayed similar
characteristics in the differentiation to adipocytes, chondrocytes and osteocytes [16–18]. However, other
studies comparing MSCs from human bone marrow, skin and adipose tissues showed considerable
differences in their growth rate and differentiation potentials [19,20], supporting the hypothesis of
preferential differentiation hierarchies [21,22]. It, therefore, remains inconclusive on the characteristics
and the differentiation potentials of MSCs obtained from various tissue sources.
With such variability in mind, a better understanding of the differences between MSCs from
different tissue origins can help identify the most suitable cell source for specific clinical purposes.
Here we compared and characterized murine MSCs obtained from the adipose tissues (AT-MSC)
and compact bone (CB-MSC) using standard isolation methods and expanded ex vivo at early and late
cell passages. Both MSCs cultured for an extended period of time showed morphological changes
and a decline in cell proliferation. We also demonstrated the tissue origin of MSC is associated
with the alterations of cell surface marker patterns and differentiation potential towards osteogenic
and adipogenic lineages. Removal of DNA methylation by pharmacological agent can alter the biased
differentiation potential of MSCs dependent on the tissue source.
2. Materials and Methods
2.1. MSC Isolation and Culture
MSCs were harvested from 8-week old C57BL/6 mice (Laboratory Animal Unit, The University
of Hong Kong). Written informed consent to use the animals was approved by the Committee on
the Use of Live Animals in Teaching and Research of the University of Hong Kong (Reference no.:
2416-11). Three mice were used for the MSC isolation experiment and a total of five experiments
were performed. The male to female ratio was 2:1. Mice were sacrificed by over-dosage of isoflurane
inhalation. The MSC isolation procedures were described previously [5,23]. For CB-MSC isolation,
muscles from femur, humerus, and tibia were removed. The epiphyseal ends of the bone were cut
and discarded. Bone marrow was released by gently crushing the bones in cold PBS with 2% FBS
(Gibco, Invitrogen, Grand Island, NY, USA) and 1 mM EDTA (Sigma-Aldrich, St. Louis, MO, USA).
The cleaned bone fragments were digested in 0.25% collagenase I (Gibco) with 20% FBS for 5 min
at 37 ◦C. The bone fragments were further chopped into 1–2 mm bits and digested for another 45 min
at 37 ◦C. CB-MSCs were separated from the bone fragments by filtering the cell suspension through
a 70 μm cell strainer (BD Biosciences, Franklin Lakes, NJ, USA). For AT-MSC isolation, adipose tissue
dissected from inguinal and subcutaneous sites was digested in 5% collagenase I (Gibco) for 1 h at 37 ◦C.
Cells were released from the adipose tissue by centrifuging for 5 min at 500× g. The released cells were
treated with ammonium-chloride-potassium (ACK) lysing buffer (Sigma-Aldrich) for 3 min at room
temperature to lyse red blood cells. The cell suspension was washed twice with α-MEM and tissue
debris was removed by filtering through a 70 μm cell strainer. The isolated cell suspension (5 × 106)
were cultured in α-MEM with 10% fetal bovine serum (FBS) (HyClone, Logan, UT, USA) and 1×
penicillin-streptomycin-glutamine (Gibco) on a 100 mm culture dish at 37 ◦C with 5% CO2. MSCs were
adhered within 48 h. The culture medium was changed every 2 days. MSCs were passaged in a 1:4
ratio when reaching 80% confluence by Accutase (Gibco) for 5 min at 37 ◦C.
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2.2. Cell Proliferation and Immunophenotypic Analysis
AT-MSCs and CB-MSCs (2 × 104 cells) were seeded into 6-well plates on day 0. The total number of
expanded cells were counted at day 1, 3 and 5. Cell doubling time (DT) was calculated by the following
formula: DT = T × ln2/ln × (Xe/Xb), where T is the incubation time in any units; Xb is the cell number
at the beginning of the incubation time; Xe is the cell number at the end of the incubation time.
Cultured cells were stained with FITC-conjugated anti-CD29 or anti-c-kit, PE-conjugated
anti-CD44, anti-CD45, anti-CD106 or anti-Sca-1, APC-conjugated anti-CD105, and APC-Cy7-conjugated
anti-CD11b (all from Biolegend, San Diego, CA, USA) at a concentration of 0.5 μg/mL for 30 min
at 4 ◦C. The corresponding fluorophore-conjugated isotype controls were used for the gating of
the positive-stained cells. Immunophenotypic analysis of 5000–10,000 cells of each sample was
performed using FACSCanto II flow cytometer (BD Biosciences). The flow cytometry data were
analyzed using Flowjo software (Tree Star, Ashland, OR, USA, ver. 10.0.7). Both assays were performed
three times with duplicated samples.
2.3. MSC Differentiation Assays
MSCs at passage 3 or 7 (6 × 104 cells) were seeded into 24-well plates. One group of MSCs was
treated with 0.5 μM 5-azacytidine (5-aza, Sigma-Aldrich) for 48 h prior to differentiation. For osteogenic
differentiation, MSCs were differentiated in α-MEM with 10% FBS and StemXVivo Mouse/Rat
Osteogenic Supplement (R&D Systems, Minneapolis, MN, USA) for 18 days. Differentiated cells
were fixed in 4% formaldehyde (Sigma-Aldrich) for 10 min at room temperature and stained with
2% Alizarin Red solution (Chemicon, Merck Millipore, Billerica, MA, USA) for 15 min at room
temperature. For adipogenic differentiation, MSCs were differentiated in α-MEM with 10% FBS
and StemXVivo Adipogenic Supplement (R&D Systems) for 14 days. Differentiated cells were fixed in
4% formaldehyde (Sigma-Aldrich) for 10 min at room temperature and stained with 0.5% Oil Red O
solution (Sigma-Aldrich) for 15 min at room temperature. For chondrogenic differentiation, MSCs
were centrifuged for 5 min at 200× g in a 1.5 mL tube and differentiated in DMEM /F-12 with 1×
Insulin-Transferrin-Selenium (Gibco) and StemXVivo Human/Mouse Chondrogenic Supplement (R&D
Systems) for 21 days. Chondrocyte spheroids were fixed in 4% formaldehyde (Sigma-Aldrich) for 1 h
at room temperature and stained with Alcian Blue 8GX solution (Sigma-Aldrich) for 30 min at room
temperature. MSCs cultured in the differentiation medium without supplements were served as
controls. The differentiation assay was performed three times with duplicated samples.
2.4. RNA Extraction and Quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from the differentiated MSCs using MiniBEST Universal RNA Extraction
Kit (Takara, Kusatsu, Japan). Genomic DNA eraser column and DNaseI treatment were used to remove
genomic DNA. cDNA was synthesized using PrimeScriptTM RT reagent kit with gDNA Eraser (Takara)
according to the manufacturer’s protocol. qRT-PCR was performed with the 7900HT Fast Real-Time
PCR System (Applied Biosystems, Waltham, MA, USA) using SYBR Premix Ex TaqTM (Takara) with
the oligo primers listed in Supplementary Table S1. Gapdh and β-Actin served as house-keeping genes
for normalization of gene expression. All samples were analyzed in triplicate. Three independent
experiments were performed and relative gene expression was calculated using 2−ΔΔCT method.
2.5. Statistical Analysis
A statistically significant difference was calculated by two-tailed unpaired Student’s t-test.
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3. Results
3.1. Ex Vivo Expansion of MSC Isolated from Compact Bone and Adipose Tissue
Murine MSCs isolated from the adipose tissue (AT) and compact bone (CB) were expanded ex
vivo. Both AT-MSCs and CB-MSCs displayed spindle-like to fibroblastoid cell morphology [4,5,23].
It was observed that cells at passage one (P1) contain a small number of cells with spherical shape,
which were presumably dividing cells or non-MSCs (Figure 1a,e). However, continuous passaging
of cells to the third passage (P3), which is one week of culture, gradually eliminated the non-MSC
populations and enriched for MSCs (Figure 1b,f). From passage three (P3) onwards, cell morphology
changed from elongated to fibroblastoid in both cultures (Figure 1b–d,f–h).
Figure 1. Cell morphology of AT-MSC and CB-MSC. Morphologies of MSCs at (a,e) passage 1,
(b,f) passage 3, (c,g) passage 5, and (d,h) passage 7 were shown. Cell morphology changed gradually
from spindle-like to flat and fibroblastoid with increasing passage number. Representative images were
taken at 20×magnification. Scale bars: 100 μm.
Ex vivo culture of AT-MSC and CB-MSC at P3 or P7 for 5 days demonstrated cell number
expansion. P3 and P7 AT-MSC showed limited expansion by 2.2- and 1.5-fold, respectively; whereas
P3 and P7 CB-MSC were expanded 4.3- and 3.3-fold, respectively (Figure 2a,b). Besides, it was found
that the doubling time of CB-MSC was comparable between both passages (2.4 days and 2.8 days
for P4 and P7, respectively); however, AT-MSC demonstrated a significant increase in doubling time
from P4 (4.3 days) to P7 (8.9 days) (Figure 2c). These results demonstrated different cell proliferation
patterns between MSCs isolated from different tissue origins. Nevertheless, prolonged culture of both
types of MSCs gradually reduced proliferation rate beyond passage 7.
3.2. Alterations of MSC Immunophenotypes by Prolonged Culture
Previous studies have shown that prolonged culture of MSC altered their immunophenotypes [24].
This prompt us to examine the expression of a panel of mesenchymal stromal cell surface markers,
including CD29, CD44, CD105, CD106, and stem cell antigen-1 (Sca-1) [25–28], in the ex vivo expanded
cells. Hematopoietic markers c-kit, CD11b, and CD45 were served as negative markers for the detection
of contamination of hematopoietic cells from the MSC isolation procedures [27,29]. c-kit+ and CD11b+
populations were generally low in both types of MSCs, particularly for the late passage culture
(Figure S1). It was observed that 38.4% of CD45+ populations were present in P3 CB-MSC, suggesting
a low degree of hematopoietic cell contamination from compact bone during MSC isolation.
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Figure 2. Ex vivo expansion of MSCs at different passage numbers. Cell proliferation assay was
performed to determine the growth rate of early (Passage 3) and late passage (Passage 7) of (a) AT-MSC
and (b) CB-MSC. Cells were counted on day 1, 3 and 5 (n = 3). (c) Doubling times of MSCs were
calculated over 5 days of culture. CB-MSCs demonstrated a higher cell proliferation rate than AT-MSCs.
The doubling time of AT-MSC was significantly increased at late passage. Experiments were performed
with three replicates. Data represent mean ± SD; *p < 0.05, ** p < 0.01 and *** p < 0.001.
Nevertheless, the CD45+ hematopoietic cells were gradually lost when cells passaging to P7.
Both AT-MSCs and CB-MSCs demonstrated high expression of most of the MSC markers at passage
3. It was noted that CD29+, CD44+, and CD106+ populations showed further increased in passage
7 (Table 1, Figure 3). However, CD105+ population was reduced significantly at late passage MSCs.
While a significant portion of the AT-MSC population retained as CD105+ (33.6± 4.3%) at P7, the CD105+
population in CB-MSC reduced drastically from 34.2% at P3 to 7.5% at P7. In contrast, CB-MSC
consisted of over 83% Sca-1+ cells at P3 and P7, whereas the Sca-1+ population dropped from 98.5%
to 26.3% in AT-MSC from P3 to P7. These immunophenotypic results demonstrated the alteration
of MSC surface marker pattern during ex vivo culture, suggesting that prolonged culture of MSC is
accompanied by the loss of MSC identity.
Table 1. Percentage of cell populations in AT-MSC and CB-MSC.
Sample Passage CD29 CD44 CD105 CD106 Sca-1 c-kit CD11b CD45
AT-MSC
P3 99.8 ± 0.1 18.3 ± 1.3 50.1 ± 2.4 38.1 ± 3.2 98.5 ± 0.7 2.1 ± 0.6 0.99 ± 0.2 0.71 ± 0.2
P7 99.9 ± 0.0 41.8 ± 3.4 * 33.6 ± 4.3 * 54.3 ± 3.6 * 26.3 ± 4.4 ** 1.8 ± 1.0 0.11 ± 0.1 * 0.1 ± 0.0 *
CB-MSC
P3 89.6 ± 4.2 87.9 ± 2.6 34.2 ± 3.3 60.2 ± 4.1 83.9 ± 5.4 6.7 ± 1.3 0.84 ± 0.4 38.4 ± 3.6
P7 99.9 ± 0.1 94.5 ± 2.7 7.5 ± 1.7 * 99.1 ± 0.5 ** 97.0 ± 1.8 * 0.3 ± 0.2 * 0.51 ± 0.3 1.1 ± 0.3 *
* p < 0.05 and ** p < 0.01 in the comparison between P3 and P7.
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Figure 3. Immunophenotypes of MSCs. Cell surface markers for MSCs, CD29, CD44, CD105,
CD106, and Sca-1 were used to characterize (a) AT-MSC and (b) CB-MSC at passage 3 (P3) and 7
(P7), respectively. Representative flow cytometry patterns were shown. Shaded peaks represent
antibody-labeled population; blank peaks represented isotype controls.
3.3. Biased Differentiation Towards the Tissue Origin
A defining feature of MSC is their ability to differentiate into multiple mesodermal lineages.
To examine the multi-lineage differentiation potentials of MSCs derived from different tissue origins,
we induced in vitro differentiation of early and late passage (P3 and P7) AT-MSC and CB-MSC into
the osteogenic, adipogenic, and chondrogenic lineages. We observed that both AT-MSCs and CB-MSCs
were able to differentiate into the three lineages (Figure 4), indicating that MSCs from adipose tissue or
compact bone are multipotent in nature. However, although both types of MSCs were able to form
the positive Alcian Blue stained chondrocyte spheroids efficiently (Figure 4i–l), we observed that fewer
cells stained positive with Alizarin Red in the AT-MSC sample (Figure 4a–d) and lower number of Oil
Red O stained cells from CB-MSC sample (Figure 4e–h). Besides, the P7 MSCs of both types appeared to
have weaker positive staining patterns when compared to the early P3 samples. These results suggest
that MSCs derived from different tissue origins exhibit differentiation bias and their differentiation
capacities reduce after prolonged culture.
To further elucidate the differentiation bias associated with the tissue origin of MSCs, we
examined the expression of osteogenic (Ocn and Opn), adipogenic (Adipoq and Pparg) and chondrogenic
(Sox9 and Col2a1) markers in the differentiated MSC samples. Induction of Ocn and Opn were high in
the osteogenic differentiation of P3 CB-MSC when compared to the P7 CB-MSC (over 4-fold for both
genes). Importantly, osteogenic differentiated AT-MSC demonstrated significantly lower expression of
these two osteogenic markers, regardless of the length of culture (Figure 5a, Figure S2a).
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Figure 4. Osteogenic and adipogenic differentiation of MSCs. AT-MSCs and CB-MSCs underwent
18-day of osteogenic, 14-day of adipogenic, or 21-days of chondrogenic differentiation conditions.
(a–d) Alizarin red staining, (e–h) Oil Red O staining, and (i–l) Alcian blue staining were used to assess
osteogenic, adipogenic and chondrogenic differentiation, respectively. Passage 3 of CB-MSCs displayed
stronger staining for Alizarin red; whereas passage 3 of AT-MSCs displayed stronger Oil-Red-O
staining. Late passage MSCs showed weaker staining in both lineage differentiations. Chondrogenic
differentiation is comparable in both types of MSCs. The white arrows indicate the stained chondrocyte
spheroids. Representative images were taken at 20× (a–h) or 5× (i–l) magnification. Scale bars:
(a–h) 100 μm; (i–l) 1 mm.
Figure 5. Cont.
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Figure 5. Expression of lineage marker genes in the differentiated MSCs. (a) Osteogenic markers,
Ocn and Opn, (b) adipogenic markers, Adipoq and Pparg, and (c) chondrogenic markers, Sox9 and Col2a1,
were used to determine the multi-lineage differentiation of AT-MSCs and CB-MSCs. MSCs cultured
in basic medium without differentiation agents for the same period of time were served as controls.
Gene expressions were normalized with housekeeping gene Gapdh. Experiments were performed with
three replicates. Data represent mean ± SD; *p < 0.05 and ** p < 0.01.
In contrast, AT-MSCs were able to express a high level of Adipoq and Pparg when compared to
the CB-MSCs in adipogenic differentiation (over 4-fold for both genes) (Figure 5b and Figure S2b).
The expression of adipogenic markers was less pronounced between different passages of MSCs.
We also noticed that the expression of Sox9 and Col2a1 was high in both types of differentiated
MSCs (Figure 5c and Figure S2c), which implies comparable chondrogenic differentiation efficiency.
Taken together, the differential expressions of osteogenic and adipogenic markers are in agreement with
the Alizarin red and Oil Red O staining patterns (Figure 4), suggesting that MSCs, although harboring
multi-lineage differentiation potential, have a preference to differentiate towards their tissues of origin.
3.4. Inhibition of DNA Methylation Alters MSC Multipotency
MSCs derived from different tissues could be modulated by the microenvironment which confers
a differential epigenetic state associated with stem cell multipotency. To determine whether DNA
methylation, a well-known epigenetic modification, is involved in the differentiation bias of CB-MSC
and AT-MSC, we treated MSCs with the DNA methylation inhibitor, 5-azacytidine (5-aza), for 48 h
prior in vitro differentiation. The 48-h treatment period was chosen based on the rationale that
the epigenetic function of 5-aza as a DNA methylation inhibitor is dependent on cell division [30],
which takes roughly 2 days (determined by the doubling time in Figure 2c) for both types of MSCs.
Both types of MSCs under 5-aza treatment were able to differentiate into osteogenic and adipogenic
lineages (Figure 6a). Interestingly, we observed that there were more osteogenic differentiated cells
stained with Alizarin red from the 5-aza-treated CB-MSCs when comparing to the untreated sample.
However, the number of osteogenic differentiated AT-MSCs remains low by the 5-aza treatment.
This observation is in agreement with the qRT-PCR results of the osteogenic marker expression,
which showed a significant increase in Ocn and Opn expression in the 5-aza-treated CB-MSCs (Figure 6b
and Figure S3a). Unexpectedly, although the AT-MSCs are more competent to undergo adipogenic
differentiation, the 5-aza treatment resulted in a lower number of Oil Red O stained cells (Figure 6a),
with a significant decrease in the expression of adipogenic markers Adipoq and Pparg (Figure 6b
and Figure S3b). By contrast, the treated CB-MSCs showed enhanced adipogenic differentiation with
a comparable level of adipogenic marker gene expression to the untreated AT-MSCs. These results
suggest that inhibition of DNA methylation can restore the biased differentiation capacity of CB-MSC
to the adipogenic lineage, whereas AT-MSC loses its multipotency under the same epigenetic condition.
It thus implies a differential epigenetic effect of 5-aza on the MSCs derived from different tissue sources.
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Figure 6. Osteogenic and adipogenic differentiation of the 5-aza-treated MSCs. (a) AT-MSCs
and CB-MSCs were pre-treated with 5-aza for 48 h prior to osteogenic (Alizarin red staining)
or adipogenic differentiation (Oil Red O staining). Representative images were taken at 20×. Scale bars:
100μm. (b) The expression of osteocyte markers (Ocn and Opn) and adipocyte markers (Adipoq and Pparg)
were determined by qRT-PCR. MSCs cultured in basic medium without differentiation agents for
the same period of time were served as controls. Gene expressions were normalized with housekeeping
gene Gapdh. Experiments were performed with three replicates. Data represent mean ± SD; * p < 0.05
and ** p < 0.01.
4. Discussion
In this study, murine MSCs were isolated from compact bone and adipose tissue. Our results
showed that prolonged culture of MSC leads to changes in cell morphology and cell surface marker
patterns, and cell proliferation rate. Importantly, the tissue origins of MSC have impact on their
77
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differentiation capacity towards the corresponding cell lineages, indicating the presence of epigenetic
memory in the MSCs. The multipotency of CB-MSC, but not AT-MSC, can be enhanced through
inhibition of DNA methylation prior differentiation, which suggests a possible strategy to erase
the epigenetic memory in certain tissue-derived MSCs. Although we were using murine MSCs in our
study, cross-species comparisons of MSC corroborated that the surface markers [31] and biological
functions [32] of MSC are similar, even though not identical, between different species. There are
numerous studies of the therapeutic applications of MSCs using mouse models for the investigation of
the molecular mechanisms and the safety concerns prior to human clinical trials [33]. With the findings of
preferential differentiation of murine MSCs derived from different tissues and the possible manipulation
of the epigenetic memory in MSCs, we propose that our findings can be applied to human MSCs for
the selection of optimal tissue source and the strategy to enhance the multipotency of human MSCs for
therapeutic applications.
The immunophenotype of MSCs is dynamic over the culture period. MSCs isolated from
various tissues were reported to express a common set of cell surface markers, such as CD105, CD90,
CD73, CD29, and CD44, with a lack of CD34, CD45, CD11b, and major histocompatibility complex
(MHC) class II expression [25]. The MSC isolation protocols retained the plastic adherent cells from
the tissue, which invariably consist of a heterogeneous cell population including hematopoietic
cells and other tissue cells. Nevertheless, the non-MSC populations presumably undergo depletion
gradually in the MSC culture condition, resulting in a more homogeneous MSC population. In our
study, we observed that nearly all the early passage MSCs from both compact bone and adipose
tissue expressed CD29 and Sca-1, but only 34–50% are CD105+ and 38–60% are CD106+, suggesting
the heterogeneity of MSC immunophenotypes. Prolonged culture of MSCs leads to loss of Sca-1
and CD105 expression, which is particularly obvious in the AT-MSCs and CB-MSCs, respectively.
Similar observation for the loss of CD15, CD90, and CD309 was also reported in the neoplastic
transformation of bone marrow-derived MSCs after numerous passages [34]. The loss of MSC
immunophenotype is correlated with the findings of fibroblastoid morphology change, reduced cell
proliferation and differentiation potentials of the late passage MSCs, suggesting that the “stemness” of
MSCs cannot be maintained by prolonged culture. This is in agreement with the previous study of
the prolonged culture of human bone marrow-derived MSCs with a loss of osteogenic potential [35].
However, the loss of stemness could be less prominent in other tissue-derived MSCs, for example,
umbilical cord MSCs, which retained comparable growth rate and osteogenic capacity after 16 passages
when compared to the freshly isolated one [36]. Although the MSC culture condition used in this study
follows a common protocol in the field, the alterations of MSC phenotypes and cell functions owing
to the prolonged culture might reflect a suboptimal condition that needs to be further optimized for
better maintenance of the stemness of MSCs. In addition, it has been reported that a subpopulation of
MSC is CD105 negative [37,38], which varies in the differentiation potentials and modulation of CD4+
T cell proliferation when comparing to the CD105+ counterpart. Interestingly, the CD105 expression
in the CD105+ MSCs can be altered by the culture condition, such as passage number, cell density,
and medium composition [37,39]. Being a component of the TGF-β receptor, CD105 also serves as
a proliferation marker of endothelial cells [40]. As we observed a reduction of MSC proliferation upon
prolonged culturing, we speculate that this could be associated with the loss of CD105 expression in
the P7 MSCs.
The biased differentiation capacity of MSCs derived from different tissues remains controversial.
While several studies have reported that bone marrow-derived MSCs were more prone to
osteogenic differentiation [17,41,42] and adipose tissue-derived MSCs showed decreased chondrogenic
differentiation capacity [43,44], others demonstrated no significant differences in differentiation
potentials of MSCs derived from various tissues [16–18]. In our study, we observed that both types of
MSCs showed comparable chondrogenic differentiation, but preferential differentiation of AT-MSCs
to adipo-lineage and CB-MSCs to osteo-lineage. It is proposed that the isolation procedures, culture
condition, such as with serum or serum-free, and the heterogeneity of MSC populations may account for
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the preferential differentiation to certain lineages through enrichment of distinct MSC subpopulations.
In addition, MSCs resided in different tissues are subjected to the distinct cellular microenvironments,
e.g., signaling molecules, extracellular matrix components, metabolites, etc. These extrinsic factors
can induce alterations of the MSC epigenome, leading to potential variations in transcriptomes
and biological responses related to stemness [45]. This is indeed supported by the global transcriptomic
and proteomic studies which demonstrated substantial differences in the expression of genes or proteins
between MSCs derived from bone marrow and adipose tissue [17,20,46,47]. The biased differentiation of
CB-MSC and AT-MSC also suggests that the altered epigenome is retained as the “epigenetic memory”
of tissue origin. It is reported that the reprogrammed stem cells showed preferential differentiation
towards their somatic lineage origins. The epigenetic memory of donor cell origin was found in Xenopus
nuclear transplanted embryos [48] and early passage of induced pluripotent stem cells (iPSCs) [49,50].
It has been shown that blood-derived iPSCs were preferentially differentiated towards blood lineages
and were defective to osteogenic differentiation, whereas bone marrow-derived iPSC demonstrated
the opposite [50]. Although the derivation of MSCs does not involve cellular reprogramming, MSCs
located at different tissues might be epigenetically reprogrammed by the tissue niche environment.
Previous studies reported that the memory status in iPSC can be erased by extensive cell culture
passages [49] or by epigenetic modifying agents, such as DNA methylation inhibitor [50]. It remains
a challenge to test if the memory status of MSCs can be erased by prolonged culture because late
passage MSCs undergo senescence and reduced overall differentiation capacity. Interestingly, our
data showed that inhibition of DNA methylation can partially restore the adipogenic differentiation
capacity of CB-MSCs, suggesting a possible way to erase the epigenetic memory in MSCs. However,
we noticed that AT-MSCs failed to restore osteogenic differentiation after 5-aza treatment, suggesting
the involvement of other types of epigenetic modifications, e.g., histone protein methylation or
acetylation. Therefore, it is worth evaluating the effects of other epigenetic inhibitors, such as histone
deacetylase inhibitors, on the multipotency of MSCs derived from other tissues.
5. Conclusions
We have demonstrated that early passage MSCs derived from compact bone or adipose tissue
are highly proliferative and retain multipotent nature. The tissue origin of the MSCs results in
epigenetic memory which implicates a preference for lineage differentiation. A better understanding
of the molecular nature of such tissue origin memory can facilitate the choice of optimal sources of
MSCs for tissue engineering and regenerative medicine.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/3/756/s1,
Figure S1: Immunophenotypes of hematopoietic markers on MSCs, Figure S2: Expression of lineage marker
genes in the differentiated MSCs with reference to β-Actin gene, Figure S3: Expression of lineage marker genes in
the differentiated 5-aza-treated MSCs with reference to β-Actin gene, Table S1: Primer sequences for qRT-PCR.
Author Contributions: Conceptualization, T.T.N. and R.K.N.; methodology, T.T.N.; validation, T.T.N., K.H.-M.M.
and C.P..; formal analysis, T.T.N., R.K.N.; investigation, T.T.N.; data curation, K.H.-M.M., C.P.; writing—original
draft preparation, T.T.N.; writing—review and editing, R.K.N.; supervision, R.K.N.; project administration, R.K.N.;
funding acquisition, R.K.N. All authors have read and agreed to the published version of the manuscript
Funding: This research was funded by Research Grants Council General Research Fund, grant number
HKU774712M, and Theme-based Research Scheme, grant number T12-708/12-N. The APC was funded by
National Natural Science Foundation of China (NSFC) - Science Fund for Young Scholars, grant number 026-NG
KIT_81200341, and NSFC-Shenzhen Matching Fund 2013, grant number 121-NG KIT_SIRI/04/04/2014/22.
Acknowledgments: The authors thank the Faculty Core Facility of the University of Hong Kong Li Ka Shing
Faculty of Medicine for assistance with the flow cytometry analyses.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study;
in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish
the results.
79
Cells 2020, 9, 756
References
1. Nombela-Arrieta, C.; Ritz, J.; Silberstein, L.E. The elusive nature and function of mesenchymal stem cells.
Nat. Rev. Mol. Cell Biol. 2011, 12, 126–131. [CrossRef] [PubMed]
2. Friedenstein, A.J.; Chailakhyan, R.K.; Latsinik, N.V.; Panasyuk, A.F.; Keiliss-Borok, I.V. Stromal
cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro
and retransplantation in vivo. Transplantation 1974, 17, 331–340. [CrossRef] [PubMed]
3. Fukuchi, Y.; Nakajima, H.; Sugiyama, D.; Hirose, I.; Kitamura, T.; Tsuji, K. Human placenta-derived cells
have mesenchymal stem/progenitor cell potential. Stem Cells 2004, 22, 649–658. [CrossRef]
4. Short, B.; Wagey, R. Isolation and culture of mesenchymal stem cells from mouse compact bone.
Methods Mol. Biol. 2013, 946, 335–347. [PubMed]
5. Zhu, H.; Guo, Z.K.; Jiang, X.X.; Li, H.; Wang, X.Y.; Yao, H.Y.; Zhang, Y.; Mao, N. A protocol for isolation
and culture of mesenchymal stem cells from mouse compact bone. Nat. Protoc. 2010, 5, 550–560. [CrossRef]
[PubMed]
6. Zhu, Y.; Liu, T.; Song, K.; Fan, X.; Ma, X.; Cui, Z. Adipose-derived stem cell: A better stem cell than BMSC.
Cell Biochem. Funct. 2008, 26, 664–675. [CrossRef]
7. Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Douglas, R.; Mosca, J.D.; Moorman, M.A.;
Simonetti, D.W.; Craig, S.; Marshak, D.R. Multilineage potential of adult human mesenchymal stem
cells. Science 1999, 284, 143–147. [CrossRef]
8. Anghileri, E.; Marconi, S.; Pignatelli, A.; Cifelli, P.; Galie, M.; Sbarbati, A.; Krampera, M.; Belluzzi, O.;
Bonetti, B. Neuronal differentiation potential of human adipose-derived mesenchymal stem cells. Stem Cells
Dev. 2008, 17, 909–916. [CrossRef]
9. Mizuno, H.; Zuk, P.A.; Zhu, M.; Lorenz, H.P.; Benhaim, P.; Hedrick, M.H. Myogenic differentiation by human
processed lipoaspirate cells. Plast. Reconstr. Surg. 2002, 109, 199–209, discussion 210–211. [CrossRef]
10. Oswald, J.; Boxberger, S.; Jorgensen, B.; Feldmann, S.; Ehninger, G.; Bornhauser, M.; Werner, C. Mesenchymal
stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004, 22, 377–384. [CrossRef]
11. Snykers, S.; De Kock, J.; Rogiers, V.; Vanhaecke, T. In vitro differentiation of embryonic and adult stem cells
into hepatocytes: State of the art. Stem Cells 2009, 27, 577–605. [CrossRef] [PubMed]
12. Trounson, A.; McDonald, C. Stem Cell Therapies in Clinical Trials: Progress and Challenges. Cell Stem Cell
2015, 17, 11–22. [CrossRef] [PubMed]
13. Spaggiari, G.M.; Capobianco, A.; Becchetti, S.; Mingari, M.C.; Moretta, L. Mesenchymal stem cell-natural
killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can
inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107, 1484–1490. [CrossRef] [PubMed]
14. Aggarwal, S.; Pittenger, M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses.
Blood 2005, 105, 1815–1822. [CrossRef] [PubMed]
15. Beyth, S.; Borovsky, Z.; Mevorach, D.; Liebergall, M.; Gazit, Z.; Aslan, H.; Galun, E.; Rachmilewitz, J.
Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.
Blood 2005, 105, 2214–2219. [CrossRef]
16. Kern, S.; Eichler, H.; Stoeve, J.; Kluter, H.; Bieback, K. Comparative analysis of mesenchymal stem cells from
bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006, 24, 1294–1301. [CrossRef]
17. Noel, D.; Caton, D.; Roche, S.; Bony, C.; Lehmann, S.; Casteilla, L.; Jorgensen, C.; Cousin, B. Cell specific
differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation
potentials. Exp. Cell Res. 2008, 314, 1575–1584. [CrossRef]
18. De Ugarte, D.A.; Morizono, K.; Elbarbary, A.; Alfonso, Z.; Zuk, P.A.; Zhu, M.; Dragoo, J.L.; Ashjian, P.;
Thomas, B.; Benhaim, P.; et al. Comparison of multi-lineage cells from human adipose tissue and bone
marrow. Cells Tissues Organs 2003, 174, 101–109. [CrossRef]
19. Al-Nbaheen, M.; Vishnubalaji, R.; Ali, D.; Bouslimi, A.; Al-Jassir, F.; Megges, M.; Prigione, A.; Adjaye, J.;
Kassem, M.; Aldahmash, A. Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue
and skin exhibit differences in molecular phenotype and differentiation potential. Stem Cell Rev. 2013,
9, 32–43. [CrossRef]
20. Izadpanah, R.; Trygg, C.; Patel, B.; Kriedt, C.; Dufour, J.; Gimble, J.M.; Bunnell, B.A. Biologic properties of
mesenchymal stem cells derived from bone marrow and adipose tissue. J. Cell. Biochem. 2006, 99, 1285–1297.
[CrossRef]
80
Cells 2020, 9, 756
21. Muraglia, A.; Cancedda, R.; Quarto, R. Clonal mesenchymal progenitors from human bone marrow
differentiate in vitro according to a hierarchical model. J. Cell Sci. 2000, 113, 1161–1166. [PubMed]
22. Satomura, K.; Krebsbach, P.; Bianco, P.; Gehron Robey, P. Osteogenic imprinting upstream of marrow stromal
cell differentiation. J. Cell. Biochem. 2000, 78, 391–403. [CrossRef]
23. Bunnell, B.A.; Flaat, M.; Gagliardi, C.; Patel, B.; Ripoll, C. Adipose-derived stem cells: Isolation, expansion
and differentiation. Methods 2008, 45, 115–120. [CrossRef] [PubMed]
24. Mosna, F.; Sensebe, L.; Krampera, M. Human bone marrow and adipose tissue mesenchymal stem cells:
A user’s guide. Stem Cells Dev. 2010, 19, 1449–1470. [CrossRef]
25. Dominici, M.; Le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.; Krause, D.; Deans, R.;
Keating, A.; Prockop, D.; Horwitz, E. Minimal criteria for defining multipotent mesenchymal stromal
cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8, 315–317.
[CrossRef]
26. Houlihan, D.D.; Mabuchi, Y.; Morikawa, S.; Niibe, K.; Araki, D.; Suzuki, S.; Okano, H.; Matsuzaki, Y. Isolation
of mouse mesenchymal stem cells on the basis of expression of Sca-1 and PDGFR-alpha. Nat. Protoc. 2012,
7, 2103–2111. [CrossRef]
27. Lee, R.H.; Kim, B.; Choi, I.; Kim, H.; Choi, H.S.; Suh, K.; Bae, Y.C.; Jung, J.S. Characterization and expression
analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell. Physiol. Biochem.
2004, 14, 311–324. [CrossRef]
28. Yamamoto, N.; Akamatsu, H.; Hasegawa, S.; Yamada, T.; Nakata, S.; Ohkuma, M.; Miyachi, E.; Marunouchi, T.;
Matsunaga, K. Isolation of multipotent stem cells from mouse adipose tissue. J. Dermatol. Sci. 2007, 48, 43–52.
[CrossRef]
29. Sung, J.H.; Yang, H.M.; Park, J.B.; Choi, G.S.; Joh, J.W.; Kwon, C.H.; Chun, J.M.; Lee, S.K.; Kim, S.J. Isolation
and characterization of mouse mesenchymal stem cells. Transpl. Proc. 2008, 40, 2649–2654. [CrossRef]
30. Taylor, S.M.; Jones, P.A. Mechanism of action of eukaryotic DNA methyltransferase. Use of
5-azacytosine-containing DNA. J. Mol. Biol. 1982, 162, 679–692. [CrossRef]
31. Ghaneialvar, H.; Soltani, L.; Rahmani, H.R.; Lotfi, A.S.; Soleimani, M. Characterization and Classification
of Mesenchymal Stem Cells in Several Species Using Surface Markers for Cell Therapy Purposes. Indian J.
Clin. Biochem. 2018, 33, 46–52. [CrossRef] [PubMed]
32. Laing, A.G.; Fanelli, G.; Ramirez-Valdez, A.; Lechler, R.I.; Lombardi, G.; Sharpe, P.T. Mesenchymal stem
cells inhibit T-cell function through conserved induction of cellular stress. PLoS ONE 2019, 14, e0213170.
[CrossRef] [PubMed]
33. Uder, C.; Bruckner, S.; Winkler, S.; Tautenhahn, H.M.; Christ, B. Mammalian MSC from selected species:
Features and applications. Cytom. Part A 2018, 93, 32–49. [CrossRef]
34. Miura, M.; Miura, Y.; Padilla-Nash, H.M.; Molinolo, A.A.; Fu, B.; Patel, V.; Seo, B.M.; Sonoyama, W.; Zheng, J.J.;
Baker, C.C.; et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells
leads to malignant transformation. Stem Cells 2006, 24, 1095–1103. [CrossRef] [PubMed]
35. Derubeis, A.R.; Cancedda, R. Bone marrow stromal cells (BMSCs) in bone engineering: Limitations and recent
advances. Ann. Biomed. Eng. 2004, 32, 160–165. [CrossRef] [PubMed]
36. Shi, Z.; Zhao, L.; Qiu, G.; He, R.; Detamore, M.S. The effect of extended passaging on the phenotype
and osteogenic potential of human umbilical cord mesenchymal stem cells. Mol. Cell. Biochem. 2015,
401, 155–164. [CrossRef] [PubMed]
37. Anderson, P.; Carrillo-Galvez, A.B.; Garcia-Perez, A.; Cobo, M.; Martin, F. CD105 (endoglin)-negative
murine mesenchymal stromal cells define a new multipotent subpopulation with distinct differentiation
and immunomodulatory capacities. PLoS ONE 2013, 8, e76979. [CrossRef]
38. Leyva-Leyva, M.; Barrera, L.; Lopez-Camarillo, C.; Arriaga-Pizano, L.; Orozco-Hoyuela, G.;
Carrillo-Casas, E.M.; Calderon-Perez, J.; Lopez-Diaz, A.; Hernandez-Aguilar, F.; Gonzalez-Ramirez, R.; et al.
Characterization of mesenchymal stem cell subpopulations from human amniotic membrane with dissimilar
osteoblastic potential. Stem Cells Dev. 2013, 22, 1275–1287. [CrossRef]
39. Mark, P.; Kleinsorge, M.; Gaebel, R.; Lux, C.A.; Toelk, A.; Pittermann, E.; David, R.; Steinhoff, G.; Ma, N.
Human Mesenchymal Stem Cells Display Reduced Expression of CD105 after Culture in Serum-Free Medium.
Stem Cells Int. 2013, 2013, 698076. [CrossRef]
81
Cells 2020, 9, 756
40. Li, C.; Guo, B.; Ding, S.; Rius, C.; Langa, C.; Kumar, P.; Bernabeu, C.; Kumar, S. TNF alpha down-regulates
CD105 expression in vascular endothelial cells: A comparative study with TGF beta 1. Anticancer Res. 2003,
23, 1189–1196.
41. Sakaguchi, Y.; Sekiya, I.; Yagishita, K.; Muneta, T. Comparison of human stem cells derived from various
mesenchymal tissues: Superiority of synovium as a cell source. Arthritis Rheum. 2005, 52, 2521–2529.
[CrossRef] [PubMed]
42. Bochev, I.; Elmadjian, G.; Kyurkchiev, D.; Tzvetanov, L.; Altankova, I.; Tivchev, P.; Kyurkchiev, S. Mesenchymal
stem cells from human bone marrow or adipose tissue differently modulate mitogen-stimulated B-cell
immunoglobulin production in vitro. Cell Biol. Int. 2008, 32, 384–393. [CrossRef] [PubMed]
43. Winter, A.; Breit, S.; Parsch, D.; Benz, K.; Steck, E.; Hauner, H.; Weber, R.M.; Ewerbeck, V.; Richter, W.
Cartilage-like gene expression in differentiated human stem cell spheroids: A comparison of bone
marrow-derived and adipose tissue-derived stromal cells. Arthritis Rheum. 2003, 48, 418–429. [CrossRef]
[PubMed]
44. Huang, J.I.; Kazmi, N.; Durbhakula, M.M.; Hering, T.M.; Yoo, J.U.; Johnstone, B. Chondrogenic potential
of progenitor cells derived from human bone marrow and adipose tissue: A patient-matched comparison.
J. Orthop. Res. 2005, 23, 1383–1389. [CrossRef]
45. Ho, Y.T.; Shimbo, T.; Wijaya, E.; Ouchi, Y.; Takaki, E.; Yamamoto, R.; Kikuchi, Y.; Kaneda, Y.; Tamai, K.
Chromatin accessibility identifies diversity in mesenchymal stem cells from different tissue origins. Sci. Rep.
2018, 8, 17765. [CrossRef]
46. Park, H.W.; Shin, J.S.; Kim, C.W. Proteome of mesenchymal stem cells. Proteomics 2007, 7, 2881–2894.
[CrossRef]
47. Wagner, W.; Wein, F.; Seckinger, A.; Frankhauser, M.; Wirkner, U.; Krause, U.; Blake, J.; Schwager, C.;
Eckstein, V.; Ansorge, W.; et al. Comparative characteristics of mesenchymal stem cells from human bone
marrow, adipose tissue, and umbilical cord blood. Exp. Hematol. 2005, 33, 1402–1416. [CrossRef]
48. Ng, R.K.; Gurdon, J.B. Epigenetic memory of active gene transcription is inherited through somatic cell
nuclear transfer. Proc. Natl. Acad. Sci. USA 2005, 102, 1957–1962. [CrossRef]
49. Polo, J.M.; Liu, S.; Figueroa, M.E.; Kulalert, W.; Eminli, S.; Tan, K.Y.; Apostolou, E.; Stadtfeld, M.; Li, Y.;
Shioda, T.; et al. Cell type of origin influences the molecular and functional properties of mouse induced
pluripotent stem cells. Nat. Biotechnol. 2010, 28, 848–855. [CrossRef]
50. Kim, K.; Doi, A.; Wen, B.; Ng, K.; Zhao, R.; Cahan, P.; Kim, J.; Aryee, M.J.; Ji, H.; Ehrlich, L.I.; et al. Epigenetic
memory in induced pluripotent stem cells. Nature 2010, 467, 285–290. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Spheroid Culture System Methods and Applications
for Mesenchymal Stem Cells
Na-Eun Ryu 1, Soo-Hong Lee 2,* and Hansoo Park 1,*
1 Department of Integrative Engineering, Chung-Ang University, Seoul 06974, Korea;
ryuskdms234@gmail.com
2 Department of Medical Biotechnology, Dongguk University, Seoul 06974, Korea
* Correspondence: soohong@dongguk.edu (S.-H.L.); heyshoo@gmail.com (H.P.);
Tel.: +82-31-961-5153 (S.-H.L.); +82-2-820-5940 (H.P.)
Received: 26 November 2019; Accepted: 9 December 2019; Published: 12 December 2019
Abstract: Owing to the importance of stem cell culture systems in clinical applications, researchers
have extensively studied them to optimize the culture conditions and increase efficiency of cell culture.
A spheroid culture system provides a similar physicochemical environment in vivo by facilitating
cell–cell and cell–matrix interaction to overcome the limitations of traditional monolayer cell culture.
In suspension culture, aggregates of adjacent cells form a spheroid shape having wide utility in tumor
and cancer research, therapeutic transplantation, drug screening, and clinical study, as well as organic
culture. There are various spheroid culture methods such as hanging drop, gel embedding, magnetic
levitation, and spinner culture. Lately, efforts are being made to apply the spheroid culture system to
the study of drug delivery platforms and co-cultures, and to regulate differentiation and pluripotency.
To study spheroid cell culture, various kinds of biomaterials are used as building forms of hydrogel,
film, particle, and bead, depending upon the requirement. However, spheroid cell culture system has
limitations such as hypoxia and necrosis in the spheroid core. In addition, studies should focus on
methods to dissociate cells from spheroid into single cells.
Keywords: 3D cell culture; spheroid culture; biomaterials
1. Introduction
Stem cells are valuable resources in regenerative medicine with clinical and research applications
(Table 1). Particularly, human mesenchymal stem cells have secretory properties constituted
by anti-inflammation, angiogenesis, and immune reaction regulation factors [1,2]. The primary
characteristic of stem cells is stemness, represented by their ability of self-renewal, which generate new
same cells from the original stem cells, and multipotency, which allows production of new differentiated
cells having relatively limited potential [3]. Another characteristic of stem cells is clonality, which is
related to lineage of stem cells [4]. Stemness enables the stem cells to have potential for application
in numerous biological therapeutic tools such as cell-based therapy, high-throughput pharmacology,
drug screening, and tissue engineering. However, stemness is actually maintained in the in vivo
microenvironment, which provides growth factors in addition to the cell–cell or cell– extracellular
matrix interactions. Therefore, conditions of the cell culture are very essential to facilitate the properties
of stemness, maintenance, and proliferation. To fully exploit the properties of stem cells, development
of cell culture methods that can increase the proliferation of cells in terms of cell count and superior
quality are important. Previously, studies have attempted to develop methods for enhancing stemness
and proliferation during in vitro cell culture process [5,6].
Cells constantly require biological signals from the substrates in cellular niches. These signals
encourage proliferation and enhance cellular viability. However, the signals can also inhibit proliferation
and biological activation of cells, thereby checking the growth [7]. In general, traditional two-dimension
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cell culture systems, wherein the cells grow as a monolayer, face some limitations in the realization
of in vivo multi-cellular conditions [8]. These limitations restrict the cellular studies involving
multi-cellular features and cancer cells [9]. When stem cells grow in two-dimensional cultures,
maintenance of the differentiation potential and stemness is relatively more difficult than in stem
cells growing in actual multi-cellular conditions [6]. However, three-dimensional cell culture
systems can reconstitute conditions similar to that in an in vivo microenvironment (Table 2). Three
dimensional systems construct cell–cell and cell–extracellular matrix (ECM) interaction networks
(Table 2), which play a significant role in various cellular mechanisms, subsequently maintaining the
cellular properties [10]. Researchers can attempt to decrease the limitations of conventional monolayer
culturing and develop progressive cellular study methods (Table 2).
Spheroid culture system is a promising three-dimensional cell culture method. Morphology of
stem cells cultured in spheroid culture system is different from that of cells in the monolayer culture
system. In addition, mesenchymal stem cells of spheroids maintain their intrinsic phenotypic properties
by cell–extracellular matrix interactions (Table 2) [11].
Spheroid stem cell cultures promote the expression of transcriptional factors of stemness markers
such as Oct-4 and Nanog (Table 2). Spheroid stem cells secrete higher levels of cytokines and chemokines
that affect the proliferation, viability, and migration of cells and also secrete higher angiogenesis than
those secreted in the monolayer stem cells (Table 2). Spheroid stem cells regulated by hypoxia-induced
upregulation of gene expression have properties of apoptosis resistance, improved viability, and
secretion of angiogenic factors and chemokines (Table 2) [12,13].
Table 1. Applications of spheroid of Mesenchymal stem cells.
Applications of Spheroid Examples
Tumor model MSCs have resistance to chemotherapies and produce biochemical
responses similar to parental tumors. Therefore MSCs-based modeling is
usable to predict in vivo therapeutic efficacy [9].
Biology research Co-culture of MSCs with other cells has been used to analyze cell–cell
interaction. The cell–cell interactions are crucial to function of tissues [9].
Tissue Engineering MSCs have been used for organ reconstruction. Spheroid of MSCs
provide advantageous conditions for organ reconstruction. The MSCs can
be transplanted to patient [9].
Transplantation therapy Differentiation of MSCs is enhanced by spheroid culture system. In vivo
tissue (cartilage [14,15], bone [16], spinal cord [17], nerve [18]) formation
may be enhanced after MSCs spheroid transplantation.
Table 2. Advantages and disadvantages of spheroid culture.
Advantages Disadvantages
• facilitate cell–cell and cell–matrix interaction
• provide a similar physicochemical environment to the
in vivo
•maintain intrinsic phenotypic properties
• promote the stemness marker expression
• secrete cytokines, chemokines and angiogenic factors
• improve viability and proliferation
• have diffusion gradient with increased spheroid
size and lack of nutrients in the core of spheroid
2. Mechanism of Spheroid Formation
In a cell culture suspension, cells tend to aggregate and go through the process of self-assembly.
Self-assembly means single cells constitute multi-cellular spheroids by themselves. Self-assembly is a
natural phenomenon that happens during embryogenesis, morphogenesis, and organogenesis. It is
affected by various factors, including gradients of nutrients, oxygen, and growth factors in cell culture
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medium, as well as cellular paracrine factors. Cell culture medium permeates inside the spheroids
by diffusion. The gradient of diffusion is induced by increasing the spheroid size during spheroid
culture. The bigger the size attained by the spheroids, the harder it becomes for the medium to reach
the core of the spheroids. In addition, the rate of production and consumption of factors can affect
self-assembly [19].
Adhesion and differentiation of cells affect the formation of multi-cellular spheroids. In particular,
cadherin and integrin are directly related to the mechanism of spheroid formation. The process of
spheroid formation is divided into several steps. Firstly, single cells present within the suspension
agglomerate to form loosely adhesive cell spheroids. In this step, extracellular matrix fibers including
complementary binding of peripheral cell surface to integrin encourages preliminary aggregation. Next,
E-cadherin promotes strong adhesion of initial cell aggregate by creating homophilic binding between
cadherins of peripheral cells. In addition, β-catenin complex facilitates cellular signal transduction.
Actin can also affect agglomeration and stemness by promoting contacts between adjacent cells [20].
As a result, strong adhesive multi-cellular spheroids are formed [21].
E-cadherin (CDH1), a Ca2+-dependent homophilic transmembrane adhesion molecule, could be a
central component of spheroid formation [22,23]. The effects of E-cadherin have been demonstrated in
cellular experiments involving human breast cancer cell lines and mouse embryonic stem cells [24].
For example, in a mouse embryonic stem cell study, E-cadherin-mediated cell attachment initiates
embryonic body agglomeration. In addition, if the reaction of E-cadherin on the embryonic body
with α-mouse E-cadherin antibodies is blocked, there is considerable inhibition of embryonic body
agglomeration [25]. Integrins are transmembrane adhesion proteins composed of α-subunits and
β-subunits of heterodimers that facilitate the cell-ECM connection during cell invasion and migration.
Apart from E-cadherin, β1-integrin also plays a role in the attachment of the early spheroid formation.
Interaction of integrin-ECM affects multi-cellular spheroid formation rates [21].
3. Spheroid Formation Methods
3.1. Technical Methods
3.1.1. Pellet Culture
In this system, cells are concentrated to the bottom of the tube by centrifugal force. Cell–cell
adhesions are maximized by proximity of the single cells at the bottom of the tube (Figure 1a), (Table 3).
To harvest the cell pellet, supernatants are removed, and cell pellets are resuspended in spheroid
formation cell culture medium. After estimating the cell count, cells in medium are dispensed into
each well of a 96-well U bottom plate with cell repellent surface [19,26].
Figure 1. Schemes of technical methods. (a) Pellet Culture, (b) Liquid Overlay, (c) Hanging Drop, (d)
Spinner Culture, (e) Rotating Wall Vessel, (f) Microfluidics, (g) Magnetic Levitation.
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Table 3. Properties of technical methods.
Technical Method Properties
Pellet Culture use centrifugal force to concentrate cells
Liquid Overlay use non-adhesive materials to inhibit cell attachment
Hanging Drop use surface tension and gravitational force
Spinner Culture use convectional force by stirring bar
Rotating Wall Vessel use constant circular rotation of vessel
Microfluidics use microfluid flow and materials permeable to soluble factors
Magnetic Levitation use magnetic force to levitate cells
Pellet culture can be used to induce differentiation of mesenchymal stem cells. In particular, a
pellet culture system is suitable for stem cell differentiation by chondrogenesis since the interaction
between adjacent cells in a pellet culture microenvironment is similar to the interaction in pre-cartilage
condensation occurring during embryonic development. In pellet culture, mesenchymal stem cells
can change their morphological shape from fibroblastic to polygonal in a manner similar to that
in chondrocytes. Therefore, pellet culture system can be used for the study of signal pathways of
chondrogenesis and for assessing the chondrogenic potentiality of stem cells [27,28].
3.1.2. Liquid Overlay
Liquid overlay culture technique, also called the static suspension culture, forms spheroids by
interrupting the adhesion of cells on non-adherent culture plates (Figure 1b), (Table 3). A non-adherent
culture layer is typically composed of agar or agarose gel. Agarose is a very efficient material for the
inhibition of cell attachment and is superior to agar with respect to its non-adherent properties. Since
the cell attachments are inhibited, cells spontaneously form spheroids above the non-adherent surface
by promoting cell–cell adhesive molecules [19,29,30].
Despite excellent non-adherent properties of agarose, this biomaterial has drawbacks in terms of
culturing cancer cells. Agarose has trouble in interacting with tumor cells and is unable to activate the
specific signaling pathways related to reaction of tumor cells to therapy process. Recently, hyaluronic
acid can be a suitable alternative biomaterial that can replace agarose. It has the capability to interact
with surface receptors of cancer cells during cancer progression. This interaction enhances transduction
of cellular signals related to proliferation, angiogenesis, survival, and differentiation, as well as
resistance to therapeutics [31,32].
3.1.3. Hanging Drop
Hanging drop culture technique allows single cells to aggregate and fabricate spheroids in the
form of droplets (Figure 1c), (Table 3). By controlling the volume of the drop or density of cell
suspension, it is possible to control the spheroid size [33]. The novel hanging drop array platform is
capable of efficiently forming definite size spheroids [34]. This technique can form circular spheroids
having a narrow distribution of size with 10% to 15% variation coefficient, while the spheroid growth
in non-adherent surface culture methods has 40% to 60% variation coefficient [35]. A general method
involves starting from a monolayer cell culture, after which the cells are prepared as suspension and
diluted with culture medium to attain the desired cell density. Subsequently, the cell suspension is
dispensed into wells of a mini-tray with the help of a compatible multistep or multichannel pipette. A
lid is placed on the mini-tray and the entire mini-tray is reversed upside down. The cell suspension
drops attached on the mini-tray would stay on the reversed surface by surface tension. In this method,
spheroids are formed as droplets owing to simultaneous action of surface tension and gravitational
force [19,36].
Besides the adjustable size of a spheroid, hanging drop system has other advantages. There is no
requirement of expensive or professional equipment to form spheroids for small scale experiments. A
huge quantity of spheroids can be produced readily by multichannel pipetting and can be harvested
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by scraping lids of culture dishes [33]. In addition, mesenchymal stem cells cultured via hanging drop
system can secrete considerable quantities of potent anti-inflammatory as well as anti-tumorigenic
factors [37].
3.1.4. Spinner Culture
Spinner culture technique refers to the technique wherein the cell suspension in spinner flask
bioreactor containers is continuously mixed by stirring (Figure 1d), (Table 3). The resultant spheroid is
dependent on size of the bioreactor container [9,38]. Conditions of the fluid and mass in the containers
are affected by the convectional force of the stirring bar, which is crucial to form the spheroid. A high
stirring rate induces damage to the spheroid cells. However, an extremely slow rate of stirring allows
spheroid cells to sink to the bottom of the container, resulting in inhibition of spheroid formation in the
container [19].
In addition to adipogenesis, osteogenic differentiation of mesenchymal stem cells is also boosted
by improved expression of osteogenic markers such as osteopontin and osteocalcin in the spinner
system [39].
3.1.5. Rotating Wall Vessel
Rotating wall vessel reconstructs microgravity by constant circular rotation [40]. Due to constant
rotation, cells are continuously in a suspended state in the vessel (Figure 1e), (Table 3) [41]. This
microgravity can affect gene expression of mesenchymal stem cells. In microgravity conditions,
chondrogenic and osteogenic gene expression of stem cells reduces, whereas adipogenic gene expression
is elevated [42]. This is because microgravity inhibits expression of Collagen I of the osteoblastic marker
gene and integrin/Collagen I signaling pathway during the osteoblastic differentiation [43]. In addition,
microgravity suppresses stress fiber development and improves intracellular lipid accumulation.
However, reduction of osteogenic gene expression by microgravity can be regulated. Expression
of RhoA protein switches these microgravitational effects and improves expression of the markers
of osteoblastic differentiation of mesenchymal stem cells [44]. Expression of chondrogenic genes is
increased by regulation of the p38 MAPK activation pathways [45].
3.1.6. Microfluidics
This microfluidic culture technique, also called lab-on-a-chip technique, is used for applications
such as single cell analysis, genetic assays, and drug toxicity studies. This culture method has microscale
dimensions corresponding to the scale of in vivo microstructures (Figure 1f), (Table 3). In addition,
microfluidic devices easily enable microscale control of the environment, mimicking the in vivo
three-dimensional environment. One of the features of the microfluidic method is that it integrates
multiple processes including cell capture, mixing, detection, and cell culturing. Another feature is a
considerably high cell throughput for cell analysis. Microfluidic devices employ materials permeable
to oxygen and growth factors affecting proliferation. This characteristic feature of microfluidics
technology can decrease hypoxia, which is an unavoidable disadvantage of spheroid culture [46].
Recently developed fluidic systems overcome the limitations posed by the conventional fluidic
system and offer advantages such as diversity of design and cost reduction through smaller requirements
for specimens and reagents for cell transport assays [47]. Presently, the fluidic system can produce a
distinct concentration of analyte mixtures and facilitates real-time monitoring of living cells. In addition,
this system can optimize cell culture conditions for the proliferation and differentiation of stem cells,
and be used for tissue engineering processes such as organ replacement and tissue regeneration, and
in future clinical trials [48–50]. The currently used microfluidics system can be used to develop a
co-culturing system related to the generation of microvascular network using mesenchymal stem cells.
The co-culture system can also induce formation of a human microvascular network [51].
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3.1.7. Magnetic Levitation
Magnetic levitation-based culturing makes use of magnetic particles and integration with hydrogels
according to the given conditions. In the magnetic levitation system, cells are mixed with magnetic
particles and subjected to magnetic force during cell culture (Figure 1g), (Table 3). This system
utilizes negative magnetophoresis, which can imitate a weightlessness condition, because positive
magnetophoresis can hinder the attainment of weightlessness [52]. Due to magnetic force, the cells
incorporated with magnetic particles stay levitated against gravity. This condition induces the geometry
change of cell mass and promotes contact between cells, leading to cell aggregation. In addition, this
system can facilitate multi-cellular co-culturing with agglomeration of different cell types [53,54].
When mesenchymal stem cells and magnetic particles are cultured with collagen gel, particle
internalization takes place. Spheroid formation can be reproducible and reduces necrosis in the spheroid
core, thus maintaining its stemness as a spheroid [54]. However, some groups have demonstrated
that artificially manipulated gravity can lead to changes in cellular structures and can result in
apoptosis [55,56].
3.2. Using Biomaterials Methods
3.2.1. Hydrogels
Hydrogels are widely used for cell culture studies. Hydrogels have been fabricated using
biocompatible materials such as alginate [57,58], fibrin [59,60], collagen [54] and hyaluronic acid [61,62].
The primary properties of hydrogels is that mesenchymal stem cells can be entrapped in them (Figure 2a),
(Table 4). This method effectively improves the viability of cells while reducing cellular apoptosis.
Furthermore, osteogenic differentiation potential is stably maintained and secretion of proangiogenic
factors is activated in the hydrogel-entrapped cells compared to that in the non-entrapped cells of the
monolayer culture [11,57,59]. Activated secretion of proangiogenic factors implies increased angiogenic
potential and highly correlates to improved osteogenesis [63,64].
Figure 2. Schemes of using biomaterials methods. (a) Hydrogels, (b) biofilms, (c) particles.
Table 4. Properties of biomaterials.
Biomaterial Properties
Hydrogel • entrap cells during culture and can deliver cells as injectable form.
• provide an environment similar to extracellular matrix and improve viability, stemness
and angiogenetic capacity of stem cells.
Biofilms • increase stemness, differentiation potential, adhesion and proliferation of stem cells.
Particles • control mechanotransductional mechanisms inside the spheroid and improve viability
and proliferation.
Physicochemical biomimetic properties of hydrogels similar to those of the extracellular matrix
are capable of offering functional niches promoting the self-renewal potential and wound healing.
These properties of hydrogels improve angiogenetic capacity and stemness of the cells (Table 4) [65].
By adjusting the physical properties of hydrogel materials, the size of a spheroid can be optimized. To
control the size of spheroids, weak adhesive materials can be used and physically embossed patterns
on the surface of the hydrogel should be fabricated [66]. In addition, another main property of a
hydrogel is the capability to deliver cells directly. Hydrogels can also be prepared in an injectable
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form that can directly deliver stem cells to in vivo models and compensate for the necrotic or defective
tissues [65,67].
Hydrogels have been developed to study the microenvironment of cancer cells. The stiffness of
hydrogels can affect the phenotype and growth of cancer cells. The number and size of cancer cells
tend to reduce when cultured in stiff hydrogels. However, tumorigenicity of cancer cells increases after
in vivo transfer in softer hydrogels. This stiffness of hydrogels can be optimized by modifying the
concentrations of the composing materials [68].
3.2.2. Biofilms
Films made of biomaterials can be constructed by various methods such as photolithography
and stamping (Figure 2b). Tumor cell spheroids can be cultured on films for their role in cancer
drug discovery [69,70]. Apart from tumor cells, stem cells can be cultured on films. Stemness
marker expression and differentiation potential are increased during culturing on film (Table 4) [71,72].
Adhesion and proliferation of stem cells can be enhanced by changing the composition and concentration
of the film materials (Table 4) [73]. The component ratios used in the films are critical to the size of
spheroids and rate of spheroid fabrication, as well as cellular adhesion and proliferation. In a previous
study, hyaluronic acid(HA) modified chitosan film was found to form larger spheroids and induce cell
aggregation in lesser time than the unmodified chitosan film [74]. The size of spheroids is also affected
by the thickness of the film. Reducing thickness of the film leads to decreased spheroid size [75].
One of the biomaterials used in such films is chitosan. Culturing on chitosan films can improve
angiogenesis, chemotaxis, and self-renewal [13,76]. Recently, graphene has been investigated as a
cell culturing material [77,78]. Graphene films can provide distinctive environments beneficial to
neurogenesis. Moreover, the neurons differentiated on graphene films have a remarkably keen sense
of external stimulations. Graphene is believed to be capable of adjusting neural differentiation and
growth of mesenchymal stem cells [79].
3.2.3. Particles
Particulate factors have been used in spheroid cultures to control the cell culture microenvironment
(Figure 2c). A drawback of spheroid cultures is the inadequate supply of nutrients and oxygen to the
core of the spheroid. This is accounted by a rise in the diffusion gradient with increased spheroid size.
However, particles within spheroids are capable of controlling conditions inside the spheroids during
culturing. Consequently, the viability and proliferation of cells improve (Table 4) [80,81].
Particles are capable of regulating stem cell differentiation by controlling the extracellular
environment [82]. Differentiation is also regulated by encapsulating stem cells in these particles.
A previous study demonstrated that mesenchymal stem cell encapsulating particles, including a
nanofibrous meshwork, could induce osteogenic differentiation [83]. However, particles can inhibit
specific stem cell differentiation while inducing differentiation of other stem cells. This is achieved by
controlling mechanotransductional mechanisms. Particles act as obstacles of internal adhesion between
adjacent cells of spheroids. Alteration of mechanical force, including internal adhesion, surface tension,
and interfacial tension in a spheroid, leads to biased differentiation of the stem cells [84].
The desired delivery of growth factors using particles can modulate the spheroid microenvironment.
By transferring suitable growth factors into spheroids, differentiation can be spatially controlled [85,86].
4. Applications of Spheroid
4.1. Study of Tumors
Tumor cells are affected by cellular structures and extracellular matrix. The conventional 2D
culture system has limitations pertaining to tumor cell culture. Spheroid culture system is a promising
method for the study of tissue structure, signaling pathways, and immune activation of cancer cells.
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Single tumor cells may form multi-cellular tumor spheroids mixed with other types of cells in
a non-adherent 3D culture system, which is more effective in creating cellular heterogeneity [87].
Morphologies of these tumor spheroids are affected by spheroid culture microenvironment. In
accordance with the conditions of culture microenvironment, morphologies may form aggregated
circles, entangled bundles, elongated ovals, or star-shaped spheroids.
Spheroid form is the most suitable model for cancer study because it has a limited oxygen
concentration at its core. This hypoxic nature of spheroids is the primary advantage of spheroid culture.
However, in the case of tumors, spheroids larger than 500 μm in diameter undergo necrosis at their
core [87] and have a concentration gradient of biological factors similar to tumor cells due to restricted
diffusion of nutrients, oxygen, and growth factors [88].
4.2. Drug Screening
A study using an animal model has a limitation in disease modelling [89]. Presently, parameters
of drug screening studies using a mouse model can possibly be overcome by adopting spheroid cell
culture [90]. However, lack of uniformity in diameter or morphology of spheroids appears as new
parameters for reproducible drug screening. By increasing the uniformity during the spheroid culture
period, tumor spheroids can provide precise information on the diseases and suppress undesired side
effects of the drugs under development [90,91].
In the context of tumor cell culture for drug screening, co-culture of normal cell and tumor cells
can be a potential technique for reconstruction of the heterogenous multi-cellular environment for
solid tumors as well as for promoting migration in tumors. The co-culture enables the investigation of
interactions between tumor cells and peripheral multi-cellular environments. In addition, because
normal host cells proximal to tumor cells can influence drug sensitivity of tumor cells, spheroid
co-cultures can be used for drug screening study.
4.3. Regenerative Medicine
Transplantation is one of the most promising strategies for regenerative therapy. The currently
used transplantation therapy has some drawbacks. In case of autografts, the amount of cellular
supply is limited and the process of cell collection is cumbersome for the donor. However, allograft
transplantation results in problems such as infection, inflammation, and host rejection [16]. Besides,
injection in the form of single cells results in the limited immobility of injected cells at the site of the
defect [92]. Injectable spheroids of stem cells are considered to improve the engraftment efficiency after
transplantation [93]. After the implantation of spheroids, stem cells may be induced to differentiate
into suitable cells for reconstructing the defective site [16,94]. Differentiation potential of spheroids has
been demonstrated in vitro. Spheroid culture method improves differentiation potential compared to
monolayer culturing [95].
Genetically modified spheroids have been developed for cell transplantation therapy [17,96].
These spheroids are prepared in the form of injectable suspensions. After transplanting these spheroids,
the altered gene expression is maintained for a longer period of time in host tissues, whereas expression
of cells cultured from monolayer plates decreases soon after transplantation. Thus, desired properties
of cells transplanted in the host tissues are preserved by the process of spheroid culture [97].
5. Conclusions
Stem cells have shown applicability in various fields such as regenerative medicine as well as
tumor and cancer research. Three-dimensional cultures enhance the applicability of stem cells by
increasing the efficiency of culture. Spheroid culture system is an attractive method to overcome
limitations of traditional monolayer culture. This system can resolve problems of monolayer culture
such as the limited realization of in vivo multi-cellular microenvironments and it can reconstruct
biological signal pathways of cell–cell and cell–ECM interactions, which encourage proliferation
and viability of cells. Therefore, maintenance of the differentiation potential, stemness and intrinsic
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phenotypic properties is improved. To conclude, development of spheroid culture is essential to further
optimize formation of spheroids and utilize them as resource in the medical field.
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Abstract: Introduction: Adipose derived stromal/stem cells (ASCs) hold potential as cell therapeutics
for a wide range of disease states; however, many expansion protocols rely on the use of fetal bovine
serum (FBS) as a cell culture nutrient supplement. The current study explores the substitution of lysates
from expired human platelets (HPLs) as an FBS substitute. Methods: Expired human platelets from an
authorized blood center were lysed by freeze/thawing and used to examine human ASCs with respect
to proliferation using hematocytometer cell counts, colony forming unit-fibroblast (CFU-F) frequency,
surface immunophenotype by flow cytometry, and tri-lineage (adipocyte, chondrocyte, osteoblast)
differentiation potential by histochemical staining. Results: The proliferation assays demonstrated
that HPLs supported ASC proliferation in a concentration dependent manner, reaching levels that
exceeded that observed in the presence of 10% FBS. The concentration of 0.75% HPLs was equivalent
to 10% FBS when utilized in cell culture media with respect to proliferation, immunophenotype,
and CFU-F frequency. When added to osteogenic, adipogenic, and chondrogenic differentiation
media, both supplements showed appropriate differentiation by staining. Conclusion: HPLs is an
effective substitute for FBS in the culture, expansion and differentiation of human ASCs suitable for
pre-clinical studies; however, additional assays and analyses will be necessary to validate HPLs for
clinical applications and regulatory approval.
Keywords: adipogenesis; adipose-derived stromal/stem cells; chondrogenesis; colony forming
unit-fibroblast; fetal bovine serum; human platelet lysate; mesenchymal stem cell; osteogenesis;
regenerative medicine
1. Introduction
Human adipose-derived stromal/stem cells (ASCs) are derived from culture expanded stromal
vascular fraction (SVF) cells isolated by collagenase digestion from adipose tissue harvested by
tumescent liposuction or abdominoplasty [1]. The ASCs are multipotent progenitors that can be
distinguished based on their surface antigen immunophenotypic profile and their differentiation
potential along the adipocyte, chondrocyte, and osteoblast lineage pathways [1,2]. In addition, there is
considerable interest in the ability of ASCs to modulate inflammation in vivo via their secretion of
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cytokines and exosome vesicles containing microRNAs and proteins [3–9]. Due to the ease of collection,
multipotent differentiation, and paracrine function, ASCs are now being applied in clinical settings to
regenerate and repair human tissues impacted by biological aging and disease processes [10,11].
In order to use human ASCs to treat disease, it has been necessary to standardize the methodology
for ex vivo expansion in accordance with Current Good Manufacturing Practice (cGMP). Due to
the presence of bovine spongiform encephalopathy (BSE) in many herds worldwide, their remains
considerable regulatory concern for potential use of FBS as a cell culture nutrient to introduce xenogeneic
material [12,13]. Historically, proliferation of ASCs has largely been performed using growth media
supplemented fetal bovine serum. While FBS has been an effective medium for cell culture, it does have
several additional disadvantages beyond those relating to the risk of BSE contamination. First, FBS
products introduce considerable cost to the manufacturing process relative to human platelet lysate
due in part to reduced proliferation rates and the need for extended culture expansion periods [14].
Second, FBS use introduces xenoproteins that bind to isolated ASCs, thereby increasing the risk of
immune rejection due to antibody development against surface protein complexes on the transplanted
ASCs. Indeed, consistent with this concern, the examination of allogeneic transplantation of ASCs in
rat models has detected subsequent FBS-related antibody production [15].
To address the potential shortcomings of FBS as a nutrient for clinical expansion of ASCs,
investigators have turned to human blood-derived products as alternatives. For example, Finnish
investigators have used human serum successfully to expand autologous ASCs for tissue regeneration
of craniofacial defects [16]. Likewise, human platelet lysates have long been used as a potential
nutrient for the growth of human cells in vitro [17,18]. Independent investigators have begun to
explore the use of human platelet lysates as an FBS substitute in culture medium for human ASC
expansion [19–30]. To extend this line of research, the current study evaluated a human platelet
lysate-derived substitute for FBS based on human ASC proliferation, colony forming unit-fibroblast
(CFU-F), and differentiation assays.
2. Methods
2.1. Materials
All reagents were obtained from Thermo Fisher Scientific (Rochester, NY, USA) or LaCell LLC
(New Orleans LA) unless stated otherwise.
2.2. Human Platelet Lysate Preparation
Platelet lysate was generated from expired bags of concentrated platelets donated by anonymous
consenting donors (n = 3 to 4 donors per lot) obtained from a local blood bank (LifeShare Blood Center,
Shreveport & Baton Rouge, LA). The platelets were stored on dry ice during transport. Platelets
underwent three rounds of freezing (−80 ◦C overnight) and thawing (18–24 h at 4–8 ◦C) and were
subsequently transferred to sterile centrifugation tubes (Thermo Scientific, Rochester, NY, USA) within
a BSL2 cabinet (Class II A/B3 Biological Safety Cabinet, Thermo Forma, USA). In order to remove
particulates, the samples were centrifuged at 4000 rpm for 15 min (Sorval Legend T, Kendro, Germany)
and the supernatant was aspirated above the pelleted material. The aspirated platelet lysate solution
from n = 3 individual donors was pooled, 0.22 μM sterile filtered, and stored at −20 ◦C prior to use.
2.3. Adipose Derived Stromal/Stem Cells
Primary human ASCs were isolated from the lipoaspirate of multiple anonymous healthy female
donors (n = 7) with a mean body mass index (BMI) of 25.77 ± 2.82 (± standard deviation) and a mean
age of 46.14 ± 14.34 years as previously described (Table 1) [31,32]. All subjects provided informed
written consent under a LaCell sponsored protocol reviewed and approved by the Western Institutional
Review Board (Pulyallup, WA, USA) as Study Number 1,138,160 and IRB (Institutional Review Board)
Tracking Number 20,130,449 with a most recent approval date of March 9, 2019. The donors were either
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Caucasian (n = 5) or African-American (n = 2). Lipoaspirate was transferred to a sterile 250 mL bottle.
The tissue was washed with an equal volume of prewarmed (37 ◦C) sterile phosphate buffered saline
(PBS), and then centrifuged at 1200 rpm for 5 min. The infranatant was aspirated before the tissue
was washed and centrifuged again. An equal volume of prewarmed (37 ◦C) sterile PBS supplemented
with type I collagenase (1 mg/mL of tissue) (Worthington Biochemical Corporation, Lakewood, NJ,
USA), Fraction V bovine serum albumin (BSA) (10 mg/mL) (Sigma-Aldrich, Saint Louis, MO, USA),
and 2 mM CaCl2 was added to the tissue. The resulting suspension was then put on a shaker (Innova
4200 Incubator Shaker, New Brunswick Scientific, Edison, NJ, USA) between 180 and 200 rpm at 37 ◦C
for between 50 and 70 min. The digested tissue was then centrifuged at 1200 rpm for five minutes.
After gently resuspending the separated tissue, this step was repeated. The supernatant was aspirated
and the cell pellet, the stromal vascular fraction (SVF), was transferred to a sterile centrifugation tube
and resuspended in prewarmed (37 ◦C) sterile PBS. The resulting solution was centrifuged at 1200 rpm
for five minutes. The PBS was aspirated before the cell pellet was resuspended in LaCell StromaQual™
media (LaCell, New Orleans, LA, USA) containing 10% FBS and plated in T150 or T175 flasks at a
density of 0.19 to 0.22 mL of digested lipoaspirate per cm2 and incubated in a humidified 5% CO2
incubator (Heratherm® microbiological incubators, Thermo Scientific, Logan, UT, USA) for 24 to 48 h.
The media was vacuum aspirated, and the flask was washed with prewarmed (37 ◦C) sterile PBS, fed
with 35 mL of fresh stromal media, and the flask returned to the incubator. Upon reaching 80% to
90% confluence, the adherent cell layer, composed of ASCs, was detached using 0.05% trypsin/EDTA
(ethylenediamine tetraacetic acid). ASCs were resuspended and stored at a density of 1.0 × 106/mL in
cryopreservation media (LaCell, LA, USA) in 2.0 mL cryogenic vials in a liquid nitrogen tank (LS 3000
Lab Systems Taylor Warton, Minnetonka, MN, USA) until use. All subsequent studies were performed
with cryopreserved and thawed ASCs used between passages 1 to 3.
Table 1. Adipose derived stromal/stem cell donor demographic information.
Donor Race Age BMI
L111110W AA 55 24.56
L110411W C 66 25.28
L110822W C 56 26.62
L100401T C 41 23.73
L100723W C 22 23.59
L100910W C 44 24.89
L145 AA 39 31.75
Average 46.14 ± 14.35 25.77 ± 2.82
2.4. Proliferation Assay
ASCs (n = 7) were seeded in stromal media containing 10% FBS, 1.0% PL (Platelet Lysate), 0.75%
PL (n = 4), 0.33% PL, or 0.1% PL in 12 well plates (Olympus Plastic, Genesee Scientific, San Diego,
CA, USA) at a density of 10,000 cells/cm2. Every 24 h for four days, one well of ASCs from each
media condition was detached using 0.05% trypsin/EDTA, stained using trypan blue, and counted
using a hemocytometer counting chamber with a phase contrast microscope (Motic Microscope, Hong
Kong, China).
2.5. Colony Forming Unit Assay
ASCs (n = 7) were seeded in six well plates (Olympus Plastic, Genesee Scientific, San Diego, CA,
USA) containing LaCell StromaQual™media supplemented with 10% FBS or 0.75% PL at densities of
100, 200, and 400 cells per well. ASCs were proliferated for two weeks, with the media being changed
each week. Colonies were stained with toluidine blue and counted using a phase-contrast microscope.
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Colonies containing 32 or more cells were counted. Linear regression was performed on the counted
colonies, and data are reported as colonies per 100 cells seeded.
2.6. Flow Cytometry Assay
Cryopreserved ASCs isolated from n = 4 donors with mean ± S.D. ages of 46.5 ± 7.8 years and
BMI of 27.50 ± 3.89 were thawed, cultured in StromaQual supplemented with either 10% FBS or 0.75%
PL until confluent, harvested by trypsin digestion, stained with fluorochrome conjugated antibodies
(anti-CD29, anti-CD105, anti-CD45, anti-CD34, anti-CD31, anti-CD73, anti-CD90, and isotype control
IgG1 (Immunoglobulin G1)), and evaluated by flow cytometry (FACSAria instrument, BD Biosciences,
San Jose, CA, USA) as previously described [31].
2.7. Differentiation Capacity of ASCs
Confluent ASCs were cultured with adipogenic, osteogenic, as well as stromal media as a control.
Passage 1 ASCs (n = 4) were cultured with LaCell StromaQual media containing 10% FBS in T-25
flasks until fully confluent. ASCs were washed with PBS, resuspended in stromal media containing
either 10% FBS or 0.75% PL, and seeded on a 12 well plate at a density of 40,000 cells/cm2. Once fully
confluent, the stromal media was aspirated, and adipogenic and osteogenic differentiation media
was introduced.
Pellet ASCs were cultured with chondrogenic containing 10% FBS or 0.75% PL, as well as stromal
media with the same concentrations of nutrient supplements as a control. Passage 1 ASCs were (n = 3)
cultured with LaCell StromaQual media containing 10% FBS in T-175 flasks until fully confluent. ASCs
were washed with PBS, and resuspended in 0.5 mL of chondrogenic differentiation media at a density
of 500,000 cells/cm2 in 15 mL conical tubes. The ASCs were centrifuged at 300 G at 22 ◦C for 5 min
to form a pellet at the bottom of the tube. The tops of the conical tubes were loosened to facilitate
gas exchange and the pellets were incubated at 37 ◦C and 5% CO2 overnight. Five pellets were then
aggregated into 50 mL conical tubes.
2.8. Adipogenic Induction
Confluent ASCs were exposed to adipogenic differentiation media (AdipoQual™ LaCell, LA,
USA) containing either 3% FBS or 0.75% PL for three days as previously described [32,33]. Adipogenic
maintenance media containing the same concentrations of FBS or PL was then introduced, and the
cells were maintained for an additional five to six more days, with the media being changed every two
to three days. Differentiated cells were fixed by aspirating the differentiation media, washing three
times with PBS, adding PBS containing 10% formalin (Thermo Scientific, Boston, UT, USA), and then
placed at 4 ◦C for one hour. The PBS containing 10% formalin was aspirated and 0.22 μm sterile filtered
5% Oil Red O (Sigma-Aldrich, Saint Louis, MO, USA) in isopropanol was added for 15 min at room
temperature. The stain was removed, and the sample rinsed three times or more with distilled water
until completely clear. Images were captured using Motic Images Plus 2.0 software (Motic, Hong Kong,
China) and a phase contrast microscope.
2.9. Osteogenic Induction
Confluent ASCs were exposed to osteogenic differentiation media (OsteoQual™, LaCell, LA, USA)
containing either 10% FBS or 0.75% PL for eight to nine days, with the media being changed every two
to three days according to a modification of previously described methods [31–34]. Differentiated cells
were fixed by aspirating the differentiation media, washing three times with 150 mM NaCl, adding ice
cold 70% ethanol (Sigma-Aldrich, Saint Louis, MO, USA), and then placed at 4 ◦C for one hour. The
70% ethanol was aspirated, and the sample washed three times with distilled water. Then, 0.22 μm
sterile filtered 2% Alizarin Red (Sigma-Aldrich, Saint Louis, MO, USA) stain was added for 10 min at
room temperature. The stain was removed, and the sample rinsed five times or more with distilled
100
Cells 2019, 8, 724
water until completely clear. Images were captured using Motic Images Plus 2.0 software and a phase
contrast microscope.
2.10. Chondrogenic Induction
ASC pellets were exposed to complete chondrogenic differentiation media (ChondroQual™,
LaCell, LA, USA) containing either 10% FBS or 0.75% PL for 14 days in pellet cultures prepared with
0.25 × 106 ASCs, with media being changed every other day according to a modification of previously
described methods [35]. As controls, equivalent pellets were maintained in StromaQual medium over
the same time period. Differentiated and undifferentiated cell pellets were fixed by aspirating the
media, and washing once with PBS. The pellets were fixed in 4% paraformaldehyde solution, paraffin
embedded, and then sectioned and stained with 1% Alcian Blue solution (pH 1.0) for 30 min at room
temperature (Scytek Laboratories, Logan, UT, USA).
2.11. Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR)
ASC pellet cultured under the control or chondrogenic inductive conditions with either 10% FBS
or 0.75% PL medium were frozen at –80 ◦C prior to isolation of total RNA using the RNeasy® Mini Kit
(Qiagen, Valencai, CA, USA) according to the manufacturer’s instructions. The resulting total RNA
(1 μg) was reverse transcribed using the iScript™ cDNA Synthesis Kit (BioRad, Hercules, CA, USA)
according to the manufacturer’s instructions. Real time PCR was performed using a CFX96 Touch™
Real Time PCR Detection System (BioRad, Hercules, CA, USA) as follows: 1 cycle at 95 ◦C for 4 min,
40 cycles of 95 ◦C for 15 s followed by 60 ◦C for 1 min, followed by a melt curve of 55 to 95 ◦C with an
increment of 0.5 ◦C. The amplification was performed in a 20 μL volume containing iQ™ SYBR Green
Supermix (BioRad, Hercules, CA, USA) 2× concentrate (10 μL), each of two primers (4 μL from a 1 μM
stock for a 200 nM final concentration), and cDNA template (25 ng). The following human primer
sets were synthesized by Integrated DNA Technologies (Coralville, IA, USA) (Gene Bank Accession
numbers are presented in parentheses):
Aggrecan Forward AAGTATCATCAGTCCCAGAATCTAGCA (NM_001135).
Aggrecan Reverse CGTGGAATGCAGAGGTGGTT.
Collagen I Forward CACCAATCACCTGCGTACAGAA (NM_000088).
Collagen I Reverse ACAGATCACGTCATCGCACAAC.
Collagen II Forward GGCAATAGCAGGTTCACGTACA (NM_001844).
Collagen II Reverse CGATAACAGTCTTGCCCCACTT.
GAPDH Forward TAAAAGCAGCCCTGGTGACC (NM_002046).
GAPDH Reverse CCACATCGCTCAGACACCAT.
Matrilin I Forward AGGGACTGCGTTTGCATTTTT (NM_002379).
Matrilin I Reverse TCAGTAAAGAAATTCACAGCACTCAGA.
The relative expression of each PCR product was normalized relative to the GAPDH
(GlycerAldehyde 3 Phosphate DeHydrogenase) as a control.
2.12. Statistical Analysis
All values are reported as mean± standard error. The student’s T-test was performed on equivalent
experiments between PL and FBS, with significance being defined as results with a p value < 0.05.
3. Results
3.1. Effect of Platelet Lysate Concentration in Culture Medium on ASC Proliferation
Initial studies evaluated the impact of platelet lysate concentration on ASC proliferation in vitro.
ASC cultures were initiated in stromal media supplemented with increasing concentrations of HPLs
(Figure 1). These displayed a concentration dependent change in cellular proliferation when compared
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to equivalent media prepared with 10% FBS. The FBS used in the study was lot characterized based
on its reproducible ability to support robust human ASC proliferation and adipogenesis in vitro.
An equivalent number of ASCs were plated in each experiment. Data indicated that increasing the
concentration of HPL provided a growth advantage relative to 10% FBS at the 72 and 96 h time points.
After comparing ASC proliferation in 0.1%, 0.33%, and 1.0% HPL versus 10% FBS, the experiment was
repeated with 0.75% HPL.
Figure 1. Effect of the concentration of HPL (Human Platelet Lysate) supplementation on ASC
proliferation compared to 10% FBS. Stromal media containing 0.1%, 0.33%, 0.75%, 1.0% PL, and 10%
FBS were tested for impact on ASC proliferation. Data is reported as the mean ± standard error.
* Significant difference; p < 0.05.
3.2. ASC Surface Immunophenotype as a Function of Medium Composition
Successive studies evaluated the impact of 0.75% human platelet lysate as compared to 10%
FBS supplementation on the surface immunophenotype of ASCs cultured in stromal medium. Flow
cytometry analyses were performed focusing on phenotypic ASC surface antigens as recommended by
the International Society for Cell Therapy (ISCT) and International Federation for Adipose Therapeutics
and Science (IFATS) consensus [1]. The outcomes indicated that the ASCs displayed comparable levels
of characteristic surface antigens CD29, CD31, CD34, CD45, CD70, CD90, and CD105 based on the
percentage of positive staining cells independent of the nutrient supplement (Figure 2 and Table 2;
mean of n = 4 ASC donors).
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Figure 2. Histograms of flow cytometry detection of surface antigens. The ASCs were culture expanded
in stromal media containing either 10% FBS or 0.75% PL and the expression determined for the following
surface antigens by flow cytometry: CD29, CD31, CD34, CD45, CD73, CD90, and CD105, with IgG
serving as a negative control. The histograms displayed are all derived from a single individual ASC
donor and are representative of n = 3 donors. CD: cluster of differentiation.
Table 2. Immunophenotype of adipose derived stromal/stem cells following expansion in 10% FBS or
0.75% HPL.
Antibody FBS HPL
CD29 PE-A 93.97 ± 3.56 81.80 ± 29.50
CD105 PE-A 95.66 ± 3.66 90.47 ± 10.52
CD45 PE-A –0.1 ± 0.82 0.02 ± 0.37
CD34 PE-A 2.98 ± 2.35 0.89 ± 0.47
CD31 PE-A 0.53 ± 1.19 0.23 ± 0.27
CD73 PE-A 93.69 ± 5.10 92.74 ± 6.44
CD90 BV605-A 93.66 ± 3.08 99.15 ± 0.75
IgG PE-A 0.32 ± 0.19 −0.10 ± 0.37
PE-A 0.74 ± 0.79 0.33 ± 0.65
3.3. Colony Forming as a Function of Medium Composition
A colony-forming unit-fibroblast assay was performed to assess ASCs’ ability to form colonies in
stromal media supplemented with 0.75% PL compared to 10% FBS at passage 1 (Figure 3). The observed
morphology of colonies grown in both media was essentially equal, with representative images shown
in Figure 3. There was no statistically significant difference in CFU-F numbers as a function of nutrient
supplement (10% FBS: 6.65 ± 2.38, 0.75% HPL: 2.56 ± 1.15 colonies, n = 7, p value = 0.11).
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Figure 3. Effect of 0.75% HPL supplementation on the colony-forming unit-fibroblast assay compared
to 10% FBS per 102 ASC. Stromal media containing 0.75% PL and 10% FBS were tested for impact on
ASC colony-forming unit-fibroblast count. Data are reported as the mean ± standard error.; n = 7,
one replicate.
3.4. Differentiation as a Function of Medium Nutrient Supplement Composition
Characterization of ASCs’ ability to differentiate along mesenchymal lineages, specifically
adipogenic, osteogenic, and chondrogenic, in differentiation media containing 0.75% PL compared
to 10% FBS was qualitatively assessed using histochemical staining (Figure 4A,B). Adipogenesis was
assessed based on Oil Red O staining of the intracellular neutral lipid droplets. Adipogenesis was
observed in ASCs cultured in AdipoQual prepared with either 0.75% HPL or 10% FBS differentiation
media. While both nutrient supplements supported differentiation, adipogenesis was more robust in
the presence of FBS. Osteogenesis was assessed based on alizarin red staining of extracellular calcium
phosphate deposition and mineralization. While OsteoQual prepared with both nutrient supplements
supported differentiation, stain uptake was greater in the presence of 0.75% HPL. Chondrogenesis
was assessed based on alcian blue staining of glycosaminoglycan deposition in 3-dimensional pellet
cultures. ChondroQual prepared with either nutrient supplement supported chondrocyte formation
based on histochemical detection of glycosaminoglycan. While the presence of ChondroQual appeared
to increase the relative diameter of the pellet cultures relative to StromaQual, the actual percentage
increase was not quantified. Additionally, ChondroQual prepared with either 0.75% HPL or 10%
FBS induced a consistent qRT-PCR fold-expression profile for the chondrogenic associated mRNAs
aggrecan, collagen type II, and matrilin 1 relative to StromaQual control medium. In contrast, the
expression of collagen I was comparable regardless of whether pellets were cultured in the presence of
medium with or without chondrogenic inductive agents.
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Figure 4. Adipogenic, chondrogenic, and osteogenic differentiation ability of ASCs cultured in
0.75% HPL or 10% FBS containing media. (A) Differentiation of ASCs confirmed by staining of
two-dimensional cultures with Oil Red O (adipogenesis in the presence of AdipoQual) or Alizarin
Red (osteogenesis in the presence of OsteoQual). (B) Differentiation of ASCs confirmed by staining
with Alcian Blue (chondrogenesis in the presence of ChondroQual vs. StromaQual controls) and by
qRT-PCR analysis of the transcribed total RNA for the mRNAs collagen I (Col I), collagen II (Col II),
aggrecan, and matrilin 1 (qRT-PCR reactions were conducted in triplicate).
4. Discussion
The current study validates HPL as a potential nutrient substitute for FBS in the culture and
differentiation of human ASCs. The HPL over a range of concentrations promotes enhanced ASC
proliferation in a dose dependent manner. Indeed, the ASC proliferation in the presence of 0.75% HPL
is approximately equal to that observed in the presence of 10% FBS. Nevertheless, the two supplements
are not identical with respect to all outcomes. While the number of CFU-F tends to be greater in the
presence of FBS compared to HPL, this did not reach statistical significance. Based on histochemical
analyses, the ASC are capable of undergoing adipogenic, chondrogenic, and osteogenic differentiation
in the presence of either FBS or HPL nutrient supplementation. This was further supported by
qRT-PCR analysis of a select panel of chondrogenic mRNA biomarkers, which were induced to a
comparable fold-expression level independent of the presence of either FBS or HPL. Nevertheless,
further quantitative analyses of histochemical stain elution and more comprehensive qRT-PCR analysis
of lineage specific mRNAs will be necessary to determine if the relative level of differentiation along
any one lineage is favored by one or the other nutrient supplement.
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These outcomes confirm findings reported by a growing body of literature. Platelet lysate was
initially used as a cell culture supplement providing growth factors to promote CFU formation from
breast cancers [17,18]. Likewise, the current study demonstrates that HPL supports CFU-F from ASCs
in a manner comparable to FBS, consistent with prior observations reported by Chowela et al. [29].
Additional studies have further examined the utility of platelet lysate as an FBS substitute for the growth
of bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) and ASCs [19–24,26–29,36–38].
Consistent with the current findings, HPL displayed support of ASC and BM-MSC proliferation
in a concentration dependent manner [19,20,23,24,27,28,30,36,39]. Further analyses correlated the
proliferative effects of HPL to the enriched presence of cytokines, including Acrp30 (Adiponectin),
bFGF (basic Fibroblast Growth Factor), IL-6, MCP-1 (Monocyte Chemoattractant Protein-1), and PDGF,
relative to FBS [39]. Additionally, mass spectroscopic analyses have determined that HPLs contains
abundant levels of actin, fibrinogen, tropomyosin, and tubulin [36]. Both Cholewa et al. and Naaijkens
et al. noted that HPLs significantly promoted ASC proliferation relative to FBS based on an increased
number of population doublings and doubling times, respectively [26,29]. Additionally, they and
Blande et al. noted that the size of individual ASCs was larger when cultured in FBS as compared to
HPL [19,26,29]. Such observations are consistent with a recent cost analysis, which concluded that
HPL is substantially more economical than FBS for clinical grade ASC expansion due to accelerated
growth rates [14]. Comparable to the current analysis, Blande et al., Cholewa et al., and Naaijikens
et al. independently demonstrated that the immunophenotype of ASCs cultured in FBS and HPL is
comparable; however, Naaijikens et al. alone reported an increased intensity of the CD73, CD90, and
CD166 surface antigens in the presence of HPL as compared to FBS [19,26,29]. Likewise, these same
groups demonstrated that the ASCs cultured in either FBS or HPL continued to display adipogenic,
chondrogenic, and/or osteogenic differentiation potential [19,26,29]. Based on this background, groups
have begun adapting HPL supplements in the large scale production of human ASCs suitable for
clinical applications [22,23].
While there are substantial advantages to the substitution of expired human platelet lysates for
FBS in manufacturing protocols for clinical grade ASCs, there are potential issues remaining to be
addressed. First is the question of how strong the supply chain will be for expired platelets from
authorized blood centers. There is a need for careful consideration of the supply and demand for
human platelets. It remains to be determined if an expanded outreach to the blood donor community
will be necessary to ensure an appropriate balance between supply and demand. Second is a better
understanding of the characterization of HPL expanded ASCs with respect to a wider range of clinical
translational applications. Further studies will be necessary to evaluate the HPL expanded ASC
product with respect to immunogenicity, immunosuppression, and exosome/secretome expression.
Each of these outcomes may influence the utility of ASCs in the context of organ transplantation,
immune regulation, and acute and chronic disease therapies [4,10,11]. Nevertheless, the current work
and existing literature demonstrate the feasibility of substituting HPL for FBS as an alternative cell
culture nutrient supplement and its practicality for in vitro and pre-clinical discovery research.
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Abstract: Background: Recently, human adipose-derived stem cells (hASCs) were discovered in the
human subcutaneous adipose tissue. PLTMax Human Platelet Lysate (PLTMax), a supplement refined
from human platelets, has been reported to have proliferative effects on bone marrow mesenchymal
stem cells. The proliferative effects of PLTMax on ASCs were investigated in this study. Methods: The
ASCs in DMEM (serum-free), DMEM+PLTMax (1%, 2%, 5%, and 10%), and DMEM+FBS (10%) were
cultivated for two, five, and seven days. The cell growth rate was examined, BrdU incorporation, and
the cell cycle and Ki-67 immunostaining were performed. The cell growth rate was investigated when
each inhibitor (PD98059, SP600125, SB203580, and LY294002) was added and phosphorylation of
ERK1/2, JNK, p38, and Akt were examined by western blotting. The cell surface marker of hASCs was
also analyzed. Results: The cells in the PLTMax (5%) group showed significantly more proliferation
compared to the cells in control (serum-free) and FBS (10%) groups, and a significant increase in
the number of cells in the S phase and G2/M phase. The number of Ki-67 positive cells increased
significantly in the DMEM+ PLTMax (5%) and the FBS (10%) groups. The addition of inhibitors
PD98059, SP600125, SB203580, and LY294002 decreased the proliferative effects of PLTMax on ASCs.
Phosphorylation of ERK1/2, JNK, p38, and Akt was observed in both the PLTMax (5%) and the
FBS (10%) groups. Conclusions: For human adipose stem cells, 5% PLTMax was the optimum
concentration, which showed a significantly higher proliferative effect than 10% FBS. PLTMax is a
useful medium additive, which can substitute FBS. The proliferative effects of PLTMax are suggested
to function via multiple signaling pathways, similar to FBS.
Keywords: human adipose-derived stem cells; human platelet lysate; stem cell proliferation; fetal
bovine serum; signaling pathway
1. Introduction
Human adipose-derived stem cells (hASCs) have the potential to differentiate into adipose, bone,
cartilage, tendons, nerves, and fat when cultivated under lineage-specific conditions [1,2]. The majority
of ASCs exhibit fibroblastic morphological features and are easily grown under standard tissue culture
conditions. Compared with bone marrow mesenchymal stem cells, hASCs are easier to obtain and
carry a relatively lower donor site morbidity at harvest [3]. Due to their convenient isolation and
extensive proliferative capacities in vitro, hASCs are a promising source of human stem cells for
regenerative medicine.
Human platelet lysate (hPL), as prepared by repeated freeze/thaw cycles and sonication from
fresh blood or outdated platelet concentrates, was found to support the proliferation of established
cell lines, fibroblasts, and bone marrow mesenchymal stem cells [4–6]. Since our initial discovery of
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the enhanced proliferative effects of hPL on hASCs in 2008 [7], this phenomenon has been validated
by Trojahn Kølle et al. [8] and Cervelli et al. [9]. However, the detailed mechanism of proliferation
or its comparison with the effects of fetal bovine serum has not been elucidated yet. Although fetal
bovine serum is the most commonly used culture supplement for hASCs at present, it has been
found to increase the risk of xenogeneic infection and immune reactions as a side effect [10]. The
risk of unknown infectious reagents in FBS is also a significant concern. Thus, alternatives to FBS are
under investigation.
PLTMax® Human Platelet Lysate (PLTMax) was a kind of hPL that has been developed as a
growth factor rich supplement that is a superior alternative to fetal bovine serum (FBS) for human cell
expansion. PLTMax is derived from normal human donor platelets collected at U.S. blood centers.
Multiple donor units are pooled in large batch sizes and manufactured to produce a consistent product.
Each donor unit was approved for human use and has been tested for infectious diseases including
HIV-1, HIV-2, HCV, HBsAg, and RPR for Syphilis. To date, although there are studies showing that
PLTMax can be used in cell cultures for oral mucosal epithelial cells and human corneal epithelial cell
lines [11], there are no reports on its proliferative effects on hASCs and its mechanism of action.
In this study, the proliferative effects of PLTMax on hASCs were investigated by evaluating the
cell proliferation, BrdU incorporation, and cell cycle changes after the addition of PLTMax to the cells.
In addition, the localization of Ki-67 was assessed using immunostaining as well as activation of
ERK1/2, JNK, p38, and Akt by western blotting and compared these results with that obtained from
FBS treated cells.
2. Materials and Methods
2.1. Reagents and Antibodies
PLTMax® Human Platelet Lysate was purchased from Merck (Darmstadt, Germany). Fetal
bovine serum (FBS) was from Hyclone (Logan, UT, USA). PD98059 (an inhibitor of MEK), LY294002
(an inhibitor of phosphatidylinositol-3-kinase-AKT), and SB203580 (an inhibitor of p38) were all from
Calbiochem-Novabiochem (San Diego, CA, USA). SP600125 (an inhibitor of JNK) was from Sigma
(St. Louis, MO, USA). Rabbit anti-phospho-ERK1/2 was from Epitomics Inc. (Burlingame, CA, USA).
Rabbit anti-phospho-AKT and rabbit anti-AKT were from Abcam (Cambridge, UK). Rabbit anti-ERK1/2
and rabbit anti-β-actin were from Cell Signaling Technology (Beverly, MA, USA). Heparin sodium
injection-N was purchased from Mochida Pharmaceutical CO., LTD. (Tokyo, Japan). Antibodies of
CD90, CD31, CD45, and CD34 were purchased from Beckton Dickinson Pharmingen (San Diego,
CA, USA). All the other reagents, unless specified otherwise, were purchased from Sigma (St. Louis,
MO, USA).
2.2. Isolation of hASCs
The study was approved by the Ethics Review Board of Kansai Medical University in accordance
with the ethical guidelines of the Helsinki Declaration of 1975 (approval code: 2006106). All specimens
were collected and used with informed consent from the volunteer donors. Adipose tissue was
obtained from the patient through plastic surgery. Briefly, the adipose tissues used in this study were
resected from fat mass, and not using liquid suction. The abdomen was defined as the donor site, where
adipose tissues from disposed tissues from skin graft operations were extracted. hASCs were isolated
using a method described previously [7,12,13]. After extensive washing with phosphate-buffered
saline (PBS), the adipose tissues were cut into small pieces and then incubated with 3 volumes of
0.1% collagenase (Sigma-Aldrich, St. Louis, MO) solution with constant shaking at 40 ◦C for 40 min.
After adding Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS and antibiotics, it was
centrifuged at 400× g for 3 min. After removing cellular remains through a 100 μm nylon mesh (BD
Falcon, Bedford, MA, USA), the cells were incubated with DMEM containing 10% FBS and antibiotics
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in a dish. The primary hASCs were cultured for 4 to 5 days until they reached confluence. For all
experiments, cells from passage 7 through 9 were used for the culture.
2.3. Cell Proliferation Assay
For the cell proliferation assays, hASCs were seeded at a density of 1.0 × 104 cells/well in 24-well
culture plates and incubated with the complete medium overnight. The cell medium was then replaced
with serum-free DMEM. After 6 h incubation, hASCs were treated with various concentrations of
PLTMax or FBS designated concentrations in serum-free DMEM for 2, 5, and 7 days. Heparin was
added to the media at a final concentration of 2 U/mL for non-coagulation of medium with PLTMax.
As the medium coagulated when PLTMax was added alone, the manufacturer′s protocol specified that
heparin should be added to the final concentration of 2 U/mL. When inhibitors were used, they were
added at 1 h before the incubation with PLTMax. Cell proliferation was determined using the Cell
Counting Kit-8 (Dojindo Molecular Technologies, Kumamoto, Japan), according to the manufacturer’s
instructions (n = 4). Absorbance was read at 450 nm on a multi-well plate reader (EnSpire 2300
Multilabel Reader; PerkinElmer, Inc., Waltham, MA, USA).
2.4. BrdU Incorporation Assay
The cells were seeded at a density of 2 × 103 cells/well in 96-well culture plates containing a
complete medium. After overnight incubation, the hASCs were first starved in a serum-free DMEM
for 6 h. These cells were then treated with PLTMax in the serum-free DMEM for 48 h. Inhibitors were
added at 1 h before the incubation withPLTMax. Quantification of cell proliferation was determined
using the Cell Proliferation ELISA BrdU kit (Roche), according to the manufacturer’s instructions
(n = 4).
2.5. Cell Cycle Assay
The MuseTM Cell Cycle reagent included propidium iodide (PI) as the binding reagent (intercalator)
for DNA. Fluorescence intensity of an intercalated fluorescent substance represents the DNA amount
and the cell cycle stage. Muse Cell Cycle Reagent was included in the Muse Cell Cycle Kit. hASCs
(1 × 106) were seeded in a 10-cm culture dish containing complete medium and cultured overnight.
The medium was then replaced with serum-free DMEM. After starvation for 6 h, the cells were then
treated with the reagents with designated concentrations for 48 h. Treated cells were collected by
trypsinization. After washing with ice-cold PBS twice, cells were fixed in 70% ethanol at −20 ◦C for
3 h. Based on the manufacturer’s instructions, the fixed cells were then stained with MuseTM Cell
Cycle reagent (200 μL) in the dark at room temperature for 30 min. Cell cycles were analyzed by flow
cytometric quantification of their DNA by MuseTM Cell Analyzer (Millipore, Hayward, CA, USA)
(n = 6 in each group).
2.6. Cell Surface Marker of hASCs
The phenotypical characterization of the ASCs was analyzed using BD FACSCalibur
(Becton-Dickinson, Heidelberg, Germany) and accompanying software. At the 7th generation, the cells
were detached with trypsin-EDTA, washed with phosphate-buffered saline (PBS), and immediately
stained with the following labeled antibodies: CD90, CD31, CD45, CD34. Regarding ASCs after 48 h
of PLTMax culturing, 1 × 106 cells were prepared per measurement, and the positive cell rate was
analyzed (n = 3).
2.7. Immunofluorescence Confocal Microscopy
The cells were plated in Celldesk LF (Sumitomo Bakelite Co Ltd., Tokyo, Japan) with serum-free
DMEM for 24 h before stimulation. Subsequently, cells were stimulated with PLTMax or FBS for
48 h. The cells were fixed with 4% formaldehyde solution for 15 min and then washed thrice with
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PBS. Following that, 0.2% Triton X-100 was added to the cells, incubated for 5 min, and then washed
thrice with PBS. Further, the cells were blocked using Protein Block Serum-Free solution (Dako Japan
Inc., Tokyo, Japan) for 1 h, stained using Phalloidin, and conjugated using Rhodamine X (FUJIFILM
Wako Pure Chemical Corporation, Osaka, Japan) for 30 min. Phalloidin is a bicyclic peptide belonging
to a family of toxins isolated from the deadly Amanita phalloides mushroom, and it is commonly
used in imaging applications to selectively label F-actin. In this study, rhodamine-labeled phalloidin
was used. After washing thrice with PBS, the cells were incubated with the Ki-67 rabbit monoclonal
antibody (Cell Signaling Technology) at a concentration in 1:400 at 4 ◦C overnight. Then, anti-rabbit
IgG (H+L) and F(ab′)2 fragment (Alexa Fluor® 488 Conjugate; Cell Signaling Technology) was added
and incubated for 2 h. After washing thrice with PBS, ProLong® Gold Antifade Reagent with DAPI
(Cell Signaling Technology) was added to the cells and enclosed. Cells were viewed using a laser
scanning confocal microscope (LSM510-META, Carl Zeiss, Jena, Germany).
2.8. Western Blot Analysis
The cells were treated with indicated compounds and lysed. Extracted cellular proteins (20 μg)
were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then
transferred to a polyvinylidene difluoride (PVDF) membrane. In the SDS-PAGE step of the Western
blotting, the cellular protein was isolated under reducing conditions using β-mercaptoethanol. The
membrane was first blocked with Blocking One-P reagent (Nacalai Tesque, Kyoto, Japan) for 30 min
at room temperature, and then incubated with primary antibodies at 4 ◦C overnight. After washing
with PBS (-), the membranes were incubated with a peroxidase-linked secondary antibody at room
temperature for 30 min. The labeled proteins were detected with the enhanced chemiluminescence
using the Prime Western blotting detection system (GE Healthcare).
2.9. Statistical Analysis
The Mann-Whitney U test was used for comparisons between groups, with p < 0.05 being regarded
as significant. Data are presented as means ± S.D.
3. Results
3.1. PLTMax Stimulated Proliferation of hASCs
The cell growth stimulated by PLTMax was confirmed by observation with phase-contrast
microscopy. Compared to the control (no serum) and FBS (10%) groups, the cells treated with PLTMax
(5%) were slightly elongated, and the nucleus was visible (Figure 1A).
Cell proliferation was increased by treatment with the 1%, 3%, 5% PLAMax group, and the FBS
(10%) group (p < 0.01 vs. control). Among them, the cells in the 5% PLTMax group showed the highest
proliferation, even higher than the 10% FBS group (Figure 1B). When the cells were incubated in
PLTMax (5%), FBS (10%), and control (no serum) conditions for 2 to 7 days, high proliferation in the
PLTMax (5%) group and FBS (10%) group on the 5th and 7th days was observed, while no proliferation
was observed in the control group, even on the 7th day (Figure 1C).
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Figure 1. (A) The morphology of human adipose-derived stem cells (hASCs) observed by phase-contrast
microscopy. Representative images of the cultures in the control group (no serum), fetal bovine serum
(FBS) (10%), PLTMax (5%) after two days are shown. (B) The proliferation of hASCs cultured using 1%,
3%, and 5% PLTMax. The 3% PLTMax group showed significantly higher proliferation compared to
the control group (no serum) and the 5% PLTMax group showed higher proliferation compared to the
10% FBS group. * p < 0.05 (C) The chronological changes in the proliferation of cells cultured on days 2,
5, and 7 in the control group, FBS-treated (10%), and PLTMax-treated (5%) cells. On days 5 and day 7,
the cells treated with PLTMax (5%) showed higher proliferation compared to FBS (10%).
3.2. PLTMax Promoted Cell Cycle Transition from G0/G1 to S Phase
In the FBS (10%) group and the PLTMax (5%) group, a decrease in the percentage of cells in the
G0/G1 period compared to that in the control group was observed. A histogram of the typical cell
cycle, as evaluated by flow cytometry is shown in Figure 2A. The cells in the G0/G1 period were
62.87% ± 1.93% in the control group, 49.62% ± 2.60% in the FBS (10%) group, and 46.89% ± 2.72% in
the PLTMax (5%) group, respectively. The cells in the S period were 5.41% ± 0.61% in the control group,
12.16% ± 1.77% in the FBS (10%) group, and 13.41% ± 1.44% in the PLTMax (5%) group, respectively.
Further, the cells in the G2/M period were 31.71% ± 1.81% in the control group, 38.19% ± 3.11% in the
FBS (10%) group, and 39.69% ± 3.05% in the PLTMax (10%) group, respectively. In the G0/G1 period,
the FBS (10%) group and the PLTMax (5%) group showed significantly lower cell counts than the
control group. In the S period and the G2/M period, the FBS (10%) group and the PLTMax (5%) group
showed significantly higher cell counts than the control group, and among them, the cell count in the
PLTMax (5%) group was the highest (Figure 2B).
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Figure 2. (A) Histogram of the typical cell cycle of hASCs from the control group (no serum), FBS
(10%) group, and PLTMax (5%) group, as evaluated using flow cytometry. (B) The percentage of hASCs
cultured in the PLTMax (5%) group in the G0/G1 phase, S phase, and G2/M phase. Compared to the
control group (no serum), the cells in the FBS (10%) and PLTMax (5%) group showed a significantly
increased percentage of cells in the S phase and G1/G2 phase. (n = 6) * p < 0.05.
3.3. Effect of PLTMax on the Number of Ki-67 Positive Cells
Fluorescent triple immunostaining was performed, which included Ki-67 fluorescent staining,
Phalloidin staining, and DAPI nuclear staining, for the cells in the control group, the FBS (10%)
group, and the PLTMax (5%) group. Ki-67 staining was found to be localized in the nucleus
(Figure 3A). The percentage of Ki-67 positive cells was 7.46% ± 11.49% in the control (no serum) group,
63.33% ± 12.92% in the FBS (10%) group, and 85.19% ± 7.01% in the PLTMax (5%) group (Figure 3B),
respectively. In the FBS (10%) group and the PLTMax (5%) group, the number of Ki-67 positive cells
was significantly higher than that in the control group with the PLTMax (5%) group showing the
highest number.
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Figure 3. (A) Typical images of hASCs cultured without serum (control), with FBS (10%), and PLTMax
(5%) immunostained for Ki-67, and with phalloidin and DAPI, or triple stained. Ki-67 staining was
localized in the nucleus. (B) Percentage of Ki-67 positive cells. Compared to the control group, FBS
(10%) and PLTMax (10%) showed a significantly increased percentage of Ki-67 positive cells. PLTMax
(5%) showed the highest percentage among the 3 groups. * p < 0.05.
3.4. Effect of PLTMax on the Cell Surface Marker of hASCs
The effects of PLTMax on the cell surface marker of hASCs after 48 h of PLTMax culturing were
analyzed. ASCs were CD90 (98.60% ± 0.99%), CD31 (0.20% ± 0.28%), CD45 (7.10% ± 3.77%), CD34
(5.77% ± 0.70%) at the seventh generation. After PLTMax culturing, they were CD90 (99.33% ± 1.15%),
CD31 (0.33% ± 0.31%), CD45 (7.27% ± 7.64%), and CD34 (9.20% ± 4.69%). There was no significant
difference between the cell surface markers before and after culturing.
3.5. PLTMax Activated ERK1/2, AKT, and JNK Signaling Pathways
The cells were treated with ERK1/2 inhibitor (PD98059, 50 μM), PI3K/AKT inhibitor (LY294002,
10 μM), JNK inhibitor (SP600125, 20 μM) and p38 inhibitor (SB203580, 20 μM), to examine the signaling
pathways involved in the stimulation of hASCs by PLTMax. The PLTMax induced proliferation
of cells was suppressed by PD98059, LY294002, SP600125, and SB203580 (Figure 4A). The PLTMax
induced BrdU incorporation of cells was also suppressed by PD98059, LY294002, SP600125, and
SB203580 (Figure 4B). The signaling pathways were further analyzed in the hASCs by Western blot.
Phosphorylation of ERK1/2, JNK, p38, and AKT pathways was increased with the stimulation of either
PLTMax or FBS. In the control group, phosphorylation of ERK1/2, JNK, p38, and AKT pathways did
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not occur. Thus, the stimulation of cell growth by PRP was mediated through multiple signal pathways
(Figure 4C).
 
Figure 4. (A)The effect of various inhibitors (PD98059, LY294002, SP600125, and SB2303580) added
in the presence of PLTMax (5%) on the proliferation of hASCs. The proliferative effect of PLTMax
was partially inhibited by all the inhibitors. * p < 0.05 (B) The effect of various inhibitors (PD98059,
LY294002, SP600125, and SB2303580) added in the presence of PLTMax (5%) on the BrdU incorporation
of hASCs. The proliferative effect of PLTMax was partially inhibited by all the inhibitors. * p < 0.05 (C)
MAP kinase-related proteins and phosphorylation seen in the hASCs in the control (no serum), FBS
(10%) and PLTMax (5%) groups. The protein expressions of phospho-ERK, phospho-JNK, phospho-p38,
and phospho-Akt were observed in FBS (10%) group and PLTMax (5%) group.
4. Discussion
PLTMax is a medium supplement that can be used as an FBS replacement. In this study, it was
shown that 5% PLTMax is the optimal concentration and its proliferative effect was significantly
higher compared to 10% FBS. PLTMax may have exerted its proliferative effect via multiple signaling
pathways, similar to FBS.
Mesenchymal stromal stem cells (MSCs) can potentially differentiate into mesenchymal cells,
including osteoblasts, adipocytes, muscle cells, and chondrocytes, and they have been considered for
their application in regenerative medicine. Although the studies conducted with MSCs thus far have
focused on the cells established from the bone marrow, recent studies have revealed that these cells can
be established from several other tissues, such as cord blood, placenta, and adipose tissues [14]. Among
them, adipose tissue contains a higher number of MSCs compared to the bone marrow, and the MSCs
established from the adipose tissues proliferate rapidly [15]. Although the studies conducted with
MSCs thus far have focused on the cells established from the bone marrow, recent studies have revealed
that these cells can be established from several other tissues, such as cord blood, placenta, and adipose
tissues. Among them, adipose tissues contain a higher number of MSCs compared to the bone marrow,
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and MSCs established from the adipose proliferate rapidly. Therefore, adipose-derived MSCs are
garnering a lot of interest [16]. In order to clinically use hASCs in regenerative medicine, hASCs have to
be prepared from a small number of adipose tissues and cultured ex vivo on a large scale to minimize
invasiveness in the donor. To date, FBS has been generally used as a supplement to culture hASCs.
However, concerns related to the use of FBS, such as bovine spongiform encephalopathy infection
and certain other unidentified infections, risks of xeno-immunization against bovine antigens, the
transmission of pathogens, and ethical issues associated with crude methods of FBS collection [17–22]
have led to the exploration of supplements that can substitute FBS.
Platelets play an essential role not only in primary hemostasis but also in wound healing and
tissue regeneration. The α-granules of the platelets contain several chemokines and growth factors,
such as isoforms of platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β),
insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), epidermal growth factor
(EGF), and basic fibroblast growth factor (bFGF) [10]. To our knowledge, our study was the first to
report that platelet-rich plasma prepared from whole blood contains high levels of PDGF and TGF-β
and has a proliferative effect when added to hASCs. Human platelet lysate (hPL) is created from single
or pooled donor-derived platelets isolated from the whole blood or by apheresis, and it is distributed
in standard platelet collection bags. Several researchers have reported the proliferative effect of hPL on
bone marrow MSCs. The proliferative effect of hPL (5% to 10%) on bone marrow MSCs was superior to
that of FBS [6,23,24]. However, there are currently no studies investigating the mechanism underlying
the effect of hPL on hASC proliferation.
PLTMax is a commercialized human platelet lysate product manufactured by Merck, created
from the whole blood of American donors, which has been checked for infections. Studies on cell
proliferation using PLTMax were recently conducted using human corneal epithelial cells [11,25]
and oral mucosal epithelial cells [26]. Huang et al. reported that in human corneal epithelial cells,
FBS seemed to have a higher proliferative effect compared to PLTMax. In addition, they reported
that a higher concentration (10%) of PLTMax showed stronger inhibitory effects on cell proliferation
compared to FBS [11]. In this study, the hASCs treated with 5% PLTMax showed significantly higher
proliferation compared to those treated with 10% FBS. Different cell-types can show different reactions
to PLTMax. PLTMax might be a better supplement for the mass cell culture of hASCs compared to FBS.
Hsueh et al. reported that they succeeded in creating an oral mucosal epithelial cell sheet without
animal-derived components with the addition of PLTMax instead of FBS [26]. Therefore, it is possible
to create a cell sheet with hASCs using PLTMax.
In this study, it was found that PLTMax increased the percentage of cells in the S phase and G2/M
phase of the cell cycle, as well as the Ki-67 positive cells. While Ki-67 is present in all cell cycle (G1,
S, G2, and M) phases in proliferating cells, the G0 phase does not occur when cell proliferation is
intermitotic. The cellular content of Ki-67 markedly increases during cell cycle progression throughout
the synthetic phase (S phase) of the cell cycle [26]. Therefore, the high nuclear expression of Ki-67 in
ASCs that were treated with PLTMax indicates an enhanced proliferative effect of the additive. This
proliferative effect is suppressed by the addition of ERK, JNK, p38, and Akt inhibitors, suggesting the
involvement of multiple signaling pathways. Studies conducted by both Chen et al. and Huang et al.
revealed that PLTMax contains PDGF, TGF-β, and EGF. These factors might be involved in inducing
the proliferative effect via several signal pathways in the treated hASCs [11,25]. Hence, in the future, it
is necessary to investigate the proliferative factors and cytokines affected by the addition of PLTMax
and to identify the factor that is most closely associated with cell proliferation.
Lensch M. et al. [27] published an article about the effect of commercially available synthetic media
designed for adipose-derived stem cell expansion, including PLTMax Human Platelet Lysate (acquired
from Sigma-Aldrich). Lensch M. et al. also performed immunophenotypic characterization of ASCs
and evaluated their ability to differentiate into osteoblasts and adipocytes after treatment with PLTMax.
They reported that PLTMax had a proliferative effect on the ASCs. In addition, they reported that cell
culture using PLTMax up-regulated CD105, which is a cell surface marker, by 21%, while it has no effect
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on CD73 and CD90. However, the PLTMax that was used in the study by Lensch M. et al. [27] was
manufactured by Sigma-Aldrich, while the PLTMax used in our study was manufactured by Merck.
Thus, it is uncertain if their composition is similar due to the difference in manufacturers. Furthermore,
they did not clearly mention the percentage concentration of PLTMax added to the medium in their
report. On the other hand, other researchers have also reported the proliferative effect of PLTMax on
ASCs. In a study by Morten et al., they added a 5% concentration of PLTMax to the ASCs and compared
it with the FBS culture, similar to our study. They reported that while the levels of CD105 and CD90
hardly changed at P0, the expression of CD19 was higher (~30%) in the ASCs cultured in FBS medium
at P0 and not in the PLAMax medium. They also reported that the expression of the secondary ASCs
marker, CD 36 generally varied between 40% and 60% for PLTMax-supplemented ASC cultures, which
decreased slightly after passaging. Interestingly, they investigated the genetic stability of ASCs till the
5th passage and they did not observe any imbalanced chromosomal rearrangements. These results are
consistent with our study results. Moreover, recently it has been reported that the expression of ASC
markers might be affected by the in vitro culture conditions and the passage number [16]. Therefore,
the genetic stability and aging after culture with PLTMax should be investigated in the future for
better understanding.
Previous studies have made efforts to develop serum-free products that can provide all the
essential nutrients and the growth factors to maintain physiological function and to promote cell
proliferation [28–31]. However, most of these serum replacements could not support cell growth [32].
Therefore, as an alternative to animal serum for cell proliferation, autoserum and allogeneic human
serum have been investigated. On the one hand, few studies have reported that human serum improved
cell growth, and on the other hand, some studies showed that it suppressed cell growth [33]. Our
study showed that human serum promoted the proliferation of adipose-derived stem cells. However,
certain concerns regarding the clinical applications, such as difficulty in collection and processing and
the difference in the quality of autoserum from patient to patient, might hamper the standardization
of culture conditions. In addition, the optimum amount of autoserum required for the expansion of
cultures exceeds the amount that a single donor can provide [29]. In the future, we plan to investigate
methods for collection and processing that can overcome these issues.
PLTMax has been suggested to be a more effective cell culture supplement for the culture of
hASCs compared to FBS. If the culture of hASCs using hPL prepared from autologous platelets is
successful, it would be possible to conduct an efficient mass cell culture without the risk of infection
by unknown pathogens derived from animals. hPL is a supplement that might replace FBS in the
future. Further studies need to be conducted to obtain the basic data for its application in regenerative
medicine, particularly data regarding the changes in the cell surface markers, differentiation potency,
and presence/absence of karyotype abnormality.
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Abstract: In this study, we investigated the influence of metformin (MF) on proliferation and
viability of adipose-derived stromal cells isolated from horses (EqASCs). We determined the
effect of metformin on cell metabolism in terms of mitochondrial metabolism and oxidative status.
Our purpose was to evaluate the metformin effect on cells derived from healthy horses (EqASCHE) and
individuals affected by equine metabolic syndrome (EqASCEMS). The cells were treated with 0.5 μM
MF for 72 h. The proliferative activity was evaluated based on the measurement of BrdU incorporation
during DNA synthesis, as well as population doubling time rate (PDT) and distribution of EqASCs in
the cell cycle. The influence of metformin on EqASC viability was determined in relation to apoptosis
profile, mitochondrial membrane potential, oxidative stress markers and BAX/BCL-2 mRNA ratio.
Further, we were interested in possibility of metformin affecting the Wnt3a signalling pathway and,
thus, we determined mRNA and protein level of WNT3A and β-catenin. Finally, using a two-tailed
RT-qPCR method, we investigated the expression of miR-16-5p, miR-21-5p, miR-29a-3p, miR-140-3p
and miR-145-5p. Obtained results indicate pro-proliferative and anti-apoptotic effects of metformin
on EqASCs. In this study, MF significantly improved proliferation of EqASCs, which manifested in
increased synthesis of DNA and lowered PDT value. Additionally, metformin improved metabolism
and viability of cells, which correlated with higher mitochondrial membrane potential, reduced
apoptosis and increased WNT3A/β-catenin expression. Metformin modulates the miRNA expression
differently in EqASCHE and EqASCEMS. Metformin may be used as a preconditioning agent which
stimulates proliferative activity and viability of EqASCs.
Keywords: adipose-derived stromal cells; equine metabolic syndrome; metformin
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1. Introduction
Currently, equine metabolic syndrome (EMS) is considered as a burning issue in veterinary
medicine, affecting more and more horses. By definition, EMS is related to insulin resistance
(IR), insulin dysregulation and obesity, as well as hyperleptinemia and past or chronic laminitis.
Until recently, it was thought that only primitive-type horses, such as ponies and cold-bloods,
suffer from EMS, but recent findings suggest that also non-obese and even sport horses might be
affected by EMS—mainly due to a high starch and high energy diet [1]. Although obesity was excluded
as a sine qua non condition in the course of the diagnostic procedure of EMS, specific local accumulation
of adipose tissue, i.e., adiposity (cresty neck) is considered a diagnostic marker. Moreover, it is thought
that EMS horses that are not overweight might accumulate abdominal adipose tissue, which is not
without physiological significance for the other organs, including liver. Adipose tissue produces a
number of factors, including cytokines, adipokines, as well as hormones, all influencing the clinical
picture of EMS horses. It was shown that adipocytes isolated from subcutaneous adipose tissue of EMS
horses produce pro-inflammatory cytokines, i.e., tumour necrosis factor-alpha (TNF-α), interleukin
1 (IL-1) and interleukin 6 (IL-6), which all may lead to the development of local inflammation [2].
Our previous studies indicate that subcutaneous adipose tissue inflammation is mediated by tissue
resident immune cells, including macrophages that, under EMS condition, are characterised by
elevated activity. This unfavourable pro-inflammatory microenvironment of adipose tissue has
an adverse effect on residing progenitor cells, i.e., adipose-derived multipotent stromal stem cells
(ASCs). Equine ASCs are characterised by the presence of mesenchymal specific surface antigens,
including CD73, CD90 and CD105, and lack of expression of hematopoietic markers, i.e., CD45 [3–5].
Additionally, this population of cells is endowed with self-renewal properties regulated by the
expression of OCT4 (octamer binding transcription factor-4), SOX2 (sex-determining region Y-box 2)
and homeobox protein Nanog [6]. Furthermore, it was shown that ASCs possess immunomodulatory
properties and secrete anti-inflammatory cytokines, such as IL-4 and IL-13. The increased proliferative
activity and immunomodulatory properties of ASC, along with low immunogenicity, makes them
promising a therapeutic tool for the treatment of various musculoskeletal diseases in horses [7].
ASCs, in general, are also characterised by unique ability for multilineage differentiation, including
osteogenic, adipogenic and chondrogenic, which is crucial for their clinical use. Our own previous
clinical research showed a positive effect of ASCs in horses with particular musculoskeletal system
disorders [8,9]. In general, the pro-regenerative properties of ASCs are explained by their autocrine and
paracrine activity [10]. For example, it was shown that application of ASCs in injured Achilles tendons
is more efficient than the application of growth differentiation factor 5 (GDF-5). The transplantation
of ASCs increased the expression of several genes (including TGFβ), which improved collagen fibre
organisation and tendon biomechanics [11]. Additionally, it was demonstrated that equine ASCs
are able to synthesise and secrete extracellular microvesicles (ExMVs), rich in broad range of growth
factors, including bone morphogenetic protein isoform 2 (BMP-2) and vascular endothelial growth
factor (VEGF) [12]. Various studies, including ours, demonstrated that regenerative potential of ASCs
depends strictly on donor age or its physiological status [13–16]. Importantly, in our previous research,
we have shown that ASCs derived from EMS horses (EqASCEMS) show impaired proliferative and
metabolic activity, reduced clonogenic potential, as well as lowered expression of KI-67, a widely
known proliferation marker. Furthermore, when determining the multipotency of EqASCEMS,
we noticed that their chondrogenic and osteogenic differentiation potential had declined, which was
associated with the reduced expression of transcripts such as BMP-2, SOX-9, COL-1/2 and vimentin [5].
Moreover, in EqASCEMS, we have observed deterioration of mitochondrial dynamics, which is related
to lowered mitochondrial metabolism and induced macroautophagy process. The results question
the utility of EqASCEMS in terms of autologous transplants, that are considered as well-established
therapeutic strategies for the treatment of tendon and joint diseases [8,9,17,18]. Bearing in mind
these facts, we see great need for the development of new preconditioning regimens to enhance the
regenerative potential of EqASCEMS. Most recently, our group has shown that EqASCEMS displayed
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anti-inflammatory properties and decreasing activity of TNF-α, IL-1 and IL-6 when preconditioned
with a combination of 5-azatacidine and resveratrol (AZA/RES). The preconditioned cells were able to
regulate and activate the anti-inflammatory response related to regulatory T lymphocytes (TREG) [19].
Additionally, we have shown that AZA/RES may rejuvenate EqASCEMS by modulating mitochondrial
dynamics and increasing their viability [20]. Our previous studies indicate that metformin and
biguanide, both anti-diabetic drugs, can be considered as promising candidates in terms of improving
progenitor cells’ viability and their proliferative potential. Using the ex vivo model, we showed
that metformin is able to increase the proliferative activity and viability of mice ASCs (mASCs).
The pro-proliferative effect of metformin towards mASCs was manifested by increased proliferation
ratio, lowered population doubling time and enhanced clonogenic potential [21]. Moreover, our other
studies have shown that metformin may also improve viability and stabilise the phenotype of mouse
glial progenitor cells, i.e., olfactory ensheathing cells (mOECs), without influence on their proliferative
status [22]. Our studies showed that increased viability of progenitor cells after metformin treatment
may be associated with its antioxidant effect and improved metabolism of mitochondria [21,22].
Additionally, it was shown that metformin suppresses proinflammatory responses of adipocyte and
improves the balance of brown/white adipose acting upon obesity effects [23–25]. Furthermore,
some clinical studies showed the beneficial effect of metformin in terms of insulin resistance treatment
in horses. For example, it was shown that metformin can reduce glycaemic and insulinaemic responses
both in healthy horses and in horses with experimentally induced insulin resistance [26]. There is also
data indicating that metformin reverses insulin resistance and decreases serum insulin concentration
during the first 6 to 14 days of treatment, however, this effect diminishes by 220 days [27]. The clinical
efficacy of metformin in terms of EMS treatment has not been proven, due to some questions concerning
its bioavailability [28,29]. Still, being aware of pro-regenerative effects of metformin towards progenitor
cells [21,22] and its pro-aging activities [30], we decided to characterise metformin influence on
viability and proliferative potential of EqASCEMS. We determined the effect of metformin on cells
morphology, apoptosis profile and mitochondrial membrane activity. We analysed the antioxidative
and anti-apoptotic effect of metformin in terms of expression of several markers both on mRNA and
miRNA level. We tested the expression of BAX and BCL-2, as well as miR-16-5p, miR-21-5p, miR-29a-3p,
miR-140-3p and miR-145-5p. The specificity of miRNA measurement was assured by highly sensitive
two-tailed RT-qPCR method [31]. It is well known that metformin acts through AMP-activated protein
kinase (AMPK) which regulates lipid, cholesterol and glucose metabolism in various metabolic tissues,
including adipose tissue, yet, it was also shown that metformin may improve cells survival through
WNT/β-catenin signalling [32]. Therefore, we were also interested in whether WNT signalling is
activated in EqASCEMS after metformin treatment. The obtained results show promise for the potential
application of metformin as a preconditioning agent, improving cellular health of adipose-derived
multipotent stromal cells isolated from horses with equine metabolic syndrome (EqASCEMS).
2. Materials and Methods
2.1. Characterisation of Equine Multipotent Stromal Cells (EqASCs)
Cells derived from healthy horses (n = 6) and horses affected by metabolic syndrome (n = 6) were
used in the study. The method to classify the animals has been detailed previously [1–4]. Subcutaneous
adipose tissue collected from horses’ tail base was used for isolation of EqASCs. The procedure of tissue
collection was performed with the standard surgical protocols in compliance with ethical standards
and approved by the II Local Ethics Committee of Environmental and Life Sciences University
(Chelmonskiego 38C, 51–630 Wroclaw, Poland; decision No. 84/2012; extension No. 84/2018).
The multipotent stromal cells were isolated from the stromal vascular fraction obtained by enzymatic
digestion of adipose tissue using collagenase type I. The precise protocol of EqASC isolation was
previously described in detail [3–5,33,34]. Primary cultures of EqASCs were maintained in Dulbecco’s
Modified Eagle’s Medium (DMEM) with F-12 Ham nutrient. The medium was supplemented with
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10% foetal bovine serum (FBS) and 1% of antibiotic solution containing penicillin, streptomycin and
amphotericin B (PSA). Constant and aseptic growth conditions were assured by maintaining the cells
in CO2 incubator at 37 ◦C and 95% humidity. Cultures were passaged using trypsin solution (TrypLE
Express; Life Technologies, Warsaw, Poland) after reaching 80% confluence. Complete growth medium
(CGM) used for the subsequent EqASC cultures consisted of DMEM containing 4500 mg/L glucose
supplemented with 10% FBS and 1% of PSA. The media were changed every two days. The cells used
for experiments were passaged three times and were characterised as multipotent stromal cells based
on a specific phenotype and ability to differentiate into adipocytes, chondrocytes and osteocytes [3–5].
2.2. The Experimental Cultures
The multipotent stromal cells isolated from adipose tissue derived from healthy horses (EqASCHE)
and horses with equine metabolic syndrome (EqASCEMS) were inoculated in a 24-well plates. The initial
inoculum was 30,000 cells per well. The cells were cultivated for 72 h in CGM containing metformin at
a final concentration equal to 500 μM. The control for the experiment was EqASCs maintained in CGM
without metformin.
2.3. The Analysis of Metformin Influence on Morphology of EqASCs and Metabolic and Proliferative Activity
The morphology of cells was evaluated using an epifluorescence microscope (EpiFM). For the
analysis, cultures were fixed using 4% paraformaldehyde and stained with atto-488-labeled phalloidin
(1:800) and with diamidino-2-phenylindole (DAPI; 1:1000). The observations were performed using
Axio Observer A.1 microscope (Zeiss, Oberkochen, Germany). The metabolic activity of cells was
monitored every 24 h using Alamar Blue assay and, additionally, population doubling time was
determined accordingly to the method described previously [22,35]. The distribution of cells in the cell
cycle was determined using Muse™ Cell Analyzer (Merck KGaA, Darmstadt, Germany) using the
Cell Cycle Assay Kit (Merck, Warszawa, Poland). The assay was performed following manufacturer’s
instructions. Each analysis was performed in triplicate.
2.4. The Analysis of Metformin Influence on Mitochondrial Metabolism of EqASCs
The mitochondrial membrane potential was assessed with Muse™ Cell Analyzer. After culture,
cells were harvested with trypsin solution and counted with trypan blue solution using a standard
protocol [36]. For the assay, 100,000 cells were stained with MitoPotential kit (Merck, Warszawa,
Poland). Staining was performed according to the protocol provided by manufacturer (Merck,
Warszawa, Poland). Each measurement was performed at least three times. The ultrastructural analyses
of EqASC mitochondria were performed using focused ion beam microscope (FIB, Cobra, AURIGA 60,
Zeiss, Oberkochen, Germany). The protocol of preparing the material for FIB imaging was previously
described by Marycz et al. [5,37]. The analysis was conducted using an SE2 detector (Zeiss, Oberkochen,
Germany) at 2 kV of electron beam voltage. Moreover, the influence of metformin on mitochondrial
metabolism was determined based on oxidative stress factors accumulation. The supernatants after
72 h of culture were collected in order to evaluate the activity of intracellular reactive oxygen species
(ROS), nitric oxide (NO) and superoxide dismutase (SOD). ROS were measured using H2DCF-DA
solution, while NO activity was measured using Griess reagent kit (both reagents from Thermo
Fisher Scientific, Warszawa, Poland). SOD was determined using a commercially available SOD
determination kit (Sigma Aldrich, Munich, Germany).
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2.5. The Analysis of Metformin Influence on the Viability of EqASC
The apoptosis and necrosis were quantified using Muse™ Cell Analyzer. For this purpose,
100,000 cells were stained with Muse® Annexin V and Dead Cell Assay Kit (Merck, Warszawa,
Poland). The procedure of staining was performed following the manufacturer’s protocol.
The analysis was performed three times. Moreover, the viability of cultures was investigated using a
well-established staining method [33,38] with a two-colour fluorescence live/dead assay according to
the manufacturer’s instructions (Double Staining Kit: Sigma Aldrich, Munich, Germany). The cultures
were analysed using an epifluorescence microscope (Axio Observer A.1; Zeiss, Oberkochen, Germany)
and images were captured using a PowerShot camera (Canon, Warszawa, Poland).
2.6. Influence of Metformin on Endogenous Levels of WNT3A and β-Catenin
The expression of endogenous WNT3A and β-catenin was determined using Western blot
technique. After harvesting, cells were lysed with ice-cold RIPA extraction buffer. The extraction
buffer contained 1% of protease and phosphatase inhibitor cocktail (Sigma Aldrich, Munich,
Germany). To normalise the amount of protein loaded onto the gel, the total concentration of
protein in the samples was determined using the Bicinchoninic Acid Assay Kit (Sigma Aldrich,
Munich, Germany). The cell extracts containing 50 μg of protein were separated using 10%
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE; 30 mA ~80 min) and
transferred to nitrocellulose membrane at 100 V for 1 h at 4 ◦C in Tris/glycine buffer using the
Mini Trans-Blot® system (Bio-Rad, Hercules, CA, USA). After transfer, the membranes were washed
with Tris/NaCl/Tween buffer (TBST) and blocked overnight at 4 ◦C with 5% bovine serum albumin
(BSA). Membranes were then washed twice with TBST, and three times with TBS. Each rinsing lasted
5 min and was performed at room temperature under agitation (15 rpm). Next, the membranes
were incubated for 2 h at room temperature with primary antibodies detecting Wnt-3a (SAB2105736),
phospho-β-catenin (SAB4300630) and β-actin (A2066) that were prepared at a dilution of 1:200 in 5% of
BSA in TBST. After incubation with primary antibody, the membranes were washed again as described
above. After rinsing, membranes were incubated with secondary antibody conjugated with alkaline
phosphatase (A9919) for 1.5 h at room temperature. All antibodies were from Sigma Aldrich (Munich,
Germany). The membranes were washed and incubated with BCIP®/NBT-Purple Liquid Substrate
(Sigma Aldrich, Munich, Germany) for 10 min. The reaction was stopped by washing the membrane
with distilled water. The Western blot analysis was repeated twice. The blots were analysed using
Bio-Rad ChemiDoc™ XRS system. The signals were captured from the bands and the intensity was
quantified using Image Lab™ Software (Bio-Rad).
2.7. The Analysis of Metformin Influence on Expression of Genes Associated with Apoptosis
The cultures were washed with Hanks’ Balanced Salt solution (HBSS) and homogenised directly
in culture dishes using TRI Reagent® (Sigma Aldrich, Munich, Germany). The isolation of total RNA
was performed accordingly to the protocol published by Chomczynski and Sacchi [39]. The quantity
of RNA was measured using NanoDrop 8000 (ThermoFisher Scientific, Waltham, MA, USA).
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2.7.1. The Analysis of mRNA Expression
The cDNA used for the qPCR was obtained from 1 μg of RNA and was synthesised accordingly to
a method described previously [40]. SensiFast SYBR & Fluorescein Kit (Bioline Reagents Ltd., London,
United Kingdom) was used for the detection of specific amplicons. The total volume of PCR was
10μL, and cDNA did not exceed 10% of the final PCR mix volume, while the concentration of the
primers was 400 nM. The primer sequences have been published previously [41,42]. All primers were
synthesised by Sigma Aldrich (Sigma Aldrich, Munich, Germany). The qPCR was performed applying
CFX Connect Real-Time PCR Detection System (Bio-Rad Polska Sp. z.o.o., Warszawa, Poland) using a
protocol described elsewhere [43]. The transcript levels were normalised to the expression of reference
gene housekeeping gene, i.e., glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
2.7.2. The Analysis of miRNA Expression
The quality of RNA was tested using capillary electrophoresis (Fragment Analyser, Agilent
Technologies, Inc., BioVendor, Brno, Czech Republic). Only fully intact RNA was used for further
analysis. The RT was performed from 10 ng of RNA using qScript Flex cDNA Kit (QuantaBio; Beverly,
MA, USA). For the reaction, target-specific primers were used, designed according to principles
described previously [31]. The primers are listed in Table S1. The final concentration of primers in
each reaction was 50 nM. To monitor the technical aspects of the experiment, a mix of artificial spike-in
miRNA molecules was added into each sample prior to RNA extraction and RT. The RT reaction was
performed in accordance to the protocol provided by the producer. Obtained cDNA was 10-times
diluted and used in subsequent qPCR reactions measuring the expression of miRNAs, reference gene
(snU6) and 5 spike assays. Each reaction was performed in triplicates. The reaction mix was composed
of TATAA SYBR® GrandMaster® Mix (TATAA), 400 nM of primers (ThermoFisher Scientific), 2.6 μL
nuclease free water (ThermoFisher Scientific) and 2 μL of diluted cDNA. qPCR was performed in
CFX384 instrument (Biorad, Hercules, California USA). The following temperature profile was used:
95 ◦C for 30 s, 45 cycles of amplification (95 ◦C for 5 s and 60 ◦C for 15 s). The specificity of products
was determined based on melting curve analysis. The primer sequences used for qPCR are shown
in Table S1. RT-qPCR data were processed and analysed with GenEx software (MultiD, Sweden).
Cq values were normalised to a reference gene (snU6), transformed into relative quantities (scaled to
the sample having the lowest expression), and converted into log2 scale as described previously [44,45].
Significant differences between data were tested by analysis of variance (ANOVA).
3. Results
3.1. Metformin Improves Metabolic Activity and Proliferation of EqASCs
Obtained results revealed that metformin may act as an agent that increases the proliferative
activity of EqASCs derived both from healthy and EMS horses (Figure 1). Microscopic evaluation of
EqASCHE and EqASCEMS cultures showed that metformin does not affect the cells’ morphology—the
cells maintain proper fibroblast-like morphotype. However, the distribution of cells and the
growth pattern indicated on increased confluency of cultures treated with metformin (Figure 1a).
Direct evidence of pro-proliferative activity of metformin towards EqASCs was found in shortened
population doubling time (PDT). The PDT decreased after metformin treatment in ASC cultures
derived from both healthy and EMS horses (Figure 1b,c). The metformin influenced the metabolic
activity of cells, which was visible, in particular, in significant improvement of metabolic activity in
cultures after 48 h of propagation. The increased metabolic activity of cells maintained for 72 h of
culture is shown in Figure 1d,e.
The analysis of cell cycle showed that metformin treatment may change the distribution of EqASCs
and induce their shift towards S-phase. Simultaneously, we observed the decrease of percentage of cells
in G0/G1-phase. Moreover, the metformin significantly (p < 0.05) increased the number of EqASCHE
in G2/M-phase (Figure 2).
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Figure 1. The influence of metformin on proliferative and metabolic activity of adipose-derived
stromal cells isolated from horses (EqASCs). The proliferative activity was evaluated based on
microphotographs obtained with epifluorescence microscope—scale bar 250 μm (a) population
doubling time ratio (b,c) and metabolic activity (d,e). The statistically significant changes were indicated
with asterisks; * p < 0.05; ** p < 0.01, while non-significant differences are marked as ns.
3.2. Metformin Enhances Mitochondrial Potential and Improves Oxidative Status in EqASCs
The analysis of mitochondrial membrane potential confirmed that metformin improves the
metabolic activity of EqASCs isolated both from healthy and from EMS individuals (Figure 3a).
The number of cells with improved mitochondrial potential increased significantly, both in EqASCHE
and EqASCEMS cultures, after metformin treatment (Figure 3c). Simultaneously, the percentage
of total depolarised cells decreased in cultures treated with metformin (Figure 3d). Nevertheless,
the impairment of mitochondrial function in EqASCEMS remained significant when compared to
EqASCHE, and metformin did not reverse mitochondrial deterioration due to EMS. We did not observe
significant changes of mitochondria morphology in EqASCHE treated with metformin; in these cells,
mitochondria had proper shape and morphology as well as visible cristae (Figure 3b). Analysis of
EqASCEMS ultrastructure showed that, in cultures treated with metformin, the number of mitochondria
increased. Additionally, elongated mitochondria were noted (Figure 3b). These ultrastructural features,
along with the lowered activity of reactive oxygen species (ROS, Figure 3e) and nitric oxide (NO,
Figure 3f), may indicate that metformin may improve the elimination of dysfunctional mitochondria
by autophagy, enhancing mitochondrial dynamics. Additionally, in EqASCEMS cultures treated with
metformin, we observed increased levels of superoxide dismutase (SOD, Figure 3g).
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Figure 2. The influence of metformin on the distribution of EqASCs during the cell cycle,
with representative histograms (a) and results of statistical analysis (b). The statistically significant
changes are indicated with asterisks; * p < 0.05; ** p < 0.01 and *** p < 0.001. Non-significant differences
are marked as ns.
Figure 3. Cont.
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Figure 3. The influence of metformin on mitochondrial membrane potential and oxidative.
Representative dot plots indicating distribution of cells accordingly to the mitochondrial membrane
potential (a). The ultrastructure of EqASCHE and EqASCEMS without metformin treatment and after
metformin treatment. Mitochondria are indicated with red arrows, and nuclei with nu symbol, scale bar:
2 μm (b). Analysis of cell viability based on mitochondrial potential (c). Comparison of total depolarised
cells in tested experiments (d). Evaluation of reactive oxygen species (e), nitric oxide (f) and superoxide
dismutase activity (g). Significant changes are indicated with asterisks: * p < 0.05; ** p < 0.01 and
*** p < 0.001, while non-significant differences are marked as ns.
3.3. Metformin Increases Viability of EqASC Cultures
Quantification of apoptosis and necrosis by annexin V binding and propidium iodide uptake
revealed that metformin exerts an anti-apoptotic effect on EqASCEMS cultures (Figure 4a). The cellular
viability of EqASCEMS was significantly restored following metformin treatment. The percentage of
early and late apoptotic cells decreased after metformin administration, not only in EqASCEMS but
also in EqASCHE (Figure 4c,d). Additionally, the viable cells were visualised with calcein-AM staining,
while dead cells were counterstained with propidium iodide. The images confirmed the previous
observations that metformin increases confluency of EqASCs in cultures. Nevertheless, based on the
pictures, it was difficult to ascertain the influence of metformin on cells viability, because dead cells
were dimly fluorescent in analysed cultures (Figure 4b). The anti-apoptotic effect of metformin towards
EqASCs was confirmed using RT-qPCR. We determined that metformin decreases mRNA expression
of BAX in EqASCEMS cultures, while increasing the mRNA expression of anti-apoptotic BCL-2. Further,
the BAX transcript level increased following metformin treatment in EqASCHE cultures, however,
the BAX/BCL-2 ratio decreased, indicating an anti-apoptotic effect correlating with low ROS activity
in those cultures (Figure 4e–g).
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Figure 4. The influence of metformin on the apoptosis profile. Representative dot plots indicating
distribution of cells after annexin V/ propidium iodide staining (a) Representative images obtained after
calcein/PI staining, scale bar—250 μm. (b) Analysis of cell viability (c) and apoptosis (d). Measured
transcript levels for BAX (e) BCL-2 (f) and their ratio (g) Statistically significant changes are indicated
with asterisks: * p < 0.05; ** p < 0.01 and *** p < 0.001, while non-significant differences are marked as ns.
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3.4. Metformin Induces Intracellular Accumulation of β-Catenin and Wnt-3a, However, Only in EqASCs
Derived from EMS Horses
The expression of WNT-3a and β-catenin was analysed on mRNA and protein levels. The mRNA
level for β-catenin increased following metformin treatment both in EqASCHE and EqASCEMS.
We also noted that metformin increases the transcript level of WNT-3A, however, only significantly in
EqASCEMS cultures. The intracellular accumulation of Wnt-3a and β-catenin was also significantly
higher in EqASCEMS (Figure 5).
Figure 5. Determination of Wnt-3/β-catenin expression (a,b) and corresponding intracellular
accumulation of protein (c–e). Statistically significant changes are indicated with asterisks: * p < 0.05;
** p < 0.01 and *** p < 0.001, while non-significant differences are marked as ns.
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3.5. Metformin Decreases miR-16-5p, miR-21-5p, miR-29a-3p, miR-140-3p and miR-145-5p Levels in EqASCs
Derived from EMS Horses
miRNA analysis showed that metformin does not influence miR-16-5p, miR-21-5p and miR-29a-3p
levels in EqASCHE, while the levels of miR-140-3p and miR-145-5p in those cultures were increased.
All tested miRNAs were significantly downregulated in EqASCEMS cultures (Figure 6).
Figure 6. miRNA expression measured with two-tailed RT-qPCR. The following miRNAs were tested:
miR-16-5p (a), miR-21-5p (b), miR-29a-3p(c), miR-140-3p (d) and miR-145-5p (e). Data are normalised
to U6 snRNA levels and expressed as fold changes compared to the sample with the lowest level.
Statistically significant changes are indicated with asterisks: * p < 0.05; ** p < 0.01 and *** p < 0.001,
while non-significant differences are marked as ns.
4. Discussion
Adipose tissue is defined by heterogenous cellular composition that may be altered during disease
conditions, such as diabetes and equine metabolic syndrome [46–49]. The morphology of mature
adipocytes is also influenced by physiological conditions and might change under specific medication
treatment, e.g., metformin was shown to reduce the diameter of adipocytes as well as to induce a
greater heterogeneity of the tissue [50]. Currently, much attention is paid to the cellular composition of
stromal vascular fraction (SVF) obtained from adipose tissue. This fraction contains a plethora of cells,
including endothelial cells, fibroblasts, B- and T-lymphocytes, macrophages, myeloid cells, pericytes,
pre-adipocytes, smooth muscle cells and, finally, culture-adherent adipose stromal cells (ASCs) [51].
Due to high cellular plasticity and enhanced self-renewal, ASCs are considered an excellent therapeutic
tool in cell-based therapies for various disorders, including diabetes and the metabolic syndrome [46].
Moreover, the great pro-regenerative potential of ASCs also relies on their paracrine activity and
immunomodulatory properties [52,53].
We have previously shown that EMS affects various aspects of ASC cellular activity and limits
their clinical application. Generally, ASCs derived from horses with EMS (EqASCEMS) exhibit lower
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proliferative and metabolic potential. Moreover, cultures of EqASCEMS are characterised by increased
senescence and cell death. Further, we noticed imbalance of the oxidative status in that EqASCEMS was
related to endoplasmic reticulum (ER) stress and deterioration of mitochondrial dynamics [2–5,41].
Currently, various pretreatment conditions and culture strategies are applied in terms of improvement
of the regenerative potential of multipotent stromal cells residing in different tissue niches [52,54].
We previously found that combination of 5-azacytydine and resveratrol (AZA/RES) has a favourable
influence on the proliferation, viability and multipotency of EqASCEMS [20]. The mechanism of
5-azacitidine (5-AZA) is related to inhibition of DNA methyltransferase (DNMT), while resveratrol
was recognised, inter alia, as an activator of AMPK/PGC-1α signalling, improving mitochondrial
biogenesis and dynamics [20]. The anti-aging and senolytic action of AZA/RES combination has been
demonstrated towards progenitor cells of adipose origin. In the experiment, we focused on another
AMPK activator, i.e., metformin, and its potential effect on the basic cytophysiological features of
ASCs, including proliferation, metabolism and viability. The metformin was described as an agent
with pleiotropic activity, which also includes anti-aging and senolytic activity [55]. Recently, we have
observed growing interest in metformin and its application as a pro-regenerative molecule [56].
Our current research shows that metformin exerts pro-proliferative effect towards EqASCs
derived from both healthy and EMS-affected horses (EqASCHE and EqASCEMS, respectively). We noted
increased proliferation and metabolic activity after metformin treatment, as well as shift of EqASCs to
the S-phase of the cell cycle. The results are consistent with our previous studies applying an ex vivo
model and showing the pro-proliferative effect of metformin on mouse ASC (mASCs) and progenitor
cells isolated from olfactory bulb [21,22]. Previously, recognising the pro-regenerative potential of
metformin, we used it as a bioactive molecule for functionalisation of sol–gel coatings covering metallic
implants. We tested cytocompatibility of the obtained biomaterials using a model of human ASCs
(hASCs) [57]. In this experiment, we found that metformin may enhance proliferation of cells, shorten
the population doubling time, and improve metabolic activity. Earlier, the pro-proliferative effect of
metformin was also established in terms of MSCs derived from bone marrow (BMSC) and osteoblast
progenitors [58,59], as well as adipose-derived stromal cells [60]. Metformin generally acts in dose-
and time-dependent manner, therefore, consideration of proper metformin dosage is crucial in terms
of obtaining a desirable effect [50,61]. Metformin is also known as an anticancer drug. We previously
tested metformin at concentrations that inhibited proliferation of various cancer cell lines, including
breast, ovarian and pancreatic [62]. Our results showed that metformin in higher concentrations exerts
an anti-proliferative effect towards mASCs [50] and mBMSCs [61].
We also indicated an improved oxidative status of mASCs derived from animals treated with
metformin. This was correlated with reduction of reactive oxygen species (ROS) and nitric oxide
(NO), and increase of SOD (superoxide dismutase) activity [21]. In the current study of EqASCs,
we have confirmed the antioxidant effect of metformin. We also show that metformin improves
mitochondrial membrane activity. The ultrastructural observations of metformin indicated enhanced
dynamics of mitochondria in cultures derived from EMS horses. In EqASCEMS, we have observed
elongated mitochondria. Mitochondria elongation occurs during macroautophagy, which is a
mechanism allowing to sustain cellular ATP production and viability of cells [63]. These results
correlate with increased viability of EqASCs in cultures treated with metformin, and are in agreement
with studies performed by Wang et al., who showed that metformin can protect H9c2 cells against
hyperglycaemia-induced apoptosis and Cx43 downregulation through the induction of the autophagy
pathway [64].
Analysis of the apoptosis profile revealed that metformin may act as anti-apoptotic agent
towards EqASCs derived both from healthy and EMS horses. The results correlate with our previous
findings, showing increased viability of mouse progenitor cells derived from animals treated with
metformin [21,22]. However, the results are in contradiction to data presented by He et al. [65],
who showed that metformin significantly induces apoptosis of MSCs isolated from human umbilical
cord, even at 0.1 mM concentration. He et al. showed that metformin induces apoptosis in cells in
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dose- and time-dependent manner, and indicated that metformin at 2 mM concentration induced a
sub-G1 peak, which is a suggestive marker of apoptosis [65]. We confirmed the anti-apoptotic activity
of metformin in EqASC cultures at different levels. Firstly, by the distribution of cells in the cell cycle,
showing a reduced percentage of cells in G0/G1-phase; secondly, by depicting increased mitochondrial
membrane potential following metformin treatment; and, finally, determining the apoptosis profile
using annexin V/PI and calcein/PI staining. Our results clearly indicate that metformin improves
EqASC viability. Additionally, we noted increased transcript levels of the anti-apoptotic BCL-2 gene,
in contrast to the findings of He et al. [65]. The discrepancy between our findings and those of He et al.
may be due to the model used, as well as different metformin concentrations. He et al. performed a
comprehensive analysis of the pro-apoptotic effect of metformin using dosages above 1 mM, which is
in agreement with our previous studies [50,61].
Due to the fact that Wnt/β-catenin signalling was indicated as a crucial pathway in terms of
modulating MSC self-renewal and differentiation, we were interested in its expression profile after
metformin treatment. It has been shown that fine-tuning of Wnt/β-catenin signalling coordinates
MSC function [66]. Particularly, Kim et al. (2015) revealed that low levels of β-catenin in MSCs result
in increased expression of genes involved in cell cycle control and DNA metabolism, while high levels
of β-catenin were linked to increased expression of genes crucial for development and metabolism [66].
Additionally, Subramaniam et al. [32] tested the influence of AICAR and metformin on hepatic stellate
cells (HSCs). The study showed that both agents activate AMPK signalling in quiescent HSCs, but elicit
distinct effects on cells function. Interestingly, AICAR rapidly induced cell death of HSCs, while the
cells remained viable after metformin treatment. Metformin induced activin membrane-bound
inhibitor (Bambi) and activated a pro-survival Wnt/β-catenin signalling pathway [32]. Wnt pathway
can also be regulated by ROS levels, which indicates crosstalk between Wnt and redox signalling.
It has been shown that low levels of ROS activate Wnt signalling and improve differentiation of
MSCs towards osteogenic cells [67]. Our results confirm that lowered levels of ROS may induce
intracellular accumulation of WNT. Increased expression of WNT in cells treated with metformin
may also explain the pro-osteogenic action of the drug towards ASCs, which was emphasised in our
previous studies [21,57].
Metformin was also found to modulate microRNA levels. The miRNA profile following
metformin treatment has previously mainly been established for cancer cell lines [68,69]. Here,
we measured the levels of the following miRNAs: miR-16-5p, miR-21-5p, miR-29a-3p, miR-140-3p
and miR-145-5p, that previously have been reported relevant for self-renewal and differentiation
of mesenchymal stem cells [70,71]. We found that, in EqASCEMS cultures, expression of miR-16-5p,
miR-21-5p and miR-29a-3p decreased following metformin treatment. miR-16-1 level has been reported
inversely correlated to BCL-2 expression in chronic lymphocytic leukaemia (CLL) [72]. Indeed, our
data indicate increased expression of BCL-2 in cultures treated with metformin. Further, it has been
reported that miR-16 controls myoblast proliferation and apoptosis via coordinated regulation of
BCL-2 activation [72]. It has also been shown that overexpression of mir-21 is related to increased
proliferation activity of BMSCs [73]. This also correlated to increased expression of BCL-2 and vascular
endothelial growth factor (VEGF), and decreased expression of BAX. This is different to the profiles
observed in our model. Firstly, we observe constitutive expression of miR-21-5p in EqASCs derived
from healthy horses. Secondly, native cultures of EqASCEMS are characterised by increased occurrence
of apoptosis and increased expression of BAX transcripts, which is associated to accumulation of
mir-21-5p. Upon metformin treatment, the pattern was reversed: we found reduced levels of mir-21-5p
and BAX, while BCL-2 level was increased. It seems that regulation of mir-21-5p is complex, and it
may influence the differentiation process of BMSCs [74]. Contradictory data exist concerning mir-21
function as a regulator of MSC fate and lineage commitment. For example, it has been shown that
overexpression of mir-21 is related to osteoclastogenesis [75], adipogenesis [76], and osteolysis [77].
Nevertheless, it was also reported that rat BMSCs overexpressing mir-21 accelerate fracture healing in
a rat closed femur fracture model [74].
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Further, miR-29a-3p, in EqASCs, was found to have the same expression pattern as what
we observed for miR-21-5p. Overexpression of miR-29a was correlated to reduced levels of Slit
glycoprotein 2 (SLIT2) and its receptor Roundabout 1 (ROBO1) which, in turn, resulted in inhibition of
mesenchymal stem cell viability and proliferation [78]. Moreover, it was shown that transfection of
miR-29 family members at an early stage of somatic cell reprogramming may decrease the number of
colonies expressing pluripotent markers, such as Oct4 [79]. These results may explain the mir-29a-3p
expression profile observed in EqASCEMS treated with metformin. These cultures were characterised
by higher proliferative activity and viability when compared to non-treated cells characterised by
increased levels of mir-29a-30.
miR-140-3p and miR-145-5p in EqASCHE and EqASCEMS were differentially modulated by
metformin. Following treatment, we observed increased levels of both transcripts in EqASCHE,
while miR-140-3p and miR-145-5 levels in EqASCEMS cultures were lower. mir-140 has been
reported to modulate proliferation and differentiation of human dental pulp stem cells (DPSCs) [80].
Overexpression of miR-140-5p improved proliferation of DPSCs and aggravated their differentiation,
whereas suppression of miR-140-5p had the opposite effect. Similarly, higher level of mir-145-5p
was related to the lower ability of MSCs to undergo chondrogenic differentiation. mir-145-5p is
generally considered suppressor of cell growth, and its reduced level in EqASCEMS cultures may
explain their increased proliferative activity. Moreover, we have previously shown that microvesicles
isolated from EMS contained high levels of mir-140 [5]. mir-140 has been reported marker for type II
diabetes (T2D) [81]. Individuals with T2D have mir-140-3p levels upregulated compared to individuals
with gestational diabetes mellitus, and downregulated compared to individuals with type I diabetes
mellitus [82].
Today, miRNA is in focus, and has been proposed to serve as new biomarker for the diagnosis
and treatment of metabolic syndrome in horses [81]. Identification of useful miRNA signatures in
horses is an emerging field [83], and highly specific and sensitive methods, such as the two-tailed
RT-qPCR used here, are vital to establish their usefulness as biomarkers for various horse diseases,
including EMS.
5. Conclusions
Our results indicate that metformin improves proliferative activity of EqASCs derived from
healthy and EMS horses. Metformin enhances mitochondrial metabolism reducing the percentage
of cells with low mitochondrial membrane potential, which was related to the increased viability of
EqASCs. Following metformin treatment, accumulation of WNT-3A and β-catenin was observed
in EqASCEMS. Metformin also modulates the expression of several miRNAs associated with cell
proliferation, viability and differentiation. Bearing in mind that metformin may also promote
differentiation of MSCs, it may be reasonable to test this drug as a preconditioning agent in osteogenic,
chondrogenic, as well as adipogenic cultures of EqASCs.
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8. Nicpoń, J.; Marycz, K.; Grzesiak, J. Therapeutic effect of adipose-derived mesenchymal stem cell injection in
horses suffering from bone spavin. Pol. J. Vet. Sci. 2013, 16, 753–754. [CrossRef] [PubMed]
9. Marycz, K.; Toker, N.Y.; Grzesiak, J.; Wrzeszcz, K. The Therapeutic Effect of Autogenic Adipose Derived
Stem Cells Combined with Autogenic Platelet Rich Plasma in Tendons Disorders in Horses In Vitro and In
Vivo Research. J. Anim. Vet. Adv. 2012, 11, 4324–4331.
10. Gnecchi, M.; Zhang, Z.; Ni, A.; Dzau, V.J. Paracrine mechanisms in adult stem cell signaling and therapy.
Circ. Res. 2008, 103, 1204–1219. [CrossRef]
11. De Aro, A.A.; Carneiro, G.D.; Teodoro, L.F.R.; da Veiga, F.C.; Ferrucci, D.L.; Simões, G.F.; Simões, P.W.;
Alvares, L.E.; de Oliveira, A.L.R.; Vicente, C.P.; et al. Injured Achilles Tendons Treated with Adipose-Derived
Stem Cells Transplantation and GDF-5. Cells 2018, 7, 127. [CrossRef] [PubMed]
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synthesis and secretion of membrane-derived microvesicles (MVs) rich in VEGF and BMP-2 in equine
adipose-derived stromal cells (EqASCs)-a new approach in veterinary regenerative medicine. In Vitro Cell.
Dev. Biol. Anim. 2015, 51, 230–240. [CrossRef] [PubMed]
138
Cells 2019, 8, 80
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Lis, A.; Śmieszek, A. Biphasic Polyurethane/Polylactide Sponges Doped with Nano-Hydroxyapatite (nHAp)
Combined with Human Adipose-Derived Mesenchymal Stromal Stem Cells for Regenerative Medicine
Applications. Polymers 2016, 8, 339. [CrossRef]
44. Dzamba, D.; Valihrach, L.; Kubista, M.; Anderova, M. The correlation between expression profiles measured
in single cells and in traditional bulk samples. Sci. Rep. 2016, 6, 37022. [CrossRef] [PubMed]
45. Pivonkova, H.; Hermanova, Z.; Kirdajova, D.; Awadova, T.; Malinsky, J.; Valihrach, L.; Zucha, D.; Kubista, M.;
Galisova, A.; Jirak, D.; et al. The Contribution of TRPV4 Channels to Astrocyte Volume Regulation and Brain
Edema Formation. Neuroscience 2018, 394, 127–143. [CrossRef] [PubMed]
46. Kornicka, K.; Houston, J.; Marycz, K. Dysfunction of Mesenchymal Stem Cells Isolated from Metabolic
Syndrome and Type 2 Diabetic Patients as Result of Oxidative Stress and Autophagy may Limit Their
Potential Therapeutic Use. Stem Cell Rev. 2018, 14, 337–345. [CrossRef] [PubMed]
47. Gallagher, D.; Kelley, D.E.; Yim, J.-E.; Spence, N.; Albu, J.; Boxt, L.; Pi-Sunyer, F.X.; Heshka, S. Adipose tissue
distribution is different in type 2 diabetes123. Am. J. Clin. Nutr. 2009, 89, 807–814. [PubMed]
140
Cells 2019, 8, 80
48. Lee, M.-J.; Wu, Y.; Fried, S.K. Adipose Tissue Heterogeneity: Implication of depot differences in adipose
tissue for Obesity Complications. Mol. Aspects Med. 2013, 34, 1–11. [CrossRef] [PubMed]
49. Dev, R.; Bruera, E.; Dalal, S. Insulin resistance and body composition in cancer patients. Ann. Oncol. 2018, 29,
ii18–ii26. [CrossRef] [PubMed]
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Abstract: Regenerative medicine is a rapidly expanding area in research and clinical applications.
Therapies involving the use of small molecule chemicals aim to simplify the creation of specific
drugs for clinical applications. Adult mesenchymal stem cells have recently shown the capacity to
differentiate into several cell types applicable for regenerative medicine (specifically neural cells, using
chemicals). Valproic acid was an ideal candidate due to its clinical stability. It has been implicated in
the induction of neural differentiation; however, the mechanism and the downstream events were
not known. In this study, we showed that using valproic acid on adult mesenchymal stem cells
induced neural differentiation within 24 h by upregulating the expression of suppressor of cytokine
signaling 5 (SOCS5) and Fibroblast growth factor 21 (FGF21), without increasing the potential death
rate of the cells. Through this, the Janus Kinase/Signal Transducer and Activator of Transcription
(JAK/STAT) pathway is downregulated, and the mitogen-activated protein kinase (MAPK) cascade is
activated. The bioinformatics analyses revealed the expression of several neuro-specific proteins as
well as a range of functional and structural proteins involved in the formation and development of
the neural cells.
Keywords: adipose derived stem cells; valproic acid; protein interactions; MAPK pathway;
JAK/STAT pathway
1. Introduction
Regenerative and translational medicine is a rapidly expanding area made possible by the
availability of an abundant source of stem cells, particularly autologous adult mesenchymal stem
cells acquired from lipoaspirates termed adipose derived stem cells (ADSCs). The application of
autologous ADSCs to neural regeneration and repair therapies is of great interest due to the potential to
reverse or limit the exacerbation of injuries that have severe effects on the quality of life while avoiding
rejection [1].
Several studies have explored the effect of small molecule chemical inducers on the potential
to drive neurogenic differentiation in stem cells. At optimized concentrations and short treatment
times, chemicals such as beta-mercaptoethanol (BME) and dimethylsulfoxide (DMSO), have shown
the potential to induce a structural and molecular phenotype in stem cells that resemble differentiating
neural cells [2,3]. Not surprisingly, these molecules had negative effects inducing a range of stress
and apoptotic markers with an increasing treatment time frame. Alternatively, less harsh chemicals
with similar actions, such as butylated hydroxyanisole (BHA), retinoic acid (RA) and other chemical
Cells 2020, 9, 619; doi:10.3390/cells9030619 www.mdpi.com/journal/cells143
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derivatives, have also shown a marked capacity for improving neural differentiation while decreasing
cellular stress and death [4–7]. Valproic acid (VPA), as a focus molecule, has garnered some attention
in neurogenic differentiation research, and was previously explored in certain stem cell types; however,
the extent of the differentiation was not completely elucidated [8,9].
Valproic acid (VPA) is a short-chain fatty acid that is well known as a histone deacetylase
(HDAC) inhibitor [10]. It is an established drug in epilepsy therapy and can be used clinically as an
anticonvulsant and a mood stabilizer [11]. Its proprieties on adult neuron cells are known and its
actions on transcription have been previously studied at variable concentrations in vitro [12]. Studies
have proven that VPA can affect the proliferation and the differentiation of neural crest progenitors
and hippocampal neural stem cells [13]. Furthermore, VPA was shown to increase white matter repair
and neurogenesis after a stroke by supporting the survival and new growth of oligodendrocytes, as
well as myelination and axonal density [14]. The effect of VPA inducing differentiation in other stem
cell types has been studied to a lesser extent.
VPA is minimally cytotoxic and biologically relevant. The induction by VPA of placental
mesenchymal stem cells toward neuronal differentiation has been analysed using the criteria of altered
cell morphology, reduced proliferation, and the expression of marker genes [13]. VPA treatment
for up to ten days induced profound changes in cell morphology, which were characterized by less
tightly packed cells within the colonies and the generation of long filamentous structures [8]. VPA
has a definite effect on stem cells and induced morphological changes that progressed to a stage of
preneuronal-like cell.
Further studies showed that VPA influences the proliferation and differentiation of neuronal cells
by expressing a small set of specific markers [15]. However, little is known about the downstream events.
The role of VPA in protein expression involved in the cell cycle and neuronal differentiation was also
investigated. It was shown that treatment with VPA during the progenitor stages resulted in the strong
inhibition of cell proliferation and the induction of neuronal differentiation, accompanied by increases
in the expression of pro-neural transcription factors and in neuronal cell numbers [15]. Furthermore,
it was previously demonstrated that VPA initiated catecholaminergic neuronal differentiation. VPA
launches differentiation mechanisms in sympathoadrenal progenitor cells that result in increased
generation of functional neurons [9]. However, the target of VPA on the neuronal differentiation
pathways is also largely unknown. A research void exists in the molecular mechanisms that play a role
in ADSCs differentiation toward neuronal phenotypes.
Previous studies on how VPA affects the neural differentiation are largely based on the impact
of the VPA on the transcription through inhibition of the histone deacetylases (HDACs). This study
focuses on the VPA effects on ADSCs as analysed by a proteomics approach, with the aim to compare
the effects of the neural induction by VPA to controls and the effects of neurobasal media B27. Media B27
supports the neural differentiation of stem cells [16,17]. Using microscopy analysis, the morphological
changes of the ADSCs after induction with VPA may be tracked photographically and at specific chosen
time points. The proteomic analysis provides a broader data pool of the global effect of the VPA, not
only on the transcription but also directly on the different neural differentiation pathways by inducing
critical interactions. Furthermore, investigation of the proteins critical in VPA induction of the cascade
pathways such as MAPK/ERK and JAK/STAT may be undertaken. In addition to proteomics, a BioPlex
analysis allows for the investigation of the roles of chemokines and cytokines as a complementary
analytical technique. This provides more specific information on the secreted cytokines and their role
in the induction of differentiation pathways in the cells [18].
2. Methods
2.1. Cell Culture
The procedures of adult human ADSCs isolation and expansion were used from Santos et al. [3]
utilising cells that were cryo-stored from UTS-HREC Santos-2013000437. All donor participants
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volunteered through informed consent for waste lipoaspirate donation as per ethics guidelines and
were de-identified for research purposes (Ethical Code: UTS-HREC Santos-2013000437, Committee:
University of Technology Sydney (UTS) Human Research Ethics Committee, Date: 02/07/2013).
Generally, ADSCs were cultured in T175 (Nunc, ThermoScientific, Carlsbad, CA, USA) in DMEM
Glutmax/F12 Gibco, Life Technologies, Carlsbad, CA, USA) with 10% foetal bovine serum (FBS, Gibco,
Life Technologies, Carlsbad, CA, USA) incubated at 37 ◦C at 5% CO2 ADSCs were passaged three to
five times post isolation by stripping the cells with TrypLE Express (12604 Gibco) before being used
in differentiation experiments. The cells were seeded on to 6-well plates (Nunc, ThermoScientific,
Carlsbad, CA, USA) at approximately 20,000 cells/mL in 5 mL of DMEM Glutmax/F12 with FBS and
maintained till 80% prior to commencing chemical induction for differentiation.
2.2. Chemical Induction for Differentiation
Sub-confluent ADSCs were washed twice in pre-warmed sterile DMEM Glutmax/F12 (Invitrogen).
The cells were then cultured for a further 24 h in a serum-free pre-induction medium consisting
of DMEM/F12 (Invitrogen), and 10% of the final concentration of the added VPA. The media was
then replaced after 24 h with the neuronal inducing media consisting of DMEM/F12 (Invitrogen),
and the final optimised concentrations of 0.2 mM VPA. The control cells were maintained in DMEM
Glutmax/F12 Gibco, Life Technologies, Carlsbad, CA, USA) with 10% foetal bovine serum (FBS, Gibco,
Life Technologies, Carlsbad, CA, USA) and a further control of ADSCs in B27 for 24 h was also
maintained for further comparative analysis.
2.3. Cell Harvesting Sample Preparation
The cells were harvested for proteomic analysis by liquid chromatography-tandem mass
spectrometry (LC-MS/MS), at the selected time points of 0, 3, 6, and 24 h post-treatment, were
completed in biological and technical triplicates. Culture media was collected from each well in
2 mL Eppendorf tubes and stored at −80 ◦C for later Bioplex, alkaline phosphatase, and Reazurin
assays. Cells were rinsed twice in 5 mL of 1× phosphate buffered saline (PBS, Merck KGaA, Darmstadt,
Germany) for 5 min each at 37 ◦C and aspirated. Cells were then scraped into 1 mL of 1× PBS using a
cell scraper (Sarstedt, Numbrecht, Germany) liberated cells were collected into an Eppendorf tube and
centrifuged at 4000× g for 10 min. The supernatant was then discarded, and the cell pellets were stored
at −80 ◦C till processing.
2.4. Alkaline Phosphatase Activity Assay
Alkaline phosphatase (ALP) is widely used as a measure of stem cell proliferative capacity as
well as a marker to show pluripotency [19] and a substantial expression increase from basal states is a
measure of osteoblastic differentiation [20]. From the collected conditioned media at the chosen time
points, 50 μL of media was combined with 50 μL of 4-nitrophenol phosphate (p-NNP), the substrate
for the colorimetric assay, and the absorbance was measured at 405 nm and recorded on a Tecan
spectrophotometer. As ALP is continuously expressed in dividing stem cells, a relative abundance
of secreted ALP can be utilized to determine the cell population proliferation in the presence of cell
culture additives. Student’s t-test was used for statistical analysis, and p-values less than 0.05 were
considered to be significant.
2.5. Cytotoxicity Assay
Similarly, the cytotoxicity assay was completed in triplicate using 100 μL aliquots of the collected
conditioned media from the chosen time points combined with 10 μL of Reazurin from the Alamar
blue kit and incubated for 2 h at 37 ◦C in a clear flat bottom 96-well plate. The plate was then scanned
on a Tecan spectrophotometer at a measurement wavelength of 575 nm with a 9 nm bandwidth
and a reference wavelength scan at 600 nm with a 9 nm bandwidth. Absorbance vs. time graphs
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were generated to examine the relative cytotoxicity for each time point. Student’s t-test was used for
statistical analysis, p-values less than 0.05 are considered to be significant.
2.6. Cytokine and Chemokine Bioplex Analysis
Bioplex analysis was performed as per Santos et al. [3] with 500 μL aliquots collected at timepoints
and controls as follows: DMEM control, starve, B27 control, 0, 3, 6, and 24 h. The assay was performed
with Bioplex human 27-plex (M50-0KCAF0Y Bio-Rad Laboratories, Hercules, CA, USA). The data
analysis was completed in DanteR software (DanteR version 1.0.0.10. R version 2.12.0 The R Foundation
for Statistical Computing, Auckland, New Zealand) [21].
2.7. Cell Lysate Protein Extraction Sample Preparation
The cell pellets were resuspended in 100 μL 8 M urea (Merck KGaA, Darmstadt, Germany) and
100 mM ammonium bicarbonate (Merck KGaA, Darmstadt, Germany), sonicated for 10 min at 50%
power at three 10 s intervals. The samples were then heated to 95 ◦C on a heat block for 10 min, then
centrifuged for 1 min at 5000× g. The solution was then reduced and alkylated by adding a final
concentration of 10 mM tributyl-phosphate (TBP, Merck KGaA, Darmstadt, Germany) and 20 mM
acrylamide (Merck KGaA, Darmstadt, Germany), then vortexed and spun down on a mini-centrifuge
(Qik Spin QS7000 Edwards Instruments) at 2000× g for 2 s. The samples were incubated for 90 min
at room temperature then quenched with a final concentration of 50 mM dithiothreitol (DTT, Merck
KGaA, Darmstadt, Germany)) and again vortexed and spun down on a mini-centrifuge at 2000× g for
2 s. The samples were then diluted 1:8 in 100 mM ammonium bicarbonate. We then added 0.5 μg of
trypsin to digest at 37 ◦C for a minimum of 12 h. The samples were then desalted using SiliaprepX SCX
SPE solid phase extraction columns (Silicycle, Quebec City, Canada). The peptide concentration was
determined using the Pierce quantitative colorimetric peptide assay (Thermofisher Scientific, NSW,
Australia) and prepared for LC-MS/MS analysis.
2.8. Liquid Chromatography-Tandem Mass Spectrometry
An Acquity M-class nanoLC system (Waters, USA) was used, loading 5 μL of the sample (1 mg) at
a rate of 15 mL/min for 3 min onto a nanoEase Symmetry C18 trapping column (180 mm × 20 mm). It
was then washed onto a PicoFrit column (75 mm ID × 250 mm; New Objective, Woburn, MA, USA)
packed with Magic C18AQ resin (Michrom Bioresources, Auburn, CA, USA). The column was then
eluted of peptides into the Q Exactive Plus mass spectrometer (Thermofisher Scientific, NSW, Australia)
using the following program: 5%–30% MS buffer B (98% Acetonitrile +0.2% Formic Acid) over 90 min,
30%–80% MS buffer B over 3 min, 80% MS buffer B for 2 min, 80%–5% for 3 min. The peptides that were
eluted were ionised at 2000 V. A data dependant MS/MS (dd-MS2) experiment was performed, with a
350–1500 Da survey scan was performed at a resolution of 70,000 m/z for peptides of charge state 2+ or
higher with an Automatic Gain Control (AGC) target of 3 × 106 and a 50 ms maximum injection time.
The top 12 peptides were selectively fragmented in the Higher-energy collisional dissociation (HCD)
cell using a 1.4 m/z isolation window, an AGC target of 1 × 105 and a 100 ms maximum injection time.
The fragments were scanned in the Orbitrap analyser at a resolution of 17,500 and the product ion
fragment masses were measured over a 120–2000 Da mass range. The mass of the precursor peptide
was then excluded for 30 s.
2.9. Mass Spectrometry, Protein Identification and Data Analysis
The MS/MS data files were searched against the Human Proteome Database and against common
contaminants using Peaks Studio version 8.5 with the following parameter settings: fixed modifications:
none; variable modifications: propionamide, oxidised methionine, deamidated asparagine; enzyme:
semi-trypsin; number of allowed missed cleavages: three; peptide mass tolerance: 30 ppm; MS/MS
mass tolerance: 0.1 Da; charge states: 2+, 3+, and 4+. The search results were filtered to include
peptides with a −log10P score (related to P-value) determined by the false discovery rate (FDR) of less
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than 1%, where the score indicates that the decoy database search matches were less than 1% of the
total matches. Each condition was made up of the biological replicates that were treated at the same
time, run in triplicate. Data analysis was completed in Microsoft Excel 365, Peaks version 8.5, DanteR
(DanteR version 1.0.0.10. R version 2.12.0 The R Foundation for Statistical Computing, Auckland,
New Zealand) [21], Cytoscape (version 3.7.1, Cytoscape Consortium, Seattle, WA, USA) [22].
3. Results
3.1. Live Cell Temporal Microscopy during Neurogenic Induction Differentiation of Human ADSCs
Live cell microscopy is a vital procedure to track cellular morphologies over time during
differentiation. The physical attributes in the cell shape and formation of substructures on cells can
specify the health status and stage of differentiation relative to the treatment [23]. The ADSC control
(Figure 1A) shows non-induced cells at passage 3 at 0 h with a typical morphology and diffuse growth
with wide cell bodies. Figure 1B–D shows the same field of view through time points 3, 6, and 24 h,
respectively, displaying the temporal changes occurring in the identical field of view. The treatment
with VPA induced morphological and phenotypical changes in the ADSCs resembling differentiating
or pre-neural cells. Generally, over time, the cells structural rearrangement shows an adopted bipolar
stretched out shape displaying a condensed cell membrane around the nuclear region within the first
3 h. Furthermore, the appearance of dendrite-like structures is also increasingly more apparent from
the 6 h time point and are marked with arrows.
By 24 h, the majority of the cells now display signs of morphological shifts from the control, with
a large majority of cells displaying uniform structural changes producing long-extensions between
cells and neurite-like outgrowth on some cells. The cell population has remained relatively unchanged
across all time points compared to the control, as shown in the average cell counts in Figure 1E. This
indicates that minimal to no damage or death due to stress and apoptosis is present in the treated cells.
Supporting the observation of minimal to no damage or death are the graphs in Figure 2 displaying
alkaline phosphatase activity on y-axis Figure 2A and Reazurin cytotoxicity assay on y-Figure 2B. The
ALP column graphs show that the ALP activity decreases marginally in the serum starved cells and for
the post VPA treated cells, the similar expression range of ALP confirms the cells are not experiencing
osteogenic differentiation secretion levels and that the ALP secretion is maintained within basal levels.
The Reazurin cytotoxicity assay line graph shows that the levels at 3 h post treatment are similar to the
pre-treatment values. The stress is marginally increased at 6 and 24 h however this is lower than the
ADSC media change at 24 h, confirming that the VPA treatment has a minimal stress and cytotoxic
effect on ADSCs at the treated concentrations relative to controls. Student’s t-test analysis revealed no
significant change in cell numbers.
Figure 1. Cont.
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Figure 1. Live cell images of the temporal differentiation of human adipose derived stem cells (ADSCs)
induced with 0.2 mM valproic acid (VPA) at (A) 0 h, (B) 3 h, (C) 6 h, and (D) 24 h at 10×magnification.
The cellular morphology changes rapidly through the time points, with cells adopting a more slender
and bipolar orientation with neurite extensions (arrows). (E) Average cell count across the treatments
including all controls with standard error bars. Relatively minimal changes in numbers are shown
across all treatments. A Student’s t-test revealed no significant change in cell numbers.
 
Figure 2. (A) shows the alkaline phosphatase (ALP) activity of cells in each treatment over time. ALP
activity decreases marginally after serum starve and remains at relative levels through the treatment
time points with standard error bars. There was no significant change seen in the t-test of data.
(B) shows the cytotoxicity assay over time as cellular stress was detected by the Reazurin level with
standard error bars. Early treatment time points are equivalent to the pre-starved ADSCs prior to
treatment. The levels increase from 6 h and 24 h; however, they remain below ADSCs control at 24 h
and B27 control at 24 h post media change. There is no statistical significance determined by the t-test.
3.2. Cytokine and Chemokine Bioplex Analysis
Cytokines and chemokines are multifunctional molecules with a plethora of roles based on
their cellular location. Briefly, some of their roles include, pro-inflammation, anti-inflammation,
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intracellular signalling, intercellular signalling, response to external stimuli, induction or response
to protein cascades, and response or guidance of differentiation in cells. Their importance in stem
cell differentiation and their response to external stimulation is paramount to clarifying their role in
response to VPA. To investigate the relative quantitative changes in the expression and secretion of
cytokines and chemokines, the Bioplex multiplex immunoassay was used to simultaneously quantify
the molecules in each sample collected from controls and VPA induced time points at 0, 3, 6, and 24 h
(Figure 3). The molecules measured were Eotaxin, Granulocyte-colony stimulating factor (G-CSF),
Interferon gamma (IFN-γ), Interleukin IL-1β, IL-1ra, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13,
IL-15, Interferon gamma-induced protein 10 (IP-10), Monocyte Chemoattractant Protein-1 (MCP-1),
Macrophage Inflammatory Proteins1 alpha (MIP-1α), MIP-1β, Tumor necrosis factor alpha (TNF-α)
and Vascular endothelial growth factor (VEGF). From the 3 h time point post VPA treatment of the
ADSCs, there were lower concentrations of all measured molecules with no expression levels of IP-10
and MIP-1b detected through any successive time points. While most of the other molecules regain
some cumulative presence post VPA treatment; IL-1β, IL-6, and TNF-α demonstrate a marked decrease
in levels below the non-treated samples and remain low through all time points with relatively closer
levels to the B27 treated cells.
Figure 3. A Bioplex heat map of the log10 measure of cytokines and interleukins expressed in ADSCs
in control DMEM media pre FBS starved; starved and in DMEM after 24 h or treated with B27 or VPA
over time. Hierarchical clustering software and a Euclidean test. Red: expression above median; Blue:
expression below the median; White: median expression across sample.
3.3. Proteome Comparisons of VPA Treated Cells
Each cell treatment was conducted in biological duplicates of tissue cultures. Subsequently, each
sample was analysed in technical triplicates by mass spectrometry. This allowed for up to six analysis
points for each treatment. This was completed for an increased stringency identification and analysis.
Mass spectrometry data compilation (Table 1) identified, at the 95% confidence cutoff, 2067 unique
proteins matched from 20,011 distinct peptides derived from a 344,510 total spectra count (Table 1).
There was an average of 2.51 peptides matched per protein with an average of 10% sequence coverage.
Proteins were removed from the analysis if they were identified by less than two quantifiable peptides
per protein. The proteins analyzed were uniquely detected per time point or expressed successively
through two or more treatment time points.
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Table 1. The number of proteins and peptides identified after liquid chromatography-tandem mass













>2.0 (99) 622 765 8286 313,119 66.8
>1.3 (95) 2067 2269 20,011 344,510 67.7
>0.47 (66) 2334 2460 34,492 406,322 68.5
Interaction network analysis (Figure 4A) using the Cytoscape overlays, the 0, 3, 6 and 24 h
VPA treatment time points combining duplicates and removing proteins with less than two peptides,
and post colour-coding for unique and shared proteins, the network displays 1256 proteins with
12,771 interactions. This was completed to locate the date interaction hubs between time points and to
visualize the protein pathways. In Figure 4A, the nodes are Blue—ADSC unique, Violet-occurs in two
or more time points, Red—3 h unique expression, Orange—6 h unique expression, and Green—24 h
unique expression. The Venn diagram breakdown (Figure 4B) displays the number of proteins that
are unique and shared between each time point as well as percentage of total proteins analysed in
the network. The proteins expressed in the ADSC VPA treated time points overlap with only the
VPA treated ADSCs total to 3 h—221 proteins, 6 h—200 proteins, and 24 h—243 proteins. The gene
ontology analysis of the proteins expressed in the VPA treated ADSCs is graphed in Figure 4C. There
are 150 proteins involved across several biological process ontologies aligned with neuron and axon
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Figure 4. (A) Cytoscape protein interaction network graph of proteins identified by mass spectrometry.
Blue—ADSC unique, Violet—occurs in two or more time points, Red—3 h unique expression, Orange—6
h unique expression, and Green—24 h unique expression. (B) Venn diagram displays breakdown of
protein numbers unique and shared between time points. (C) Gene ontology biological process analysis
of the proteins expressed in Red—3 h, Orange—6 h, and Green—24 h shows a high percentage of
proteins linked to neural, neuron, or axon development.
3.4. Pathway Analysis of Gene Ontology Clustered Proteins
The above-mentioned neural-related proteins identified in gene ontology biological process
categories were analysed in ClueGO (version 2.5.4) for group clustering and interaction pathway
process analysis (Figure 5). Graphing only the neural-related proteins allowed for a concise interaction
map of the probable roles played in the differentiated process as well as links in the signalling pathways.
Table 2 breaks down the gene ontology type, number of proteins identified in this dataset as well as the
GO term p-value Bonferroni step down to validate multiple pair wise tests.
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Figure 5. The ClueGo analysis of clustered proteins within each GO node for biological process
interaction and signalling pathway analysis involved in the VPA treated cells. Node sizes are relative
to number of proteins in dataset identified in that GO. Coloured nodes and labels represent important
GO terms in the network.
Figure 6 is a reductive schematic derived from the previous ClueGO graph; it presents the
proposed key proteins (summarized in Table 3) and possible summary pathway involved in VPA’s
action in directing signalling and differentiation in the treated ADSCs. VPA is known to be an HDAC
inhibitor, by this direct interaction, HDAC secondary interaction with H1 and H2A is closed. These
two proteins have further downstream affects in regulating the RAS/ERK and JAK/STAT pathway
via EGRF signalling. By closing this loop, the FGF signalling pathway is upregulated by direct and
indirect interactions of VPA which promote the MAPK1 expression and activity. This is a gateway
control for initiating the MAPK pathway, which is involved in several neural differentiation lineages.
VPA also has an activity in oxidative stress which also acts as a dualistic interaction hub for MAPK
pathway promotion.
Figure 6. Reductive schematic of the proposed VPA induction pathway in the treatment of ADSCs
toward neural differentiation.
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4. Discussion
The variety of neural related applications of Valproic acid, including its use as an anticonvulsant
to use in treating disorders, such as epilepsy, bipolar, Schizophrenia, Parkinson’s, and stroke, holds
significant value in its role in directing in vivo neural cell modulation and repair. In vitro studies
have observed a VPA effect on several factors in molecular responses of stem cells treated with the
chemical, indicating shifts toward neural-like outgrowth with the expression of specific markers and
morphological ques associated with differentiation. In this study we aimed to observe and measure the
effect of VPA on the wide changes over chosen time points of the proteome of adult stem cells to gain a
global understanding of the early mechanisms that are involved in the VPA induction of stem cells.
4.1. Cellular Morphology
The microscopy analysis exhibits the first evidence of differentiation. VPA induces morphological
changes on the ADSCs within 3 h, and the cells show long cytoplasmic extensions and become thicker
relative to the untreated cells. This indicates that VPA may influence cytoskeletal modifications.
Dendrite-like structures appear from 6 h provides further evidence that ADSCs are taking on a neuronal
differentiation path. At the final time point, examined at 24 h, the treated cells have a vastly changed
appearance from the original form. Much of the population appears slender and has a directed polar
outward growth pattern. Furthermore, the dendrite extensions are present in most cells. VPA does not
have an influence on the death rate, the cell population has had minimal variation over the treatment
time points as opposed to studies with other small chemicals, such as BME and DMSO [2,3,23]. The
cell counts and subsequent ALP and Reazurin assays support the stability of the cell culture population
with nominal changes over time.
4.2. Secreted Molecules Role in Signalling Pathways Controlling Neural Differentiation
The pleiotropic nature of secreted cytokines assists in the molecular signalling and pathway
modulation across various systems in almost all cell types. They are particularly interesting due to
the multifunctional roles within cellular responses and differentiation, by primarily promoting or
closing pathways as well as regulating the expression of specific cascades leading to the release of
neurotrophic factors in the case of neural differentiation. Tracking their expression patterns from
treated cells utilizing the Bioplex system, allows for a relative quantification and group clustering to
identify trends between multiple molecules.
In the Bioplex results, it is noticeable that for almost all cytokines, post VPA treatment, the
quantified amounts are reduced from that time point. The levels seem to increase by the final time
point with variable expression patterns that are cytokine specific.
We found that VPA has effects on every cytokine measured within this study, thus it has a
large action spectrum of modulating cytokine expression, however, is very specific for targets such
as IP-10 and MIP-1b. For these two cytokines, IP-10 and MIP-1b, VPA definitively stops their
expression upon treatment. IP-10 is not detected after the first control time point across all replicates.
This may indicate that VPA has an irreversible action on these particular cytokines. Whereas, the
other cytokine trends indicate possible reversible action as variable expression patterns are viewed
across time points. IP-10 and MIP-1b have known interactions and roles with the JAK/STAT protein
pathway [24,25]. The JAK/STAT canonical pathway is a system of linked interactions involved in
the phosphorylation of tyrosine residues in receptors creating active binding sites for proteins with
Src-Homology (SH2) domains.
In this receptor—SH2 activation the ligand proteins are translocated to the cell nucleus to initiate
the transcription of genes that are vital in development, immunity and oncogenesis [26]. MIP-1b
and STAT-1 protein interaction were previously implicated in the development of human glial cells
and astrocytes [27]. IP-10 has also been shown to play a critical role in the maintenance of maturing
astrocytes in vitro [28]. The limitation of these two molecules expression and subsequent interactions
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could limit the astroglial lineage commitment and instead promote neuronal development via the
MAPK pathway. Supporting this, astrogliogenesis has been noted to require a high expression of
neuroinflammatory cytokines IL-1β, IL-6, and TNF-α during the development process [29].
These molecules were detected within the VPA treatments at levels substantially below the
non-treated ADSC controls. Higher expression levels of IL-1β [30,31], IL-6 [32] and TNF-α [33]
are known to be inhibitory or to limit to neurogenesis as well as promote cellular proliferation.
Chen et al., found that increased IL-1β limited neurogenesis by co-stimulation of STAT in the JAK/STAT
pathway [34]. Jian et al., noted that the repression of the STAT occurs by activating the MAPK
pathway [35], thus supporting the dualistic nature of JAK/STAT versus MAPK. The reduced expression
of the abovementioned cytokines by modulation of VPA treatment favours neurogenesis induction
over astrogliogenesis.
The expression changes in cytokines involved in one or several pathways like the ERK/MAPK or
JAK/STAT pathways affect, even if it is temporally, the pathways and inductive effects on the cellular
cycle and the induction of differentiation.
4.3. Protein Expression and Interaction Pathways Affected by VPA Treatment
The proteomics and network analysis show that VPA induces the expression of a variety of neural
developmental and differentiation related proteins. An interesting protein expressed due to VPA
influence is SOCS5. It is found in the 3 h samples, so the VPA effect on its expression is short; however,
its functional role is considerable. SOCS5 is categorised in the protein family group of suppressors of
cytokine signalling. SOCS5 gene expression is repressed by histone deacetylation [36], and we know
that VPA inhibits class I HDAC [11]. Thus, VPA treatment assists in increasing the expression of SOCS5
by inhibiting the HDAC. Studies proved that SOCS5 inhibits the JAK/STAT pathway [37] by decreasing
STATs activation [38]. SOCS5 is also involved in the negative regulation of IL4 and IL7 signalling [38];
this is seen in this studies Bioplex results. The expression of SOCS5 could be one of the responsible
elements in decreasing IL4 and IL7 expression and possibly other cytokines. Its effect may only be
temporary for most of the cytokines expressions and definitive for IP-10 and MIP-1b.
SOCS5 has also been previously annotated to interact with epidermal growth factor receptor
(EGFR). EGFR primary binding partner is epidermal growth factor (EGF) which activates several signal
transduction pathways including PI3K/AKT, RAS/ERK and JAK/STAT pathways [39]. The role of EGFR
is particularly important for maintaining proliferative capacities in cells which is directly promotes
JAK/STAT family proteins and dysregulates mTOR pathways useful in downstream neurogenesis.
Furthermore, EGFR role in JAK/STAT promotes gliogenesis in direct competitive opposition to the
activation of the Ras/ERK-MAPK signalling pathway [40]. The interaction of SOCS5 and EGFR is a
SH-2 domain associated inhibition of EGFR, thereby the SOCS5 again has another multifunctional
influence on limiting the JAK/STAT pathway [41]. SOCS5 could indirectly activate the MAPK pathway
through this pathway alternation. Furthermore, the appearance of JAK3 protein in the last time
points could prove that the JAK/STAT is downregulated and an intermediary protein of the cascade of
reaction as JAK3 accumulates. The events conducting to this result require further investigation. By
this protein interactivity the expression of SOCS5 downregulates the activation of the RAS/ERK and
JAK/STAT pathways.
4.4. The Oxidative Stress Role in Neural Differentiation Activation
Oxidative stress is another effect of VPA treatment, by increasing the formation of reactive oxygen
species [42]. In several case studies, it was noted that increasing levels of oxidative stress can be
counterproductive to cellular function; however, there is now a growing body of evidence that indicates
that oxidative stress is necessary in neurogenesis [43]. A recent study by Okubo et al. [44] supports
VPAs role in modulating oxidative stress by through NO-signalling. The expression of apolipoprotein
A-4 (APOA4) is a marker of cellular response against oxidative stress [45]. Similarly, the calcium
binding mitochondrial carrier proteins (SLC25A24) is also expressed by the cells to protect themselves
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from oxidative stress [46]. Within the biological process GO graph (Figure 4), these proteins were
found to be database annotated [47] in cell differentiation and neuron specific ontologies, namely;
generation of neurons, neurogenesis, neuron development and neuron projection development. These
ontologies were found to have several subsidiary groupings, examined through the ClueGo interaction
map (Figure 5), to specific neuronal developmental checkpoints supported by pathway signalling.
The presence of p38 MAPKs allows for the activation of the MAPK cascade and mitotic arrest under
a low level of oxidative stress, which has also been reported by Kurata et al. [48]. VPA’s role in p38
MAPK expression and the subsequent activation of the MAPK cascade is a supplementary route over
the Ras/ERK signalling forbearer activation of MAPK and neurogenesis pathways. VPA creates an
environment with low oxidative stress triggering the ADSCs to activating the MAPK cascade.
4.5. Functional Roles of Identified Neural Proteins in VPA Treated MSCs
Studies show that VPA promotes the production of Fibroblast growth factor 21 (FGF21) while
suppressing HDAC [49]. FGF21 expression in this study was noted onward from the 6 h time point
FGF21 is a regulator of metabolic processes and has strong links to neurogenesis and neuron maturation
and myelination [50]. Its receptor FGFR3 is expressed at 3 h, 6 h, and 24 h. Studies proved that
following the FGF21 activation of FGFR, the MAPK pathway is initiated, involving phosphorylation
of ERK 1 and 2 [51]. In the ClueGo analysis, the FGFR signalling pathway is proximal to several
downstream processes, particularly in cerebral cortex development and neuron maturation. In a recent
study by Shahror et al. [52] it was shown that MSCs over expressing FGF21 transplanted to a mouse
model enhanced neurogenesis and recovery. Furthermore, their results also show the FGF21 promoted
maturation of the hippocampal neurons. The expression of the FGF21 and FGFR3 post VPA treatment
of the stem cells is useful indicator of the neurogenic potential of VPA and MSCs.
A pertinent dataset, supportive of neuronal induction and differentiation, is the presence of
neuronal markers, which appear from the first treatment time point. Table 2 presents a list of identified
proteins and their correlative biological process in neurodevelopment according to gene ontology.
Exploring several key markers and their interaction partners allows for a greater view of the molecular
changes occurring during treatment and differentiation. The early expression of glial fibril associated
protein (GFAP), neuropilin and tolloid like 2 (NETO2), and RUN and FYVE Domain Containing 3
(RUFY3) are particularly interesting. GFAP is known to be expressed in developing central nervous
systems, and is particularly expressed in glia, astrocytes, neural stem cells, and neuron progenitor cells,
with its expression declining in mature neurons [53].
It plays a vital role in neuron development, and is classed in the GO category of neuron projections
along with its GO category and interaction partner, Thy1-membrane glycoprotein (THY1). The
interaction of these two proteins are thought to guide cell-to-cell extension in the early phases of
synapse formation. The expression of NETO2 and RUFY3 were of great interest as these proteins were
annotated as specifically expressed in neurons [54,55]. NETO2 interacts with several other proteins and
falls in with certain ontologies related to neurotransmitter update and glutamate receptor regulation.
NETO2 is also known to assist in the development of neurite outgrowth [55].
RUFY3 is also involved in the growth of neurons, specifically associated with the guidance of
axon growth [54], fittingly, the ontologies analysis and graphs correlate its role in neuron development,
the positive regulation of cell morphogenesis involved in differentiation, and the regulation of neuron
projection development. Their presence in this study of treated stem cell samples eludes to the early
stages of differentiation and commitment toward neuronal lineage. Some markers appear in later
time points like advillin (AVIL) and proteins involved in voltage-gated channel and that are specific
in generating the neuronal action potential, such as SCN3A, KCNG4, KCBN1 and KCNT2. AVIL is
involved in neuron development by cytoskeletal organization in neuron projection and morphogenesis
through its interaction with intermediary filaments and is a downstream partner in the MAPK pathway.
These proteins are evidentiary developing neuron markers. Their presence in the VPA treated ADSCs
shows that the cells are following a neuronal differentiation pathway.
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5. Conclusions
In this study we presented the temporal treatment of VPA on ADSCs and the proteomic, Bioplex,
interaction network and pathway analysis. We found that VPA induces a cascade of reactions using its
different properties. Inhibiting HDACs, it promotes the expression of SOCS5, which downregulates
the JAK/STAT pathway. In this way, the glial differentiation is silenced, and the neuronal differentiation
can be promoted.
We demonstrated that VPA activates the MAPK cascade by creating a low oxidative stress and by
upregulating the expression of FGF21. However, the ERK pathway is downregulated by SOCS5 as
well; however, this can operate as a regulator of the activation of the ERK/MAPK cascade. Specific
neuronal markers are found in the induced ADSCs and their expressions confirm that VPA induced a
neuronal differentiation pathway on the ADSCs.
This study opens a new opportunity to further differentiate ADSCs into neurons using a chemical
that is already used clinically. VPA can be a key to finding new neuro-regenerative methods.
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DMEM Dulbecco’s Modified Eagle’s Medium: Nutrient Mixture F-12
DMSO dimethylsulfoxide
ERK Extracellular Receptor Kinase
FGF21 Fibroblast growth factor 21
FGFR3 Fibroblast growth factor receptor 3
GFAP Glial fibrillary acidic protein
hADSCs human Adipose Derived Stem Cells
HDAC histone deacetylase
JAK Janus kinase
JAK3 Tyrosine-protein kinase JAK3
KCNB1 Potassium voltage-gated channel subfamily B member 1
KCNG4 Potassium voltage-gated channel subfamily G member 4
KCNT2 Potassium channel subfamily T member 2
LC-MS/MS Liquid chromatography tandem mass spectrometry
MAPK1 Mitogen-activated protein kinase
NETO2 Neuropilin and tolloid-like protein 2
PBS Phosphate-buffered saline
RA Retinoic acid
SLC25A24 Calcium-binding mitochondrial carrier protein SCaMC-1
SLC8A3 Sodium/calcium exchanger 3
STAT1 Signal transducer and activator of transcription 1-alpha/beta
STAT6 Signal transducer and activator of transcription 6
VPA Valproic Acid
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Abstract: Mesenchymal stem/stromal cells (MSCs) have immunosuppressive and regenerative
properties. Adipose tissue is an alternative source of MSCs, named adipose-derived mesenchymal
stem cells (ASCs). Because the biology of ASCs in rheumatic diseases (RD) is poorly understood,
we performed a basic characterization of RD/ASCs. The phenotype and expression of adhesion
molecules (intracellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1)
on commercially available healthy donors (HD), ASC lines (n = 5) and on ASCs isolated from patients
with systemic lupus erythematosus (SLE, n = 16), systemic sclerosis (SSc, n = 17) and ankylosing
spondylitis (AS, n = 16) were analyzed by flow cytometry. The secretion of immunomodulatory
factors by untreated and cytokine-treated ASCs was measured by ELISA. RD/ASCs have reduced basal
levels of CD90 and ICAM-1 expression, correlated with interleukin (IL)-6 and transforming growth
factor (TGF)-β1 release, respectively. Compared with HD/ASCs, untreated and tumour necrosis
factor (TNF) + interferon (IFN)-γ (TI)-treated RD/ASCs produced similar amounts of prostaglandin
E2 (PGE2), IL-6, leukemia inhibiting factor (LIF), and TGF-β1, more IL-1Ra, soluble human leukocyte
antigen G (sHLA-G) and tumor necrosis factor-inducible gene (TSG)-6, but less kynurenines and
galectin-3. Basal secretion of galectin-3 was inversely correlated with the patient’s erythrocyte
sedimentation rate (ESR) value. IFN-α and IL-23 slightly raised galectin-3 release from SLE/ASCs and
AS/ASCs, respectively. TGF-β1 up-regulated PGE2 secretion by SSc/ASCs. In conclusion, RD/ASCs
are characterized by low basal levels of CD90 and ICAM-1 expression, upregulated secretion of
IL-1Ra, TSG-6 and sHLA-G, but impaired release of kynurenines and galectin-3. These abnormalities
may modify biological activities of RD/ASCs.
Keywords: adipose-derived mesenchymal stem cells; phenotype; secretory potential;
ankylosing spondylitis; systemic lupus erythematosus; systemic sclerosis
1. Introduction
Rheumatic diseases (RD), triggered by a complex interplay of genetic and environmental
factors and mediated by autoimmune and/or autoinflammatory mechanisms, are characterized
by chronic inflammation, progressive damage and functional impairment of affected tissues and
organs [1]. Systemic lupus erythematosus (SLE) is a multisystemic disease of autoimmune background.
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Overactivation of B cells, production of numerous autoantibodies, and defective immunoregulation are
pivotal in SLE pathogenesis [2]. Systemic sclerosis (SSc), a rare autoimmune disease, is characterized
by vascular derangement, abnormal fibroblast activation and progressive multi-organ fibrosis [3].
In SSc and SLE, serious life-threatening manifestations are common. Patients require long-term
conventional immunosuppression but, despite an improvement in treatment opportunities, both
diseases are still incurable [2,3]. Ankylosing spondylitis (AS) is accompanied by inflammatory
back pain, damage to joint structures, and pathological bone formation, leading to spine ankylosis.
Early long-lasting anti-inflammatory therapy may slow the progression of this irreversible structural
damage [4]. This disease has certain autoinflammatory features and is mediated by interactions
between innate and adaptive immune cells and cytokines [4,5].
Mesenchymal stromal/stem cells (MSCs), present in many embryonic and adult tissues, are endowed
with regenerative potential and exert immunomodulatory effects on different components of the immune
system, acting through cell-to-cell contact and/or secreted factors [6,7]. For these reasons, MSCs are
thought to represent a promising therapeutic tool in autoimmune and inflammatory diseases [8].
However, depending on local conditions, tissue-resident MSCs can exhibit either anti- or pro-inflammatory
capabilities, and thus may exert either protective effects or contribute to disease development [9]. In SLE
and SSc, a growing body of data indicates numerous abnormalities of bone marrow derived MSCs
(BM-MSCs), suggesting their possible contribution to disease pathology and raising questions about
their autologous therapeutic application [10–13]. The knowledge about BM-MSC biology in AS is much
less; limited data show aberrant function of these cells, and therefore several ongoing clinical trials
apply allogenic MSCs [14–16]. Because of low expression of class II major histocompatibility complex
(MHC) molecules, MSCs are claimed to be immune privileged and allogenic MSC therapy is generally
regarded as harmless [17]. However, animal studies question this dogma by showing recipient immune
responses and rejection of transplanted allogenic MSCs [18,19]. In humans, the clinical consequences of
the therapeutic application of MHC-mismatched MSCs are unknown and, if possible, administration
of autologous MSCs is recommended [19]. Human adipose tissue is a rich source of MSCs that possess
stronger immunomodulatory capability than BM-MSCs [20,21]. Little is known about the biological
properties of adipose tissue-derived MSCs (ASCs) from SLE, SSc and AS patients. These cells have been
assessed in several SLE and SSc animal models with promising results [10]. At present, several clinical
trials for curing SLE and SSc patients with allogeneic or autologous stromal vascular fraction (SVF),
obtained from adipose tissue, are in progress (National Clinical Trials: NCT 02975960, NCT 02866552,
NCT 02741362, clinicaltrials.gov) [22]. Unfortunately, SVF preparations contain variable proportions
of ASCs and other cells, which may lead to unpredictable effects, makes standardization difficult and
limits SVF therapeutic application [10]. By contrast, ASCs represent a more homogeneous population
of cells and early phase clinical trials reported beneficial effects of autologous ASC transplantation in
the alleviation of cutaneous symptoms in SSc patients [23–25]. However, there is still controversy over
the use of autologous or allogeneic ASCs in the clinic because there are studies suggesting functional
alterations of these cells in SSc [26,27]. Therefore, with the view of the potential therapeutic application of
autologous ASCs in mind, we have performed a basic characterization of these cells and compared the
phenotype and secretory potential of RD patients’ ASCs (RD/ASCs) with the corresponding features of
ASC lines originating from healthy donors (HDs).
2. Materials and Methods
2.1. Patients and Sample Collection
Three groups of patients who fulfilled the criteria for SLE (n = 16), SSc (n = 17) or AS (n = 16),
were included in the study [28–30]. This study meets all criteria contained in the Declaration of Helsinki
and was approved by the Ethics Committee of the National Institute of Geriatrics, Rheumatology,
and Rehabilitation, Warsaw, Poland (approval protocol number: KBT-8/4/20016). All patients gave
their written informed consent prior to enrolment.
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2.2. ASC Isolation and Culture
Specimens of subcutaneous abdominal fat (approximately 300 mg) were taken from the patients
by 18 G needle biopsy. Tissue processing, ASC isolation and culture were performed as described
previously [31]. Five human adipose-derived mesenchymal cell lines (Lonza Group, Lonza Walkershille
Inc., MD, USA, donor numbers: 0000440549, 0000410252, 0000535975, 0000605220, 0000550179) were
used as a control. All experiments were performed using ASCs at 3–5 passages. The medium used for
ASC culture was composed of DMEM/F12 (PAN Biotech UK Ltd., Wimborn, UK), 10% fetal calf serum
(FCS) (Biochrom, Berlin, Germany), 200 U/mL penicillin, 200 μg/mL streptomycin (Polfa Tarchomin S.A.,
Warsaw, Poland) and 5 μg/mL plasmocin (InvivoGen, San Diego, CA, USA). For some experiments, ASCs
were stimulated for 24 h with recombinant human tumor necrosis factor (TNF)-α and interferon (IFN)-γ
(both from R & D Systems, Minneapolis, MN, USA; each used at 10 ng/mL), 2000 U/mL of IFN-α, (R&D
Systems), 5 ng/mL of transforming growth factor (TGF-β1) or 20 ng/mL of interleukin (IL)-23 (both from
PeproTech Inc. Rocky Hill, NY, USA). Then, culture supernatants (SNs) and cells were harvested for further
analysis by enzyme-linked immunosorbent assays (ELISAs) or flow cytometry, respectively.
2.3. Flow Cytometry Analysis
For ASC phenotype analysis, cells were treated with non-enzymatic cell dissociation solution
(ATCC Manassas, VA, USA) and washed with FACS buffer (phosphate-buffered saline, 0.1% NaN3,
1% FCS). Then, 5 × 104 cells were resuspended in 50 μL of FACS buffer and stained for 30 min on
ice with fluorochrome conjugated murine anti-human monoclonal antibodies against the following
surface markers: CD90-FITC, CD105-PE, CD73-APC (eBioscience, San Diego, CA, USA), CD34-PE-Cy7,
CD45-PE, CD19-PE and CD14-APC (BD Pharmingen, San Diego, CA, USA). For evaluation of
intracellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) expression,
ASCs were detached as described above, then stained with anti-ICAM-1-PE and anti-VCAM-1-APC
antibodies (both from Biolegend, San Diego, CA, USA). After the washing step, cells were acquired
and analyzed using a FACSCanto cell sorter/cytometer and Diva software. The gating strategy and
applied isotype controls are shown in Figure S1 in the Supplementary Materials.
2.4. ELISAs
The concentrations of cytokines were measured in culture SNs in duplicate using specific ELISAs.
The IL-6 ELISA was performed according to our own procedure using a goat polyclonal neutralizing
antibody specific for human IL-6 (R & D Systems, Minneapolis, MN, USA), and an IL-6 specific rabbit
polyclonal antibody (Sigma-Aldrich, St. Louis, MO, USA) as the capture and detection antibodies,
respectively, followed by horseradish peroxidase-conjugated goat anti-rabbit immunoglobulins and
o-phenylenediamine dihydrochloride (OPD) (both from Sigma) as a substrate. Human recombinant IL-6
(R & D Systems) was used a standard. The concentrations of TGF-β1, galectin-3, leukemia inhibiting factor
(LIF) and IL-1 receptor antagonist (IL-1Ra) were measured using ELISA DuoSet kits, while PGE2 was
measured using the Parameter kit (all from R & D Systems). The soluble form of human leukocyte antigen
G (sHLA-G) concentration was measured using a specific ELISA kit from Biovendor, Brno, Czech Republic.
Tumor necrosis factor-inducible gene 6 protein (TSG-6) concentration was assessed using a specific ELISA
from RayBiotech, Norcross, GA, USA. Kynurenine concentration was measured spectrophotometrically as
described elsewhere [32]. Briefly, SNs were mixed with 30% trichloroacetic acid at a 2:1 ratio and incubated
for 30 min at 5 ◦C, then centrifuged at 10,000× g for 5 min and finally diluted at a 1:1 ratio in Ehrlich’s
reagent (100 mg p-dimethyl benzaldehyde and 5 mL glacial acetic acid; Sigma-Aldrich). The optical
density of the samples was measured at wavelength of 490 nm. L-kynurenine (Sigma-Aldrich) diluted in
culture medium was used to prepare the standard curve.
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2.5. Data Analysis
Data were analyzed using GraphPad Prism software version 7. The Shapiro–Wilk test was used as a
normality test. The results are shown as median ± interquartile range (IQR) or range. One-way analysis
of variance (ANOVA) with repeated measures and post-hoc Tukey test was used to compare untreated
and cytokine-treated ASCs. The differences between ASC lines from healthy donors (HD/ASCs) and
ASCs from SLE (SLE/ASCs), SSc (SSc/ASCs) and AS (AS/ASCs) patients were analyzed using the
Kruskal–Wallis and Dunn’s multiple comparison tests. For comparison of two groups (e.g., HD/ASCs
vs. SLE/ASCs for IFN-α-treated cells), the Mann–Whitney U test was applied. Parametric (Pearson’s
linear) and non-parametric (Spearman’s rank) correlation tests were used to assess an association
between tested parameters. Probability values less than 0.05 were considered significant.
3. Results
3.1. Patients
The patient cohort was heterogeneous with respect to demographic and clinical data (Table 1).
There were no significant differences between patient groups in body mass index (BMI), disease duration,
and erythrocyte sedimentation rate (ESR) values, but SLE patients were younger than SSc patients, and AS
patients had a slightly higher concentrations of C-reactive protein (CRP) than other patients. All AS patients
were HLA-B27 positive and they were mostly treated with non-steroid anti-inflammatory drugs (NSAIDs).
The majority of SLE and SSc patients had disease-specific autoantibodies (anti-dsDNA or Scl70, respectively)
and received immunosuppressive drugs, usually with (SLE) or without (SSc) glucocorticosteroids. A similar
proportion of SSc patients had localized (52.9%) or diffused (47%) disease form. A minority of patients
received non-biologic disease-modifying anti-rheumatic drugs (DMARDs).












Age, years 41 (20–54) # 52 (20–77) 43 (25–70)
Sex, female (F)/male (M), n 15 F/1 M 12 F/7 M 8 F/8 M
BMI 24.3 (16.4–39.1) 25.8 (16.5–38.7) 26.9 (21.4–35.8)
Disease duration, years 8 (0–47) 3 (1–23) a/5 (1–40) b 6 (1.5–17)
Clinical data
Disease activity *, score 7 (0–32) 1 (0–8) 6.3 (1.0–8.2)
Laboratory values
CRP, mg/L 5 (1–23) 5 (3–18) 8 (5–59) ##
ESR, mm/h 16.5 (3–73) 16 (4–59) 15 (1–59)
Proteinuria, mg/24 h 185 (0–7550) 0 (0–0.2) n/a
C3, mg/dL 73.5 (23.2–133) 98.1 (65.8–141) n/a
C4, mg/dL 15.45 (5.38–20.6) 17.35 (13–27.1) n/a
ANA, titre (1:x) 960 (160–10,240) 2560 (320–20,480) n/a
anti-dsDNA antibody, % 75 n/a n/a
anti-dsDNA antibody, IU/mL 68.85 (0–666.9) n/a n/a
Scl-70 antibody, % n/a 88.9 n/a
Autoantibody specificities, no. 3 (1–7) 3 (2–4) n/a
Medications, %
NSAIDs 81.25
Immunosuppressive drugs 92.8 55 0
Non-biologic DMARDs 28.6 27.3 37.5
Glucocorticosteroids 75 23.5 21.25
Except where indicated otherwise, values are the median (range). BMI, body mass index; * SLEDAI, SLE Disease
Activity Index, * EUSTAR, the European League Against Rheumatism Scleroderma Trials and Research revised
index, or * BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; ESR, erythrocyte
sedimentation rate; C, complement components; ANA, antinuclear antibody; Scl-70, anti-topoisomerase I antibody;
NSAIDs, non-steroid anti-inflammatory drugs; DMARDs, disease-modifying anti-rheumatic drugs; n/a, not
applicable. # p = 0.03 for SLE vs. SSc patient comparison; ## p = 0.03 for AS vs. SLE and SSc comparisons.
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3.2. Phenotype of ASCs
Almost all HD/ASCs and RD/ASCs possessed MSC specific surface markers (CD105, CD90, CD73)
and the percentage of triple positive cells was similar in every group (Figure 1A). There was also
no significant difference in the level of CD105 and CD73 marker expression, shown as the median
fluorescence intensity (MFI). However, RD/ASCs expressed less CD90 molecules than HD/ASCs, both
on triple (CD105+/CD90+/CD73+) (Figure 1B) and single (CD90+) (data not shown) positive cells.
The proportion of ASCs expressing hematological markers was low and similar in every group, i.e., less
than 4% of HD/ASCs and RD/ASCs were positive for CD14, CD19, CD45, or CD34 (Figure 1C,D).
However, four RD/ASC lines contained ≥10% CD34+ cells. The median percentage of HLA-DR+
cells was below 10, and the majority of HD/ASCs and RD/ASCs lines contained less than 1–2% of
HLA-DR+ cells. Nevertheless, some of them (one HD/ASC and seven RD/ASCs) contained ≥20% of
these cells (Figure 1D). There was a strong inverse correlation between CD90 MFI on HD/ASCs and
basal secretion of PGE2 by these cells (Figure 1E), while in the RD group, CD90 MFI correlated positively
but moderately with IL-6 secretion (Figure 1F). Both HD/ASCs and RD/ASCs differentiated in vitro
into osteoblastic, chondrogenic and adipogenic lineages (data not shown; manuscript in preparation).
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Figure 1. The phenotype of ASCs from healthy donors (HD) and patients with rheumatic diseases
(RD). Expression of MSC specific (A,B) and non-specific (C,D) markers was assessed quantitatively
(B) and/or qualitatively (A,C,D) using ASCs from healthy donors (HD/ASCs; n = 5), systemic lupus
erythematosus (SLE/ASCs; n = 14), systemic sclerosis (SSc/ASCs; n = 13) and ankylosing spondylitis
(AS/ASCs; n = 12) patients. Data are expressed as the median (horizontal line) with interquartile range
(IQR, box), lower and upper whiskers (data within 3/2xIQR) and outliers (points) (Tukey’s box) (A,B)
or as the median with IQR (C,D). # p = 0.05–0.01; ## p = 0.01–0.001 for HD/ASCs versus RD/ASCs
comparison. Pearson’s (R) and Spearman’s rank (Rs) correlation coefficients. Solid cirle—HD/ASC
samples, hollow circles RD/ASC samples (E,F).
3.3. Expression of Adhesion Molecules by ASCs
A similar proportion of untreated and cytokine (TNFα + IFNγ; TI) treated HD/ASCs and
RD/ASCs expressed the surface adhesion molecules ICAM-1 and VCAM-1 (Figure 2A,B). VCAM-1 was
co-expressed by a small fraction of ICAM-1+ cells and no single VCAM-1+ cells were found. By contrast,
the frequency of single ICAM-1+ cells predominated over the proportion of double ICAM-1+/VCAM-1+
cells. Amongst untreated cells, a slightly higher proportion of SSc/ASCs co-expressed ICAM-1 and
VCAM-1 compared to other RD/ASCs (Figure 2A). Upon TI treatment, the percentage of single positive,
double positive, and consequently all ICAM-1+ cells increased significantly (Figure 2B). Basal levels
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(MFI) of VCAM-1 expression on HD/ASCs and RD/ASCs were similar (Figure 2C), and TI treatment
did not modify it (Figure 2D). However, basal levels of ICAM-1 expression on single and double
positive cells were significantly lower in SSc/ASCs and AS/ASCs than in HD/ASCs, and in the case
of SLE/ASCs, a similar tendency was also noted (Figure 2C). Upon TI treatment, these differences
disappeared (Figure 2D). In the RD group, the ICAM-1 MFI on ASCs positively correlated with TGF-β
secretion by these cells (Figure S2, Supplementary Materials).
Figure 2. Expression of adhesion molecules on untreated and cytokine-treated ASCs. Healthy donors
(HD; n = 5), systemic lupus erythematosus (SLE; n = 16), systemic sclerosis (SSc; n = 16) and ankylosing
spondylitis (AS; n = 15) ASCs were cultured in medium alone (untreated ASCs) or in the presence
of tumor necrosis factor (TNF)-α and interferon (IFN)-γ (TI treated ASCs) for 24 h. The qualitative
(A,B) and quantitative (C,D) assessments of intracellular adhesion molecule (ICAM)-1 and vascular
cell adhesion molecule (VCAM)-1 expression were performed. Results are expressed as the Tukey’s
boxes (see Figure 1). # p = 0.05–0.01, ## p = 0.01–0.001 for HD/ASCs versus patients’ ASCs, while * p =
0.05–0.01, ** p = 0.01–0.001, *** p = 0.001–0.0001 for untreated versus TI treated ASC comparisons, + p =
0.05–0.01 for patients’ versus patients’ ASCs. Solid circles (points) represents outliers.
3.4. Basal and Cytokine-Triggered Secretory Activity of ASCs
As shown in Figure 3A,B, both untreated and cytokine-stimulated RD/ASCs secreted significantly
smaller amounts of kynurenines and galectin-3 than HD/ASCs. Treatment with TI, but not other
cytokines, significantly increased kynurenine secretion in HD/ASCs and, to a lesser extent, in RD/ASC
cultures (Figure 3A), but failed to change the release of galectin-3 by both HD/ASCs and RD/ASCs
(Figure 3B). However, the slight elevation of galectin-3 secretion by RD/ASCs was observed when
disease-specific cytokines (IFN-α for SLE/ASCs and IL-23 for AS/ASCs) were used as the stimuli
(Figure 3B). In addition, basal release of galectin-3 by RD/ASCs correlated weakly and inversely
with patient ESR value, especially in the SSc group in which the correlation was much stronger
(Figure 3C,D). On the other hand, RD/ASCs released more IL-1Ra, sHLA-G and TSG-6 than HD/ASCs,
and cytokine treatment had a significant effect on their secretion (Figure 4). By contrast, both untreated
and cytokine-stimulated HD/ASCs and RD/ASCs released similar amounts of the other tested factors
(PGE2, IL-6, TGF-β and LIF) (Figure 5). Upon TI treatment, HD/ASCs and RD/ASCs upregulated their
secretion of IL-6; there was also increased release of LIF from HD/ASCs and PGE2 from RD/ASCs while
no changes were observed in the case of TGF-β, with the only exception of a smaller secretion of this
cytokine by TI treated compared to untreated SSc/ASCs.
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Figure 3. Impaired secretion of galectin-3 and kynurenines by ASCs of patients with rheumatic
diseases (RD). Five healthy donor (HD) ASCs lines from two different passages (n = 10), systemic lupus
erythematosus (SLE; n = 16), systemic sclerosis (SSc; n = 16–17) and ankylosing spondylitis (AS; n = 15)
patients’ ASCs were cultured in medium alone (C, control), or in the presence of the indicated cytokines
(TI, TNF-α + IFN-γ). Galectin-3 and kynurenine concentrations were measured in culture supernatants.
(A,B) Data are expressed as Tukey’s boxes (see Figure 1); * p = 0.05–0.01, *** p = 0.001–0.0001 for
control versus cytokine-treated cells; # p = 0.05–0.01, ## p = 0.01–0.001, ### p = 0.001–0.0001, #### p <
0.0001 for HD/ASCs versus RD/ASCs comparisons. (C,D) Rs, Spearman’s rank correlation coefficient.
Hollow circles represents RD/ASC samples, solid circle represents SSc/ASC samples. ESR - erythrocyte
sedimentation rate.
Figure 4. Enhanced secretion of IL-1Ra, soluble human leukocyte antigen G (sHLA-G) and tumor
necrosis factor-inducible gene (TSG)-6 by ASCs of patients with rheumatic diseases (RD). Culture
conditions of ASC lines from healthy donors (HD; n = 10), systemic lupus erythematosus (SLE; n =
12–16), systemic sclerosis (SSc; n = 10–17) and ankylosing spondylitis (AS; n = 9–15) patients were
the same as described in Figure 3. Concentrations of indicated factors were measured in culture
supernatants. Data are expressed as the Tukey’s boxes (see Figure 1). No differences between untreated
(C) and cytokine-stimulated cells were found. # p = 0.05–0.01; ## p = 0.01–0.001; ### p = 0.001–0.0001;
#### p < 0.0001 for HD/ASCs versus RD/ASCs comparison.
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Figure 5. Similar secretion of other factors by ASCs of healthy donors and patients with rheumatic
diseases. Culture conditions of ASC lines from healthy donors (HD; n = 10) and from patients with
rheumatic diseases (RD), i.e., systemic lupus erythematosus (SLE; n = 16), systemic sclerosis (SSc; n =
16–17) and ankylosing spondylitis (AS; n = 15), were the same as described in Figure 3. Concentrations
of indicated factors were measured in culture supernatants. Data are expressed as the Tukey’s boxes
(see Figure 1). * p = 0.05–0.01, *** p = 0.001–0.0001 for untreated (C) versus cytokine-treated cells; # p =
0.05–0.01, ## p = 0.01–0.001 for HD/ASCs versus RD/ASCs.
4. Discussion
MSCs are not constitutively immunosuppressive but acquired such capabilities upon exposure
to appropriate local environments, and control immune responses through cell–cell contact and
paracrine secretion of numerous soluble factors [9]. To assess the basic biological features of RD/ASCs,
the cells exposed in vivo to chronic inflammatory milieu, we first analyzed the phenotype of these
cells. According to a revised statement of the International Fat Applied Technology Society (IFATS),
there are three minimal criteria for the definition of ASCs: plastic adherence, differentiation potential
into adipocytes, chondrocytes and osteoblasts, as well as characteristic surface phenotype. More than
80% of these cells should express primary stable positive markers (CD105, CD90, CD73), while the
expression of primary negative markers (CD45 and others) should be below 2% [33]. Other authors
observed expression of positive and negative markers on more than 90% and less than 5% of ASCs,
respectively [34]. The present results show that ASCs isolated from subcutaneous abdominal adipose
tissue of RD patients fulfill the above phenotypic criteria of MSCs (Figure 1A,C,D). Observed individual
variation in the proportion of CD34+ cells in ASC lines of both HD and RD patients (Figure 1D) may
be explained by unique features of this molecule, which is a primary unstable ASC positive marker,
present at variable levels and lost gradually during cell culture [33]. Although MSCs are thought to
be devoid of surface HLA-DR, expression of these molecules on ASCs has been reported [35]. Thus,
presence of HLA-DR molecules on some HD/ASC and RD/ASC lines, observed in our study (Figure 1D),
is unsurprising. Altogether, our results show that in terms of surface marker expression, RD/ASCs
resemble ASCs obtained from healthy volunteers, which is consistent with other reports [36–38].
In comparison with HD/ASCs, we found significantly reduced levels of CD90 expression
on RD/ASCs (Figure 1B). CD90 is a glycoprotein endowed with numerous immunological
and non-immunological functions, including cell–cell and cell–matrix interactions, cell motility,
inflammation, and fibrosis [39]. It was reported that CD90 expressed on MSCs promotes osteogenic
differentiation, but inhibits adipogenic differentiation of these cells, while MSCs with reduced expression
177
Cells 2019, 8, 1659
of CD90 lose their immunosuppressive activity [40,41]. Therefore, it is likely that impaired CD90
expression on RD/ASCs contributes to the abnormal regenerative and immunoregulatory function of
these cells. Consistent with this supposition, our results suggest that the level of CD90 expression
may affect the secretory potential of ASCs (Figure 1E,F). According to our observation, high CD90
expression may restrict PGE2 release in HD/ASCs, while it may promote IL-6 secretion in RD/ASCs.
The reason for CD90 downregulation on RD/ASCs is unknown, but prolonged in vivo exposure of these
cells to inflammatory milieu is the probable cause. Unfortunately, we failed to notice any significant
changes in CD90 expression after three days exposure of HD/ASCs and RD/ASCs to TI stimulation
(data not shown). Although this observation does not rule out the likelihood of CD90 loss due to the
action of other factors contributing to chronic inflammation, alternative explanations, e.g., intrinsic
defects, also exist [12].
The adhesion molecules ICAM-1 and VCAM-1 regulate the migration of MSCs and provide
their interaction with co-operating immune cells, making them indispensable for MSC-mediated
immunosuppression [42,43]. Similar to other reports [18], we failed to observe single VCAM-1 bearing
ASCs, found mostly single positive ICAM-1 cells and, less frequently, cells co-expressing both of these
molecules (Figure 2A). Importantly, compared with HD/ASCs, both single and double positive RD/ASCs
had lower basal ICAM-1 expression (Figure 1C), which, in addition, correlated moderately with TGF-β1
release by these cells (Figure S2, Supplementary Materials), suggesting that ICAM-1 may also have an
impact on RD/ASC secretory function. Upon TI treatment, there was a similar upregulation of ICAM-1,
but not VCAM-1, expression on HD/ASCs and RD/ASCs (Figure 1B,D). Therefore, the reason for
impaired basal ICAM-1 expression on RD/ASCs is not related to pro-inflammatory cytokine exposure
in vivo. Based on the present findings, we conclude that reduced basal expression levels of CD90 and
ICAM-1 are characteristic for RD/ASCs. Neither the reason nor the consequences of these abnormalities
are known yet. We did not find any association between basal CD90 and ICAM-1 expression and
patient demographic and clinical data, including age, BMI, disease duration, ESR/CRP values, disease
activity, etc. (data not shown). Nevertheless, our results suggest that both defects may affect RD/ASC
secretory activity.
MSCs regulate immune responses by the release of various immunomodulatory factors and
indoleamine 2,3-dioxogenase (IDO)-1-mediated catabolism of tryptophan into kynurenines [6,35,44].
Our results show significant differences between RD/ASCs and HD/ASCs in the secretion of these
factors. Firstly, both untreated and cytokine-treated RD/ASCs produced less kynurenines and
galectin-3 (Figure 3A,B). Activation of the kynurenine pathway, triggered mostly by IFN-γ, mediates
the immunosuppressive action of MSCs in vitro and in vivo and exerts strong inhibitory effects mostly
on the proliferation and cytotoxicity of T cells and natural killer (NK) cells [44]. Galectin-3, a member of
the β-galactoside binding protein family, is a multifunctional protein with immunomodulatory effects
on cell apoptosis, activation, differentiation and migration [45]. This protein is a critical mediator
of MSC suppression of T cell proliferation and its secretion is considered as a biomarker for the
immunomodulatory potential of MSCs [46]. We observed that TI treatment upregulated kynurenine
release by HD/ASCs and RD/ASCs, but the latter cells responded poorly, suggesting that they are rather
refractory to kynurenine pathway activation. In addition, we found that disease-specific cytokines were
unable to trigger the kynurenine pathway in ASCs, while IFN-α and IL-23 activated, to a small extent,
the galectin-3 pathway in SLE/ASCs and AS/ASCs, respectively. In contrast, secretion of galectin-3 by
HD/ASCs was stable, which is consistent with its reported constitutive expression in BM-MSCs [47].
Since we found an inverse correlation between basal secretion of galectin-3 by RD/ASCs and ESR
value (Figure 3C,D), it is likely that impairment of galectin-3 production by ASCs may contribute to
inefficient control of systemic inflammation in these patients.
Secondly, compared with HD/ASCs, we found significant elevation of IL-1Ra, sHLA-G, and TSG-6
secretion by RD/ASCs (Figure 4). Applied stimuli did not alter the release of these factors. IL-1Ra
counteracts the inflammatory effects of IL-1; its role in mediating the immunosuppressive effect of
MSCs lies mostly in the polarization of macrophages toward the anti-inflammatory M2 phenotype and
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inhibition of B cell differentiation [48]. In collagen-induced arthritis in mice, inhibition of T-helper
(Th)17 cells generation by IL-1Ra producing MSCs was also shown [49]. HLA-G, a non-classical HLA
class I molecule, inhibits functions of innate and adaptive immune cells. Both surface-expressed and
soluble forms (present in body fluids) of HLA-G are involved in the suppression of the cytotoxic
function of T cells and NK cells, the maturation and function of dendritic cells (DC), and the generation
of regulatory T cells (Tregs) [50]. TSG-6 mediates many of the immunomodulatory and reparative
activities of MSCs and exerts therapeutic effects in various animal disease models [50]. This protein
acts by binding to numerous ligands, e.g., extracellular matrix components and chemokines, where it
inhibits neutrophil migration and macrophage activation and promotes M2 macrophage switching
and Treg generation [51].
Independently of activation status, HD/ASCs and RD/ASCs secreted similar amounts of the other
tested factors (PGE2, IL-6, TGF-β1, and LIF; Figure 5). In general, RD/ASCs and HD/ASCs responded
in similar way to applied stimuli, and a significant increase of secretion, if any, was triggered by TI
treatment. The only exception was an elevation of PGE2 release by TGF-β1 treated SSc/ASCs (Figure 5).
All these ASC-derived factors were reported to mediate the immunomodulatory effects of MSCs in
several ways, including inhibition of T cell proliferation. In addition, IL-6 and PGE2 were shown to
inhibit maturation of DCs and mediate switching of M1 inflammatory macrophages to an M2-like
phenotype, while LIF and TGF-β1 were suggested to contribute to Treg generation [52–54].
As discussed above, there is a redundancy in the biological activities of MSC secreted factors.
In addition, to achieve therapeutic immunosuppressive effects, a combination of these factors is usually
required. For example, in SLE patients, the therapeutic effect of allogeneic MSC application was
accompanied by an upregulation of Tregs and downregulation of Th17 cells, which was dependent
on sHLA-G and TGF-β1, or PGE2 action, respectively [55,56]. Therefore, it is hard to predict how the
presently found abnormalities in the secretory activity of RD/ASCs may affect the immunoregulatory
function of these cells. Nevertheless, observed upregulation of IL-1Ra, sHLA-G and TSG-6 secretion
and normal release of IL-6, PGE2, TGF-β1 and LIF suggest that RD/ASCs, exposed in vivo to a chronic
inflammatory microenvironment, may preferentially use these factors to control excessive immune
responses. However, impaired kynurenine and galectin-3 secretion may contribute to inefficiency of
ASC control. It is likely that galectin-3 deficiency is more critical, as low production of this protein
by RD/ASCs is associated with higher-grade systemic inflammation. Interestingly, disease-specific
cytokines seem to trigger a compensatory mechanism by upregulating the release of galectin-3 from
ASCs in SLE and AS and PGE2 secretion in SSc patients.
Our study has some limitations. Firstly, it is well known that the type of harvesting procedure used
may affect viability, yield or the biology of ASCs [57]. Because of ethical reasons, we had to apply the
needle-aspiration technique, which is not commonly used. However, for ASC isolation, we utilized the
enzymatic digestion-based method [31], intended mainly for experimental purposes [57]. In addition,
to perform these analyses, isolated ASCs had to be expanded in vitro. Fortunately, the applied ASC
isolation method turned out to be good enough to obtain a homogeneous population of cells with the
MSC phenotype (Figure 1), even from scanty specimens of adipose tissue. Secondly, our RD patient
cohort was heterogeneous in terms of some demographic data (age), clinical symptoms and treatment
(Table 1). Obviously, these differences may also influence the phenotype and secretory activity of
ASCs. Surprisingly, despite all the differences between SLE, SSc and AS patients, their ASCs show
similar alterations in CD90 and ICAM-1 expression and immunoregulatory factor release. Because the
aforementioned RDs are inflammatory disorders, chronic in vivo exposure of ASCs to the inflammatory
environment of adipose tissue is a more likely explanation for the observed abnormalities.
5. Conclusions
In summary, we report that RD/ASCs are characterized by a low basal level of CD90 and ICAM-1
expression, elevated spontaneous secretion of IL-1Ra, TSG-6 and sHLA-G, but impaired release of
kynurenines and galectin-3, and there are only small differences between ASCs obtained from SLE,
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SSc, and AS patients. Exposure of RD/ASCs to a pro-inflammatory cytokine cocktail (TI) normalizes
ICAM-1 expression, but not the secretion of immunoregulatory factors. We suggest that the observed
alterations are caused by in vivo exposure of ASCs to an inflammatory milieu and may contribute to
the inadequate immunoregulatory function of these cells.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/8/12/1659/s1,
Figure S1: Representative gating strategy and representative dot plots/histograms for assessing ASC phenotype,
Figure S2: Correlation of basal ICAM-1 expression and TGF-β release by ASCs of patients with rheumatic diseases.
The quantitative assessment of basal ICAM-1 expression (MFI, median fluorescence intensity) on ASCs obtained
from patients with rheumatic diseases (RD/ASC lines) and basal secretion of TGF-β by these cells were done as
described in the Materials and Methods. The correlation was assessed using Spearman’s rank test; Rs and p values
are shown. Note that the regression lines were used for graphic purposes only.
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PE-Cy7 tandem fluorochrome of phycoerythrin coupled to the cyanine dye Cy7
PGE2 prostaglandin E2
RD rheumatic diseases
Scl-70 anti-topoisomerase I antibody
sHLA-G soluble human leukocyte antigen G
SLE systemic lupus erythematosus
SLEDAI SLE Disease Activity Index
SN supernatants
SSc systemic sclerosis
SVF stromal vascular fraction
TGF-β1 transforming growth factor β1
TI TNF-α + IFN-γ
TNF-α tumor necrosis factor α
TSG-6 tumor necrosis factor-inducible gene 6 protein
VCAM-1 vascular cell adhesion molecule-1
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Abstract: In the treatment of obesity and its related disorders, one of the measures adopted is weight
reduction by controlling nutrition and increasing physical activity. A valid alternative to restore the
physiological function of the human body could be the increase of energy consumption by inducing
the browning of adipose tissue. To this purpose, we tested the ability of Histogel, a natural mixture
of glycosaminoglycans isolated from animal Wharton jelly, to sustain the differentiation of adipose
derived mesenchymal cells (ADSCs) into brown-like cells expressing UCP-1. Differentiated cells
show a higher energy metabolism compared to undifferentiated mesenchymal cells. Furthermore,
Histogel acts as a pro-angiogenic matrix, induces endothelial cell proliferation and sprouting in a
three-dimensional gel in vitro, and stimulates neovascularization when applied in vivo on top of
the chicken embryo chorioallantoic membrane or injected subcutaneously in mice. In addition to
the pro-angiogenic activity of Histogel, also the ADSC derived beige cells contribute to activating
endothelial cells. These data led us to propose Histogel as a promising scaffold for the modulation of
the thermogenic behavior of adipose tissue. Indeed, Histogel simultaneously supports the acquisition
of brown tissue markers and activates the vasculature process necessary for the correct function of the
thermogenic tissue. Thus, Histogel represents a valid candidate for the development of bioscaffolds
to increase the amount of brown adipose tissue in patients with metabolic disorders.
Keywords: angiogenesis; adipose derived mesenchymal cells; Histogel
1. Introduction
Obesity represents a major health problem associated with increased mortality and co-morbidities,
including many metabolic diseases [1]. Obesity is characterized by an increase in adipose mass due to
increased energy intake, decreased energy expenditure, or both. Several elements including lifestyle,
environmental, neuro-psychological, genetic, and epigenetic factors contribute to increase the energy
intake (calories) and to reduce the energy expenditure (metabolic and physical activity). The treatment
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options for patients with severe obesity are the modification of lifestyle, limiting the intake of total
fats and sugars, increasing consumption of fruits, vegetables, and whole grains and practicing regular
physical activity or pharmacological treatments currently available in the market, which are commonly
associated with severe side effects. Indeed, increased risk of psychiatric disorders and non-fatal
myocardial infarction or stroke have been described in pharmacologically treated patients [2–4]. In the
treatment of obesity, only 1% of patients receive bariatric surgery despite its safety and the better
outcomes achieved [5]. Therefore, several groups are working on the development of different and new
therapeutic approaches [3]. The increase of energy consumption through the increase of metabolism
and thermogenesis of the adipose tissue may be a valid alternative [6].
Adipose tissue (AT) contains adipocytes and pre-adipocytes surrounded by stromal cells
(fibroblasts, endothelial cells, macrophages), which make the adipose tissue the most plastic organ
in the human body. AT is the major organ that controls the overall energy homeostasis in a living
organism, storing the superabundant nutrients in the form of triglycerides, and suppling the nutrients
to other tissues through lipolysis [7]. Two different types of adipose tissue have been described
in mammalians. White adipose tissue (WAT) stores energy, while brown adipose tissue (BAT) is
specialized for energy expenditure. The cellular structure of these tissues well reflects their biological
functions: WAT contains adipocytes with a single large lipid droplet and few mitochondria, while
BAT cells are characterized by the presence of several small lipid droplets and many mitochondria
expressing uncoupling proteins (UCPs). UCP-1 contributes to energy loss as heat; in particular, it
controls the dissipation as heat of the proton gradient produced by the mitochondria respiration
chain. In humans, BAT mass declines with age, and it is less active in obese patients. The adipose
tissue (AT) can be considered an endocrine organ, as both WAT and BAT secrete many cytokines,
hormones, and adipokines. Recently, an additional/intermediate AT cell type termed “beige” has been
described. Beige adipocytes sporadically reside with white adipocytes and emerge in response to
certain environmental cues [8]. Under specific stimuli, beige adipocytes can exert BAT-like or WAT-like
functions. Although beige adipocytes express a low level of UCP-1, they retain a remarkable ability to
activate the expression of this gene powerfully and to turn on a robust program of respiration and
energy expenditure that is equivalent to that of classical brown fat cells [8,9]. These cells represent
a cellular mechanism to provide flexibility in adaptive thermogenesis and metabolism. Thus, the
possibility to generate and control the amount of beige adipocytes may represent an alternative therapy
for obese patients.
Blood vessels play a key role in the regulation of AT behavior. AT is the most plastic organ in
the human body, subjected to continuous expansion and regression. This plasticity requires constant
growth, regression, and remodeling of blood vessels, under the control of several metabolites secreted
by AT itself. The adipose vasculature supports AT in multiple manners. The vascular network provides
nutrients and oxygen, which are essential for tissue maintenance, and removes metabolic products of
AT. Moreover, it exports the AT derived growth factors, adipokines, and cytokines from AT to body
tissues, regulating physiological functions via an endocrine mechanism [10]. Furthermore, similar to
mesenchymal cells [11], the adipocyte precursor cells within WAT and BAT express VEGF-A, promoting
the angiogenic process and endotheliogenesis through VEGFR2 signaling [12].
Tissue engineering represents an interdisciplinary approach to regenerate damaged tissues,
instead of replacing them, by developing biological substitutes that improve or restore tissue functions.
Tissue engineering can help to boost human metabolism through the integration of cell biology and
biomaterial sciences [13]. With particular attention to adipose tissue, tissue engineering is a promising
approach to improve energy balance and metabolic homeostasis controlling the amount of beige
cells [14,15]. Several biological or synthetic scaffolds have been developed to support and/or promote
tissue regeneration or organ repair [16–20]. All the scaffolds share some characteristics including
biocompatibility, neglectable immunoreactivity, and suitability for cell growth. Furthermore, scaffolds
should be biodegradable, and their derivates should not be toxic to the body.
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Here, we tested the ability of a novel bioscaffold able to promote both the differentiation of
mesenchymal cells into beige adipose tissue and to sustain the angiogenic process. The Histogel-alginate
scaffold promotes adipose tissue derived stem cell (ADSC) differentiation into adipocytes expressing
PPARγ, PdK4, and UCP1 proteins supporting vessel recruitment and growth. Our results suggest that
Histogel based scaffolds may represent good candidates for the development of scaffolds aimed at
regulating energy expenditure in obese patients.
2. Materials and Methods
2.1. Hyaluronan Analysis
Commercial low, high molecular weight HA was electrophoretically analyzed on 1% agarose gel
and stained with Stains-All solution HA (25 mg in 500 mL ethanol:water 50:50) overnight in the dark.
Then, agarose gels were de-stained with water. The same protocol was used to explore the amount and
the molecular weight of HA in Histogel preparations.
2.2. Cell Cultures and Differentiation
ADSCs were isolated from lipoaspirate (Histocell, Spain, in compliance with Certification of
Laboratory 4269-E for the manufacture of research drugs (cell therapy products), Spanish Agency of
Drugs and Medical Devices (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS)
and were cultured in DMEM, complemented with Glutamax, penicillin/streptomycin, 10% FBS, and
gentamicin sulfate (identified as basal medium). ADSCs were differentiated for 15 days in basal
medium in the presence of 20 nM insulin (Sigma, St. Louis, MO, USA), 5 μM dexamethasone (Sigma),
125 μM indomethacin (Sigma), 1 nM triiodothyronine (T3) and 0.5 mM 3-isobutyl-1-methylxanthine
(IBMX). Lipid vesicles formed starting from Day 6 of differentiation [21]. Human umbilical vein
endothelial cells (HUVECs) were isolated from umbilical cords from healthy informed volunteers and
used at early passages (I–IV). Cells were grown on culture plates coated with Porcine Gelatin Type I, in
M199 medium supplemented with 20% FCS, endothelial cell growth factor (10 μg/mL), and porcine
heparin (100 μg/mL) [22].
2.3. Identification of Angiogenic Factors
Pro- and anti-angiogenic molecules released by ADSCs and ADSC derived beige cells
were analyzed using the Human Angiogenesis Antibody Array (R&D System) according to the
manufacturer’s instructions.
2.4. Quantitative RT-PCR
The expression of brown adipocyte markers was analyzed by RT-PCR. Briefly, total RNA was
isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions from 3 independent differentiation experiments. Two micrograms of total RNA were
retro-transcribed with M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA) using random
hexaprimers in a final 20 μL volume. Quantitative RT-PCR was performed using the iTaqTM Universal
SYBR® Green Supermix (Bio-Rad, Hercules, CA, USA). Each PCR reaction was performed in triplicate
on one plate, and fluorescence data were recorded using a Viia7 Real Time PCR System (Thermo
Fisher Scientific, Waltham, MA, USA). Relative expression ratios were calculated by the Relative
Expression Software Tool. The mRNA expression levels of target genes were normalized to the level of
GAPDH transcript.
The following specific primers were used: Hs UCP1_Fw CGCAGGGAAAGAAACAGCAC;
Hs UCP1_Rv TTCACGACCTCTGTGGGTTG; HsPdk4_FwATTTAAGAATGCAATGCGGGC; HsPdk
4_RvACACCACCTCCTCTGTCTGA; Hs PPARγ_Fw CCGTGGCCGCAGAAATGA; Hs PPARγ_Rv
TGATCCCAAAGTTGGTGGGC; MmCD31 FwAAGCCAAGGCCAAACAGA; Mm_CD31_Rv
GGGTT TTACTGCATCATTTCC; Mm_CD45_Fw TATCGCGGTGTAAAACTCGTCAA; Mm_CD45
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_Rv GCTCAGGCCAAGAGACTAACGTT; Hs GAPDH_Fw GAAGGTCGGAGTCAACGGATT;
Hs_ GAPDH_Rv TGACGGTGCCATGGAATTTG.
2.5. Mitochondrial Activity
Mitochondrial activity was monitored with Seahorse XFe24 instrument technology analysis.
Oxygen consumption rate (OCR) (pmol/minute) was monitored over time before and after sequential
injection of oligomycin (100 μM), carbonyl cyanide p-trifluoromethoxy-phenylhydrazone (FCCP,
100 μM), and rotenone/antimycin A (50 μM) inhibitors (which inhibit ATPase, the proton gradient, and
complex I/III, respectively). Thus, ATP-linked respiration and maximal respiration were measured.
Extracellular acidification rate (ECAR; mpH/minute) was also measured to observe glycolytic capability.
The colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test was used
to analyze the effect of isoproterenol and norepinephrine on the metabolic activity of cells, using the
reducing ability of ubiquinone and CyrC and B of the mitochondrial electron transport system. For this,
differentiated ADSCs were treated with 10 μM isoproterenol or 1 mM norepinephrine for 24 h. Then,
cells were incubated in the presence of 0.2 mg/mL of MTT substrate for 1 h. The amount of metabolized
formazan was measured by recording absorbance at 570 nm using a plate reader spectrophotometer
(ELx-800 Bio-Tec Instrument).
2.6. EC Sprouting Assay
The collagen gel invasion assay was performed on HUVEC spheroids [23]. Briefly, spheroids
were prepared in 20% methylcellulose medium, embedded in collagen gel or collagen gel:Histogel
(1:5) in the absence or in the presence of ADSCs or differentiated cells. The formation of radially
growing cell sprouts was observed during the next 24 h. Sprouts were counted and photographed
using an Axiovert 200M microscope equipped with an LD A PLAN 20X/0,30PH1 objective (Carl Zeiss,
Oberkochen, Germany).
2.7. In Vitro Angiogenesis Assay
Wells of μ-Slide Angiogenesis chambers (Ibidi, Martine Marne, Germany) were coated with
a 0.8 mm thick layer of gel matrix by adding 10 μL of Cultrex Reduced Growth Factor Basement
Membrane Matrix. After gel polymerization, 5000 HUVECs were seeded in M199 added with 5%
FCS and treated with conditioned medium of undifferentiated or differentiated ADSCs. Cell viability
was confirmed using calcein-AM. In live cells, the non-fluorescent calcein-AM is converted into
green-fluorescent calcein. Calcein-AM is a permeant dye. After 5 h, samples were photographed using
an inverted Axiovert 200 M epifluorescence microscope equipped with an LD A PLAN 20X/0,30PH1
objective (Carl Zeiss, Oberkochen, Germany). Images were analyzed using ImageJ software with the
Angiogenesis plugin to detect total closed structures [24].
2.8. Immunofluorescence Analysis
Cells were seeded on glass coverslips and fixed in 4.0% paraformaldehyde (PFA)/2.0% sucrose in
PBS, permeabilized with 0.5% Triton-X100, and saturated with goat serum in PBS. Then, cells were
incubated with UCP-1 (sc-6529, SantaCruz, CA, USA), PPARγ (sc-7273, SantaCruz), and ACRP30
(sc-26497, SantaCruz) antibodies. Cells were analyzed using a Zeiss Axiovert 200M epifluorescence
microscope equipped with a Plan-Apochromat 63X/1.4 NA oil objective.
2.9. CAM Assay
Alginate beads containing PBS, or 100 ng of recombinant human VEGF-A, or 5% of Histogel, or
30,000 cells were placed on the chicken chorioallantoic membrane (CAM) of fertilized white Leghorn
chicken eggs at Day 11 of incubation [25]. After 72 h, newly formed blood vessels converging toward
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the implant were counted at 5×magnification using an STEMI SR stereo-microscope equipped with an
objective f of 100 mm with adapter ring 475,070 (Zeiss, Oberkochen, Germany).
2.10. Murine Angiogenic Assay
All the procedures involving mice and their care conformed to institutional guidelines that
complied with national and international laws and policies (EEC Council Directive 86/609, OJ L 358,
12 December 1987). Seven-week-old C57BL/6 mice (Charles River Laboratories International, Inc.,
Wilmington, MA, USA) were injected subcutaneously with 400 μL of 5% alginic acid (Sigma) containing
PBS or 500 ng of VEGF-A, in the absence or in the presence of 5% Histogel solution. One week after
injection, mice were sacrificed, and plugs were harvested and processed for RT-qPCR as previously
described [26]. The mRNA expression levels of murine CD31 and CD45 were normalized to the levels
of human GAPDH. Data are expressed as relative expression ratios (ΔΔCt—fold increase) using one
PBS plug as the reference.
2.11. Data Representation and Statistical Analyses
Data are expressed as the mean± SEM. Statistical analyses were performed using one-way ANOVA
followed by Bonferroni’s test or Student’s t-test. The indicated p-value was set as statistically significant.
3. Results
3.1. Histogel Is a Pro-Angiogenic Bio-Scaffold
Histogel is a natural mixture of glycosaminoglycans including, among others, high grade
hyaluronic acid (HA) and chondroitin sulfate obtained from the Wharton jelly found in umbilical cords
of animal origin [20]. Histogel modulates inflammation, induces the release of extracellular matrices
(ECM), and supports cell recruitment and growth [20]. On these bases, Histogel represents a suitable
scaffold to drive cell differentiation. Since hyaluronan is a mix of molecules with different masses
and the molecular weight confers different biological properties to hyaluronan preparations, a first
set of experiments was performed to compare the amount and the molecular weight of hyaluronan
contained in different Histogel preparations. Two different Histogel preparations were analyzed,
pre-autoclaved (p.a.) or not, on agarose gel, and stained with Stains-All reagent. The amount of HA
was similar in both analyzed batches, and it was around 76–80%. Moreover, the ratio between high
and low molecular weight molecules remained approximately constant. Of note, this ratio is not
affected by the autoclave sterilization cycles used for the preparation of 5% Histogel working dilutions
(Figure 1a). Next, we tested the proangiogenic activity of Histogel preparation in several in vitro
angiogenesis assays. Angiogenesis is a multistep process starting with the activation of endothelial
cells (ECs) and the degradation of ECM of the basal membrane. Then, ECs invade the surrounding
tissue, proliferate, and reorganize themselves in capillary-like structures. Among the variety of in vitro,
ex vivo, and in vivo assays that mimic the individual aspects of the angiogenic cascade, in vitro models
of angiogenesis represent cost effective and rapid tools for testing angiogenic compounds. In particular,
the use of 3D culture techniques able to recapitulate all steps of endothelial capillary sprout formation
may serve as an effective strategy for these purposes. 3D endothelial cell spheroids were embedded
in collagen or collagen:5% Histogel (1:1 ratio) gels. VEGF-A was used as the positive control and as
the reference for the angiogenic activity. Figure 1b shows that, in keeping with the pro-angiogenic
activity of commercial high molecular weight HA (Figure A1a,b), Histogel stimulates the formation of
endothelial cell sprouts from aggregates of HUVEC cells embedded in a 3D gel. To assess the in vivo
pro-angiogenic activity, Histogel loaded alginate beads were implanted onto the chicken embryo
CAMs at 11 days of development. After 72 h, a robust angiogenic response was observed around the
Histogel implants when compared to alginate or VEGF engrafted embryos (Figure 1c). The number of
vessels converging towards the pellets was equal to 7.4 ± 0.6, 33.1 ± 1.0, and 58.3 ± 9.1 for alginate,
VEGF, and Histogel implants, respectively. In keeping with these observations, Histogel modulates the
189
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recruitment of CD45+ cells and the consequent pro-angiogenic response when injected subcutaneously
in mice (Figure 1d). All these data suggest that Histogel is endowed with stronger pro-angiogenic
activity if compared to VEGF-A. The pro-angiogenic ability of Histogel makes it a suitable candidate
for the development of a bioscaffold for BAT differentiation.
Figure 1. Histogel modulates the angiogenic response. (a) Five percent and 10% of two different
Histogel preparations were electrophoretically analyzed on agarose gel and stained with Stains-All
solution. p.a., pre-autoclaved. Three different standard molecules (2 × 103, 1.1 × 103, 300 kDa) were
used as markers of molecular weight (MK). (b) HUVEC spheroids were embedded in collagen or
in collagen:5% Histogel 1:1 (HG) gels. Fifty nanograms per milliliter of VEGFA165 were used as the
positive control. The formation of radially growing sprouts was evaluated after 24 h of incubation.
Data are the mean ± SEM of three independent experiments (** p < 0.001 vs. CTRL; # p < 0.001
vs. VEGF, one-way ANOVA followed by Bonferroni’s test versus the control). (c) Alginate beads
containing vehicle, or 100 ng of VEGFA165, or 5% Histogel (v/v 1:1) were implanted on the top of chick
embryo chorioallantoic membrane (CAM) at Day 11 of development. After 72 h, newly formed blood
vessels converging toward the implant were counted in ovo at 5×magnification using an STEMI SR
stereomicroscope equipped with an objective f equal to 100 mm with adapter ring 475,070 (Carl Zeiss).
Data are the mean ± SEM (n = 6–8) (*** p < 0.0001 vs. control; # p < 0.0001 vs. VEGF, one-way ANOVA
followed by Bonferroni’s test versus the control). (d) Five percent of liquid alginic acid was mixed
with 1.0 μg/mL VEGFA165 in the absence or in the presence of v/v 1:1 of 5% Histogel and injected
subcutaneously into the flank of C57BL/6 mice. Plugs with vehicle alone were used as negative controls
(CTRL). One week after injection, plugs were harvested. CD31 and CD45 mRNA expression levels
were measured by RT-qPCR. Data are the mean ± SEM (n = 10) and are expressed as relative expression
ratios (ΔΔCt – fold increase) using one vehicle plug as the reference. * p < 0.05; ** p < 0.01; *** p < 0.005;
**** p < 0.001, one-way ANOVA followed by Bonferroni’s test versus the control.
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3.2. ADSCs Differentiate in Beige Adipocytes
Several protocols for ADSCs’ differentiation were tested. ADSCs were maintained for 15 days in
commercial specific media (such as StemMACS AdipoDiffMedia from Milteny Biotec), or in DMEM
supplemented with hBMP7, or supplemented with adipo-growth factors and analyzed for the expression
of adipocyte markers including PPARγ, AdipoR, Prdm16, UCP-1, and Pdk4 (Figure A2). Among all
the tested conditions, the custom medium was found to be the most promising in terms of expression
of brown tissue markers. Thus, in all the experiments listed below, confluent ADSCs were cultured
for 15 days in basal medium complemented with insulin and dexamethasone to stimulate adipogenic
differentiation, indomethacin, and 3-isobutyl-1-methylxanthine (IBMX) to modulate the expression of
the PPARγ receptor and with triiodothyronine (T3) to increase UCP-1 expression. Figure 2a shows the
morphological changes occurring in ADSCs upon differentiation. A clear sign of differentiation was the
presence of small lipid droplets in differentiated ADSCs’ cytoplasm. Immunofluorescence and RT-PCR
analyses for the expression of PPARγ, ACRP30, UCP-1, and PdK4 confirmed that ADSCs acquired
brown cell molecular markers during the differentiation protocol (Figure 2b–d). Finally, we tested
the metabolic activity of differentiated ADSCs using the Seahorse Cell Mito Stress Test. Although
the basal oxygen consumption (OCR) of undifferentiated and differentiated ADSC seemed to be very
similar, the maximal mitochondrial activity was significantly increased in differentiated ADSCs as
demonstrated by the higher oxygen consumption measured by treating cells with the uncoupling agent
FCCP. Furthermore, extracellular acidification increased in differentiated ADSCs compared to control
ADSCs (Figure 2e,f). These data were confirmed by the ability of norepinephrine and isoproterenol to
positively modulate the mitochondrial activity (Figure 2g) of differentiated ADSCs. Taken together,
our results confirm that our protocol was suitable to drive ADSCs differentiation into ADSC derived
beige cells.
3.3. ADSCs-Derived Beige Cells Show Pro-Angiogenic Properties
It is well known that mesenchymal stem cells support vessel recruitment and growth by producing
and releasing several growth factors and chemokines. To assess whether ADSC derived beige cells
maintain this pro-angiogenic activity, we evaluated their capacity to activate HUVECs in different
angiogenic assays. To this, conditioned mediums were collected from ADSCs or ADSC derived beige
cells cultured in basal medium for 48 h and tested in the tube formation assay. The conditioned
medium of ADSC derived beige cells accelerated the morphogenesis of HUVE cells as demonstrated
by the higher number of closed structures formed in 18 h compared to that induced by the conditioned
medium of undifferentiated ADSCs (Figure 3a). Of note, VEGF-A, used as a positive control, exerted a
pro-angiogenic effect, comparable to the one of the conditioned medium of undifferentiated ADSCs.
The presence of pro-angiogenic factors in the conditioned medium of ADSC derived beige cells was
confirmed by the human angiogenesis antibody array. For this, all proteins of conditioned medium
were labelled with biotinylated antibodies and incubated on a spotted specific capture antibody
membrane. The antibody array showed that ADSC derived beige cells continued to express and
release in the extracellular environment high levels of several pro-angiogenic molecules including
VEGF, FGF, PlGF, and PDGF (Figure 3b). To overcome the possible partial or total degradation of the
soluble factors contained in the conditioned medium and to ensure a continuous release of soluble
molecules, we set up an in vitro endothelial–ADSC co-culture system in which ADSCs were plated and
differentiated for 15 days in the same well used for the co-culture. Then, 3D Cultrex gel was stratified
in the well, and HUVECs were plated on it. Again, the ADSC derived beige cells accelerated the
morphogenesis of HUVEC cells in terms of the number of closed structures. Of note, HUVECs cultured
with undifferentiated ADSCs remained non-organized (Figure 4a,b). ADSC derived beige cells induced
more sprouts from HUVEC-formed spheroids when embedded in 3D collagen gel in the co-culture
system (Figure 4c,d). Importantly, in both co-culture systems, no physical interaction occurred between
HUVEC and ADSCs. Furthermore, to mimic the co-culture system in an in vivo assay, ADSCs and
ADSC derived beige cells were delivered on the top of the chick embryo chorioallantoic membrane
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(CAM) at Day 11 of development. In agreement with the in vitro results, ADSC derived beige cells
supported the recruitment of host vessels from the surrounding tissues into the cell-enriched-3D
scaffold on chick embryo CAM (Figure 4e,f).
Figure 2. ADSCs differentiate into beige-like adipocytes. (a) The morphology of ADSCs and ADSC
derived beige cells (Diff.) was analyzed at Day 15 of differentiation (Scale bar 100 μm). (b,c)
Immunofluorescent detection of expression levels of UCP-1 (green) and ACRP30 (red) (b) and PPARγ
(red) (c). Nuclei were counterstained with DAPI. (Scale bar 10 μm). (d) PPARγ, Pdk4, and UCP1
mRNA expression levels were measured by RT-qPCR analysis. Data are the mean ± SEM (n = 6)
and are expressed as relative expression ratios (ΔΔCt – fold increase). (e,f) Mitochondrial energy
metabolism was measured using the Agilent Seahorse Cell Mito Stress Test. The oxygen consumption
rate (OCR) (e) and extracellular acidification rate (ECAR) (f) of ADSCs and ADSC derived beige
cells was recorded before and after treatment with 10 μM oligomycin, 10 μM carbonyl cyanide
p-trifluoromethoxy-phenylhydrazone (FCCP), and 5 μM rotenone/antimycin A. Data were analyzed
according to the Agilent Seahorse XF Cell Mito Stress Test Report Generator. (g) Mitochondrial activity
of ADSC derived beige cells was measured by the MTT test in the absence or in the presence of
norepinephrine and isoproterenol. * p < 0.05; ** p < 0.01; *** p < 0.005; **** p < 0.001, one-way ANOVA
followed by Bonferroni’s test versus the control.
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Figure 3. Conditioned medium of ADSC derived beige cells contains pro-angiogenic factors.
Conditioned media were collected from confluent ADSCs and ADSC derived beige cells (Diff. ADSCs)
cultured in basal medium for 48 h. (a) HUVEC cells (40,000 cells/cm2) were plated on reduced growth
factor Cultrex and stimulated with conditioned medium obtained from ADSCs or ADSC derived
beige cells. After 5 h, endothelial cell morphogenesis in terms of the formation of closed structures
was examined using ImageJ software. Data are the mean ± SEM of three measurements per sample.
* p < 0.05, Student’s t-test. (b) The Proteome Profiler Human Angiogenesis Antibody Array was used
to detect angiogenesis related proteins in the conditioned medium of ADSCs and ADSC derived beige
cells. Densitometry analysis of positive spot signals was normalized to positive and negative antibody
array controls. Data are the mean of duplicate spots and expressed by color code (n = 2). Negative spots
in both ADSCs and ADSC derived beige cell conditioned medium were not included in the analysis.
3.4. Histogel Supports the Pro-Angiogenic Activity of ADSC-Derived Beige Cells
Finally, we tested whether the pro-angiogenic ability of Histogel supports beige adipocyte
potentiality. ADSC or ADSC derived beige cells were embedded in a co-culture system in a 3D
bioscaffold containing a 1:1 ratio of Histogel/collagen on HUVEC sprout growth. Of note, the
Histogel/collagen scaffold did not affect cell viability of either ADSCs or ADSC derived beige cells
as demonstrated by the ability of their intracellular esterase to hydrolyze calcein-AM also for a
long time (Figure 5a). ADSCs and ADSC derived beige cells were seeded and covered by HUVEC
spheroids incorporated in the Histogel/collagen bioscaffold prototype. Results demonstrated that
brown-like cells, also in the presence of the Histogel based bioscaffold, increased by 33% the angiogenic
capacity of HUVEC cells as demonstrated by the higher number of newly formed sprouts (Figure 5b,c).
ADSC derived beige cells synergized with the Histogel-collagen scaffold to induce angiogenesis as
demonstrated by the ratio between endothelial sprouts formed in the 3D Histogel/collagen gel with
respect to the 3D collagen gel co-cultured respectively with ADSCs or ADSC derived beige cells
(Figure 5c).
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Figure 4. The differentiation into ADSC derived beige cells positively modulates the pro-angiogenic
ability of ADSCs. (a) Confluent monolayers of ADSCs and ADSC derived beige cells (Diff.cells) were
cultured in 24 wells. Two-hundred microliters of growth factor reduced Cultrex were added on the
monolayers, and HUVEC cells were plated on gel. After 18 h, the formation of capillary-like structures
was examined using a Zeiss Axiovert 200 M microscope (Scale bar 500 μm). Data are the mean ± SEM
of three measurements per sample. * p < 0.05, Student’s t-test. (b) The number of closed structures.
(c–d) HUVEC spheroids embedded in collagen gel and plated on an ADSC monolayer. The formation
of radially growing sprouts was evaluated after 24 h of incubation. Data are the mean ± SEM of three
independent experiments (* p < 0.05, **** p < 0.001, one-way ANOVA followed by Bonferroni’s test
versus the control). (e–f) Alginate beads containing 3 × 104 ADSCs or ADSC derived beige cells were
implanted on the top of chick embryo chorioallantoic membranes (CAMs) at Day 11 of development.
After 72 h, newly formed blood vessels converging toward the implant were counted in ovo at 5×
magnification using an STEMI SR stereomicroscope equipped with an objective f equal to 100 mm with
adapter ring 475,070 (Carl Zeiss) (Scale bar 2 mm). Data are the mean ± SEM (n = 6–8) (* p < 0.05,
one-way ANOVA followed by Bonferroni’s test versus the control).
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Figure 5. Histogel supports the angiogenic ability of ADSC derived beige cells. (a) ADSC derived
beige cells were cultured in collagen or collagen:5% Histogel 1:1 for five days. Cells were photographed
after 1 h of calcein-AM treatment (Scale bar 200 μm). (b,c) HUVEC spheroids were embedded in
collagen gel or in collagen:5% Histogel 1:1 and plated on confluent monolayers of ADSCs and ADSC
derived beige cells. The formation of radially growing sprouts was evaluated after 24 h of incubation.
Representative figures (b). (c) describes the ratio of the number of sprouts formed from the endothelial
cell spheroid co-cultured in 5% Histogel-collagen or in collagen gel with ADSCs or ADSC derived beige
cells (ratio ± SEM of three independent experiments (**** p < 0.0001, ** p < 0.01, Student’s t-test versus
the control).
4. Discussion
Obesity and its related disorders are mostly preventable conditions, but their treatment has proven
to be a complex endeavor that has been mostly unsuccessful. The countermeasure usually suggested
against overweightness and obesity is an increase in physical activity and/or a reduction of energy
intake. A valid alternative to restore the normal physiological function of the human body could be the
increase of energy consumption. BAT regulates the thermoregulation and metabolism, generating heat
via non-shivering thermogenesis. In addition, beige adipocytes located in WAT also have thermogenic
properties characterized by the expression of UCP1 [14]. Thus, the increase of brown tissue mass may
represent a healthy and practical way to increase energy consumption, thus helping the individuals
to control the weight balance [27]. For this purpose, here, we proposed the use of Histogel based
bioscaffolds to promote the browning of adipose tissue. Histogel is a natural bioscaffold derived from
porcine Wharton jelly. It is non-cytotoxic and non-hemolytic, and it does not induce inflammation [20].
Wharton jelly is a porous connective tissue found in umbilical cords of animal origin, forming a 3D
spongy structure of fibrillar collagen and highly hydrated mucopolysaccharides, including hyaluronic
acid proteoglycans [28,29]. The physiological function of Wharton jelly is to prevent the compression
of the umbilical cord vessels. Decellularized Wharton jelly is a biocompatible scaffold with mechanical
properties suitable to support cell adhesion, proliferation, and reorganization in 3D structures [30],
appropriate for tissue engineering [31]. Furthermore, the low cost to obtain it and the “zero waste”
material should not be underestimated. Histogel was isolated from porcine farming systems and
by transforming them into high-end products with high potentiality for regenerative medicine and
cosmetic devices by means of an eco-friendly processing. Here, we showed that Histogel promoted
an angiogenic response both in vitro and in vivo. Histogel induced the migration, invasion, and
reorganization into a tube-like structure of HUVEC cells and supported the recruitment of new blood
vessels when implanted on the chorioallantoic membrane of chick embryos. Of note, the angiogenic
process is necessary in tissue regeneration; thus, the pro-angiogenic ability of Histogel makes it a good
bioscaffold for tissue engineering.
Biodegradability and porosity are critical features to keep in mind when designing bioscaffolds
for tissue engineering. A good bioscaffold must remain in the tissue for the time necessary to support
the engraftment of implanted cells, the recruitment of cells from surrounding tissue, and to sustain the
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metabolism of cells. Thus, the bioscaffold must remain in the host for a long time and not be degraded
too quickly. To delay Histogel degradation and to achieve a longer permanence of Histogel in the
host, we combined it with alginate or type I collagen gels. Both matrixes are currently used in the
production of scaffolds for tissue engineering. Alginate is a polymer of mannuronic and glucuronic
acid, extracted from brown algae [32]. Alginate has found numerous applications in biomedical
sciences and engineering, such as controlled drug delivery for cartilage repair and regeneration [33].
Mammals lack alginase; thus, alginate results in being a non-degradable polymer. Therefore, in our
protocol, alginate depolymerization was only dependent on the presence of monovalent ions in the
microenvironment [34]. One critical drawback of alginate is its inherent lack of cell adhesivity [35].
In our system, this drawback was overcome by the high adhesivity of Histogel. Then, we tested
Histogel-Type I collagen combinations. Type I collagen is a biodegradable material with remarkable
water retention ability, low antigenicity, and cytocompatibility. Collagen is an efficient scaffold
used for bone repair. It is also employed in regenerative medicine to promote regeneration of skin,
cartilage, or ligaments [36]. The presented results supported that both Histogel based materials were
biocompatible and provided good mechanical support, creating a scaffold suitable for cell adhesion and
proliferation. Histogel based scaffolds allowed adhesion, migration, and endothelial cell reorganization
and supported the adhesion and the survival of undifferentiated and differentiated ADSCs in vitro
and in vivo.
Both histogel-alginate and Histogel-type I collagen gel scaffolds well supported on the one hand
the differentiation of adipose tissue derived stem cells (ADSCs) into brown-like adipose cells expressing
PPARγ, PdK4, and UCP-1 proteins and on the other hand the recruitment of blood vessels. The
expression of specific adipose markers and the increase of OCR in differentiated ADSCs confirmed
that our models well supported ADSCs differentiation. As expected, norepinephrine and isoproterenol
increased the mitochondrial activity of ADSC derived beige cells [37,38].
Blood vessels are a necessary requirement to support BAT maintenance. In human adults,
BAT consists of brown adipocytes, adipocyte progenitor cells, and blood vessels. BAT is a highly
vascularized tissue located in the thorax in quantities inversely proportional to the size of the animal.
Therefore, to increase brown adipose tissue or to promote the browning of WAT, it is essential to support
the growth of new blood vessels. In our model, the ADSC derived beige cells produced and released
in the microenvironment several pro-angiogenic factors, which, in association with the pro-angiogenic
behavior of the Histogel based scaffolds, may contribute to supporting the vascularization of BAT.
The regeneration of BAT has been largely ignored in tissue engineering. Here, we proposed the
use of biological scaffolds to support the proliferation and differentiation of the adipose tissue resident
stem cells into a brown-like tissue and to allow the recruitment of vessels from the surrounding tissues.
The employment of such devices will result in heavy BAT mass gain and efficient body weight loss.
This would substantially improve the already existing applications in regenerative medicine and
metabolic disease treatments.
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Appendix A
Figure A1. (a) Commercial low, high molecular weight HA was electrophoretically analyzed on
agarose gel and stained with Stains-All solution. p.a. means pre-autoclaved. Three different standard
molecules (2 × 103, 1.1 × 103, 300 kDa) were used as markers of molecular weight (MK). (b) HUVEC
spheroids embedded in collagen gel were stimulated with commercial HA. The formation of radially
growing sprouts was evaluated after 24 h of incubation. Data are the mean ± SEM of three independent
experiments (** p < 0.001, one-way ANOVA followed by Bonferroni’s test versus the control).
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Figure A2. Confluent ADSCs were differentiated in different conditions, i.e., DMEM 10% FCS,
AdipoDiff (Milteny Biotech), DMEM complemented with 10% FCS and 3.3 nM of BMP7, DMEM 10%
complemented with 20 nM insulin (Sigma), 5 μM dexamethasone (Sigma), 125 μM indomethacin
(Sigma), 1 nM triiodothyronine (T3), and 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) in the absence
or in the presence of 3.3 nM of hBMP7 for 15 days. Expression of adipose markers was analyzed
by RT-PCR. ADSC derived beige cells were analyzed on Day 15 of differentiation. PPARγ, AdipoR,
Prdm16, UCP-1, and Pdk4 mRNA expression levels were measured by RT-qPCR analysis. Data are the
mean ± SEM (n = 5) and are expressed as relative expression ratios (ΔΔCt – fold increase).
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Abstract: Metabolic characterization of human adipose tissue-derived mesenchymal stromal/stem
cells (ASCs) is of importance in stem cell research. The monitoring of the cell status often requires
cell destruction. An analysis of volatile organic compounds (VOCs) in the headspace above cell
cultures might be a noninvasive and nondestructive alternative to in vitro analysis. Furthermore,
VOC analyses permit new insight into cellular metabolism due to their view on volatile compounds.
Therefore, the aim of our study was to compare VOC profiles in the headspace above nondifferentiating
and adipogenically differentiating ASCs. To this end, ASCs were cultivated under nondifferentiating
and adipogenically differentiating conditions for up to 21 days. At different time points the
headspace samples were preconcentrated by needle trap micro extraction and analyzed by gas
chromatography/mass spectrometry. Adipogenic differentiation was assessed at equivalent time
points. Altogether the emissions of 11 VOCs showed relevant changes and were analyzed in more
detail. A few of these VOCs, among them acetaldehyde, were significantly different in the headspace
of adipogenically differentiating ASCs and appeared to be linked to metabolic processes. Furthermore,
our data indicate that VOC headspace analysis might be a suitable, noninvasive tool for the metabolic
monitoring of (mesenchymal stem) cells in vitro.
Keywords: adipose tissue-derived mesenchymal stromal/stem cells (ASCs); cell differentiation;
volatile organic compounds; metabolic monitoring
1. Introduction
Due to their capacity for self-renewal and multipotent differentiation, mesenchymal stem/stromal
cells (MSCs) have been identified as playing an essential role in tissue homeostasis and regeneration [1].
In recent years, increasing attention has been paid to MSCs from human adipose tissue (adipose
tissue-derived MSCs, referred to as ASCs), as they show promising potential as a clinical alternative to
other MSCs, like bone marrow-derived MSCs (bmMSCs) [2–4]. Zuk et al. were the first to characterize
the mesenchymal differentiation potential of ASCs in more detail [5,6]. Furthermore, nonmesenchymal
differentiation (e.g., neuron-like morphology) of ASCs has also been demonstrated [7].
Data concerning the energy metabolism of MSCs in vitro are available but have not been worked
out in detail. It has been shown that bmMSCs mainly facilitate glycolysis with subsequent lactate
production rather than oxidative phosphorylation [8]. Furthermore, it was demonstrated that
Cells 2019, 8, 697; doi:10.3390/cells8070697 www.mdpi.com/journal/cells201
Cells 2019, 8, 697
nondifferentiating and osteogenically differentiating bmMSCs facilitated oxidative phosphorylation
as well as glycolysis in order to fulfill their energy metabolic needs [9]. It has been reported that the
function of mitochondria also regulates the differentiation of MSC [10,11]. Adipogenic differentiation
of ASC is accompanied by increasing mitochondrial enzyme activities, indicating a growing capacity
for oxidative phosphorylation and β-oxidation and, thus, a shift towards lipid metabolism [12].
In addition, in human differentiated adipocytes, the enzymes involved in mitochondrial metabolism
showed significantly higher activity rates than in the CD34+ stromal vascular fraction of human adipose
tissue containing the nondifferentiated progenitors of adipocytes, the ASCs [13]. Thus, in recent years
the idea matured that metabolic pathways regulate cellular differentiation processes that go beyond
ATP production [14]. To determine metabolic activities in different phases of differentiation, further
information is needed. Ideally, gathering this data should not influence or even disturb the cell culture.
For conventional metabolomics studies in vitro, sufficient cell material is necessary.
Especially when working with human stem cells, often low cell numbers are available. In contrast to
those conventional methods, an analysis of volatile organic compounds (VOCs) has the great advantage
of being nondestructive and noninvasive [15]. Such a destruction-free analysis can be done by means
of bidirectional preconcentration combined with a versatile, standardized set-up and has, therefore,
gained more attention during the last decades. Besides the occurrence of VOCs in human breath,
they are also emitted in trace concentrations by cell and bacteria cultures [16–18].
Headspace analysis by means of needle trap microextraction (NTME) coupled with gas
chromatography and mass spectrometry (e.g., GC-MS with electron impact quadrupole detection)
allows the identification and quantification of compounds down to the parts per trillion by volume
(pptV) range. Conventional headspace techniques require larger volumes and, therefore, may affect
the investigated system itself. Hence, microextraction techniques are better suited for this kind of
setup [19]. In contrast to solid phase microextraction (SPME), the sensitivity of NTME can be enhanced
by increasing the sampling volume, as the sample volume is usually limited. Bidirectional NTME
sampling can be applied to reach a high sensitivity in the VOC extraction [20] without significant
effects on volume or pressure of the in vitro system. A crucial step for a reliable and reproducible VOC
headspace analysis in in vitro cultures is also a standardized set-up [21].
Data from several studies suggest that different cell lines and bacterial strains can be distinguished
from each other by means of their volatile emissions [22–24]. Some volatiles have been shown to be
associated with different pathways in cell metabolism [25]. For example, acetone is produced by the
decarboxylation of acetoacetate, and acetaldehyde is produced by ethanol oxidation [26]. Previous work
has established that volatile substances over cell cultures correlate with stem cell growth [27].
Therefore, the aim of our study was to assess VOC emissions in the headspace of cell cultures to
gather complementary information on metabolic changes of ASCs during differentiation. This raises
the question of whether we can detect the differences in VOC emissions from cell cultures between
nondifferentiating and differentiating ASCs. This in turn leads to the next question: can the differences
in VOC emission be related to metabolic changes in ASCs during differentiation?
2. Materials and Methods
2.1. Isolation, Cultivation, and Differentiation of Adipose Tissue-Derived Mesenchymal Stromal/Stem
Cells (ASCs)
ASCs used in this study were isolated from human lipoaspirate. Tissue donation was approved by
the ethics committee of the Rostock University Medical Center (http://www.ethik.med.uni-rostock.de/)
under the registration number A2013-0112. It complies with the ethical standards of the World Medical
Association Declaration of Helsinki. Informed consent was obtained from all patients. The material
for the different analyses was retrieved from four patients. Data, as supplied by the surgeons,
showed one male and three female patients. Patients were on average 39.5 years old (ranging from
32 to 47). Liposuction procedures were performed by waterjet-assisted liposuction or a tumescent
suction technique.
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ASC isolation was performed as previously described [12]. ASCs were cryopreserved in passage
2 until they were used for the experiments. To achieve this, the cell suspension was transferred
into a cryovial (Greiner bio-one, Germany) containing 150 μL DMSO (Sigma-Aldrich, Germany) and
350 μL fetal calf serum (FCS, PAN Biotech, Germany). The cryovials were cooled to −80 ◦C overnight
at 1 ◦C per minute in a freezing container (Thermo Fisher Scientific, Berlin, Germany). Vials were
then stored in liquid nitrogen at −165 ◦C until further use. For use in the planned experiments,
the cells were thawed stepwise by gently shaking the vial at 37 ◦C in a water bath for 1 min. The cell
suspension was then gradually transferred into cell culture medium (Dulbecco’s Modified Eagle
Medium/DMEM GlutaMAX-I, Thermo Fisher Scientific, Germany), containing 10% FCS and antibiotics
(100 U/mL penicillin, 100 mg/mL streptomycin, Thermo Fisher Scientific, Germany; hereinafter called
maintenance medium) at room temperature and centrifuged for 5 min at 400× g. The resulting
cell pellet was resuspended in maintenance medium and centrifuged again for 5 min at 400× g.
Cells were resuspended in maintenance medium and seeded onto cell culture flasks for cultivation
at 37 ◦C and 5% CO2 in a humidified atmosphere. When confluency was reached after 5 d, cells
were detached from the cell culture flasks by incubation with 0.25% Trypsin EDTA for 5 min at 37 ◦C.
The cells were seeded into cell culture petri dishes (Greiner bio-one, Frickenhausen, Germany) at
a density of 20,000 cells/cm2. After 24 h of incubation the medium was replaced. After further
48 h (Day 0), additional to the nondifferentiating cultures, adipogenic differentiation of ASCs was
induced by adding a differentiation-stimulating medium: i.e., a maintenance medium containing
1 μM dexamethasone, 500 μM IBMX, 200 μM indomethacin, and 10 μM insulin (Sigma-Aldrich,
Munich, Germany). Adipogenic stimulation (AS) took place with every replacement of medium
three times a week (every second or third day). The medium replacement of differentiating ASCs
and undifferentiating ASCs without specific differentiation factors was performed (unstimulated/US)
simultaneously. To also assess the emissions of the cell culture medium, pure culture medium without
ASC (medium control) was treated and analyzed in a manner identical to the ASC cultures.
2.2. Analysis of Cell Numbers
Cell numbers were determined according to the manufacturer’s instructions using the
Nucleocounter NC200 and the Via1-Cassettes™ (ChemoMetec, Lillerod, Denmark).
2.3. Analysis of Adipogenic Differentiation
In order to assess the adipogenic differentiation of the ASCs over the course of the experiment,
fluorescent staining of the nuclei and lipid-filled vacuoles was done at the corresponding time
points of 1, 7, 14, and 21 d. Cells were seeded into 96-well μClear® cell culture plates (Greiner,
Frickenhausen, Germany) at a density of 20,000 cells/cm2. Media changes were done according to the
same schedule as the VOC quantification. At the corresponding time points the cells were washed
twice with PBS and fixed with 4% paraformaldehyde for 30 min at room temperature. Thereafter,
the cells were incubated with a Bodipy/Hoechst-staining solution (100 μL of 1 μg/mL Bodipy (Life
Technologies, California, Carlsbad, USA) and 5 μg/mL Hoechst 33,342 (AppliChem, Darmstadt,
Germany) in 150 mM NaCl) for 10 min at room temperature in the dark. After incubation, the cells
were washed twice with PBS and twice with water for injection. Subsequently, pictures were taken
with the microscopic plate scanning system Hermes WiScan (IDEA Bio-Medical, Rehovot, Israel) with
a 10-fold magnification objective.
2.4. Volatile Organic Compound (VOC) Sampling by Means of Needle Trap Micro Extraction
For headspace sampling, three cell culture dishes (without lid) containing culture medium and
ASCs were introduced into a hermetically closed sampling box under a sterile hood (schematically
shown in Figure 1). The sampling box was constructed from emission-free materials (Teflon® and
glass) to ensure a reliable measurement of trace VOC profiles [28]. As a negative control, three cell
culture dishes containing pure cell culture medium without ASCs were analyzed in parallel in a second
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box. After introduction of the cell culture dishes, the boxes were flushed with 3 L of clean synthetic air
(containing 75% N2, 20% O2, and 5% CO2; Air Liquide, Düsseldorf, Germany). After an incubation
time of 60 min at 37 ◦C in an incubator, headspace sampling by means of NTME was done. A detailed
description of the sampling setup was described before [23]. Headspace samples were taken at day 4
after seeding the cells, which means 24 h after changing from maintenance to adipogenic differentiation
medium and on day 7, 14, and 21 of differentiating cultures, nondifferentiating cultures, and medium
control dishes, respectively (see experimental setup in Figure 1).
Figure 1. Schematic depiction of the experimental setup. VOC—volatile organic compound.
NTME was done with needle trap devices (NTDs, needleEX), obtained from Shinwa Ltd.
(Kyoto, Japan). The NTDs were equipped with 3 cm of a copolymer of methacrylic acid and
ethylene glycol dimethacrylate. Before sampling, NTDs were preconditioned for 30 min at 200 ◦C
in a heating device (PAS Technology Deutschland GmbH, Magdala, Germany) under a helium flow.
Teflon caps (PAS Technology Deutschland GmbH, Magdala, Germany) were used to seal the NTDs
before and immediately after collecting the headspace samples.
For VOC preconcentration, NTDs were connected to a 1 mL sterile singleuse syringe (Omnifix-F,
B. Braun Melsungen AG, Melsungen, Germany) and pierced through the septum of a Luer Lock cap
(IN-Stopper, B. Braun Melsungen AG, Melsungen, Germany) at one connection port of the sampling
box. Bidirectional headspace sampling was done by filling and releasing 1 mL of headspace gas
20 times, as described previously [20].
2.5. Gas Chromatography and Mass Spectrometry (GC-MS) Analysis
For VOC analysis, an Agilent 7890 A gas chromatograph coupled to an Agilent 5975 C inert XL
MSD (Agilent, Santa Clara, CA, USA) with a triple axis detector was used. At an injector temperature
of 200 ◦C, VOCs were thermally desorbed from the NTDs. Sample injection was operated in splitless
mode (60 s splitless). The GC was equipped with a 60 m RTX-624 column (0.32 mm ID, 1.8 μm column
thickness). Helium carrier gas flow was constant at 1.5 mL min−1. The temperature program was as
follows: 40 ◦C for 5 min, 8 ◦C min−1 to 120 ◦C for 2 min, 10 ◦C min−1 to 220 ◦C, and 20 ◦C min−1 to
240 ◦C for 4.5 min. Analysis of the samples was performed via electron impact ionization (EI—70 eV) in
full scan mode, a mass range of 35–250 amu, and a scan rate of 2.73 scan/s. Volatile organic compounds
were tentatively identified by mass spectral library search (NIST Version 2.0). Substance attribution
was confirmed by comparing GC retention times and mass spectra of all selected substances with those
of pure reference substances. Quantifications were made in parts per billion per volume (ppbV) and
then calculated to nmol/L. To quantify the detected substances, a six-point calibration curve (from 1
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to 500 ppbV) was established. Humidity-adapted standards were prepared by means of a liquid
calibration unit (LCU, Ionicon Analytik GmbH, Austria). Limits of detection were calculated as a
signal-to-noise ratio of 3:1, whereby limits of quantification corresponded to a signal-to-noise ratio of
10:1. Ten blank NTDs were analyzed for this purpose. Quantitative parameters (limit of detection
(LOD), limit of quantification (LOQ), and standard deviation (SD)) for all identified VOCs are shown
in Table S1 in the Supplementary Materials.
2.6. Reference Substances
Acetone, 2-butanone, heptanal, octanal, and acetaldehyde were acquired from Ionimed Analytik
GmbH (Insbruck, Austria). Benzaldehyde and 1,3-di-tert-butylbenzene were purchased from
Sigma-Aldrich (Germany); tert-butanol, ethylbenzene, as well as 2-ethylhexanol were purchased
from TCI (Eschborn, Germany) and pentane from Fluka (Munich, Germany).
2.7. Statistical Analysis
Figures 2–5 show numerical data represented as medians and percentiles (25–75%).
Correlation analysis and statistical testing was performed by using RStudio (version 1.0.136) and R
software (version 3.3.2_ 2016-10-31). By using the Kruskal–Wallis test with the Nemenyi post hoc test,
statistically significant differences in median values between all groups were identified. Values of
p < 0.05 were considered statistically significant.
Figure 2. Depiction of adipose tissue-derived mesenchymal stromal/stem cells (ASCs) under
nondifferentiating conditions (referred to as non-diff ASC, subfigures (a,c,e,g) for cultivation days
1, 7, 14, 21, respectively) and under adipogenic stimulation (adipo ASC, subfigures (b,d,f,h) for cultivation
days 1, 7, 14, 21, respectively) Ffluorescence staining of nuclei (blue) and lipids (green), scale bar: 100 μm.
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Figure 3. Emissions of acetaldehyde, pentane, 1,3-di-tert-butylbenzene, ethylbenzene, benzaldehyde,
and heptanal from nondifferentiating (non-diff ASC, blue) and adipogenically differentiating ASC
(adipo ASC, green). Concentrations in the headspace are shown in nmol/L on the Y-axis. The X-axis
shows the time points of measurements. The boxplots represent data from three independent
experiments. Significance was tested within all groups. Symbols (*, #, $) indicate significant differences
to the corresponding highlighted group (p-values < 0.05).
206
Cells 2019, 8, 697
Figure 4. Example of two VOCs showing lower emissions in adipogenic differentiating ASC (adipo
ASC) cultures than in the culture media controls. Concentrations in the headspace in nmol/L are shown
on the Y-axis. The X-axis shows the time point of measurements. The diagram shows cell culture with
adipogenically differentiating ASC (referred to as Adipo ASC, in blue) and medium controls (samples
without cells, in red). Boxplots represent the data from three independent differentiation experiments.
Significance was tested within all groups. Symbols (*, #, §, $) indicate significant differences to the
corresponding highlighted group (p-values < 0.05).
Figure 5. Acetone and 2-ethylhexanol as exemplary medium-dependent VOCs in adipogenically
differentiated ASCs (referred to as Adipo ASC). The concentration in the headspace in nmol/L is
shown on the Y-axis. The X-axis shows the measurement time points. The diagram shows cell
culture with adipogenically differentiating ASC (referred to as Adipo ASC, in blue) and medium
controls (samples without cells, in red). Boxplots represent data of three independent differentiation
experiments. Significance was tested within all groups. Symbols (*, #, $) indicate significant differences
to the corresponding bold highlighted group (p-values < 0.05).
3. Results
3.1. Adipogenic Differentiation of ASCs
The assessment of adipogenic differentiation by fluorescent lipid staining revealed that
nondifferentiating conditions did not induce lipid accumulation in ASCs at any time point
(Figure 2a,c,e,f), After 24 h, adipogenic stimulation did not lead to lipid accumulation (Figure 2b).
After 7 d of adipogenic stimulation, distinct lipid vacuole formation was visible (Figure 2d). With the
progression of adipogenic differentiation of ASCs (day 14 and 21), the lipid vacuoles appeared larger
and showed a higher fluorescence intensity (Figure 2f,h). Thus, considerable adipogenic differentiation
was clearly visible in almost all cells of the adipogenic cell culture model. This was not the case in
nondifferentiating ASCs.
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3.2. Comparision of VOC Emissions of Non-Differentiating and Adipogenically Differentiating ASCs
Thirty-one potential volatile marker substances were identified in the headspace above the
cell cultures (concentration ranges and quantitative parameters are depicted in Table S1 of the
Supplementary Materials). To focus on the most relevant substances, we excluded substances having
concentrations below the limit of detection (LOD) at more than 3 time points as well as substances
having concentrations in the same range (± 10%) as in pure media samples. Based on these criteria,
11 VOCs were selected for further analysis. These substances were identified and quantified by using
pure reference substances. Six of these VOCs that were differentially emitted and dependent on the
differentiation are depicted in Figure 3.
The compounds acetaldehyde, pentane, and 1,3-di-tert-butylbenzene displayed different trends of
emission during cultivation with maintenance media compared with cultivation with differentiation
medium (Figure 3).
Concentrations of the emitted acetaldehyde changed significantly between days 7, 14, and 21 of
adipogenically differentiated ASCs. In nondifferentiating ASCs, no significant concentration differences
could be detected between the days of cultivation.
Pentane concentrations decreased in nondifferentiating ASCs, whereas a slight increase
in adipogenically differentiating ASCs was detected from day 14 to day 21 of differentiation.
The production of pentane in the adipogenically differentiating cell cultures peaked on day 1 and was
significantly higher than on day 7 and on day 14.
The concentration of 1,3-di-tert-butylbenzene in the headspace of nondifferentiating ASCs
remained lower as well as constant over the time, whereas the emissions in the headspace of
adipogenically differentiating cell cultures showed a slight increase.
Concentrations of ethylbenzene and benzaldehyde differed between nondifferentiating and
adipogenically differentiating ASCs in terms of concentration and time course. Both substances
showed lower emissions in adipogenically differentiating ASCs compared with nondifferentiating ASCs.
For benzaldehyde, these differences were significant. Heptanal showed a significant decrease over time in
nondifferentiating ACSs and an increase in adipogenically differentiating ASCs. Concentrations of heptanal
on day 21 of cultivation were higher in adipogenically differentiating compared with nondifferentiating
ASCs. Detailed statistical information can be found in the Supplementary Materials (Table S2).
To emphasize the differences between nondifferentiating and adipogenically differentiating ASCs,
Table 1 presents concentrations of emitted VOCs normalized to the cell number at day 21. All substances
other than benzaldehyde showed higher concentrations in differentiating cells than in undifferentiating
ASCs. The most prominent differences were found for acetaldehyde and heptanal. In both substances,
a nearly threefold increase of emitted concentrations could be detected on day 21 of the experiment.
Table 1. Ratio of VOC production in the headspace per cell from nondifferentiating and adipogenically
differentiating ASCs at day 21 of cultivation. Concentrations were calculated per 1 × 106 cells from
one experiment as an example. VOC concentrations are shown in pmol per L (pmol/L) ± standard
deviation (SD). Statistical significance was tested by a t-test (p < 0.05).
Substance
Normalized VOC Concentration






Acetaldehyde 229.3 (± 34.5) 686.4 (± 14.4) Yes
Pentane 64.2 (± 8.7) 86.9 (± 1.1) Yes
1,3-bis-(1,1-dimethylethyl)
Benzene 0.368 (± 0.04) 1.4 (± 0.2) Yes
Ethylbenzene 0.94 (± 0.1) 1.9 (± 0.4) Yes
Benzaldehyde 6.17 (± 2.1) 5.93 (± 1.2) No
Heptanal 9.6 (± 1.9) 25.4 (± 5.1) Yes
Octanal 11.5 (± 1.1) 23.8 (± 0.6) Yes
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3.3. Comparision of VOC Emissions from Medium Control and Corresponding Cell Cultures
Apart from emissions of the cells, VOCs were also emitted from the cell culture medium without
cells. Therefore, the headspace of the medium without cells was used as a “medium control” for
each time point tested. The detailed depictions of emissions of differentiating and nondifferentiating
ASCs compared to the medium control are shown in Figures S1 and S2, respectively. In the following,
exemplary results from adipogenically differentiating ASCs are presented.
Acetaldehyde, pentane, and 1,3-di-tert-butylbenzene showed medium independent emissions
in adipogenically differentiating cultures. Acetaldehyde and 1,3-di-tert-butylbenzene emissions
increased at every measurement time point. Most other VOCs (especially aldehydes) showed lower
and decreasing concentrations compared to the medium controls.
3.3.1. VOC Consumption during Adipogenic Differentiation
The emissions of three aldehydes (heptanal, octanal, and benzaldehyde) and one aromatic
hydrocarbon (ethylbenzene) were higher in the pure cell culture media compared with cell cultures.
As examples, ethylbenzene and benzaldehyde of this VOC group are depicted in Figure 4 (heptanal
and octanal can be found in Figure S1 of the Supplementary Materials).
Ethylbenzene concentrations were significantly higher in medium controls compared with cell
culture samples at three time points analyzed. For benzaldehyde, we could find significant differences
in the emissions from all cell culture samples compared with the pure medium control at all time
points. In nondifferentiating ASCs, ethylbenzene and benzaldehyde emissions showed the same
profile of higher emissions in the medium control compared with the cell culture (see Figure S2). Thus,
the specific consumption or binding of these VOCs by the cells is indicated.
3.3.2. Culture Medium-Dependent VOCs
The emissions of 2-ethylhexanol, acetone, tert-butanol, and 2-butanone from adipogenically
differentiating ASCs complied with the emissions of the medium controls. Heptanal and octanal
emissions also appeared media-dependent in nondifferentiating ASCs (see Figure S2 in the
Supplementary Materials).
The emissions of two exemplary VOCs, acetone and 2-ethylhexanol, over 21 days of cultivation
in adipogenically differentiating ASCs are presented in Figure 5. The emissions of tert-butanol and
2-butanone for adipogenically differentiating ASCs showed a slight decreasing trend over the first
two weeks of differentiation and peaked at day 21. This trend was similar in the medium control
(Supplementary Figure S1). The more comprehensive depiction of adipogenically differentiating and
nondifferentiating ASC VOCs from Figures 4 and 5 can also be found in the Supplemenary Figure S1.
4. Discussion
A nondestructive technique that could save time and material and gain more detailed information
on cellular metabolism would be desirable. The analysis of VOCs by means of NTME preconcentration
of headspace air coupled with GC-MS could be a fast and nondestructive method for the analysis of
metabolic processes in cell cultures [29–31].
In this study, our previously developed versatile sampling system [28] was applied to monitor VOC
emissions of cellular differentiation under standardized conditions. This method, however, presents
some challenges. Physical, chemical, and biological processes (e.g., the degradation of FCS in culture
medium) might affect VOC emissions. Therefore, the analysis of an adequate control—in this case pure
cell culture medium without cells—is a crucial step in order to obtain reliable results. Large variations
in VOC concentrations emitted from pure culture medium have been observed previously [21] and
might be due to physical and chemical processes during heating and cooling as well as aging of the
media. Furthermore, lipophilic VOCs (such as ethylbenzene, heptanal, or 2-ethylhexanol) might also
be bound to lipids of cellular structures (e.g., membranes) in general [32].
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In our study we utilized an established cell culture model that showed clear differences between
nondifferentiated cells and cells in adipogenic differentiation. Analysis of the formation of lipid-filled
vacuoles clearly confirmed the differentiation of the ASCs after adipogenic stimulation, whereas the
nondifferentiated ASCs did not show any signs of adipogenesis. This cell culture model has already
been examined for energy metabolic aspects, and it has been shown that adipogenic differentiation
induces a shift towards lipid metabolism [12].
In the headspace of both ASC cultures (adipogenically differentiating and nondifferentiating),
some VOC emissions seem to be related to culture media emissions rather than to emissions from the
cells in culture. This applies to four substances (2-ethylhexanol, acetone, tert-butanol, and 2-butanone)
in the headspace of adipogenically differentiating ASC cultures and two substances (heptanal and
octanal) in the headspace of nondifferentiating ASC cultures. Whether these changes are specific and
biochemically driven or merely induced by unspecific chemical conversion remains unclear. However,
since the VOCs acetaldehyde, pentane, and 1,3-di-tert-butylbenzene showed clear emission differences
dependent on the differentiation conditions, a specific link to metabolic processes might be possible.
Our data indicated that ASCs undergoing adipogenic differentiation increased the emission
of acetaldehyde, whereas nondifferentiated ASCs reduced the emissions down to almost zero.
Acetaldehyde emissions were nearly three times higher on day 21 of cultivation in adipogenically
differentiating ASCs compared with nondifferentiating cultures. When taking into account the cell
number, which is lower in adipogenically differentiating ASCs due to a stop in proliferation [12],
this effect becomes even more distinctive. Thus, in our study, acetaldehyde is the VOC with the most
variable differentiation-dependent behavior.
Acetaldehyde might be connected to mitochondrial pyruvate decarboxylation [33,34].
Whether acetaldehyde is consumed or produced could indicate the demands for intracellular acetyl-CoA.
The energy metabolism of nonstimulated cells and adipogenically stimulated ASCs might be based
predominantly on carbohydrate oxidation with a flux of pyruvate to acetyl-CoA. Under these conditions,
it is possible that acetaldehyde can be used as well for acetyl-CoA production.
However, acetaldehyde can also be the product of ethanol degradation. Since some
differentiation-inducing additives are dissolved in ethanol, a general, slightly increased level of
acetaldehyde emissions compared with ASCs in maintenance medium might result from higher
ethanol levels in the differentiation medium. This might be reflected in the increase of acetaldehyde
emissions in the medium controls at an early time point (up to seven days). Ethanol dehydrogenase
activity was detected in brown adipose tissue of rats [35]. Whether ethanol dehydrogenase is also
present in the ASCs of white adipose tissue needs to be determined.
1,3-di-tert-butylbenzene emissions showed a significant increase in adipogenically differentiating
ASCs compared to nondifferentiating ASCs. Tang et al. [36] found 1,3-di-tert-butylbenzene emitted
differentially in cancer cells lines compared with nonmalignant cells. No further information is
available about this substance in the current literature.
When normalized to cell numbers, pentane concentrations were higher in adipogenically
differentiating ASCs than in nondifferentiating ones. Pentane is produced through the peroxidation
of lipids and other biomolecules under the action of reactive oxygen species [37]. As shown before,
adipogenic differentiation of ASCs correlates with an increase of the antioxidative defense activities of
glutathione reductase [12]. This could conform with our current findings, which indicate an increase
in the production of reactive oxygen species in adipogenically differentiating cells, and which could be
followed by an increase in the antioxidative defense systems of ASCs.
Ethylbenzene showed higher concentrations in the headspace of medium controls than in the
headspace of cultivated cells. In general, lower and less-deviating concentrations were observed in
the headspaces of adipogenically differentiating ASCs compared with nondifferentiating ASCs. We,
thus, conclude that cells in culture with and without differentiation stimulation consume or bind this
compound. Previous studies established that ethylbenzene undergoes α- and ω-oxidation [38].
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The aldehydes benzaldehyde, heptanal, and octanal were also consumed or bound by the cells
from the culture media under both cultivation conditions. A consumption of aldehydes from the
culture media might be based on the activity of aldehyde dehydrogenase [39,40] (e.g., benzaldehyde
concentrations were reduced in the headspace of all cells but were even lower in adipogenically
differentiating than in nondifferentiating cells). Zimmermann et al. [41] described NAD-aldehyde
dehydrogenase as a possible enzyme for metabolizing benzaldehyde in fatty acid metabolism and
tryptophan metabolism [42,43]. Amino acids are necessary for proliferation and differentiation,
and their consumption was also observed in stem cell lines [27].
Heptanal and octanal showed relatively higher concentrations on day 21 in the adipogenically
stimulated ASC cultures when related to the cell number. Since heptanal can be a product of lipid
peroxidation [44,45], increasing enzyme activity for lipid oxidation during differentiation could lead
to a higher turnover of heptanal. Other studies linked octanal to oxidative stress [46,47]. While this
process includes lipid oxidation, octanal might increase during adipogenic differentiation due to an
increase of the oxidation processes.
5. Conclusions
In this study we were able to identify differentially emitted VOCs, which might be linked to a
changed metabolic activity in ASCs dependent on cellular differentiation. Whether these changes
are driven by specific, enzyme-mediated processes or are the result of unspecific reactions has to
be investigated. Irrespective of the fact that these are early stage results, the data presented are in
agreement with the results of adipogenic-differentiating cells to date. Thus, further experiments might
reveal if headspace VOC measurements serve as a marker for the quality and quantity of adipogenic
differentiation of ASCs.
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Abstract: A hallmark of ageing is the redistribution of body fat. Particularly, subcutaneous fat
decreases paralleled by a decrease of skin collagen I are typical for age-related skin atrophy. In this
paper, we hypothesize that collagen I may be a relevant molecule stimulating the differentiation of
adipose-derived stem cells (ASCs) into adipocytes augmenting subcutaneous fat. In this context
lipogenesis, adiponectin, and collagen I receptor expression were determined. Freshly isolated
ASCs were characterized by stemness-associated surface markers by FACS analysis and then
transdifferentiated into adipocytes by specific medium supplements. Lipogenesis was evaluated
using Nile Red staining and documented by fluorescence microscopy or quantitatively measured
by using a multiwell spectrofluorometer. Expression of adiponectin was measured by real-time
RT-PCR and in cell-free supernatants by ELISA, and expression of collagen I receptors was observed
by western blot analysis. It was found that supports coated with collagen I promote cell adhesion
and lipogenesis of ASCs. Interestingly, a reverse correlation to adiponectin expression was observed.
Moreover, we found upregulation of the collagen receptor, discoidin domain-containing receptor 2;
receptors of the integrin family were absent or downregulated. These findings indicate that collagen I
is able to modulate lipogenesis and adiponectin expression and therefore may contribute to metabolic
dysfunctions associated with ageing.
Keywords: adipose-derived stem cells; adipocytes; differentiation; collagen I; adiponectin; integrins;
discoidin domain-containing receptor; ageing; subcutaneous fat
1. Introduction
Adipose-derived stem cells (ASCs), residing within fat tissue, display multilineage plasticity,
which makes them interesting for regenerative medicine. Minimal invasive procedures allowing
liposuction facilitate access, particularly to superficial adipose tissue. After purification and plating, the
fate of native ASCs can be directed by specific culture conditions. As a result, different phenotypes can
be induced that are characteristic for adipocytes [1,2], fibroblasts [3], endothelial cells [4], osteoblasts [5],
chondrocytes [6], cardio-myocytes [7], neural-like cells [2], hepatocytes [8], pancreatic cells [9],
and others.
Skin ageing is triggered by intrinsic and extrinsic factors, leading to a massive remodeling of the
extracellular matrix (ECM) [10,11]. In this study, we hypothesize that the age-related decrease of ECM
molecules also has an impact on the adipogenic differentiation potential in ASCs. In this context, we
focus on the role of collagen I, which is the most prominent constituent of ECM molecules distributed
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throughout the interstitium, making up to 90% of the total connective tissue. Besides providing
mechanical rigidity, collagen fibrils also act as guidance structures for contacting cells. Among cellular
collagen receptors, the surface receptors of the integrin family are most prominent. They are composed
of noncovalently associated α and β subunits forming a heterodimer that recognizes specific amino acid
motifs within collagen molecules, hereby initiating intracellular signaling cascades. Besides integrins,
two receptor tyrosine kinases, namely discoidin domain receptors 1 and 2 (DDR1 and DDR2), have
also been identified to be activated upon collagen binding [12,13]. Particularly, DDR2 is characteristic
for cells of mesenchymal origin, such as fibroblasts and smooth muscle cells [14].
In order to characterize adipogenic differentiation, we put particular emphasis on lipogenesis by
measuring the lipid content. Moreover, another characteristic of adipocytes is the signature pattern of
secreted factors that have been collectively termed ‘adipokines’. Prominent among those are leptin,
adiponectin, resistin, and visfatin, as well as cytokines and chemokines, such as tumor necrosis factor-α
and interleukin-6 [15]. It is assumed that these factors contribute to a subinflammatory state that
triggers the development of many chronic obesity-correlated diseases. In this present paper, we focus
on adiponectin, a multifaceted adipokine, known as a modulator of inflammation [16,17].
The data presented in this paper show that the contact of ASCs to collagen I is a relevant factor
in adipogenic differentiation as characterized by lipogenesis and adiponectin secretion. It could be
speculated that collagen synthesis under physiological conditions might control the fate of ASCs.
2. Materials and Methods
2.1. Ethics Statement
This study was conducted according to the Declaration of Helsinki Principles and in agreement
with the Local Ethic Commission of the faculty of Medicine of the Johann Wolfgang Goethe University
(Frankfurt am Main, Germany). The Local Ethic Commission waived the need for consent.
2.2. Isolation and Characterization of ASCs
Isolation and initiation of human ASC cultures were performed as described [18]. As source
served abdominal subcutaneous fat tissue derived from plastic surgeries, generously provided
by Dr. Ulrich Rieger (Klinik für Plastische und Ästhetische Chirurgie, Wiederherstellungs und
Handchirurgie, Markus Krankenhaus, Frankfurt/Main, Germany). The fat tissue was placed in PBS
with 2% penicillin/streptomycin (Biochrom, Berlin, Germany) incubated overnight (4 ◦C). On the next
day, skin and blood vessels were mechanically removed by scissors and forceps. Small pieces, with
approximately 5 mm lengths, were given to a collagenase type I solution (Worthington, Lakewood,
USA) and incubated for 3 h at 37 ◦C. Cell debris was discarded by filtration through sterile gauze. Then,
the cell suspension was centrifuged (400× g, 6 min, 4 ◦C), the cell pellet resuspended in medium, and
passed through a cell strainer (70 μm, Greiner, Frickenhausen, Germany). Next, cells were separated
by density filtration using a Biocoll solution with a specific density of 1.077 g/mL. After another
centrifugation (400× g, 30 min, 4 ◦C), ASCs were isolated from the opaque interphase and seeded in
DMEM supplemented with 1% UltroSerG (Pall, Dreieich, Germany) and 1% penicillin/streptomycin.
The medium was renewed every 3 days.
2.3. Flow Cytometry
Phenotypical characterization of ASCs was performed using the BD FACSCalibur and analyzed
with the CellQuest software (v. 1.0.1, Becton–Dickinson, Heidelberg, Germany). The cells were
trypsinized, placed on ice for 30 min, and treated with the following labeled stemness-associated
antigen markers: CD31-, CD34+, CD45–, CD54–, CD90+, CD105+, CD166+, HLA-ABC+, HLA-DR–.
CD34-PE, CD90–FITC, and CD105-PerCP were part of the BD Stemflow Kit (Becton Dickinson, 562245).
The other antibodies with the indicated specifications were purchased separately: CD31-FITC (R &
D, Systems, Wiesbaden, Germany, FAB3567F), HLA-DR-PE (Becton Dickinson, 347401), CD166-PE
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(Becton Dickinson, 559263), CD34-APC (Becton Dickinson, 555824), CD54-FITC (Beckman Coulter,
Krefeld, Germany, PN IM0726U), HLA-ABC-FITC (Becton Dickinson, 555552), and CD45-PE (Becton
Dickinson, 555483). Table 1 shows the results from three donors. All experiments shown in this paper
were performed with cells until reaching passage 5.
Table 1. Characterization of ASCs.
Surface Marker
Positive Cells [%]
Donor 1 Donor 2 Donor 3
CD31/PECAM-1 0.75 ± 0.29 1.30 ± 0.19 0.83 ± 0.02
CD34 53.94 ± 7.09 63.98 ± 13.67 78.00 ± 1.29
CD45 0.85 ± 0.10 1.10 ± 0.13 0.97± 0.11
CD54/ICAM-1 1.36 ± 0.36 1.88 ± 0.57 2.76 ± 1.06
CD90/Thy-1 99.96 ± 0.03 99.88 ± 0.11 99.09 ± 1.39
CD105/Endoglin 91.07 ± 4.92 90.82 ± 11.62 60.17 ± 5.36
CD166/ALCAM 98.93 ± 0.82 97.83 ± 1.80 99.12 ± 0.11
HLA-ABC 99.74 ± 0.17 99.88 ± 0.05 99.48 ± 0.27
HLA-DR 0.78 ± 0.46 0.72 ± 0.11 0.56 ± 0.10
2.4. Adhesion Assay
For the adhesion experiments, ASCs were trypsinized and seeded at a concentration of
1× 104 cells/well onto microtiter plates coated with collagen I (Becton-Dickinson, Heidelberg, Germany).
The coating procedure was performed as previously described [19]. Briefly, collagen type I was dissolved
with sterile acetic acid and given in the specific vessels (5 mg/cm2). After drying, solvent and collagen
remnants were removed by washing with PBS. Regular plastic dishes served as controls. After seeding,
the cells were allowed to attach for 30, 60, 90, and 120 min at 37 ◦C. Then, non-anchored cells
were removed by two washings with PBS, and the nuclei of anchored cells were stained with the
DNA-binding fluorochrome bisbenzimide (2 mg/mL, 20 min, RT). After two washing steps, fluorescence
was detected using the CytoFluor multi-well plate reader (Applied Biosystems, Langen, Germany) at
360/460 nm [19,20]. Experiments were performed three times with three triplicates.
2.5. Induction of Adipogenesis
ASCs were seeded in 24-well culture dishes at a concentration 5 × 104 cells/well. Adipogenic
differentiation was induced by Adi-medium consisting of DMEM supplemented with 10 μM
insulin, 0.5 mM 3-isobutyl-1-methylxanthine, 1 μM dexamethasone, 200 μM indomethacine,
1% penicillin/streptomycin solution, and 2% UltroserG [2,18].
2.6. Detection of Lipids
ASCs were cultured in Adi-medium (or standard medium) on collagen I-coated and non-coated
supports for 9, 11, and 15 days. Consecutively, the lipid content was quantitatively detected as
described [21]. Briefly, cultures were washed with PBS and then stained with nile red (1 μg/mL, 20 min,
37 ◦C). After two washing steps with PBS, fluorescence documented by fluorescence microscopy or
quantitatively measured using a multiwell spectrofluorometer (Cytofluor, Applied Biosystems, Langen,
Germany) equipped with 485/560 nm filters for neutral lipids. Moreover, cell nuclei were stained
with bisbenzimide (2 μg/mL, 20 min, 37.4 ◦C) and the fluorescence, as a measure for cell count, was
detected at 360/460 nm. In order to normalize the lipid values to different cell counts, a ratio was
formed between nile red and bisbenzimide measurements. The values derived from cells cultured
on plastic were set to 100% and all other values were related to that. Experiments were performed in
quadruplicate, with 4 parallel determinations for each condition.
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2.7. Western Blot
Cells cultured as described above were lysed in 100 mL SDS sample buffer (62.5 mM Tris-HCl
[pH 6.8], 2% SDS, 10% glycerol, 50 mM DTT, 0.1% bromphenol blue), sonicated and boiled for 5 min,
and separated on SDS-polyacrylamide gels. Consecutively, proteins were immunoblotted to a PVDF
membrane. The membrane was blocked in blocking buffer (TBS [pH 7.6], 0.1% Tween-20, 5% nonfat dry
milk) for at least 3 h at 4 ◦C followed by incubation with the primary antibody in TBS (pH 7.6), 0.05%
Tween-20, and 5% BSA. Bound primary antibodies were detected using anti-mouse IgG-horseradish
peroxidase conjugate and visualized with the LumiGlo detection system (Cell Signaling, Frankfurt,
Germany). The following primary antibodies were used: Integrin β1 (Santa Cruz, sc-6622), integrin α1
(R & D, MAB5676-SP), integrin α2 (Becton-Dickinson, 611016), integrin α11 (R & D, AF4235-SP), and
discoidin domain-containing receptor 2 (DDR2) (R & D, AF2538).
2.8. Adiponectin ELISA
Cells were seeded on collagen or plastic supports and exposed to either Adi-medium (or standard
medium) for 9, 11, and 15 days. Cell-free supernatants were obtained and assayed for human
adiponectin using a commercial ELISA test kit (R & D) according to the manufacturers’ instructions.
Briefly, supernatants were placed in microwell plates coated with antibodies against adiponectin. After
incubation with a biotin-labeled secondary antibody, a streptavidin horseradish-peroxidase conjugate was
added. A colorimetric reaction was exerted by addition of a substrate (tetramethylbenzidine/peroxide),
giving rise to a colored product measured at 450 nm in a scanning multiwell spectrophotometer (ELISA
reader MR 5000, Dynatech, Guernsey, UK).
2.9. Real-Time RT-PCR Analysis
Total cellular RNA was isolated from cells cultured as described above using the ExtractMe Total
RNA Kit (Blirt, Gdansk, Poland). After DNase digestion, a total amount of 25 ng RNA was used for
first-strand cDNA synthesis using a QuantiTect SYBR Green RT-PCR Kit (Qiagen, Hilden, Germany).
Real-time PCRs were performed on a Light Cycler system 2.0 (Roche Diagnostics, Mannheim, Germany).






The relative expression of transcripts was determined using the 2-ΔΔCT method [22].
2.10. Statistics
All data are presented as mean values ± standard deviation. Statistical significance of the data was
calculated by Wilcoxon-Mann-Whitney-U-test (BIAS, Frankfurt, Germany). Data sets were statistically
compared as indicated in the graphics.
3. Results
Although most cell cultures were carried out on uncoated plastic dishes, it is known that
extracellular matrix molecules have impacts on cell physiology. Therefore, we initially tested the
adherence of ASCs held in standard medium to collagen I in comparison to uncoated plastic (Figure 1).
Representative photographs of time-dependent adhesion are shown in Figure S1. It was found that
ASCs in suspension feature a significant faster adherence to collagen I-coated substrates in the first
30 min. In the further course, the cell count adherent to either plastic or collagen I was similar in the
observed time span. These results indicate that naïve ASCs also express adhesion molecules with
avidity to collagen I.
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Figure 1. Quantitative adhesion of ASCs on plastic vs collagen I. ASCs were plated at a density of
1 × 104 cells per well into microtiterplates either non-coated or coated with collagen I. After 30, 60, 90,
and 120 min, non-adherent cells were discarded and the remaining cells were stained with bisbenzimide.
Fluorescence, as a measure for adherent cells, was quantified using a CytoFluor multi-well plate
reader at 360/460 nm. Each point represents the mean of five independent experiments. The standard
deviations are indicated. * p < 0.05. The whole experiment was repeated three times with similar results.
Furthermore, we investigated the impact of adhesion to collagen I on cell morphology and
differentiation (Figure 2). Cells were seeded on supports coated with collagen I or plastic for control
and then cultured for 19 days in either standard medium (DMEM) or adipogenic medium (Adi-medium).
On plastic (Figure 2A), ASCs feature a domed cell center with filigree dendritic plasma extrusions in
the periphery. These dendritic branches are less pronounced in cells on collagen I (Figure 2B). When
cells were held in adipogenic medium, the cell morphology changed massively. Cells form a large
interconnected network with many extended cell branches reminding on a network of nerve cells
(Figure 2C,D). Moreover, cells accumulate tightly packed vesicles in the cell center, which putatively
represent lipid droplets. In order to verify the nature of these droplets, a nile red staining was
performed (Figure 2E–H). Positive nile staining was found around the cell nucleus, stained in blue
with bisbenzimide, indicating the presence of lipids. Of note, on the photographs, the expression of
lipids seems to be more distinct in cells cultured on collagen I.
Figure 2. Cont.
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Figure 2. ASCs cultured on plastic or collagen I. (A,B) show the cell morphology after cultivation in ASC
standard medium (ctr) for 19 days, (C,D) after cultivation in adipogenic medium (Adi). (E–H) display
cellular lipids (red) after cultivation in adipogenic medium for 19 days stained with the fluorescence dye
nile red; cell nuclei (blue) are stained with bisbenzimide. Photographs show representative sections.
In order to validate this first impression, nile red staining was quantified at different time points
(9, 11, 15 days) by fluorometric means as described. Figure 3 shows the content of neutral lipids of ASCs
in dependence to culture medium (DMEM vs Adi-medium) and cell support (plastic vs collagen I).
The value determined for ASCs cultured in DMEM on plastic was set to 100%. In these cells, which are
absent of lipid droplets, nile red stains showed lipid-containing membranes only. All other measured
values were related to this. It was found that cultivation on collagen I led to a slight, but significant
increase in lipid content at all examined time points in DMEM (black bars). Moreover, the change to
Adi-medium induced the expected massive and significant increase in lipids in cells on plastic and
collagen I (striped bars). Of note, cultures on collagen I showed an increase in lipids compared to their
counterparts held on plastic. In sum, these results indicated a lipogenic effect of collagen I in ASCs.
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Figure 3. Quantitative lipogenesis of ASCs on plastic or collagen I. ASCs were plated at a density of
1 × 104 cells per well into microtiterplates either non-coated (plastic) or coated with collagen I. One part
was held in regular DMEM medium (ctr) and the other in adipogenic medium (Adi). After (A) 9 days,
(B) 11 days, and (C) 15 days, cells were stained with nile red and bisbenzimide and the fluorescence was
measured (see Materials and Methods). Each point represents the mean of 16 independent experiments.
The standard deviations are indicated. Data sets were statistically compared as indicated. * p < 0.05.
Next, the release of adiponectin, a prototypical adipokine, was evaluated in cell-free supernatants
by ELISA after 9, 11, and 15 days (Figure 4A–C). ASCs cultured in DMEM showed no significant
release of adiponectin in the period under observation regardless of whether they were cultured on
plastic or collagen I (black bars). Changing the medium to Adi-medium induced a massive release
of adiponectin (striped bars). Comparison of both cell substrates shows that the measured levels of
adiponectin on collagen I were significantly reduced.
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Figure 4. Adiponectin release of ASCs on plastic or collagen I. ASCs were plated at a density of
1 × 104 cells per well into microtiterplates either non-coated (plastic) or coated with collagen I. One part
was held in regular DMEM medium (ctr) and the other in adipogenic medium (Adi). After (A) 9 days,
(B) 11 days, and (C) 15 days, supernatants were examined for adiponectin by ELISA. Each point
represents the mean of 20 independent experiments. The standard deviations are indicated. Data sets
of Adi/plastic and Adi/collagen I were statistically compared as indicated. * p < 0.05.
To learn more about the level of this regulation, mRNA transcripts of adiponectin were quantified
by real-time RT-PCR analysis (Figure 5). As found for the adiponectin release, almost no adiponectin
mRNA expression was found in ASCs held in DMEM (black bars). In contrast, massive induction was
initiated by changing the medium to Adi-medium (striped bars). Similar to the measured protein
levels, this induction was gradually diminished by cultivation on supports coated with collagen I.
The measured Ct values ranged from ca. (circa) 29 for non-differentiated to ca. 22 for differentiated cells.
The Ct values for reference gene (PBGD) expression were ca. 27 independent from culture conditions.
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Figure 5. Adiponectin mRNA expression of ASCs on plastic or collagen I. ASCs were plated at
a density of 1 × 104 cells per well into microtiterplates either non-coated (plastic) or coated with
collagen I. One part was held in regular DMEM medium (ctr) and the other in adipogenic medium
(Adi). After (A) 9 days, (B) 11 days, and (C) 15 days, total RNA was extracted and real-time RT-PCR
analysis was performed. The values for ASCs in DMEM are less than 1%. Data sets of Adi/plastic and
Adi/collagen I were statistically compared as indicated. * p < 0.05.
Our results demonstrate that collagen I has an impact on the cell physiology in ASCs. Therefore,
the expression of collagen receptors was determined by western blot analysis (Figure 6). Surface
receptors of the integrin family form heterodimers composed of α and β subunits, which convey
substrate specific recognition. For the recognition of collagens, the α1, α2, α11, and β1 subunits
are relevant. Positive controls for the detection of α1 and α11 were protein lysates derived from
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normal human fibroblasts; for α2 and β1, lysates from HaCaT keratinocytes were used. It was found
that ASCs in DMEM produce distinct amounts of α1 on plastic as well as on collagen I (Figure 6A).
A change to Adi-medium significantly reduced this expression. Likewise, α11 was massively reduced
in ASCs cultured in Adi-medium. Interestingly, the basal level in ASCs held in DMEM was in the
range of the positive control. Integrin α2 was only present in the positive control. The β1 subunit was
even more pronounced than in the positive control, particularly in ASCs held in DMEM. A shift to
Adi-medium caused a decrease in β1 expression. Moreover, DDR2, another collagen receptor present
in mesenchymal cells, was investigated (Figure 6B). Here, a moderate expression in ASCs cultured in
DMEM was found. Of note, a shift to Adi-medium caused a profound upregulation. Lysates derived
from fibroblasts served as a positive control.
Figure 6. Expression of collagen I receptor molecules. ASCs, plated on regular plastic supports or
supports coated with collagen I, were held for 9 days in standard DMEM medium (ctr) or in adipogenic
medium (Adi). Protein extracts were subjected to western blot and tested for (A) α1, α2, α11, β1
integrin, and (B) DDR2. Equal loading was monitored by using antibodies directed against α-tubulin.
The blots show representative results (n = 3). + indicates positive controls.
4. Discussion
Collagen I, as the most abundant ECM molecule, is produced by fibroblasts. It is known to provide
a structural scaffold for cell attachment with impacts on tissue organization and tissue homeostasis
by affecting cell growth, motility, viability, and differentiation [23]. The omnipresence of collagen in
the mesenchym makes this molecule interesting as a potential trigger factor determining the cell’s
fate. It is known that the amount of collagen decreases during ageing with implications to the
above mentioned physiological parameters [24]. An imbalance of the production and degradation
leads to the accumulation of fragmented collagen molecules on which fibroblast cannot efficiently
attach to. The absence of a mechanical load, which is a trigger factor for proliferation [25], marks the
entry to a self-perpetuating detrimental cycle, accelerating the decrease of collagen [24]. Moreover,
224
Cells 2019, 8, 302
another hallmark of ageing is the redistribution of fat, with a decrease of peripheral subcutaneous
fat [26]. It is an interesting issue if both observations are somehow functionally linked. ASCs
residing in subcutaneous fat tissue have the potential to transdifferentiate into adipocytes, serving
to compensate the age-dependent volume loss. In this paper, we showed that ASCs produce more
lipids, a marker for adipogenic differentiation, when cultured in collagen coated dishes. This effect
was measured both in cells cultured in standard medium containing no differentiation factors, and
also in cells cultured in Adi-medium, described to promote adipogenic differentiation. Against this
background, the stimulation of collagen synthesis by topical retinoic acid [27–29] or carbon dioxide
laser resurfacing [30] may also support the differentiation of ASCs into adipocytes. Furthermore,
injectable preparations containing animal collagen, which are widely used in cosmetic medicine as
injectable fillers to increase lip volume, to minimize wrinkles, or to correct post-acne and traumatic
scars [31], impact this differentiation process.
In addition to lipogenesis, the expression of adiponectin was also examined, a fat-derived
hormone that is predominantly produced by adipocytes [32]. Corroboratively, ASCs in standard
medium produce no adiponectin while cultivation in Adi-medium leads to a massive induction,
indicating successful transdifferentiaton to adipocytes. Although adiponectin has pleiotropic metabolic
effects, it is mainly known for its action as an insulin sensitizer with anti-apoptotic and anti-inflammatory
properties [33–35]. Interestingly, the presence of collagen suppressed the expression of adiponectin.
In humans, an inverse correlation between fat mass and adiponectin plasma levels was observed [36,37].
In this context, the inhibitory effect of collagen may represent a countermeasure in response to the
massive induction of lipogenesis.
After we learnt that collagen impacts on metabolic parameters in ASCs, we looked at the potent
receptors conveying such a signal, namely integrins and DDR2. In higher vertebrates, there are 18 α
subunits and 8 β subunits, which form 24 distinct integrins. Specific for collagen binding are the
following heterodimers: α1β1, α2β1, α10β1, and α11β1 [38]. Therefore, in western blot analysis, the
expression of these integrins were investigated. An inverse regulation between lipogenesis/adiponectin
expression and the expression ofα1, α11, andβ1 was found (α2 was not detectable in ASCs independent
from culture conditions). In contrary, DDR2 was massively induced in ASCs when transdifferentiated to
adipocytes. These findings suggest a contribution of this receptor in the collagen I-induced regulations
of lipogenesis and adiponectin expression.
In sum, the presented results identified collagen I as a new regulator of adipogenic differentiation of
ASCs. These findings have implications for the understanding of changes in age-related fat metabolism.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/8/4/302/s1,
Figure S1: Time-dependent cell adhesion of ASCs to plastic vs collagen I.
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Abstract: During cancer progression, breast tumor cells interact with adjacent adipose tissue,
which has been shown to be engaged in cancer aggressiveness. However, the tumor-directed
changes in adipose tissue-resident stromal cells affected by the tumor–stroma communication are
still poorly understood. The acquired changes might remain in the tissue even after tumor removal
and may contribute to tumor relapse. We investigated functional properties (migratory capacity,
expression and secretion profile) of mesenchymal stromal cells isolated from healthy (n = 9) and
tumor-distant breast adipose tissue (n = 32). Cancer patient-derived mesenchymal stromal cells
(MSCs) (MSC-CA) exhibited a significantly disarranged secretion profile and proliferation potential.
Co-culture with MDA-MB-231, T47D and JIMT-1, representing different subtypes of breast cancer,
was used to analyze the effect of MSCs on proliferation, invasion and tumorigenicity. The MSC-CA
enhanced tumorigenicity and altered xenograft composition in immunodeficient mice. Histological
analysis revealed collective cell invasion with a specific invasive front of EMT-positive tumor cells as
well as invasion of cancer cells to the nerve-surrounding space. This study identifies that adipose
tissue-derived mesenchymal stromal cells are primed and permanently altered by tumor presence in
breast tissue and have the potential to increase tumor cell invasive ability through the activation of
epithelial-to-mesenchymal transition in tumor cells.
Keywords: mesenchymal stromal cells; adipose tissue; breast cancer; tumor microenvironment;
perineural invasion
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1. Introduction
The interaction of breast epithelium and stroma promotes normal breast structure and function [1].
However, adipose tissue surrounding breast tumors is no longer recognized as a passive structural
element, but as a key component contributing to breast cancer progression [2,3]. Diverse stromal
cells, including myofibroblasts, pericytes, endothelial cells and cancer-associated fibroblasts (CAF),
are recruited from adjacent adipose tissue, and these become an integral component of the tumor
microenvironment [4,5]. Mesenchymal stromal cells (MSCs) also migrate to tumors, which are
commonly perceived as wounds that never heal [6]. Several studies have elucidated MSC ability to
transform into a carcinoma-associated fibroblast phenotype when treated in vitro with breast cancer
cell-secreted factors [7–9]. This change is demonstrated by a higher expression of αSma, Vimentin,
fibroblast specific protein 1 (FSP-1), stromal-derived factor 1 (SDF1) and C-C motif chemokine
ligand 5 (CCL5) [10,11]. At least five tumor-associated stromal fibroblast cell subtypes have been
identified in the tumor stroma, and these are differentiated by the expression of specific markers
associated with various levels of tumor aggression. The most aggressive subtype is characterized by
extensive matrix remodeling and the increased expression of FSP-1 and fibroblast activating protein
(FAP) [12]. We previously established that factors secreted by tumor cells alter the MSCs’ molecular
traits and angiogenic ability. We also confirmed that these changes correlate with their subsequent
pro-tumorigenic action and that chemotherapeutically pre-treated MSCs produce a similar effect [13,14].
Additionally, Yeh et al. associated the CXCL1 secreted by stromal cells in breast adipose tissue with
doxorubicin resistance mediated by ABCG2 up-regulation [15]. Although studies provide evidence
that in vitro MSCs are prone to differentiation into carcinoma-associated fibroblasts induced by tumor
secretome [16], there is no experimental evidence as to whether breast malignancy affects the MSCs in
distant adipose tissue remaining in the breast after surgery and if those changes may persist even after
the tumor removal. Since has also been suggested that interactions between tumor and normal tissue
are bi-directional [17,18], we hypothesize that malignant cells and their secretome shape the normal
distant tissue and alter its properties.
Herein, we performed a detailed comparison of the functional properties of MSCs from the
following four origins in healthy donors and breast cancer patients to determine the influence of
malignancy on normal stromal precursors: (1) the first MSC group was isolated from the breast adipose
tissue of healthy donors undergoing planned aesthetic breast surgery; (2) the second group comprised
MSCs from cancer patient breast adipose tissue adjacent to pre-malignant lesions; (3) the third group
was MSCs obtained from adipose tissue of breast cancer patients diagnosed with invasive tumor type
and (4) this group contained tissue similar to that in the third group but also harboring the BRCA gene
mutation. The results establish that breast cancer patient-derived MSCs are inherently altered; they
promote in vivo tumor growth and they also increase tumor cell invasiveness. Finally, identification
of key functional changes in the MSCs located in the tumor micro-environment and increased
understanding of the mechanisms involved in MSC-enhanced tumor growth and metastasis could
initiate new methods of normalizing tumor micro-environments, and thus regulate disease progression.
2. Materials and Methods
2.1. Cell Cultures
Mesenchymal stromal cells were isolated from the breast adipose tissue of four different donor
groups: Group No.1 MSC-H (n = 9), isolated from breast adipose tissue of healthy donors, Group No.2
MSC-DCIS (n = 2), isolated from adipose tissue adjacent to pre-malignant lesions, Group No.3 MSC-CA
(n = 24), isolated from adipose tissue adjacent to malignant lesions, and Group No.4 MSC-BRCA+ (n
= 6), isolated from adipose tissue adjacent to malignant lesions harboring the BRCA gene mutation.
We used tumor-adjacent adipose tissue obtained during surgery, and the samples ranged from 1.5
to 5 cm3. All donors provided informed consent and all procedures were approved by the Ethics
Committee of the Ruzinov University Hospital and the National Cancer Institute (TRUSK-003).
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The MSCs were isolated as previously described [19]. The isolated cells were maintained in low-glucose
(1 g/L) Dulbecco’s modified Eagle medium (DMEM, PAA Laboratories GmbH, Pasching, Austria)
supplemented with 10% fetal bovine serum (FBS, Biochrom AG, Berlin, Germany). Breast cancer
cell lines were cultured in high-glucose (4.5 g/L) Dulbecco’s modified Eagle medium (DMEM, PAA
Laboratories GmbH) supplemented with 10% fetal bovine serum (FBS, Biochrom AG). Both culture
media were supplemented with 2 mM glutamine (PAA Laboratories GmbH), 10.000 IU/mL penicillin
(Biotica, Part. Lupca, Slovakia), 5 μg/mL streptomycin (PAA Laboratories GmbH) and 2.5 μg/mL
amphotericin B (Sigma-Aldrich, Taufkirchen, Germany). The cells were maintained at 37 ◦C in
humidified atmosphere and 5% CO2, and the MSCs were then expanded and used for experiments not
exceeding the 10th passage.
Human mammary gland adenocarcinoma cell line MDA-MB-231 (ATCC® Number: HTB-26™),
T47D (ATCC® HTB-133™) and JIMT-1 (DSMZ no.: ACC 589) were purchased from stated sources
and their identity was confirmed by STR profiling in July 2018. The cells were transduced with
IncuCyte® NucLight Lentivirus Reagents (Essen BioScience, Ann Arbor, MI, USA) to express nuclear
red fluorescent protein (mKate2) according to manufacturer protocol. These cells are referred to as
NLR-T47D, NLR-MDA-MB-231 and NLR-JIMT-1 (in manuscript shortened to NLR-T47D, NLR-MDA231
and NLR-JIMT).
2.2. MSC Differentiation
Adipogenic differentiation was evaluated in MSCs plated at 3500 cells/well density in 96-well
plates and maintained in low-glucose (1 g/L) DMEM medium supplemented with 60 μM indomethacin,
0.5 mM isobutylmethylxanthine, 0.5 μM hydrocortisone and 10% fetal bovine serum, GlutaMAX and
antibiotic-antimycotic mix. The medium was changed every 2–3 days. The cells were washed with
PBS after the 21st day of culture, fixed in 10% formalin and stained with Oil Red O (Sigma-Aldrich)
for 2–5 min. The presence of adipocytes was detected by red stained lipid droplets. Osteogenic and
chondrogenic differentiation was performed by StemPro Differentiation Kit (Gibco, Life Sciences,
Carlsbad, CA, USA), where osteogenic differentiation was confirmed by detection of red stained
calcium deposits using Alizarin Red S (Sigma-Aldrich) and chondrogenic positivity was proven by
blue stained proteoglycans synthesized by chondrocytes using Alcian Blue stain (Sigma-Aldrich).
Finally, the MSCs maintained in standard culture medium served as controls.
2.3. Immunophenotype
The identification and phenotyping of cultured MSCs was based on the defined International
Society for Cellular Therapy (ISCT) standards and the use of human MSC Phenotyping Kit (Miltenyi
Biotec, Bergisch Gladbach, Germany) [20]. The expression of CD90, CD105, CD14, CD20, CD34 and
CD45 was assessed by BD FACSCanto™ II Flow cytometer (Becton Dickinson, USA) equipped with
the FacsDiva program, and the data were then analyzed by FCS Express program.
2.4. Morphology and Wound Healing Assay
For MSC morphology analysis, 5 × 103 MSCs in passage 2–4 were seeded in a 96-well plate and
captured by IncuCyte ZOOM™ kinetic imaging system over 72-h period. For immunofluorescent
analysis, cells were seeded on slides and, after reaching desired confluence, they were fixed with
4% PFA for 15 min, washed three times in PBS and subsequently stained with Actin-AF488 (1:500,
diluted in ROTI) for 1 h at 37 ◦C and then with DAPI (1:500) for 15 min at 37 ◦C to stain the nuclei.
MSC migration was evaluated in 96-well plates, where 23 × 103 MSCs per well were seeded and
analyzed by IncuCyte® Scratch Wound Cell Migration and Invasion System and documented by the
IncuCyte ZOOM™ kinetic imaging system. To assess the invasion capacity, 1 × 104 MSCs + 2 × 104
NLR-MDA231/NLR-T47D and 1.5 × 104 MSCs + 3 × 104 NLR-JIMT were seeded on ECM-coated
96-well plates and, after executing the scratch wound, they were immediately covered with 50% ECM
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(Matrigel, Sigma-Aldrich). MSCs were stained with Vybrant™ CFDA SE Cell Tracer Kit (Thermo-Fisher
Scientific, Waltham, MA, USA) according to the manufacturer protocol.
2.5. Evaluation of Proliferation
MSC doubling-time was evaluated by RealTime-Glo™ MT Cell Viability Assay (Promega
Corporation, Madison, WI, USA). This was performed in a 96-well plate with 5 × 103 cells per
well seeded in eight replications. Relative luminescence was determined on LUMIstar GALAXY reader
(BMG Labtechnologies, Germany) approximately every 12 h for 3 days. The luminescence values were
extrapolated by a graph and trend line equation, and the mean luminescence after 24 and 48 h was
determined by formula. The doubling-time was calculated as follows: doubling time = duration × log
(2)/log (luminescence value after 48 h) − log (luminescence value after 24 h). The experiments were
repeated at least twice with similar results, and the mean results were reported.
Fluorescently labeled tumor cells and MSCs were mixed in a 2:1 ratio for co-culture experiments;
4 × 103 NLR-JIMT and 2 × 103 MSC or 2 × 103 NLR-MDA231 and 1 × 103 MSC were seeded in standard
culture medium in 96-well plates. Each well was imaged every two hours by IncuCyte ZOOM™Kinetic
Imaging System (Essen BioScience, Newark Close, UK) until cells reached confluence. The tumor cell
number was evaluated by IncuCyte ZOOM™ software (Essen BioScience) based on the enumeration
of tumor cells’ red nuclei by kinetic imaging scanning. The values are expressed as means of replicates
± SD. Three-dimensional multicellular spheroids were prepared by seeding 2 × 103 tumor cells mixed
with 1 × 103 MSCs in 96-well ultra-low attachment plates (Corning 7007, Corning Inc., Corning,
NY, USA) in 100 μL of culture medium. Representative pictures of spheroids were taken after 7 days of
culture by IncuCyte ZOOM™Kinetic Imaging System (Essen BioScience) and the relative luminescence
of spheroids was evaluated by the CellTiter-Glo™ 3D Cell Viability Assay (Promega Corporation).
2.6. Gene Expression Array
The Human Mesenchymal Stem Cells RT2 Profiler™ PCR Array then analyzed specific
human mesenchymal stem cell gene expression in individual MSC groups (PAHS-082ZD; Qiagen,
Hilden, Germany). RNA from 5 × 105 MSCs was isolated by AllPrep RNA/Protein kit (Qiagen) and
reverse transcribed with RT2 First Strand Kit (Qiagen). The expression of 84 human MSC-related genes
was analyzed by RT2 SYBR Green Mastermix (Qiagen) and Bio-Rad CFX96™ Real-Time PCR Detection
system (Bio-Rad Laboratories Ltd, Watford, UK). The CT cut-offwas set at 35, and targets expressed
at very low levels or undetected in MSC-H were excluded from relative expression calculations.
The expression profile of MSC-H was used as a reference. Relative expression exceeding 4-fold
alteration in tested samples was considered for further analysis.
2.7. Proteome Profiler
Proteome profile analysis of human cytokines and chemokines was performed with the XL
Cytokine Array Kit (R&D Systems™, Minneapolis, MN, USA). ImageJ software (NIH, Bethesda,
MD, USA) was used for the quantitative evaluation; the pixel density was determined and calculated.
Serum-free conditioned media obtained from 2× 105 MSC-H or MSC-CA were loaded on the membranes
with blotted antibodies and evaluated as recommended by the manufacturer.
2.8. Enzyme-Linked Immunosorbent Assay (ELISA)
IGF1 and leptin levels were quantified in the conditioned media from 1 × 105 MSCs using a
quantitative sandwich ELISA kit (Fine Biotech, China). The PTX3 level was quantified in the same way
from the obtained media using a quantitative sandwich ELISA kit (R&D Systems).
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2.9. In Vivo Experiments
Six-week-old female SCID/Beige mice from SCID/bg, Charles River in Germany were used
in accordance with institutional guidelines and approved protocols. The animals were bilaterally
subcutaneously injected with a mixture of 5 × 105 MSCs and 1x106 NLR-JIMT cells re-suspended in
100 μL serum-free DMEM diluted 1:1 with ECM gel (Sigma-Aldrich). The animals were divided into
five groups according to the type of injected MSC: control group of NLR-JIMT alone (n = 6), MSC-H
(n = 6), MSC-DCIS (n = 6), MSC-CA (n = 6) and MSC-BRCA+ (n = 5). Alternatively, a mixture of
5 × 105 NLR-JIMT cells and 2.5 × 105 MSCs in 100 μL serum-free DMEM diluted 1:1 with ECM gel
(Sigma-Aldrich) was injected bilaterally into the mammary fat pad of SCID/Beige mice. The animals
were also divided into five groups according to the type of injected MSC: control group of NLR-JIMT
alone (n = 3), MSC-H (n = 3), MSC-CA (n = 3), MSC-BRCA+ (2) (n = 3) obtained from breast tissue
where prophylactic mastectomy was performed and MSC-BRCA+ (1) (n = 3) from contralateral breast
of the same patient with confirmed relapsed invasive ductal carcinoma (pT1bpNx). The animals were
regularly inspected for tumor growth, and tumor volume was calculated according to the formula:
volume = (length ×width2)/2. The animals were sacrificed according to the ethical guidelines when the
tumor volume exceeded 1 cm3. The tumors were analyzed histologically and immuno-histochemically
as described below.
All in vivo experiments were performed in the authorized animal facility under license No.
SK UCH 02017 and approved by the institutional ethic committee and by the national competent
authority of the State Veterinary and Food Administration of the Slovak Republic (Registration Number
Ro:1976/17-221) in compliance with Directive 2010/63/EU of the European Parliament and the European
Council and Regulation 377/2012 for the protection of animals used for scientific purposes.
2.10. The Immunofluorescence Analysis of Fresh Cryosections
Tissues were embedded in Tissue-Tek (Sakura Finetek Europe, Alphen aan den Rijn, Netherlands),
snap-frozen on dry ice and then cut into 10 μm sections on cryostat. The sections were gently washed
three times with phosphate-buffered saline (PBS), fixed with 4% PFA for 15 min, washed three times
in PBS and then permeabilized with 0.05% Triton X-100 in PBS for 15 min. The washed sections
were incubated with ROTI protein free blocking solution (Carl Roth, Germany) for 30 min at 37 ◦C.
Staining was performed by incubation with primary antibody Actin-AF488 (1:500, diluted in ROTI) for
1 h at 37 ◦C and then with DAPI (1:500) for 15 min at 37 ◦C to stain the nuclei. Finally, the slides were
washed three times with PBS, and Fluormount-G® medium (SouthernBiotech, Birmingham, AL, USA)
was used to mount the coverslips. The staining patterns were analyzed using a Zeiss fluorescent
microscope and automated imaging Metafer (MetaSystems GmbH, Altlussheim, Germany) (630×
magnification).
2.11. Immunohistochemistry
Formalin-fixed, paraffin-embedded tumor tissues were cut into 5-μm sections. De-parafinization,
rehydration and epitope retrieval via Target Retrieval solution high-pH (DAKO, Carpinteria, CA, USA)
were performed under PT Link (Pre-Treatment module for tissue Specimens, DAKO) at 96 ◦C for 20 min.
The slides were then washed in FLEX wash buffer (Tris-buffered saline solution containing Tween 20,
pH 7.6) prior to loading onto the automated DAKO Autostainer_Link 48. Endogenous peroxidase was
blocked by 5 min of incubation with FLEX peroxidase Block (DAKO), and sections were then incubated
with primary antibodies, anti-human Ki67 MIB-1, anti-human Vimentin or anti-human smooth
muscle actin (αSMA) for 20 min at RT (FLEX, DAKO). This was followed by incubation with LSAB2
System-HRP, Biotinylated Link for 15 min and then Strepatavidin-HRP for 15 min. Positive staining
was visualized by the brown color from 3.3′-Diaminobenzidine (DAB substrate-chromogen solution,
DAKO) after 5 min, and counterstaining was performed with hematoxylin (FLEX, DAKO) for 5–8 min.
Sections with DAB-evident double-staining were incubated with other primary antibodies (Vimentin or
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αSMA) for 20 min, and in the same manner with LSAB2 system-HRP. Positive staining was visualized
by Magenta (EnVision FLEX HRP Magenta Substrate Chromogen, DAKO) for 8 min (red color) and
final sample counterstaining was with hematoxylin. The slides were washed between each incubation
with 1× FLEX wash buffer and dehydrated by washing in alcohol, aceton:xylen (1:1) and xylen, each for
10 min. The slides were mounted with Q-D media (Bamed, Czech Republic) and the staining patterns
were analyzed by Axio Scope A1, Zeiss microscope with Axiocam 105 color.
3. Results
3.1. Characterization of Mesenchymal Stromal Cells
Herein, we isolated mesenchymal stromal cells from breast adipose tissue and assigned each isolate
to one of the following four groups schematically depicted in Figure 1: breast adipose tissue-derived
MSCs from healthy donors (MSC-H), MSCs derived from breast adipose tissue from patients with
pre-malignant lesions (MSC-DCIS) and adipose-derived MSCs from tissue adjacent to malignant
lesions (MSC-CA and MSC-BRCA+).
Figure 1. Mesenchymal stromal cells (MSCs) were isolated from four breast adipose tissue origins;
healthy donors (MSC-H), breast cancer patients with non-invasive (MSC-DCIS) or invasive tumors
(MSC-CA), and BRCA+ breast cancer patients (MSC-BRCA+). In breast cancer patients, adipose tissue
at a distance of 1.5-2 cm from the tumor was used.
Each MSC isolate fulfilled the essential minimum criteria for multipotent stromal cells. MSCs were
positive for CD90, CD105 and CD73 (>95%), but did not express CD14, CD20, CD34 and CD45 markers,
as expected (<5% positive cells, representative sample in Figure 2A). Some MSC isolates were subjected
to in vitro differentiation assay to confirm multi-lineage differentiation potential. MSCs readily
differentiated into adipocytes (red stained lipid droplets), osteocytes (red stained calcium deposits) and
chondrocytes (blue stained proteoglycans) under the in vitro culture conditions depicted in Figure 2B.
Each MSC isolate produced actively proliferating cells which adhered to the plastic surface, and all
isolates had fibroblast-like spindle-shape morphology. The phase-contrast photographs and actin
immunofluorescence staining obtained 72 h after seeding revealed no morphological difference in
the MSC-H, MSC-DCIS and MSC-CA groups (Figure 2C left) and also no age-dependent changes
(Figure 2C right).
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Figure 2. (A) MSC-specific marker expression was analyzed by flow cytometry. MSCs expressed
CD73, CD90 and CD105 on their surface, but lacked hematopoietic/endothelial marker expression.
(B) MSC multipotency was analyzed by their differentiation potential into adipocytes, osteocytes,
and chondrocytes. Magnification 100×. (C) MSC phenotype was documented by IncuCyte
ZOOM™ kinetic imaging system and actin immunofluorescent staining (actin - green, DAPI - blue).
The morphology of MSCs obtained from donors with different diagnosis (left) or age (right) did not
differ over the analyzed period. Scale bar 200 μm. One representative picture from each group is shown.
We also compared proliferation rates for individual MSC isolates and correlated these with patient
age, BMI and diagnosis. Even though no significant difference was noted in age-related proliferation,
a slightly lower proliferation trend was observed in the older MCS donors (Figure 3A left). However,
the doubling-time of MSC-CA was significantly higher when compared to MSC-H (Figure 3A middle,
p < 0.05, Mann Whitney test). This could be explained by the lower proliferation trend in older patients
when solely MSC-CA doubling time was analyzed (Figure 3A right). It is well known that MSCs are
endowed with the capacity to migrate towards tumors or the site of injury. Therefore, to see if this
MSC trait could also be affected by tumor proximity, we compared the MSC migration in a standard
wound healing assay. A wounded MSC monolayer was regularly imaged by live-cell kinetic imaging
system and relative wound density was determined by wound confluence after 24 h. All MSC isolates
showed high migratory capacity, with average 24-h wound confluence of 69% for 30–49-year-olds and
62% for those over 50. The migratory process, however, had no significant correlation with patient
diagnosis (Figure 3B left) or age (Figure 3B middle). A moderately better wound healing process was
evidenced in the MSC-DCIS, MSC-CA or MSC-BRCA+ of older patients (Figure 3B right).
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Figure 3. Functional changes in cancer patient adipose tissue-derived MSCs (A) Left: MSC
doubling-time in all MSC isolates had increasing tendency in older donors, but this tendency was not
statistically significant. Middle: Based on the diagnosis of MSC donors, we observed significantly
longer doubling-time in MSCs isolated from patients with invasive cancer compared to healthy MSCs
(* p < 0.05; Mann-Whitney test). Right: The trend of increased doubling-time was present also in
the MSC-CA group. (B) MSC migration potential analysis based on diagnosis (left), age in all MSC
groups (middle) or age in solely cancer patients (right) showed no statistically significant differences.
MSCs used for analysis did not exceed 10th passage.
In an aspiration to analyze the expression profile of mesenchymal stromal cells derived from
different origin, RT2 Profiler™ PCR array for human mesenchymal stem cell expression profiles
was conducted on representative isolates from each group. The common alterations were noted in
the MSC-DCIS and MSC-CA expression profiles (Figure 4A). These included; (1) up-regulation of
brain-derived neurotrophic factor (BDNF), neurogenic locus notch homolog protein 1 (NOTCH1) and
cytoskeletal Vimentin and (2) down-regulation of growth differentiation factor 15 (GDF15), insulin-like
growth factor 1 (IGF1), matrix metallopeptidase 2 (MMP2), platelet-derived growth factor receptor β
(PDGFRB) and transforming growth factor β3 (TGFB3). In addition, the MSC-BRCA+ cells exhibited
down-regulation of Bone morphogenic protein 4 (BMP4) and up-regulation of SRY-box 9 (SOX9) and
vascular cell adhesion molecule 1 (VCAM1). To examine how the MSC isolates within each group
resemble each other in terms of expression profile, two different patient isolates from each group were
compared. While the expression of mesenchymal stem cell markers in healthy donors was similar,
with only a few genes being expressed differentially (Figure 4B left), the expression profiles in the
MSC-CA (Figure 4B middle) and MSC-BRCA+ groups (Figure 4B right) were considerably different.
This suggests that not only adjacent stroma but distant adipose tissue is affected by the presence of
tumor mass as well and these changes remain in the MSCs even after the tumor-secreted factors are no
longer present, as suggested by the altered expression profiles even after a certain time of culturing.
However, if these tumor-caused changes are permanently retained in MSCs, such altered MSCs may
later contribute to (or even cause) tumor recurrence.
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Figure 4. Expression profiles of healthy and cancer patient adipose tissue-derived MSCs. (A) RT2
Profiler™ PCR human mesenchymal stem cells array of individual MSC isolates used in in vivo study
revealed several gene expression changes. (B) Scatter plot of mesenchymal stem cell gene expression at
the mRNA level comparing two different healthy (left), cancer (middle) and BRCA+ isolates (right).
Lateral diagonal lines indicate a 2-fold increase or decrease. Results were obtained using the RT2
Profiler PCR Array Data Analysis software (at Qiagen data analysis web portal). MSCs used for analysis
did not exceed 10th passage.
Further, we performed ELISA assays on more isolates to prevent misleading results caused by
differences between individual MSC isolates. We have shown significantly lower concentrations of
IGF1 in MSC-CA and MSC-BRCA+ (Figure 5A). As the molecular interplay between IGF1 and leptin,
as well as its association with the pathogenesis of breast cancer, was shown previously, we have also
analyzed the level of leptin which was significantly decreased in the group of MSC-CA (Figure 5B).
After observing that the secretion of analyzed factors was decreased in cancer patient-derived MSCs,
we were intrigued to see whether MSC-CA generally release less cytokines compared to MSC-H.
The relative levels of human cytokines and chemokines in MSC culture medium were determined via
a cytokine array kit. We were able to detect only nine out of 105 cytokines in MSC-CA media after
48-h culture compared to 20 out of 105 in MSC-H (Figure 5C). To see if this halted cytokine production
could be connected to the tumor-released factors present in the tumor-adjacent adipose tissue used for
MSC-CA isolation, we cultured healthy MSCs in NLR-MDA231 conditioned medium (CM-BCC) for 2
weeks. The analysis of the exemplary cytokine PTX3 concentration released to the media showed that
it was decreased in MSC-H cultured in CM-BCC compared to the same isolate cultured in standard
growth control media (Figure 5D).
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Figure 5. Secretion profile of cancer patient adipose tissue-derived MSCs is halted by tumor cell-secreted
factors. (A) Decreased expression of IGF1 correlated with decreased IGF1 concentration detected in
MSC-CA cell media (* p < 0.05; ** p < 0.01; Mann–Whitney test). (B) Leptin concentration in MSC-CA was
also lower compared to MSC-H. The IGF1 and leptin concentration was measured by ELISA test in MSC
medium after 48 h of culture (* p < 0.05; ** p < 0.01; Mann–Whitney test). (C) Cytokine analysis revealed a
decreased release of cytokines and chemokines in MSC-CA isolate. The relative change in analyte level
between MSC groups was determined by subtraction of each pair of capture antibody from the reference
spot signal on the corresponding membrane. (D) The PTX3 concentration was decreased in healthy MSCs
cultured for 2 weeks in NLR-MDA231 conditioned media. The concentration of PTX3 was measured by
ELISA test in MSC medium after 48 h. MSCs used for analysis did not exceed 10th passage.
3.2. MSC Interactions with Breast Cancer Cells
After seeing that the cytokine production in MSC-CA is seemingly halted, we speculated different
ways of communication between MSCs and tumor cells. We looked at the presence of direct cell-to-cell
contacts in MSC-breast cancer cell co-culture and observed thin plasma membrane structures formed
between cancer cells and MSC, which could allow cellular cross-talk leading to alteration of cell
properties (Figure 6A). The altered functions and phenotype of breast cancer cells were analyzed in
co-culture with MSCs of different origins. Direct co-culture of MSCs with breast cancer cells resulted
in a more mesenchymal-like morphology of NLR-T47D and NLR-JIMT cells (Figure 6B) and their
proliferation, regardless of the co-cultured MSC origin, was increased (Figure 6C middle, right).
The NLR-MDA231 cell proliferation in vitro, however, was not affected by direct contact with MSCs
(Figure 6C left).
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Figure 6. MSC–tumor cell interactions in 2D in vitro conditions. (A) Thin plasma membrane structures
are formed between cancer cells and MSCs in co-culture allowing cell-to-cell communication and
signaling. Magnification 200×. Cytoplasmic actin was stained green, nuclei were stained with DAPI
(blue). The nuclei of tumor cells also expressed red fluorescent protein, therefore they appear as
magenta colored. (B) MSC co-culture with tumor cells expressing red fluorescent nuclear protein
resulted in more mesenchymal-like cell morphology of co-cultured NLR-T47D and NLR-JIMT cells.
Scale bar: 200 μm. (C) Direct 7-day co-culture of NLR-JIMT and NLR-T47D breast cancer cells with
MSCs of different origins highlighted the supportive role of MSCs in tumor cell proliferation, but no
diagnosis-specific effects on proliferation were observed. NLR-MDA231 proliferation was not enhanced
by the presence of MSCs.
To test the MSCs’ effect on NLR-JIMT and NLR-T47D cell proliferation in a more relevant in vitro
model, we proceeded to co-culture in 3D non-adherent culture conditions (Figure 7A). Although in
NLR-T47D co-culture the spheroid size was bigger, the structure was less compact, and the luminescent
assay showed significantly less ATP in all MSC groups (Figure 7B left). NLR-JIMT-MSC co-culture in 3D
conditions showed MSC support of tumor cell proliferation, and this was also confirmed by luminescent
assay (Figure 7B right). While this leads to the assumption that the MSC-mediated augmentation of
cancer cell proliferation is cell-line specific, there was no difference in effect regarding whether the
MSCs were isolated from the adipose tissue of healthy donors or cancer patients. To gain deeper
insight into how the MSCs affect breast tumor cells, the invasion profiles of both MSC populations in
co-culture with tumor cells were evaluated in IncuCyte® Scratch Wound Invasion assay. Interestingly,
239
Cells 2020, 9, 480
MSC-CA invaded the 50% ECM much more rapidly than MSC-H and, moreover, they augmented the
invasion of NLR-MDA231 cells as well (Figure 7C).
Figure 7. Faster invading cancer patient-derived MSCs are followed by more rapidly invading
tumor cells. (A) Monoculture vs. co-culture in 3D non-adherent culture conditions showed less
compact NLR-T47D-MSC spheroids and bigger NLR-JIMT-MSC spheroids, but no difference between
MSC isolates was observed. Scale bar: 100 μm. Breast cancer cells—red color, MSCs—unstained.
(B) Luminometric measurement of spheroid cultures after 7 days revealed significantly lower ATP
amount in NLR-T47D-MSC co-culture and higher ATP amount in NLR-JIMT-MSC co-culture (* p <
0.05; ** p < 0.01; Mann–Whitney test). In the control group (only breast cancer cells without MSC), 8
samples were analyzed. In each group with MSC, 4 spheroids were analyzed. (C) MSC-CA exhibited
increased invasion potential in Scratch wound invasion assay after 24 or 48 h. The invasion of tumor
cells was also increased in co-culture with MSC-CA compared to MSC-H (1 × 104 MSCs + 2 × 104
NLR-MDA231/NLR-T47D and 1.5 × 104 MSCs + 3 × 104 NLR-JIMT were seeded on Matrigel coated
96-well plates and covered with 50% Matrigel). Scale bar: 200 μm. MSCs used for analysis did not
exceed 10th passage. MSCs were stained with Vybrant™ CFDA SE Cell Tracer Kit (green color), breast
cancer cell lines expressed red fluorescent protein.
3.3. The Effect of MSCs on Tumor Growth In Vivo
To evaluate the effects of MSCs on tumorigenicity in vivo, immuno-compromised SCID/Beige mice
were subcutaneously injected solely with NLR-JIMT cells or with NLR-JIMT cells mixed with MSCs
from different origins (Figure 8A). The NLR-JIMT cell line represents the HER2-enriched non-luminal
tumor type characterized by aggressive growth with intermediate prognosis. The confirmed insensitivity
to HER-2 inhibiting drugs (trastuzumab and pertuzumab) makes it a valuable experimental model for
studies of resistance mechanisms. Subsequent tumor volume analysis on Day 15 revealed the supportive
effect of MSCs on tumor growth in the co-injected xenografts compared to those composed solely of
tumor cells (Figure 8B). In addition, the NLR-JIMT co-injected with cancer patient-derived MSC-BRCA+,
MSC-DCIS and MSC-CA produced a significantly higher tumor volume than NLR-JIMT co-injected with
healthy donor-derived MSC-H (p < 0.01 in MSC-H vs. MSC-CA and MSC-H vs. MSC-BRCA+; p < 0.05
in MSC-H vs. MSC-DCIS). The highest pro-tumorigenic effect, however, was observed in xenografts
formed by NLR-JIMT cells co-injected with invasive cancer patient-derived MSC-CA. When the NLR-JIMT
were co-injected with MSC-CA, the average tumor volume on Day 15 was 338.3 mm3 compared to 76.6
mm3 volume of the MSC-H co-injected tumors. This demonstrates a striking MSC-CA pro-tumorigenic
effect. The experimental mice were sacrificed when tumors reached more than 11 mm in any dimension.
Subsequent histological analysis of the tumor xenografts showed decreased Ki67 expression in the center
of xenografts formed by NLR-JIMT co-injected with cancer patient-derived MSC-BRCA+, MSC-DCIS
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and MSC-CA than in NLR-JIMT co-injected with healthy donor-derived MSC-H, or NLR-JIMT alone
(Figure 8C, 1st column). This is explained by MSC localization in the xenograft center, and the subsequent
denser micro-environment surrounding the tumor cells.
Figure 8. Cancer patient adipose tissue-derived MSCs showed a pro-tumorigenic effect on subcutaneous
tumor xenografts in vivo. (A) Actin immunofluorescence staining of mice xenograft cryosection shows
xenograft composition formed by tumor cells and MSCs (left—xenograft periphery, right—xenograft
center; red—cancer cell nuclei, green—actin cytoplasm staining, blue - nuclei staining with DAPI.
Magnification 630×.) (B) 5 × 105 MSCs of different origin were subcutaneously co-injected with 1
× 106 NLR-JIMT cells in immuno-compromised SCID/Beige mice. Tumor volume examination on
Day 15 revealed profound supportive effect of MSCs on tumor growth in the co-injected xenografts.
Xenografts composed solely of tumor cells failed to induce significant tumor volume in the analyzed
period. Tumor volume was calculated by formula: volume= (length × width2)/2 (* p < 0.05, ** p <
0.01, Man-Whitney test). The significantly most supportive effect was observed in mice injected with
NLR-JIMT +MSC-CA. (C) Detection of Ki67, αSMA and VIM markers by immuno-histochemistry in
tumor tissue sections. Mice were sacrificed when the tumor xenograft reached 1 cm3. Xenografts were
fixed with formaldehyde, embedded in paraffin and processed for immuno-histochemical staining with
monoclonal antibodies. Representative images of tumors formed by NLR-JIMT co-injected with cancer
patient-derived MSCs (BRCA+, DCIS, CA) showed lower Ki67 positivity in the tumor center than in
NLR-JIMT co-injected with healthy donor-derived MSC-H. The αSMA and Vimentin (VIM) staining
showed that mainly the MSC-CA and MSC-BRCA+ attempted to form aligned pathway-like structures
around the tumor cells. Magnification 200×. (D) Representative Ki67-stained pictures of xenograft
periphery showed clusters of tumor cells invading surrounding stroma in tumors formed by NLR-JIMT
co-injected with MSCs (MSC-H, -DCIS, -BRCA) and collective cell migration with a distinguishable
invasive front was observed in the group co-injected with MSC-CA. (E) Immuno-histochemical staining
of αSMA and Vimentin revealed up-regulation in tumor cells located in the invasive front of the
xenografts co-injected with MSC-CA. This suggests the epithelial-to-mesenchymal transition of tumor
cells. Asterisks identify smaller adipocytes with dilated inter-cellular spaces near the tumor invasive
front. (F) Detail of the xenograft periphery showing Vimentin positivity in tumor cells.
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The αSMA and Vimentin staining in Figure 8C suggests that in tumors injected with cancer
patient-derived MSCs, and particularly in those with MSC-BRCA+, the MSCs attempt to form aligned
structures around the tumor cells that resemble cellular pathways. α-SMA was used to visualize the
localization of MSCs within the tumor xenografts, and although human αSMA antibody was used,
the mouse endothelial cells in xenografts formed by NLR-JIMT cells were stained as well. Therefore,
additional staining with the MSC marker Vimentin was performed, and confirmed that the αSMA
positive cells were indeed MSCs. This was independently evaluated by a pathologist (MA) and
histology specialist (MBu) who confirmed specific MSC-positive staining in the carcinoma-associated
MSC-containing xenografts. In addition, Figure 8D confirms that Ki67 staining of the xenograft
periphery depicts clusters of tumor cells invading surrounding tissue in NLR-JIMT co-injected with
MSC-H, MSC-BRCA and MSC-DCIS xenografts. This manifest substantial effect of these MSCs on
tumor cell invasiveness and also highlights collective cell-scattering, where the tumor cells detach
and spread in small clusters. In contrast, the histological analysis of tumors formed by NLR-JIMT
co-injected with MSC-CA showed collective cell migration with a distinguishable invasive front
(Figure 8E; indicated with arrow). These tumor cells were in immediate proximity to adipocytes and
spread along adipocyte intercellular spaces. Moreover, the adipocytes closest to the tumor invasive
front are clearly smaller and have wider intercellular spaces (Figure 8E; indicated with asterisks).
Finally, Vimentin staining in these tumor cells suggested epithelial-to-mesenchymal transition (EMT).
Vimentin staining was positive in the tumor cell cytoplasm of xenografts co-injected with MSC-CA
located in the invasive front (Figure 8F). Ki67 staining quantification revealed its uneven distribution
throughout the tissue section, but its expression in all groups proved similar when a greater number of
zones was investigated (Table 1).
Table 1. Ki67 score in tumor xenografts. Ki67 expression analysis in several areas of tissue section
revealed its uneven distribution throughout the xenograft. When a higher number of zones was
investigated, the Ki67 staining quantification showed similar expression in all groups.





















In order to verify the observed effects in a clinically more relevant model, an orthotopic model of
mammary carcinogenesis was used (Figure 9A). The mixture of NLR-JIMT and MSC-CA resulted in a
higher tumor volume in the mammary glands of injected mice compared to the mixture of NLR-JIMT
and MSC-H. The co-injection of tumor cells with MSC-BRCA (2) obtained from patient breast tissue
where prophylactic mastectomy was performed and MSC-BRCA (1) from contralateral breast of
the same patient with confirmed relapsed invasive ductal carcinoma (pT1bpNx) demonstrated that
MSCs isolated from the adipose tissue adjacent to a tumor mass have a more aggressive phenotype
and augmented tumor volume in NLR-JIMT + MSC-BRCA (1) (Figure 9B). Ki67 staining of the
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xenograft periphery confirmed the invasive character of tumor cells co-injected with MSCs isolated
from tumor-adjacent adipose tissue. Interestingly, the increased metastatic potential in the presence of
MSC-CA was confirmed also by the increased innervation of tumor xenografts. The perineural and
intraneural invasion of CK7- and vimentin-positive tumor cells was detected (Figure 9C), as well as
the presence of tumor cells inside the blood vessels (Figure 9D).
Figure 9. Pro-tumorigenic effect of MSC-CA in orthotopic mouse model. (A) Mixture of 5 ×
105 NLR-JIMT cells and 2.5 × 105 MSCs in 100 μL serum-free DMEM diluted 1:1 with ECM gel
(Sigma-Aldrich) was injected bilaterally into mammary fat pad of SCID/Beige mice. The animals were
divided into five groups according to the type of injected MSC: control group of NLR-JIMT alone (n = 6),
MSC-H (n = 6), MSC-CA (n = 6), MSC-BRCA (2) (n = 6) obtained from breast tissue where prophylactic
mastectomy was performed and MSC-BRCA (1) (n = 6) from contralateral breast of the same patient
with confirmed relapsed invasive ductal carcinoma. Tumor volume was calculated according to the
formula: volume = (length × width2)/2. The animals were sacrificed when the tumor volume exceeded
1 cm3. The most supportive effect was observed in mice injected with NLR-JIMT + MSC-CA and
MSC-BRCA (1). (B) Ki67 staining of xenograft periphery showed collective cell invasion in the group
co-injected with MSC-CA. This manner of invasion was also observed in the MSC-BRCA (1), but was
lacking in the MSC-BRCA (2) co-injected group. While both MSC-BRCA isolates come from the same
patient, the former were isolated from a breast with relapsed ductal carcinoma and the later from a
contralateral healthy breast where prophylactic mastectomy was performed. MSCs derived from breast
adipose tissue with confirmed presence of tumor (MSC-BRCA (1)) increased the invasion of tumor
cells in xenograft periphery. (C) Nerve fibers were detected in serial sections of NLR-JIMT +MSC-CA
orthotopic xenografts using IHC staining with specific neuronal marker PGP9.5. The perineural and
intraneural tumor cell invasion (yellow arrow pointing at invading single tumor cell in the left picture
and group of tumor cells in the right picture) was present only in the MSC-CA group. (D) CK7 antibody
(breast cancer marker) staining confirmed the presence of tumor cells in the perineural space and also
inside the blood vessel.
4. Discussion
Tumor–stroma interaction, and particularly the cytokine–cytokine receptor interaction pathway,
is significantly altered in highly aggressive tumors [21]. While many studies have evaluated the role of
mesenchymal stromal cells in the tumor microenvironment [22], the majority were based on adipose
MSCs from non-breast origins [23,24]. In contrast, we compared normal breast adipose tissue-derived
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MSCs and their tumor-activated counterparts and revealed phenotypic, molecular and functional
changes which determined the stromal cell activation status.
There is a growing substantial interest in identifying MSC proliferation properties for future
application in cell therapy and tissue engineering [25,26]. Herein, the growth kinetics and population
doubling-time were influenced by age when younger and older donors were compared, as shown
by others [27,28]. While the correlation between MSC doubling-time and age or BMI status in MSC
donors was not significant at first sight, the separate analysis of doubling-time in younger and older
patient groups for healthy and cancer patient-derived MSCs highlighted an increased doubling-time in
the older group. Apparently, the conflicting observations are likely related to increased doubling-time
in MSC-CA compared to MSC-H.
MSC morphological analysis did not reveal any changes related to diagnosis or age. The changes
might be evident only when MSCs differentiate into CAF in the tumor micro-environment [10],
while adjacent adipose tissue-derived MSC morphology remains unaffected or the tumor cell influence
in the culture is lacking.
In addition to doubling-time changes, we also identified altered gene expression and cytokine
production in breast cancer-derived MSCs. The most evident was the down-regulation of GDF5, GDF6,
IGF1, PDGFRB and TGFB3 genes in MSC-CA compared to MSC-H. Morales et al. [21] identified 76
differentially expressed genes associated with the metastasis of relapsed primary tumors. Two of these,
down-regulated GDF5 and TGFB3, corresponded to the results observed in our analysis. NOTCH1
expression has also been implicated in cancer cell metastasis, and breast cancer patients positive for
NOTCH1 have experienced shorter disease-free survival [29,30]. Here, it is most likely that adipose
tissue’s close proximity to a breast tumor correlates with the observed MSC expression changes,
and these could well explain the increased in vivo invasion of NLR-JIMT +MSC-CA tumor xenografts.
It was reported that BMP4 possesses both tumor-suppressive and oncogenic properties in breast
cancer and that it is a potent suppressor of breast cancer metastasis [31,32]. Therefore, the decreased
BMP4 expression in MSC-BRCA+ could contribute to the in vivo cell cluster migration we observed in
the more distant parts of tumors. In addition, BMP4 down-regulation in the tumor micro-environment
could lead to the formation of these clusters and thus increase tumor cell metastatic ability. Furthermore,
increased SOX9 expression in MSC-BRCA+ correlates with prognostic significance in invasive ductal
carcinoma and metastatic breast cancer [33]. Therefore, we assume it can also be associated with the
observed invasive nature of NLR-JIMT +MSC-BRCA+ tumors. We also suggest that the up-regulation
of brain-derived neurotrophic factor (BDNF), which supports innervation in tumor xenografts, could
be a promising determinant of tumor cell invasion and metastasis. We propose that mesenchymal
stromal cells in the tumor proximity are pushed by tumor cells to help in nerve recruitment and,
interestingly, these alterations in MSCs become permanent as they remain even when the tumor is not
present anymore.
In MSC-CA and MSC-DCIS, here we determined the decreased expression of GDF15 and IGF,
but this conflicts with published results which show increased expression of these genes in the tumor
micro-environment [34].
We propose that the decreased cytokine production by MSC-CA could correlate with tumor
presence in adipose tissue, as also healthy MSCs cultured in NLR-MDA231 conditioned media
showed altered cytokine production. However, tumor cells co-cultured with MSC-CA exhibited a
more aggressive phenotype in vitro and in vivo, which could be associated with direct cell-to-cell
communication and connections, indicating the presence of nanotubes in MSC–tumor cell cultures.
Moreover, histological tumor xenograft analysis revealed functional changes associated with
epithelial-to-mesenchymal transition induction and increased tumor cell invasion in co-culture with
MSC-CA. While the collective migration of tumor cells was combined with high Ki67 and VIM positivity
in the invasive front, the cell invasion differed in tumor cells co-injected with MSC-DCIS compared to
MSC-CA. This identifies that MSC-CA have a more aggressive phenotype.
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Vimentin up-regulation is an EMT-specific marker of increased cancer cell motility and
migration [35,36]; therefore, its positive staining in NLR-JIMT-MSC-CA xenograft suggests significant
functional changes in cancer patients’ MSCs where breast adipose tissue has close proximity to the
tumor. The functional changes are also suggested by the smaller adipocytes and wider intercellular
spaces in close proximity to the xenograft invasive front, suggesting additional extracellular matrix
alterations [37].
Finally, the combined data provide the conclusion that MSCs in cancer patient adipose tissue have
inherently altered expression profiles and functional characteristics which enhance their ability
to support in vivo tumor cell propagation. Moreover, the adipose tissue MSCs derived from
closely adjacent tumor tissue increased the volume of tumor xenografts when co-injected with
NLR-JIMT subcutaneously and orthotopically, and also supported the release of tumor cell clusters.
Orthotopic model confirmed the pro-tumorigenic phenotype of MSC-CA which induced the perineural
invasion of tumor cells. Our data suggest the capacity of cancer patient-derived MSCs to support cell
scattering and invasion by involving tumor cell epithelial-to-mesenchymal transition.
5. Conclusions
To the best of our knowledge, we have described permanent proliferative and functional changes
in tumor-adjacent adipose tissue-derived MSCs for the first time. The analysis of MSCs isolated from
breast cancer patients provides improved understanding of the changes provoked in adipose tissue
by close proximity to the tumor and also identifies MSCs’ role in the promotion and progression of
tumor growth.
Herein, we showed that the micro-environment of adipose tissue closely adjacent to breast tumor
tissue is composed of tumor-exposed MSCs which differ in doubling-time, expression profile, cytokine
production and tumor-promoting ability shown by perineural invasion in vivo compared to the MSCs
in healthy adipose tissue. Further study focused on the specific molecular pathways responsible for the
activation and re-programming of MSCs exposed to tumor micro-environment should reveal potential
therapeutic strategies which will block the tumor-induced alterations caused to adjacent adipose tissue.
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Abstract: There is an active search for the ideal strategy to potentialize the effects of Mesenchymal
Stem-Cells (MSCs) over the immune system. Also, part of the scientific community is seeking
to elucidate the therapeutic potential of MSCs secretome and its extracellular vesicles (EVs), in
order to avoid the complexity of a cellular therapy. Here, we investigate the effects of human
adipose MSCs (AMSCs) licensing with INF-γ and TLR3 agonist over AMSCs proliferation, migration,
as well as the immunomodulatory function. Furthermore, we evaluated how the licensing of
AMSCs affected the immunomodulatory function of AMSC derived-secretome, including their
EVs. INF-γ licensed-AMSCs presented an elevated expression of indoleamine 2,3-dioxygenase (IDO),
accompanied by increased ICAM-1, as well as a higher immunosuppressive potential, compared to
unlicensed AMSCs. Interestingly, the conditioned medium obtained from INF-γ licensed-AMSCs
also revealed a slightly superior immunosuppressive potential, compared to other licensing strategies.
Therefore, unlicensed and INF-γ licensed-AMSCs groups were used to isolate EVs. Interestingly,
EVs isolated from both groups displayed similar capacity to inhibit T-cell proliferation. EVs isolated
from both groups shared similar TGF-β and Galectin-1 mRNA content but only EVs derived from
INF-γ licensed-AMSCs expressed IDO mRNA. In summary, we demonstrated that INF-γ licensing
of AMSCs provides an immunosuppressive advantage both from a cell-cell contact-dependent
perspective, as well as in a cell-free context. Interestingly, EVs derived from unlicensed and INF-γ
licensed-AMSCs have similar ability to control activated T-cell proliferation. These results contribute
towards the development of new strategies to control the immune response based on AMSCs or their
derived products.
Keywords: mesenchymal stem cells; T-cells; conditioned medium; extracellular vesicles; TLR; INF-γ
1. Introduction
Mesenchymal Stem-Cells (MSCs) are adult multipotent cells, which present a series of important
biological properties, rendering them promising tools for cell-based therapy. One of the critical
properties of these cells—which has attracted the attention of the scientific community decades ago—is
the ability of MSCs to control the immune response. Specifically, regarding T-cells, MSCs exert their
immunomodulatory effects through a broad range of mechanisms, including cell contact, secretion of
anti-inflammatory molecules and induction of regulatory T-cells [1].
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Over the last few years, the field of cellular therapy using MSCs to control immune-related
diseases has grown enormously [2]. The use of MSCs to treat steroid-refractory acute Graft
Versus Host Disease (aGVHD) represents one of the many explored applications of MSC-based
therapy. Nevertheless, despite the promising potential of MSCs, there is a consensus that the clinical
response to this therapeutic modality is not homogenous [3–5]. Therefore, in order to enhance the
immunomodulatory function of MSCs and achieve more consistent results, several strategies have
been sought. Among them, the activation and licensing of MSCs [6] with inflammatory cytokines
such as INF-γ [7,8] and Toll-like receptor (TLR) agonists [9,10] has been heavily investigated.
In addition to the search for MSCs licensing strategies, another strategy that has also been subject
of intensive discussion is the possibility of establishing cell-free therapies, in which the effects of MSCs
are guaranteed without the need for cellular infusion. Emerging data suggest that MSCs-mediated
effects appear to be partly dependent on paracrine factors, such as proteins and hormones, as well
as on the transference of extracellular vesicles (EVs) to target cells [11,12]. In this scenario, several
researchers are investigating the effects of MSCs-derived secretome and -EVs in various contexts,
in which their parental cells effectively revealed their therapeutic potential. However, information
concerning the influence of MSCs licensing over the immunosuppressive potential of their secretome
and derived EVs is still scarce in the literature.
With this in mind, in the present work we evaluated whether human adipose MSCs (AMSCs)
licensing with INF-γ alone or in combination with Poly (I:C) (a TLR3 agonist) influenced their
phenotype, proliferation, migration capacity and immunosuppressive potential. Furthermore, we
collected the conditioned medium from licensed and unlicensed AMSCs and investigated their
immunosuppressive capacity. Finally, we isolated, characterized and analyzed the immunomodulatory
potential of licensed and unlicensed AMSCs-derived EVs.
2. Materials and Methods
2.1. AMSCs Obtention, Culture and Characterization
AMSCs (n = 3) were kindly obtained from Cellseq Solutions, as control cell batches. Each lot of
these cells was obtained from a single, healthy donor after lipoaspiration procedure. The cells were
cultured in Minimum Essential Medium alpha (alpha-MEM) supplemented with 15% v.v. fetal bovine
serum (FBS—HyClone, Logan, UT, USA), 2 mM glutamine and 100 U/mL penicillin/streptomycin
(Sigma, St. Louis, MO, USA), at 37 ◦C and 5% CO2. Medium was changed every two days and the
cells were split when they reached 80–90% confluence.
AMSCs were phenotypically characterized at 3rd passage by flow cytometry (FACSVerse, BD
Biosciences), using the BD Stemflow™ hMSC Analysis Kit, following manufacturer’s instructions
(Pharmingen, BD Biosciences, Franklin Lakes, NJ, USA). Briefly, control and licensed AMSCs were
incubated with CD105-PerCP-Cy5.5, CD73-APC, CD90-FITC, CD44-PE and with the negative cocktail
markers, which included CD45/CD34/CD11b/CD19/HLA-DR antibodies, all conjugated with PE.
The cells were used between the 3rd to 6th passages for all experiments. This study was
conducted with the approval of the Institutional Ethics Committee of the Faculty of Health Sciences
of the University of Brasilia (35640514.5.0000.0030) and written informed consent was obtained from
all participants.
2.2. AMSCs Licensing
For all performed experiments, we included a control group of untreated AMSCs. Licensing was
performed following three different treatment strategies, which included 48h incubation of AMSCs
with (i) 50 ng/mL of INF-γ; (ii) 1 μg/mL of Poly (I:C); or 50 ng/mL of INF-γ and 1 μg/mL of Poly
(I:C) [13,14]. After treatment, cells were washed with PBS for three times before the beginning of
the experiments.
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2.3. AMSCs Viability and Proliferation
The effect of AMSCs licensing over cellular growth (proliferation and/or viability) was
assessed by MTT [3-(4.5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay, as previously
described [15]. Briefly, cells were plated at 2 × 103 in 96-well plates and submitted to the different
licensing protocols, as described above. Then, cells were washed 3 times with PBS and received basal
medium. Cell viability assay was performed at days 1, 3 and 5, counted from the end of the licensing
procedure. In these time-points, 20 μL of MTT (5 mg/mL) was added in each well and the plates
incubated for 3 h. After this period, MTT and medium were removed and replaced by DMSO and
the plate was homogenized for 15 min. The optical density was read on a DTX 800 Series Multimode
Detector (Beckman Coulter, Brea, CA, USA) at 570 nm.
2.4. AMSCs Migration
AMSCs migration was investigated following the licensing procedure, by wound scratch
assay [16]. To this end, 2 × 105 AMSCs were seeded in 6 well plates and licensed for 48 h, under the
different licensing conditions. Next, AMSCs monolayers were washed with PBS and then scratched
across the center of the well using a 200 μL pipette tip. AMSCs were maintained in alpha-MEM without
FBS or in alpha-MEM containing 2% FBS, as a positive control. The scratch zones were photographed
at 0, 12 and 24 h post-scratch using a Zeiss Primo Vert microscope equipped with a digital camera (Carl
Zeiss, Heidelberg, Germany). The open area post-scratch was measured using the software ImageJ
(National Institutes of Health, Bethesda, MD, USA).
2.5. Isolation and Activation of Peripheral Blood Mononuclear Cells (PBMCs)
Peripheral Blood Mononuclear Cells (PBMCs) were obtained from healthy volunteers by
centrifugation using Ficoll-Paque PLUS (Amersham Biosciences, Uppsala, Sweden). After isolation,
PBMCs were activated with 5 μg/mL of Phytohaemagglutinin (PHA, Sigma-Aldrich, St. Louis,
MO, USA) and stained with 2.5 μM carboxyfluorescein succinimidyl ester (CFSE), as previously
described [17–19]. T-cell proliferation was analyzed by Flow Cytometry (BD Biosciences, San Jose,
CA, USA) after culturing PBMCs for 5 days with either AMSCs, AMSCs-conditioned medium or EVs
isolated from unlicensed and licensed AMSCs, as detailed below.
2.6. AMSCs Co-Culture with PBMCs
The immunosuppressive effect of licensed and unlicensed AMSCs was determined by flow
cytometry. Following AMSCs licensing, the medium was removed, cells were washed 3 times with
PBS and immediately co-cultured with 3 × 105 PHA-activated PBMCs (1:10 ratio) for 5 days [17,18].
Then, PBMCs were recovered and stained with APC-conjugated anti-CD3 antibody and assessed for
T-cell proliferation.
2.7. PBMCs Culture with AMSCs-Derived Conditioned Medium
To analyze the effects of the medium obtained from the different strategies of AMSCs licensing
over T-cell proliferation, we removed the supernatants after the AMSCs licensing protocols and added
fresh RPMI medium supplemented with 10% FBS to AMSCs cultures. After 24 h, the medium was
collected, centrifuged and used to culture 3 × 105 PBMCs activated with 5 μg/mL PHA [19]. In the
5th day of culture, PBMCs were collected, stained with anti-CD3 and T-cell proliferation determined
by Flow Cytometry.
2.8. Vascular Cell Adhesion Protein 1 (VCAM-1) and Intercellular Adhesion Molecule 1 (ICAM-1) Expression
on AMSCs
Considering the importance of the adhesion molecules in MSCs-mediated immunosuppression,
we investigated the expression of ICAM-1 (CD54) and VCAM-1 (CD106) in licensed and unlicensed
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AMSCs, using monoclonal antibodies. Briefly, after licensing, cells were washed with PBS, harvested
and stained with anti-CD54 (conjugated with allophycocyanin—APC), anti-CD106 (conjugated
with fluorescein isothiocyanate—FITC) or isotype controls (eBioscience, San Diego, CA, USA).
After incubation with the antibodies, the cells were analyzed by Flow Cytometry.
2.9. EVs Isolation and Characterization
After observing that the most suppressive conditioned medium was obtained from INF-γ licensed
AMSCs, we isolated EVs from this group, as well as from unlicensed AMSCs, in order to assess their
capacity of controlling activated T-cell proliferation. Briefly, AMSCs were cultured until confluence
in 75 cm5 flasks containing 10 mL basal medium supplemented with 10% v.v. of microvesicles-free
FBS. When AMSCs reached confluence they were licensed for 24 h, the supernatant was collected
and, EV isolation was immediately performed using total exosome isolation reagent (Invitrogen,
Life Technologies, Carlsbad, CA, USA), as described by the manufacturer. Cell culture medium was
centrifuged at 2000 g for 30 min to remove cellular debris, mixed with 5 mL of total exosome isolation
reagent and incubated at 4 ◦C overnight. After incubation, samples were centrifuged at 10,000× g for
1 h and the pellets containing EVs were resuspended in PBS. Protein concentration was determined by
Bradford method [20].
EVs were initially characterized according to average diameter using Zetasizer Nano ZS (Malvern
Instruments, Malvern, UK), following to manufacturer’s instructions. EVs diameter was also
determined by transmission electron microscopy (TEM). For this, 5μL of EVs samples were mounted
on formvar copper grids and fixed in Karnovsky EM fixative solution (2% formaldehyde and 2.5%
glutaraldehyde in 0.1 mol/L sodium cacodylate buffer, pH 7.4). Samples were then negatively stained
using 2% aqueous phosphotungstic acid (PTA), examined and photographed with a JEOL JEM1011
transmission electron microscope operating at 80 kV.
EVs were also phenotypically characterized by flow cytometry using CD105-PerCP-Cy5.5 and
CD90- FITC antibodies. For this, EVs were coupled with 4-μm-diameter aldehyde/sulfate latex beads
and then blocked by incubation with FBS. EVs-coated beads were washed three times in PBS and
resuspended in 50 μL of PBS. Next, beads were incubated with the aforementioned antibodies and
analyzed by Flow Cytometry.
2.10. Immunosuppressive Effects of AMSCs-Derived EVs
To access the immunosuppressive potential of AMSCs-derived EVs, 3 × 105 PBMCs were activated
with 5 μg/mL of PHA and cultured for 5 days with 0.25, 0.75 or 3.0 μg of EVs isolated from both
unlicensed and INF-γ licensed AMSCs [21]. After this period, PBMCs were collected, stained with
anti-CD3 and T-cell proliferation was determined by Flow Cytometry.
2.11. RNA Isolation and Real-Time PCR
Gene expression analysis was performed in unlicensed and licensed AMSCs, as well as their EVs.
RNA samples were obtained using Trizol reagent. RNA amount and quality were determined by
NanoDrop 1000 spectrophotometer (Wilmington, DE, USA). One microgram of RNA was converted
to single-stranded cDNA, using the High Capacity Kit (Applied BioSystems, Foster City, CA, USA)
according to manufacturer’s recommendations. Real-time PCR was performed using TaqMan probes
and MasterMix (Applied BioSystems, Foster City, CA, USA), following manufacturer’s instructions.
Real time PCR for TNF (Hs01113624), TGF-β (Hs00998133), IDO (Hs00984148), Galectin-1
(Hs00355202), IL-1β (Hs00174097) and IL-10 (Hs00961622) was run in duplicates and the relative
fold change obtained by the 2−ΔΔCt method [22]. GAPDH was used as internal reference. The median
Ct values of unlicensed AMSCs and their EVs were used as reference. Cycling parameters were 95 ◦C
for 10 min followed by 40 cycles of 95 ◦C for 15 s and 60 ◦C for 1 min.
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2.12. Statistical Analysis
The results are presented as mean ± SEM of three independent experiments. Statistical
analyses were performed using Prism 7 software (GraphPad Software Inc., San Diego, CA, USA).
Statistical significance was calculated using t-test analyses, considering p < 0.05.
3. Results
3.1. INF-γ and/or Poly (I:C) Licensing Maintain AMSCs Phenotype
AMSCs had a typical MSCs immunophenotype, with positive expression of CD44, CD73,
CD90 and CD105 markers and negative expression of CD34, CD45, CD11b, CD19 and HLA-DR.
We also investigated if the licensing treatments with INF-γ and/or Poly (I:C) would alter AMCSs
immunophenotype, however, the phenotypic pattern was maintained in all samples, regardless of the
licensing strategy adopted (Supplementary Figure S1).
3.2. INF-γ and/or Poly (I:C) Licensing did not Influence AMSCs Proliferation
Considering that MSCs immunosuppressive effects are dose-dependent, we evaluated if INF-γ
and/or Poly (I:C) licensing could modulate AMSCs proliferation. Obtained results revealed that none
of the licensing strategies tested modified AMSCs proliferation (Figure 1).
Figure 1. Proliferative capacity of licensed and unlicensed AMSCs. Control AMSCs, AMSCs licensed
with 1 μg/mL of Poly (I:C), AMSCs licensed with 50 ng/mL of INF-γ; and AMSCs licensed with
50 ng/mL of INF-γ and 1 μg/mL of Poly (I:C) were cultured and cell proliferation was assessed by
MTT in the days 3, 5 and 7 of the culture. No difference of proliferation/viability was observed among
the groups. Values represent the means ± SEM. Three independent experiments were performed.
3.3. INF-γ and/or Poly (I:C) Licensing Did not Alter AMSCs Migration
Control and licensed AMSCs were investigated regarding their migration potential by wound
scratch assay, but, once again, we observed that the licensing regimes did not affect the migratory
behavior of AMSCs after 12 h and 24 h (Figure 2).
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Figure 2. Migratory potential of licensed and unlicensed AMSCs. (A) Wound scratch assays for
unlicensed AMSCs, as well as licensed AMSCs treated with either 1 μg/mL Poly (I:C), 50 ng/mL
INF-γ or with both 50 ng/mL of INF-γ and 1 μg/mL of Poly (I:C). Confluent cells were wounded by a
scratch with a pipette tip and cell migration was assessed under the microscope at 12 h and 24 h (B).
Results are presented as mean ± SEM of three independent experiments.
3.4. INF-γ Enhances AMSCs-Mediated Immunomodulation
Consistent with published literature [23], our data revealed that AMSCs co-culture markedly
decreased activated T-cell proliferation (p = 0.0003). Wondering whether licensed AMSCs presented
different immunosuppression effect compared to unlicensed cells, we performed the same co-culture
assay with licensed AMSCs. Interestingly, INF-γ licensed AMSCs presented significantly higher
capacity to inhibit activated T-cell proliferation (p = 0.003). On the other hand, licensing with Poly
(I:C) alone did not influence AMSCs-mediated immunosuppression capacity. Even though we did
not detect a statistically significant difference, the licensing of AMSCs with both Poly (I:C) and INF-γ
increased their suppressive potential in 35% (mean), compared to unlicensed AMSCs (Figure 3A,B).
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Figure 3. Immunosuppressive capacity of licensed AMSCs and their conditioned medium.
(A) unlicensed AMSCs, as well as AMSCs licensed with either 1 μg/mL of Poly (I:C), 50 ng/mL of
INF-γ or with both 50 ng/mL of INF-γ and 1 μg/mL of Poly (I:C) were cocultured with PHA-activated
PBMCs (1:10 ratio) and T-cell proliferation was determined by Flow Cytometry after 5 days. Results are
presented as mean ± SEM of three independent experiments; (B) Representative CFSE histograms
of one AMSCs sample investigated; (C) After AMSCs licensing, medium were discarded, cells were
washed 3 times with PBS and fresh medium was added to each condition. After 24 h, the AMSCs
conditioned medium (from licensed and unlicensed samples) were harvested and used to culture
PHA-activated PBMCs, so that T-cell proliferation could be analyzed after 5 days of treatment.
Results are presented as mean ± SEM of three independent experiments; (D) Representative CFSE
histograms from conditioned medium from one AMSCs sample investigated. * p < 0.05. ** p < 0.01.
*** p < 0.001.
3.5. Conditioned Medium from INF-γ Licensed AMSCs Has Increased Capacity to Control the T-Cell Response
Aiming to further investigate the possible use of the AMSCs secretome in a cell free perspective,
we isolated the conditioned medium of licensed and unlicensed AMSCs and investigated their
immunosuppressive potential. We observed that the conditioned medium obtained from unlicensed
AMSCs suppress T-cell proliferation (p = 0.004). The conditioned medium derived from AMSCs
licensed with Poly (I:C) and INF-γ presented a slightly increased capacity to suppress T-cell
proliferation (p = 0.01) compared to conditioned medium obtained from unlicensed AMSCs (p = 0.01).
Importantly, the conditioned medium isolated from INF-γ licensed AMSCs showed the highest
capacity to inhibit activated T-cell proliferation (p = 0.005) among tested groups (Figure 3C,D).
3.6. INF-γ Enhances ICAM-1 Expression on AMSCs
Considering the importance of adhesion molecules in the context of contact-dependent
MSCs-immunosuppression, we investigated the expression of VCAM-1 and ICAM-1 on licensed
and unlicensed AMSCs. Flow cytometry data of unlicensed AMSCs presented a mean expression of
VCAM-1 and ICAM-1 of 14.38 and 54%, respectively (Figure 4A,C). While none of the licensing
strategies altered the expression of VCAM-1 on AMSCs (Figure 4A,B), ICAM-1 expression was
increased in INF-γ licensed AMSCs (p = 0.01), as well as in INF-γ and Poly (I:C) licensed cells (p = 0.03)
(Figure 4C,D). Interestingly, when we licensed AMSCs using 25, 50 and 100 ng/mL of INF-γ, we
noticed that the effect of this inflammatory factor over the AMSCs expression of ICAM-1 is increased
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(p < 0.01) between lower (25 ng/mL; mean value 95.4%) and higher concentrations (50/100 ng/mL;
mean values 98.3/98.2%) (Figure 4E).
Figure 4. VCAM-1 and ICAM-1 expression of licensed and unlicensed AMSCs. (A) unlicensed AMSCs,
as well as AMSCs licensed with either 1 μg/mL of Poly (I:C), 50 ng/mL of INF-γ or with both 50 ng/mL
of INF-γ and 1 μg/mL of Poly (I:C), were used to assess VCAM-1 expression by Flow Cytometry.
Results are presented as mean ± SEM of three independent experiments; (B) Representative histogram
showing VCAM-1 expression of one sample of unlicensed AMSCs;. (C) unlicensed AMSCs, as well
as AMSCs licensed with either 1 μg/mL of Poly (I:C), 50 ng/mL of INF-γ or with both 50 ng/mL of
INF-γ and 1 μg/mL of Poly (I:C) were also used to investigate ICAM-1 expression by Flow Cytometry.
Results are presented as mean ± SEM of three independent experiments; (D) The influence of
INF-γ over ICAM-1 expression on AMSCs was confirmed using three different concentrations of this
inflammatory factor. (E) ICAM-1 expression on unlicensed AMSCs and AMSCs licensed with 25, 50
and 100 ng/mL of INF-γ. * p < 0.05, ** p < 0.01, **** p < 0.0001.
3.7. EVs Characterization
EVs isolated from unlicensed AMSCs showed the mean size of 262.4 nm, as determined by
Zetasizer Nano ZS measurement (Figure 5A) and TEM (Figure 5B). INF-γ licensed AMSCs did
not present significant differences regarding average size, which was 264.2 nm (data not shown).
EVs characterization was also performed by Flow Cytometry, being that the isolated EVs were
immunophenotypically characterized and showed positive expression of MSCs markers CD90 (76.5%)
and CD105 (60.7%) (Figure 5C,D).
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Figure 5. Characterization of EVs isolated from unlicensed and INF-γ licensed AMSCs and their
capacity to control T-cell proliferation. (A) EVs average size estimated using Zetasizer Nano ZS; (B)
Transmission electron microscopy of EVs (representative image of one unlicensed sample); CD90
(C) and CD105 (D) expression of EVs isolated from unlicensed AMSCs were determined by Flow
Cytometry; (E) EVs isolated from unlicensed and INF-γ licensed AMSCs were quantified according to
their protein concentration by Bradford assay and used in different concentrations (0.25, 0.75 and 3.0 μg)
to treat PHA-activated PBMCs, in order to access their immunosuppressive capacity. Results are
presented as mean ± SEM of three independent experiments. ** p < 0.01, *** p < 0.001 **** p < 0.0001.
3.8. AMSCs-Derived EVs Present Immunosuppressive Potential
After characterization, we evaluated if EVs derived from unlicensed and INF- γ licensed AMSCs
presented immunoregulatory potential of inhibiting activated PBMCs proliferation. Notably, PBMCs
incubation with 0.25, 0.75 and 3.0 μg of unlicensed AMSCs-derived EVs successfully suppressed
activated T-cell proliferation (p = 0.0005; p = 0.0002 and p < 0.0003, respectively). Likewise, PBMCs
incubation with 0.25, 0.75 and 3.0 μg of INF-γ licensed AMSCs also suppressed T-cell proliferation
(p < 0.0001; p = 0.0002 and p < 0.0001, respectively). Importantly, even though both groups effectively
promoted immunosuppression at all concentrations tested, when used at 0.25 μg, we detected a slight
increase in the suppressive potential of EVs isolated from INF-γ licensed AMSCs compared to EVs
from unlicensed AMSCs (p = 0.004) (Figure 5E).
3.9. Expression of Inflammatory Transcripts in Licensed and Unlicensed AMSCs and in Their EVs
Gene expression of TNF, TGF-β, IDO, Galectin-1, IL-1β and IL-10 was assessed in licensed and
unlicensed AMSCs by Real Time PCR. Compared to unlicensed AMSCs, INF-γ treatment increased
the expression of TNF (p = 0.002), IL-1β (p = 0.001) and IDO (p < 0.0001), the latter with more
intensity. Interestingly, this licensing protocol abrogated IL-10 transcription. AMSCs licensing with
Poly (I:C) induced a higher expression of TNF (p = 0.04), IL-1β (p = 0.008) and IDO (p = 0.001), as well.
Interestingly, AMSCs licensing with both Poly (I:C) and INF-γ induced the most intense transcriptional
differences compared to unlicensed AMSCs, leading to the highest expression of TNF (p = 0.0003),
IL-1β (p = 0.0003) and IDO (p = 0.001). Of note, none of the tested strategies of AMSCs licensing
influenced Galectin-1 and TGF-β expression (Figure 6A). We also assessed the transcriptional levels
of TGF-β, IDO, Galectin-1 and IL-10 in EVs isolated from unlicensed and INF-γ licensed AMSCs.
Interestingly, EVs from INF-γ licensed AMSCs showed decreased expression of Galectin-1 transcript
(p = 0.0002). However, IDO was detected only in EVs isolated from INF-γ licensed AMSCs (p = 0.0001).
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No statistically significant difference was detected regarding TGF-β expression between groups
(Figure 6B). IL-10 expression was not detected in the analyzed EV transcripts.
Figure 6. Gene expression analysis of selected transcripts in unlicensed and licensed AMSCs.
(A) Radial plot demonstrating the differences in overall transcripts between unlicensed AMSCs,
as well as AMSCs licensed with 1 μg/mL of Poly (I:C), AMSCs licensed with 50 ng/mL INF-γ and
AMSCs licensed with both 50 ng/mL of INF-γ and 1 μg/mL of Poly (I:C). Solid vertices represent
the mean fold change of individual transcripts. Median Ct value of unlicensed AMSCs was used
as a reference. Results are presented as the mean of three independent experiments; (B) Expression
of Galectin-1, IDO, IL-10 and TGF-β transcripts in EVs isolated from unlicensed and INF-γ licensed
AMSCs. To analyze IDO expression in EVs, the CT value of EVs obtained from unlicensed AMSCs was
arbitrarily defined as 40. *** p < 0.001.
4. Discussion
In the present study, we have demonstrated that the licensing of AMSCs with INF-γ and/or
Poly (I:C) maintain the classic AMSCs phenotypic pattern and does not significantly alter AMSCs
proliferative capacity and migratory behavior. Importantly, though, our data reveal that INF-γ
licensing markedly induces AMSCs to produce higher levels of IDO, increased the expression of
ICAM-1 adhesion molecule and potentializes the capacity of licensed cells to suppress activated
T-cell proliferation, compared to unlicensed counterparts. On the other hand, we have also clearly
demonstrated that under a perspective of a cell free therapy, the strategy of licensing of AMSCs with
INF-γ was effective in promoting immunoregulatory advantages when compared to unlicensed cell
samples. Finally, our data reveal that AMSCs present a constitutive potential to inhibit activated T-cell
proliferation and to secrete biologically active EVs, which harbor the capacity of effectively controlling
T-cell response.
Several processes contribute for MSCs immunoregulatory potential. For instance, to exert their
immunoregulatory effects with the greatest potential, MSCs must survive and reach sites of injury.
However, it is currently established that only a small number of infused cells can achieve this
goal, following stem cell therapy. Therefore, the search for strategies capable of enhancing the
suppressive capacity of MSCs is paramount to guarantee the efficacy and commercial viability of
such therapy [24,25]. In this sense, among the several strategies under investigation to boost MSC
therapy efficacy, lie the licensing protocols. According to this rationale, it may be possible to stimulate
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MSCs to boost their pro-survival and immunomodulation properties, by treating them with specific
molecules prior to treatment. Several licensing strategies have been tested so far, such as the treatment
of MSCs with INF-γ and Poly (I:C). According to previous reports, INF-γ signaling did not improve
the migratory capacity of bone marrow and cord blood-derived MSCs [26]. Accordingly, we have not
found any effect of INF-γ regarding the migratory capacity of AMSCs. Considering the role of TLR
signaling in MSCs migration, it has been showed that Poly (I:C) stimulation enhanced the migratory
capacity of MSCs derived from bone marrow [27]. In contrast to previous reports, we have not noticed
any impact of TLR3 signaling over AMSCs migratory behavior. In part, these discrepant results can
be explained by the fact that MSCs present different migratory capacity depending on their source
of obtention, as described recently [28] and probably also differ in the response to variable stimuli.
This hypothesis may be subsidized by the observation that circulating MSCs are derived from bone
marrow [29,30], suggesting that MSCs from other tissues may not respond to the same migration
stimuli similarly.
The development of strategies to enhance MSCs proliferation has particular relevance considering
that their immunomodulatory effects are dose-dependent [31]. In this context, data concerning the
influence of TLR3 and INF-γ signaling on human AMSCs proliferation are markedly scarce in the
literature. Our results showed that the licensing of these cells with TLR3 and/or INF-γ did not change
AMSCs proliferation. In agreement with our observation, others also failed to detect any influence
of TLR3 signaling in AMSCs proliferative capacity [32,33]. Long term stimulation with INF-γ, on
the other hand, has been documented to reduce the proliferation of bone marrow derived MSCs [34].
More recently, it has been demonstrated that 5 days stimulation of bone marrow-derived MSCs with
low a concentration of INF-γ (i.e., 0.1 ng/mL), actually increased cell proliferation but also that, when
stimulated with higher levels of INF-γ (i.e., 10 ng/mL), cell proliferation was markedly compromised.
In this conflicting scenario, it is important to note that, in contrast to our experimental design, MSCs
were continuously maintained in the presence of INF-γ in the studies mentioned above [35].
Since the demonstration that murine MSCs licensing with INF-γ could completely prevent GVHD
mortality [36], several efforts have been made to better understand the effects of this inflammatory
factor over MSCs-mediated immunomodulation. Here, we have shown that AMSCs licensing with
INF-γ was indeed an effective strategy to enhance AMSCs’ capacity to control activated T-cell
proliferation. Interestingly, this licensing protocol increased the expression of ICAM-1 protein
expression and of IDO transcript levels in AMSCs, both of which have important roles in the
immunomodulation exerted by these cells [37,38].
Another important strategy that has been explored to enhance MSCs-mediated
immunomodulation is the stimulation of such cells with TLR3 agonists. In this sense, the
results presented in the literature indicate that the positive effects of this strategy seem to be
inconsistent and dependent on the MSCs source under investigation. While TLR3 signaling improves
the immunosuppressive effects of MSCs isolated from the umbilical cord [39] and bone marrow [40],
we have not noticed any influence on AMSCs. Accordingly, Lombardo and colleagues reported
that TLR3 signaling in AMSCs did not influence their immunoregulatory phenotype [33]. In our
hands, we have also explored the effects of AMSCs licensing with a combination of INF-γ and Poly
(I:C). Surprisingly, though, we have observed only a slight reduction in lymphocyte PHA-induced
proliferation. Besides, even though the combined INF-γ and Poly (I:C) licensing strategy significantly
enhanced ICAM-1 and IDO expression, it also promoted a substantial increase in TNF and IL-1b
transcript levels, two critical proinflammatory factors [41,42]. We noticed that AMSCs licensing
with INF-γ abrogated IL-10 transcription, in contrast to the licensing with Poly (I:C), where IL-10
transcription was stimulated. Importantly, IL-10, as well as PGE2, TGF-β, IGF and HLA-G5, play an
important role to generate Tregs, which enhance MSCs-mediated immunosuppression [43–46].
Importantly, the conditioned medium from unlicensed AMSCs showed capacity to control T-cell
proliferation. In accordance with this data, Matula and colleagues also showed that conditioned
medium from unlicensed AMSCs has immunosuppressive potential [47]. More importantly, we
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demonstrated that this immunomodulatory potential can be enhanced by INF-γ licensing. Given that
AMSCs licensing with INF-γ was able to potentialize the intrinsic capacity of AMSCs conditioned
medium to control activated T-cell proliferation, we continued our investigation with the isolation of
EVs from this group and from unlicensed AMSCs, considering that the analysis of such EVs could
provide new insights to the field of cell free technologies. In fact, the conditioned medium and the
EVs isolated from MSCs are currently being explored for the most varied applications and already
showed promising effects in animal models of acute myocardial infarct, as well as lung, kidney and
brain injuries [48]. Interestingly, isolated EVs showed positive expression of MSCs markers and an
average size compatible with previous results reported by Blazquez et al. [21]. These authors also
demonstrated that EVs derived from AMSCs are able to control T-cell proliferation. In addition,
we showed that both EVs isolated from unlicensed and INF-γ licensed AMSCs showed potential
to significantly suppress activated T-cell proliferation and that in lower EVs concentrations, INF-γ
licensed group presented a greater immunoregulatory effect. A previous work failed to detect any
differences regarding the immunosuppressive potential of EVs derived from unlicensed and INF-γ
licensed MSCs [49]. However, it is important to point that, despite being performed with murine bone
marrow MSCs, the licensing strategy used in this study was performed with lower concentrations of
INF-γ. In order to investigate molecular mechanisms that could be involved in the immunosuppressive
effects observed, we investigated the presence of anti-inflammatory factors in EVs from unlicensed
and INF-γ licensed AMSCs. Importantly, we demonstrated that these EVs carry transcripts of
anti-inflammatory genes, involved in MSCs mediated immunoregulation, such as galectin-1 [50]
and TGF-B [44]. IDO transcripts were detected only in EVs derived from INF-γ licensed AMSCs,
however, we did not observe any striking immunosuppressive advantage in this group, suggesting that
other anti-inflammatory players may have more significant roles in the immunosuppressive potential
of AMSCs-derived EVs. The demonstration that both AMSCs conditioned medium and derived EVs
are immunologically active has particular relevance, especially when taking into consideration the
significant advantages of cell-free components compared to their cellular counterparts. For instance,
cell-free material obtention, handling and production yields are more attractive compared to cell
products, as well as the elimination of the risks associated to cellular infusion.
5. Conclusions
In summary, in the present work, we sought to comprehensively investigate the
immunosuppressive potential of AMSCs under different licensing strategies, considering their direct
use, as well as their conditioned medium and derived EVs. Our results clearly show that the licensing
of AMSCs with INF-γ increases their immunoregulatory potential, which is accompanied by an
increase in the expression of IDO and ICAM. Additionally, we have shown that conditioned medium
obtained from INF-γ licensed AMSCs display a higher capacity to control T-cell proliferation compared
to conditioned medium from unlicensed counterparts. Finally, our data clearly demonstrated that
both EVs isolated from unlicensed and INF-γ licensed AMSCs are also capable to control the T-cell
proliferation. These results contribute to the better elucidation of the suppressive potential of AMSCs
and their products, serving as the basis for the development of new therapeutic approaches to control
the immune response.
Supplementary Materials: The following is available online. Figure S1: Immunophenotypic characterization
of AMSCs.
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Abstract: Pulmonary failure is the main cause of morbidity and mortality in the human chromosomal
instability syndrome Ataxia-telangiectasia (A-T). Major phenotypes include recurrent respiratory tract
infections and bronchiectasis, aspiration, respiratory muscle abnormalities, interstitial lung disease,
and pulmonary fibrosis. At present, no effective pulmonary therapy for A-T exists. Cell therapy
using adipose-derived mesenchymal stromal/stem cells (ASCs) might be a promising approach for
tissue regeneration. The aim of the present project was to investigate whether ASCs migrate into the
injured lung parenchyma of Atm-deficient mice as an indication of incipient tissue damage during A-T.
Therefore, ASCs isolated from luciferase transgenic mice (mASCs) were intravenously transplanted
into Atm-deficient and wild-type mice. Retention kinetics of the cells were monitored using in vivo
bioluminescence imaging (BLI) and completed by subsequent verification using quantitative real-time
polymerase chain reaction (qRT-PCR). The in vivo imaging and the qPCR results demonstrated
migration accompanied by a significantly longer retention time of transplanted mASCs in the lung
parenchyma of Atm-deficient mice compared to wild type mice. In conclusion, our study suggests
incipient damage in the lung parenchyma of Atm-deficient mice. In addition, our data further
demonstrate that a combination of luciferase-based PCR together with BLI is a pivotal tool for tracking
mASCs after transplantation in models of inflammatory lung diseases such as A-T.
Keywords: tracking; mesenchymal stromal/stem cells; bio imaging; bioluminescence; qRT-PCR;
Ataxia telangiectasia; Atm
1. Introduction
Pulmonary failure is a frequent cause of morbidity and mortality in Ataxia-telangiectasia (A-T).
At present, no effective pulmonary therapy for A-T exists [1]. Thus, the development of new strategies to
preserve lung function in A-T is urgently needed due to limited clinical intervention options. Aside from
immunodeficiency and inflammation, fibrotic changes are a major factor leading to progressive lung
destruction. A direct connection between the ATM protein (A-T Mutated) and TGF-β1, one of the key
Cells 2020, 9, 1444; doi:10.3390/cells9061444 www.mdpi.com/journal/cells265
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mediators responsible for fibrotic changes in the lung, has been described [2]. In addition, we provided
evidence for reduced lung function and increased inflammation in the lung of Atm-deficient mice
displaying the human pulmonary A-T phenotype [3]. Therefore, inhibition of inflammation and fibrosis
might open new avenues in the treatment of the lung disorder in A-T. Recently, we demonstrated that
bone marrow transplantation (BMT) significantly improves the immunological phenotype and inhibits
tumorigenesis in Atm-deficient mice [4]. Donor bone marrow derived cells (BMDCs) migrated into bone
marrow, blood, thymus, spleen, and lung tissue of Atm-deficient mice. However, although the BMT
overcame the immunodeficiency, migration of the donor cells into the lung tissue was low, and most of
the cells were of hematopoietic origin. To improve cellular migration and to provide anti-inflammatory,
anti-fibrotic, and anti-oxidative activity, a promising approach could be transplantation of mesenchymal
stromal/stem cells (MSCs).
In principle, MSCs have been detected throughout the body as immature, undifferentiated cells.
For the first time, their isolation from bone marrow was described, but in the meantime, they have also
been described from almost all adult tissues (e.g., fatty tissue) and solid organs (e.g., liver, kidney) [5,6].
More recent data show that MSCs represent a rare population (or populations) in the perivascular niche
of all tissues. A number of studies have demonstrated that MSCs preferentially migrate to injured lung
tissue where they are involved in lung repair and control of injury [7]. MSCs provide both structural
and functional support to the parenchymal cells of multiple organs and possess immunomodulatory,
anti-fibrotic properties and relative immune privilege [8]. MSCs release a number of anti-inflammatory,
proangiogenic, regeneration-promoting, and immunomodulating factors that can improve regeneration
in injured cells in tissues and organs [9]. Furthermore, MSCs preferentially migrate into injured or
inflamed tissues. Therefore, we investigated in this study whether infused murine adipose-derived
MSCs (mASCs) displayed an increased retention in injured pulmonary tissue of Atm-deficient mice
compared to wild type mice, which could then result in an increased regeneration of the damaged
lung tissue.
2. Materials and Methods
2.1. Animals
Atm-deficient mice (Atmtm1(Atm)Awb; 8 to 10 weeks old) and corresponding wild-type mice,
in a 129S6/SvEv background, were used as the animal model. A total of 24 Atm-deficient mice were
included in the study (histological lung sections, n = 4; lung function testing, n = 12; bioluminescence
imaging and PCR, n = 8). The experiments were performed using respective wildtype controls
(littermates). Transgenic Luc+ mice with C57BL/6 background were used to isolate mesenchymal
stromal/stem cells from murine inguinal fat. All animal procedures were performed according to the
protocols approved by the Animal Care and Use Committee of the state of Hessen (RP Darmstadt (Gen.
Nr. FK/1034)).
2.2. Cell Isolation and Culture
Adipose tissue was harvested from transgenic Luc+ C57BL/6 mice (Janvier, France) as described
earlier [10]. Briefly, mice were killed by cervical dislocation, and adipose tissue from inguinal fat
pads was immediately dissected to isolate adipose-derived stromal/stem cells (mASCs). Tissue was
minced with two scalpels (crossed blades) and then incubated in a 0.5% collagenase/phosphate buffered
saline (PBS) solution (Collagenase Type: CLS; Biochrom, Berlin, Germany; PBS; Sigma, Taufkirchen,
Germany) for 1 h at 37 ◦C with constant shaking. The digested tissue solution was then separated
through a 100 μm strainer, and the resulting filtrate was centrifuged at 300× g for 5 min. The resulting
pellet was washed twice with medium and centrifuged again at 300× g for 5 min. Finally, cells were
plated and cultured at 37 ◦C in an atmosphere of 5% CO2 in 100% humidity. Dulbecco’s Modified
Eagle’s Medium (DMEM; Sigma, Taufkirchen, Germany) with a physiological glucose concentration
(100 mg/dL) was supplemented with 10% fetal bovine serum (Biochrom, Berlin, Germany) and used as
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standard culture medium (DF10). The medium was replaced every three days. Subconfluent cells
(90%) were passaged by trypsinization. Cells between passages 2 and 5 were used throughout the
experiments. Cell morphology was examined by phase contrast microscopy and flow cytometry,
as described earlier [10].
2.3. Immunohistochemistry
Mice were anesthetized with an intraperitoneal injection of a Ketamin–Rompun mixture (20%
Ketamin, CuraMED GmbH, Karlsruhe, Germany; 8% Rompun, Bayer Vital GmbH, Leverkusen,
Germany). They were perfused transcardially with 4% paraformaldehyde in PBS. Lung tissue sections
were prepared from fixed, paraffin-embedded organs and stained with hematoxylin/eosin or with
chloracetate esterase staining as neutrophil-specific marker [4,11].
2.4. Pulmonary Function
Pulmonary function was tested in Atm-deficient mice and wild-type mice using
a computer-controlled piston ventilator (flexiVent, SCIREQ Inc., Montreal, QC, Canada).
Briefly, mice were anesthetized, a tracheotomy was performed, and the trachea was cannulated.
After that, the mice were placed on a temperature controlled heat blanket, the trachea was exposed,
and the previously calibrated cannula (1.2 cm, 18 gauges) was inserted and fixed using a suture.
Ventilation was maintained at a rate of 150 breaths/min, a tidal volume of 10 mL/kg, and a positive
end-expiratory pressure of 3 cm of water. Mice were allowed to acclimate to the ventilator for 2–3 min
before measurement. Lung function parameters were calculated by fitting pressure and volume data to
the single compartment model by measuring respiratory system resistance (Rrs), dynamic compliance
(Crs) and elastance (Ers) and by analyzing with flexiWare 7 Software [3].
2.5. Transplantation
Three wildtype mice and 4 Atm-deficient mice were transplanted with 0.5 × 105 Luc+ mASCs in
DMEM containing Heparin (10 U/100 μL). Viability of the cells was checked by trypan blue exclusion
immediately before transplantation. A single injection of 100 μL was conducted via the tail vein into
each mouse. Cells were tracked via bioluminescence imaging (BLI) on days 1, 3, 6, and 9 and via
qRT-PCR at the indicated endpoints (day 15 and 50). The mice were weighed every two to three
days, and no significant weight changes could be detected. The mice were sacrificed at the end
of the experiment by cervical dislocation under anesthesia with ketamine-xylazine, and the organs
were collected.
2.6. In Vivo Bioimaging
Tracking of the transplanted Luc+ mASC was performed in vivo using the PerkinElmer IVIS
Lumina II Imaging Chamber System. For this purpose, the mice were injected i.p. with 100 μL
D-luciferin. They were then placed under anesthesia with isoflurane. After 10 min, the mice were
placed dorsally or ventrally next to one another in the heated measuring chamber of the bioimaging
system. Anesthesia was maintained during the measurement via a breathing mask. Images of the
detectable luminescence signal were acquired at 1, 30, 60, 180, and 360 s and then evaluated using the
“LivingImage” software with Region of Interest (ROI) placed over the thorax. In addition, a background
field was placed on the dark border. The quantification was done in photons/s (total flux), and the
background was subtracted from the measured values.
2.7. PCR Analyses
Total RNA extraction was performed using single-step RNA isolation from cultured cells by
a standard protocol, as described earlier [10]. After RNA extraction, cDNAs were synthesized for 30 min
at 37 ◦C using 1 μg of RNA, 50 μM random hexamers, 1 mM of deoxynucletide-triphosphate-mix,
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50 units of reverse transcriptase (Fermentas, St. Leon-Rot, Germany) in 10× PCR buffer, 1 mM
β-mercaptoethanol, and 5 mM MgCl2. An Absolute qPCR SYBR Green Rox Mix was used (Thermo
Scientific, Hamburg, Germany) for the master mix; primer mix and RNAse-free water were added.
Quantitative PCR was carried out in 96-well plates using the following conditions: 15 min at 95 ◦C
for enzyme activation, 15 s at 95 ◦C for denaturation, 30 s for annealing, 30 s at 72 ◦C for elongation,
followed by a melting curve analysis. Products were checked by agarose gel electrophoresis in selected
experiments. Quantification of the PCR fragment was carried out using the Eppendorf realplex2
Mastercycler epgradient S (Eppendorf, Hamburg, Germany). Standard curves were prepared for
the amplification specific efficiency correction, and the efficiencies (E) were calculated according to
the equation E = (10−1/m−1) × 100, where m is the slope of the linear regression model fitted over
log-transformed data of the input cDNA concentrations versus CT values [12,13]. E for actin-beta was
1.9164, and for luciferase = 1.9399. The relative efficiency-corrected mRNA expression of the target gene
was calculated based on efficiencies and the CT (Threshold cycle) deviation of an unknown sample
versus a positive control (ΔCT) and was expressed in comparison to a reference gene [12,13]. Data were
calculated (rel. expression = (E Luc = 1.9164)ΔCT Luc/(E actin = 1.9399)ΔCT actin) and expressed as percent
(the calculated rel. expression 1.0 refers to 100%, the value 0.02 refers to 2%). The luciferase primer was
constructed using the firefly luciferase gene from Photinus pyralis (GenBank No. AB644228.1, forward:
TGAAGAGATACGCCCTGGTT, reverse: CTACGGTAGGCTGCGAAATG; product size 288 bp) and the
reference primer for murine actin-beta (NM_007393, forward: F: CCACCATGTACCCAGGCATT, reverse:
AGGGTGTAAAACGCAGCTCA, product size 253 bp) (Invitrogen (Karlsruhe, Germany). In addition,
PCR products were separated by agarose electrophoresis and observed under UV illumination [10].
2.8. Statistical Analysis
The data were expressed as mean ± standard deviation (SD) and were analyzed using an unpaired
student’s Test or a Mann–Whitney test. For multiple comparisons, analysis of variance (ANOVA)
with Bonferroni’s multiple comparison test was used for statistical analysis. p values < 0.05 were
considered significant.
3. Results
3.1. Atm-Deficient Mice Exhibited Signs of Lung Disease
Comparison of the lung parenchyma showed slight tendency for alveolar septal thickening and
patchy areas of neutrophilic inflammation in Atm-deficient mice (Figure 1B,D) compared to wild-type
mice (Figure 1A,C) accompanied by significantly increased lung resistance (Rrs) (Figure 1E) and
respiratory system elastance (Ers) (Figure 1F) as well as decreased tissue compliance (Figure 1F) in
comparison to control mice.
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Figure 1. Lung injury in Atm-deficient mice. Representative histological lung sections of (A,C)
wild-type (WT) and (B,D) Atm-deficient (Atm−/−) mice stained with hematoxylin and eosin (A,B) or
with chloracetate esterase staining (C,D), respectively. Lung function testing using a FlexiVent mouse
ventilator, respiratory system resistance (E), compliance (F), and elastance (G) in Atm−/− mice compared
to a WT control group (n = 10–12). Bar = 100 μm.
3.2. Luc+ mASCs Stayed Longer in Lung Tissue of Atm-Deficient Mice Compared to Wildtype Mice
Examination of in vivo luciferase expression showed a positive bioluminescent signal in all
transplanted mice on day one after transplantation with no differences between Atm-deficient and
wildtype mice (Figure 2A). After three days, the bioluminescent signal in wildtype mice rapidly
dropped down and disappeared completely on day six. In contrast, the transplanted Atm-deficient
mice showed a strong bioluminescent signal even after nine days. At day 14, the bioluminescence signal
decreased to undetectable levels in all mice including the four Atm-deficient mice (data not shown).
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Figure 2. Retention of adipose-derived mesenchymal stromal/stem cells (ASCs) isolated from luciferase
transgenic mice (mASCs) into the lung tissue of Atm-deficient mice. (A) Bioluminescence imaging
of mASCs transgenic for the firefly luciferase gene (Luc+) in the lung tissue of Atm-deficient mice
(Atm−/−, n = 4) and wild type mice (Atm+/+, n = 3). MSCs were analyzed at days 1, 3, 6, and 9 after
transplantation. (B) Quantitative analysis of the light emission data of the analyzed bioluminescence
signals from untransplanted Atm−/− mice (black bars, n = 3), Luc+ mASCs transplanted Atm−/− mice
(grey bars, n = 4), and Atm+/+ mice (white bars, n=3). ** p < 0.01.
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Quantification of the light emission of the analyzed bioluminescence signals confirmed the above
findings (Figure 2B). A strong signal was seen on day one for both genotypes after transplantation,
whereas the mock-transplanted animals, which were signal negative in the overlay recordings,
showed a constant-low total flux background value on all days. Up to day three, the total flux
of the bioluminescent signal revealed no differences between MSC-transplanted Atm-deficient and
wildtype mice. After that, the signal in transplanted wildtype mice dropped down to the level
of the untransplanted mice. In contrast, the total flux signal maintained in the MSC-transplanted
Atm-deficient mice.
3.3. Transplanted mASCs Exhibited a Long Retention Time in the Lung Parenchyma of Atm-Deficient Mice
Quantitative real-time PCR was used on days 15 and 50 to follow the retention time of Luc+
mASCs after the bioluminescence signal disappeared (Figure 3). After transplantation of Luc+ mASCs,
Atm-deficient mice showed a 50-fold higher luciferase gene expression in lung parenchyma compared
to wildtype mice (Atm−/−: 2.0% ± 0.59; Atm+/+: 0.04% ± 0.004, p < 0.05), whereas no differences could
be detected in the kidney and the thymus (Figure 3).
Figure 3. Detection of Luc+ mASCs on day 15 after transplantation of Atm-deficient (Atm−/−, n = 4) and
wild type mice (Atm+/+, n = 3) knock-out using PCR. Quantitative analysis of the relative expression
(expressed as percent; MW ± SEM) (left side) and results of the gel electrophoresis of lungs, kidney,
and thymus (right side). Controls: RNA from Luc negative tissue (Neg), RNA from Luc positive tissue
(Pos = 100%). Luc=luciferase, mActB=murine actine-beta. * p < 0.05.
An exemplary examination of long-term stay revealed still a positive Luc-signal in the lung
parenchyma of the Atm-deficient mouse at day 50 (n = 1). Although the Luc signal in the lungs
decreased on day 50 compared to day 15, it was still detectable (Figure 4). While a very slight increase
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of the signal was observed in the kidney at day 50, no signal was detected in the thymus on day 15 or
day 50.
Figure 4. Detection of Luc+mASCs on day 15 (D15, n= 4) and on day 50 (D50, n= 1) after transplantation
in Atm−/− mice. Graph shows fold Luc+ expression in lung, kidney, and thymus at days 15 and 50
in relation to Luc+ expression in the lung at day 15 (quantitative analysis of the relative Luc-mRNA
amounts (percent of signal, lung D15 = 100%)).
4. Discussion
Respiratory disease accounts for significant morbidity and mortality in patients with A-T [14].
Major phenotypes include recurrent respiratory tract infections and bronchiectasis, aspiration,
respiratory muscle abnormalities, interstitial lung disease, and pulmonary fibrosis [15]. Aside from
the immunodeficiency, it has been proposed that ongoing low grade inflammation and oxidative stress
might be responsible for the clinical pathogenesis causing lung failure [1,16]. Recent studies further
demonstrated restricted lung function, high sensitivity to inflammatory agents, and a significant
amount of oxidative DNA damage in the lung parenchyma of Atm-deficient mice, especially after
triggering inflammation [3,11].
Cell therapy using MSCs might be a promising approach for tissue regeneration in A-T. MSCs
have been shown to integrate into the damaged sites in a variety of tissues, including lung tissue,
showing positive effects on tissue regeneration [7]. There are recent studies using administration of
MSCs or their derivates (e.g., extracellular vesicles) in in vivo studies [17] or human clinical trials to
treat pulmonary fibrosis [18]. Averyanov and co-workers evaluated the safety and the tolerability of
repeated infusions of high doses of MSCs up to the total cumulative dose of two billion cells in subjects
with rapidly progressing idiopathic pulmonary fibrosis. They showed that the treatment was safe and
well tolerated. Transplanted patients had an increased lung function compared to the placebo group,
where a sustained decrease in lung function was observed. Currently, it could be shown that MSCs
improved the outcome of patients with COVID-19 pneumonia [19]. Transplantation of MSCs was
shown to cure or significantly improve the functional outcomes of seven COVID-19 patients without
observed adverse effects. The pulmonary function and symptoms of seven patients were significantly
improved in two days after MSC transplantation [19]. Nevertheless, it should be noted in this context
that others reported that reduced migration of transplanted MSCs correlated with decreased fibrosis in
the lungs [20].
However, lung disease in A-T is a creeping process that slowly develops over time, and experience
with MSCs in A-T is scarce. Even in the Atm-mouse model, lung damage is difficult to determine
without induction of experimental inflammation, as the mice died from thymic lymphomas within
3–6 months before lung failure could occur. This prompted us to investigate whether mASCs remained
in the lung parenchyma of Atm-deficient mice in an increased manner compared to healthy controls.
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It is important to note that the mice were housed in individually ventilated cages to protect them from
any harmful microorganism.
Although tissue damage and inflammation are hard to detect in Atm-deficient mice without
exogenous trigger, our present data showed signs of lung disease and damage in Atm-deficient
mice [3,4]. These findings are underlined by our in vivo imaging and qPCR results, which demonstrated
increased retention of MSCs into the lung parenchyma of Atm-deficient mice compared to wild-type.
Because MSCs preferentially migrate into injured or inflamed tissues, such as during wound healing
or in association with tumors, these findings together with the pathological changes in lung function
parameters indicate that the Atm-deficient mouse has some kind of ongoing pulmonary damage [21].
It should be mentioned that signals in the lung do not necessarily reflect transgenic donor cells.
They may derive from inflammatory host cells (e.g. macrophages or others) in the lung, which have
phagocytosed donor cells. Nevertheless, our results shown here are in line with earlier findings
showing an engraftment of CD31+CD45− endothelial cells and EpCAM+ epithelial cells into the
lung tissue of Atm-deficient mice after bone marrow transplantation [4]. In addition, impaired lung
resistance and respiratory system elastance in Atm-deficient mice has also been described in other
studies without the presence of inflammation [3,11]. In this regard, an earlier study from our group
also showed increased spontaneous oxidative stress and damage in the lung tissue of Atm-deficient
mice and alveolar basal epithelial cells in the presence of the ATM-kinase inhibitor KU55933 [3,16].
Thus, in the absence of inflammatory signals, oxidative stress could attract MSCs in our experimental
setting. Due to their ability to counteract reactive oxygen species, further experiments investigating
the effect of MSCs on oxidative stress should be performed. Luc-based real-time PCR together with
BLI is an important tool for cell tracking after transplantation in models of inflammatory lung diseases
such as A-T [10].
In conclusion, tracking of transplanted Luc+ mASCs, by a combination of luciferase-based PCR
together with BLI showed an increased migration into lung parenchyma accompanied by a significantly
longer retention time in Atm-deficient mice, pointing to ongoing pulmonary damage in the lung tissue
in these animals. To what extent these cells improve the regeneration of damaged lung tissue in Atm−/−
mice will now be investigated in further studies. Therefore, further experiments are necessary to
confirm the regenerative impact of MSCs on lung disease in A-T.
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